US20210094940A1 - Modulators of ror-gamma - Google Patents

Modulators of ror-gamma Download PDF

Info

Publication number
US20210094940A1
US20210094940A1 US17/023,871 US202017023871A US2021094940A1 US 20210094940 A1 US20210094940 A1 US 20210094940A1 US 202017023871 A US202017023871 A US 202017023871A US 2021094940 A1 US2021094940 A1 US 2021094940A1
Authority
US
United States
Prior art keywords
methyl
benzo
imidazole
carboxamide
dioxol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/023,871
Inventor
David A. Claremon
Lawrence Wayne Dillard
Yi Fan
Stephen D. Lotesta
Suresh B. Singh
Colin M. Tice
Wei Zhao
Linghang Zhuang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vitae Pharmaceuticals LLC
Original Assignee
Vitae Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitae Pharmaceuticals LLC filed Critical Vitae Pharmaceuticals LLC
Priority to US17/023,871 priority Critical patent/US20210094940A1/en
Assigned to VITAE PHARMACEUTICALS, LLC reassignment VITAE PHARMACEUTICALS, LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: VITAE PHARMACEUTICALS, INC.
Assigned to VITAE PHARMACEUTICALS, INC. reassignment VITAE PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CLAREMON, DAVID A., FAN, YI, SINGH, SURESH B., LOTESTA, STEPHEN D., TICE, COLIN M., DILLARD, LAWRENCE WAYNE, ZHAO, WEI, ZHUANG, LINGHANG
Publication of US20210094940A1 publication Critical patent/US20210094940A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/10—Radicals substituted by halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • ROR ⁇ novel retinoic acid receptor-related orphan receptor gamma
  • processes for their preparation pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic, autoimmune and other diseases mediated by ROR ⁇ .
  • RORs Retinoic acid receptor-related orphan receptors
  • the ROR family consists of ROR alpha (ROR ⁇ ), ROR beta (ROR ⁇ ) and ROR gamma (ROR ⁇ ), each encoded by a separate gene (in human: RORA, RORB and RORC, respectively; in mouse: rora, rorb and rorc, respectively).
  • RORs contain four principal domains shared by the majority of nuclear receptors: an N-terminal domain, a highly conserved DNA-binding domain (DBD) consisting of two zinc finger motifs, a hinge domain, and a ligand binding domain (LBD). Each ROR gene generates several isoforms, differing only in their N-terminal domains.
  • ROR ⁇ has two isoforms: ROR ⁇ 1 and ROR ⁇ 2 (also known as ROR ⁇ t).
  • ROR ⁇ refers to ROR ⁇ 1 and/or ROR ⁇ t.
  • ROR ⁇ 1 is expressed in a variety of tissues including thymus, muscle, kidney and liver, but ROR ⁇ t is exclusively expressed in the cells of the immune system, has a critical role in thymopoiesis and the development of several secondary lymphoid tissues, and is a key regulator of Thl7 cell differentiation (Jetten, 2009, Nucl. Recept. Signal., 7:e003, doi:10.1621/nrs.07003, Epub 2009 Apr. 3).
  • Thl7 cells are a subset of T helper cells which preferentially produce the pro-inflammatory cytokines IL-17A, IL-17F, IL-21 and IL-22. Thl7 cells and their effector molecules, such as IL-17, IL-21, IL-22, GM-CSF and CCL20, are associated with the pathogenesis of several autoimmune and inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis, inflammatory bowel disease, allergy and asthma (Maddur et al., 2012, Am. J. Pathol., 181:8-18).
  • autoimmune and inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis, inflammatory bowel disease, allergy and asthma
  • Thl7 cells are also potent inducers of inflammation associated with endometriosis, a chronic inflammatory disease (Hirata et al., 2010, Endocrinol., 151:5468-5476; Hirata et al., 2011, Fertil Steril., July; 96(1):113-7, doi: 10.1016/j.fertnstert.2011.04.060, Epub 2011 May 20). Additionally, Thl7 cells have a key role in the mouse autoimmune models of experimental autoimmune encephalomyelitis (EAE), collagen-induced arthritis (CIA) and adjuvant-induced arthritis (AIA) (Bedoya et al., 2013, Clin. Dev. Immunol., 2013:986789. Epub 2013 Dec.
  • EAE experimental autoimmune encephalomyelitis
  • CIA collagen-induced arthritis
  • AIA adjuvant-induced arthritis
  • Thl7 cells are activated during inflammatory and autoimmune disease processes and are responsible for recruiting other inflammatory cell types, particularly neutrophils, to mediate pathology in target tissues (Miossec & Kolls, 2012, Nature Rev., 11:763-776; Korn et al., 2009, Annu. Rev. Immunol., 27:485-517). Aberrant Thl7 cell function has been implicated in a variety of autoimmune diseases, including multiple sclerosis and rheumatoid arthritis. Autoimmune disease is believed to arise from the disruption of the equilibrium between effector and regulatory T cells (Solt et al., 2012, ACS Chem. Biol., 7:1515-1519, Epub 2012 Jul. 9).
  • IL-17-producing neutrophils have been identified as promoting inflammation leading to both microbial clearance and IL-17-associated tissue damage in the cornea and other tissues (Taylor et al., 2014, J. Immunol, 192:3319-3327; Taylor et al., 2014, Nat. Immunol., 15:143-151), supporting a role for compounds that inhibit ROR ⁇ activity in the treatment of corneal ulcers and other diseases and disorders associated with IL-17 expressing neutrophils.
  • Circadian rhythms are daily cycles of behavioral and physiological changes that are regulated by endogenous circadian clocks.
  • a number of studies have established links between nuclear receptor (including ROR ⁇ ) function and expression, the circadian regulatory circuitry, and the regulation of various physiological processes (Jetten (2009) op. cit.).
  • OSAS Obstructive sleep apnea syndrome
  • T lymphocytes a chronic inflammatory disease regulated by T lymphocytes.
  • OSAS patients have a significant increase in peripheral Thl7 cell frequency, IL-17 and ROR ⁇ t levels (Ye et al., 2012, Mediators Inflamm., 815308, doi: 10.1155/2012/815308, Epub 2012 Dec. 31).
  • ROR ⁇ has also been identified to have a regulatory role in lipid/glucose homeostasis, and has been implicated in metabolic syndrome, obesity (Meissburger et al., 2011, EMBO Mol. Med., 3:637-651), hepatosteatosis, insulin resistance and diabetes.
  • ROR ⁇ activity and Thl7 cell differentiation and activity are of significant therapeutic benefit.
  • Compounds that inhibit ROR ⁇ activity and hence have utility in the treatment of e.g., inflammatory, autoimmune, metabolic, circadian effect, cancer, and other diseases mediated by ROR ⁇ are described in WO 2014/179564 and WO 2015/116904.
  • new and improved drugs that modulate ROR ⁇ and are useful in the treatment of disease are described in WO 2014/179564 and WO 2015/116904.
  • the provided compounds can be used alone (i.e., as a monotherapy) or in combination with one or more other therapeutic agent effective for treating any of the indications described herein.
  • FIG. 1 depicts a powder X-ray diffractogram of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-130.1) HCl salt.
  • FIG. 2 depicts a powder X-ray diffractogram of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-130.1) free base.
  • FIG. 3 depicts a powder X-ray diffractogram of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-11.1) Form I.
  • FIG. 4 depicts a powder X-ray diffractogram of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-11.1) Form II.
  • FIG. 5 depicts a powder X-ray diffractogram of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-11.1) Form III.
  • FIG. 6 depicts a powder X-ray diffractogram of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide (I-131.1) HCl salt.
  • FIG. 7 depicts a powder X-ray diffractogram of (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide (I-132.1) free base.
  • the present disclosure provides a compound of Formula I
  • X is —C(O)NH— or —NHC(O)—;
  • R 1 is (C 1 -C 4 )alkyl —C( ⁇ O)OR c , halo(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, halo(C 1 -C 4 )alkoxy, —NR d R e , monocyclic heterocyclyl, or monocyclic cycloalkyl, wherein said (C 1 -C 4 )alkyl is optionally substituted with —OR c , said monocyclic heterocyclyl is optionally substituted with (C 1 -C 4 )alkyl or ⁇ O, and said monocyclic cycloalkyl is optionally substituted with —C( ⁇ O)OR c , —CN, or one or more halo;
  • L 2 is CH 2 , CHMe, or cyclopropyl
  • Cy 1 is aryl, heteroaryl, heterocyclyl, or cycloalkyl, each of which is optionally substituted with 1 to 3 groups independently selected from R 5 ;
  • Cy 2 is aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with 1 to 3 groups independently selected from R 6 ;
  • R 5 and R 6 are each independently selected from halo, —CN, —OR c , —NR d R e , —S(O) k R b , —NR c S(O) 2 R c , —S(O) 2 NR d R e , —C( ⁇ O)OR c , —OC( ⁇ O)OR c , —OC( ⁇ O)R c , —OC( ⁇ S)OR c , —C( ⁇ S)OR c , —OC( ⁇ S)R c , —C( ⁇ O)NR d R e , —NR c C( ⁇ O)R c , —C( ⁇ S)NR d R e , —NR c C( ⁇ S)R c , —NR c C( ⁇ O)OR c , —OC( ⁇ O)NR d R e , —NR(C ⁇ S)OR c ,
  • R 7 and R 8 are each independently hydrogen, OR c , —C( ⁇ O)OR c , monocyclic heterocyclyl, halophenyl, or (C 1 -C 3 )alkyl, wherein the (C 1 -C 3 )alkyl is optionally substituted with OR c , —NR d R e , —O(C 1 -C 3 )alkyl-C( ⁇ O)OR c , —C( ⁇ O)OR c , —C( ⁇ O)NR d R e , or halophenyl;
  • k 0, 1 or 2;
  • each R b is independently selected from hydrogen and (C 1 -C 3 )alkyl optionally substituted with OH, —O(C 1 -C 3 )alkyl, —C(O)O(C 1 -C 3 )alkyl, —C(O)NH 2 , —C(O)NH(C 1 -C 3 )alkyl, or —C(O)N((C 1 -C 3 )alkyl) 2 ;
  • each R c is independently selected from hydrogen and (C 1 -C 3 )alkyl optionally substituted with one or more halo;
  • each R d and R e is independently selected from hydrogen and (C 1 -C 3 )alkyl.
  • halo and “halogen” as used herein refer to an atom selected from fluorine (fluoro, —F), chlorine (chloro, —Cl), bromine (bromo, —Br), and iodine (iodo, —I).
  • alkyl used alone or as a part of a larger moiety such as e.g., “haloalkyl”, means a saturated monovalent straight or branched hydrocarbon radical having, unless otherwise specified, 1-10 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl and the like.
  • “Monovalent” means attached to the rest of the molecule at one point.
  • haloalkyl or “halocycloalkyl” include mono, poly, and perhaloalkyl groups where the halogens are independently selected from fluorine, chlorine, and bromine.
  • cycloalkyl refers to a cyclic hydrocarbon having from, unless otherwise specified, 3 to 10 carbon ring atoms.
  • Monocyclic cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, and cyclooctyl.
  • cycloalkyl or cycloaliphatic group may be present on any substitutable position and, include, e.g., the position at which the cycloalkyl or cycloaliphatic group is attached.
  • aryl used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to an aromatic carbocyclic ring system having, unless otherwise specified, a total of 6 to 10 ring members.
  • aryl may be used interchangeably with the term “aryl ring”, “aryl group”, “aryl moiety,” or “aryl radical”.
  • aryl refers to an aromatic ring system which includes, but is not limited to, phenyl (abbreviated as “Ph”), naphthyl and the like. It will be understood that when specified, optional substituents on an aryl group may be present on any substitutable position and, include, e.g., the position at which the aryl is attached.
  • heteroaryl used alone or as part of a larger moiety as in “heteroarylalkyl”, “heteroarylalkoxy”, or “heteroarylaminoalkyl”, refers to a 5- to 12-membered aromatic radical containing 1-4 heteroatoms selected from N, O, and S.
  • heteroaryl may be used interchangeably with the terms “heteroaryl ring”, “heteroaryl group”, or “heteroaromatic”.
  • a heteroaryl group may be mono- or bi-cyclic.
  • Monocyclic heteroaryl includes, for example, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl,
  • Bi-cyclic heteroaryls include groups in which a monocyclic heteroaryl ring is fused to one or more aryl or heteroaryl rings.
  • Nonlimiting examples include indolyl, benzooxazolyl, benzooxodiazolyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, quinazolinyl, quinoxalinyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyrrolopyridinyl, thienopyridinyl, thienopyrimidinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. It will be understood that when specified, optional substituents on a heteroaryl group may be present on any substitutable position and, include, e.g., the position at which the heteroaryl is attached.
  • heterocyclyl means a 4- to 12-membered saturated or partially unsaturated heterocyclic ring containing 1 to 4 heteroatoms independently selected from N, O, and S.
  • heterocycle means a 4- to 12-membered saturated or partially unsaturated heterocyclic ring containing 1 to 4 heteroatoms independently selected from N, O, and S.
  • heterocycle means a 4- to 12-membered saturated or partially unsaturated heterocyclic ring containing 1 to 4 heteroatoms independently selected from N, O, and S.
  • heterocycle “heterocyclyl”, “heterocyclyl ring”, “heterocyclic group”, “heterocyclic moiety”, and “heterocyclic radical”, are used interchangeably herein.
  • a heterocyclyl ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.
  • a heterocyclyl group may be mono- or bicyclic.
  • Examples of monocyclic saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, morpholinyl, dihydrofuranyl, dihydropyranyl, dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl, and tetrahydropyrimidinyl.
  • Bi-cyclic heterocyclyl groups include, e.g., unsaturated heterocyclic radicals fused to another unsaturated heterocyclic radical, cycloalkyl, or aromatic or heteroaryl ring, such as for example, benzodioxolyl, dihydrobenzodioxinyl, 6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazolyl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyridinyl, 1,2-dihydroquinolinyl, dihydrobenzofuranyl, tetrahydronaphthyridine, indolinone, dihydropyrrolotriazole, quinolinone, dioxaspirodecane. It will be understood that when specified, optional substituents on a heterocyclyl group may be present on any substitutable position and, include, e.g., the position at which the heterocyclyl is attached.
  • the terms “subject” and “patient” may be used interchangeably, and means a mammal in need of treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, pigs, horses, sheep, goats and the like) and laboratory animals (e.g., rats, mice, guinea pigs and the like).
  • the subject is a human in need of treatment.
  • Stereoisomers are compounds that differ only in their spatial arrangement. Enantiomers are pairs of stereoisomers whose mirror images are not superimposable, most commonly because they contain an asymmetrically substituted carbon atom that acts as a chiral center. “Enantiomer” means one of a pair of molecules that are mirror images of each other and are not superimposable. Diastereomers are stereoisomers that contain two or more asymmetrically substituted carbon atoms. The symbol “*” in a structural formula represents the presence of a chiral carbon center. “R” and “S” represent the configuration of substituents around one or more chiral carbon atoms. Thus, “R*” and “S*” denote the relative configurations of substituents around one or more chiral carbon atoms.
  • a hyphen (“-”) at the beginning or end of a recited group designates the point at which a recited group is attached to a defined group.
  • —SO 2 —(C 1 -C 3 )alkyl-(C 2 -C 6 )cycloalkyl means that the group is attached via the sulfonyl.
  • Racemate or “racemic mixture” means a compound of equimolar quantities of two enantiomers, wherein such mixtures exhibit no optical activity, i.e., they do not rotate the plane of polarized light.
  • “Geometric isomer” means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Atoms (other than H) on each side of a carbon-carbon double bond may be in an E (substituents are on opposite sides of the carbon-carbon double bond) or Z (substituents are oriented on the same side) configuration. “R c ,” “S,” “S*,” “R*,” “E,” “Z,” “cis,” and “trans,” indicate configurations relative to the core molecule.
  • the compounds of the herein may be prepared as individual enantiomers by either enantio-specific synthesis or resolved from an enantiomerically enriched mixture.
  • Conventional resolution techniques include forming the salt of a free base of each isomer of an enantiomeric pair using an optically active acid (followed by fractional crystallization and regeneration of the free base), forming the salt of the acid form of each enantiomer of an enantiomeric pair using an optically active amine (followed by fractional crystallization and regeneration of the free acid), forming an ester or amide of each of the enantiomers of an enantiomeric pair using an optically pure acid, amine or alcohol (followed by chromatographic separation and removal of the chiral auxiliary), or resolving an enantiomeric mixture of either a starting material or a final product using various well known chromatographic methods.
  • the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight pure relative to all of the other stereoisomers. Percent by weight pure relative to all of the other stereoisomers is the ratio of the weight of one stereoisomer over the weight of the other stereoisomers.
  • the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight optically pure. Percent optical purity by weight is the ratio of the weight of the enantiomer over the weight of the enantiomer plus the weight of its optical isomer.
  • stereochemistry of a disclosed compound is named or depicted by structure, and the named or depicted structure encompasses more than one stereoisomer (e.g., as in a diastereomeric pair), it is to be understood that one of the encompassed stereoisomers or any mixture of the encompassed stereoisomers are included.
  • stereoisomeric purity of the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight pure relative to all of the other stereoisomers.
  • the stereoisomeric purity in this case is determined by dividing the total weight in the mixture of the stereoisomers encompassed by the name or structure by the total weight in the mixture of all of the stereoisomers.
  • a disclosed compound is named or depicted by structure without indicating the stereochemistry and e.g., the compound has more than one chiral center (e.g., at least two chiral centers)
  • the name or structure encompasses one stereoisomer free of other stereoisomers, mixtures of stereoisomers, or mixtures of stereoisomers in which one or more stereoisomers is enriched relative to the other stereoisomer(s).
  • the name or structure may encompass one stereoisomer free of other diastereomers, mixtures of stereoisomers, or mixtures of stereoisomers in which one or more diastereomers is enriched relative to the other diastereomer(s).
  • the compounds of the herein may be present in the form of pharmaceutically acceptable salts.
  • the salts of the compounds of the invention refer to non-toxic “pharmaceutically acceptable salts.”
  • Pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts.
  • Pharmaceutically acceptable basic/cationic salts include, the sodium, potassium, calcium, magnesium, diethanolamine, n-methyl-D-glucamine, L-lysine, L-arginine, ammonium, ethanolamine, piperazine and triethanolamine salts.
  • Pharmaceutically acceptable acidic/anionic salts include, e.g., the acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, carbonate, citrate, dihydrochloride, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrobromide, hydrochloride, malate, maleate, malonate, mesylate, nitrate, salicylate, stearate, succinate, sulfate, tartrate, and tosylate.
  • the present disclosure provides a compound of Formula I
  • Cy 2 in Formula I is heteroaryl or heterocyclyl, each of which are optionally substituted with 1 to 3 groups independently selected from R 6 , wherein the remaining variables are as described above for Formula I.
  • Cy 2 in Formula I is bi-cyclic heterocyclyl or bi-cyclic heteroaryl, each of which are optionally substituted with 1 to 3 groups independently selected from R 6 , wherein the remaining variables are as described above for Formula I and the second embodiment.
  • Cy 2 in Formula I is selected from:
  • Cy 2 in Formula I is selected from:
  • Cy 2 in Formula I is a monocyclic heteroaryl optionally substituted with 1 to 3 groups independently selected from R 6 , wherein the remaining variables are as described above for Formula I and the second embodiment.
  • Cy 2 in Formula I is pyridyl or pyrimindinyl, each of which are optionally substituted with 1 to 3 groups independently selected from R 6 , wherein the remaining variables are as described above for Formula I and the second or seventh embodiment.
  • Cy 2 in Formula I is phenyl, optionally substituted with 1 to 3 groups independently selected from R 6 , wherein the remaining variables are as described above for Formula I.
  • L 2 in Formula I is CH 2 or CHMe, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment.
  • the compound of Formula I is of the Formula II:
  • the compound of Formula I is of the Formula III:
  • the compound of Formula I is of the Formula IV:
  • the compound of Formula I is of the Formula V:
  • Cy 1 in Formulae I to V is selected from aryl, monocyclic heteroaryl, and monocyclic heterocyclyl, each of which are optionally substituted with 1 to 3 groups independently selected from R 5 , wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth embodiment.
  • Cy 1 in Formulae I to V is selected from phenyl, pyridyl, and piperidinyl, each of which are optionally substituted with 1 to 3 groups independently selected from R c , wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, or fifteenth embodiment.
  • Cy 1 in Formulae I to V is phenyl or pyridyl optionally substituted with 1 to 3 groups independently selected from R c , wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, or sixteenth embodiment.
  • R 7 in Formulae I to V is hydrogen, OR c , or (C 1 -C 3 )alkyl optionally substituted with OR c or NR d R e ; and R 8 when present is hydrogen, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, or seventeenth embodiment.
  • R 7 in Formulae I to V is hydrogen or (C 1 -C 3 )alkyl optionally substituted with OR c ; and R 8 when present is hydrogen, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, or eighteenth embodiment.
  • R 7 in Formulae I to V is hydrogen or —(C 1 -C 3 )alkyl-OH; and R 8 when present is hydrogen, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, or nineteenth embodiment.
  • R 1 in Formulae I to V is selected from (C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkyl, cyclobutyl, tetrahydrofuranyl, (C 1 -C 4 )alkoxy, —N((C 1 -C 3 )alkyl) 2 , —(C 1 -C 3 )alkyl-O—(C 1 -C 2 )alkyl, —C(O)O(C 1 -C 2 )alkyl, and cyclopropyl, wherein said cyclobutyl and cyclopropyl are each optionally substituted with C( ⁇ O)OMe, —CN, or 1 to 3 halo, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth
  • R 1 in Formulae I to V is selected from (C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, cyclobutyl, and cyclopropyl, wherein said cyclobutyl and cyclopropyl are each optionally substituted with 1 to 3 halo, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, or twenty-first embodiment.
  • R 1 in Formulae I to V is halo(C 1 -C 4 )alkyl, cyclobutyl, or cyclopropyl, wherein said cyclobutyl and cyclopropyl are optionally substituted with 1 to 3 halo, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first or twenty-second embodiment.
  • R 1 in Formulae I to V is CF 3 , CHF 2 , cyclobutyl, or cyclopropyl, wherein said cyclobutyl and cyclopropyl are optionally substituted with 1 to 2 fluoro, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, or twenty-third embodiment.
  • R 1 in Formulae I to V is —C( ⁇ O)OR e , (C 1 -C 4 )alkoxy, halo(C 1 -C 4 )alkoxy, —NR d R e , monocyclic heterocyclyl, or monocyclic cycloalkyl, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, or twenty-fourth embodiment.
  • R 1 in Formulae I to V is cyclobutyl, tetrahydrofuranyl, (C 1 -C 4 )alkoxy, —N((C 1 -C 3 )alkyl) 2 , —C(O)O(C 1 -C 2 )alkyl, or cyclopropyl, wherein said cyclobutyl and cyclopropyl are each optionally substituted with C( ⁇ O)OMe, —CN, or 1 to 3 halo, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, or twenty-fifth embodiment.
  • R 1 in Formulae I to V is selected from (C 1 -C 4 )alkoxy, cyclobutyl, and cyclopropyl, wherein said cyclobutyl and cyclopropyl are each optionally substituted with 1 to 3 halo, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, or twenty-sixth embodiment.
  • R 5 in Formulae I to V is selected from halo, —CN, —OR c , —NR d R e , —NR c S(O) 2 R c , —S(O) 2 NR d R e , —C( ⁇ O)OR c , —C( ⁇ O)NR d R e , —NR c C( ⁇ O)R c , —NR c C( ⁇ O)OR c , —OC( ⁇ S)NR d R e , —C( ⁇ O)R c , —SO 2 R c , and (C 1 -C 4 )alkyl optionally substituted with 1 to 3 halo, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth,
  • R 5 in Formulae I to V is selected from —CN, —S(O) 2 NR d R e and —SO 2 R b , wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, or twenty-eighth embodiment.
  • R 5 in Formulae I to V is selected from —S(O) 2 NR d R e and —SO 2 R b , wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, or twenty-ninth embodiment.
  • R 5 in Formulae I to V is —SO 2 (C 1 -C 3 )alkyl, —SO 2 NH 2 , —SO 2 NH(C 1 -C 3 )alkyl, —SO 2 (C 1 -C 3 )alkyl-OH, —SO 2 (C 1 -C 3 )alkyl-C(O)O(C 1 -C 3 )alkyl, —SO 2 (C 1 -C 3 )alkyl-C(O)NH(C 1 -C 3 )alkyl, —SO 2 (C 1 -C 3 )alkyl-O(C 1 -C 3 )alkyl, and —SO 2 (C 1 -C 3 )alkyl-C(O)NH 2 , wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth
  • R 5 in Formulae I to V is —SO 2 (C 1 -C 3 )alkyl or —SO 2 NH(C 1 -C 3 )alkyl, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, or thirty-first embodiment.
  • R 6 in Formulae I to V is selected from halo, —CN, —OR c , —NR d R e , —NR c S(O) 2 R c , —S(O) 2 NR d R e , —C( ⁇ O)OR c , —OC( ⁇ O)OR c , —OC( ⁇ O)R e , —C( ⁇ O)NR d R e , —NR c C( ⁇ O)R c , —C( ⁇ S)NR d R e , —NR c C( ⁇ S)R c , —NR c C( ⁇ O)OR c , —OC( ⁇ O)NR d R e , —NR c (C ⁇ S)OR c , —OC( ⁇ S)NR d R e , —NR c (C ⁇ S)OR c , —OC( ⁇ S)NR d R e ,
  • R 6 in Formulae I to V is selected from halo, —CN, —OR c , (C 1 -C 4 )alkyl and (C 1 -C 4 )alkyl optionally substituted with 1 to 3 halo, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first, twenty-second, or twenty-third embodiment.
  • R 6 in Formulae I to V is selected from halo, —CN, —OR c , and (C 1 -C 3 )alkyl; and R c is (C 1 -C 3 )alkyl, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first, twenty-second, twenty-third, or twenty-fourth embodiment.
  • the compound of Formula I is of the Formula VI:
  • A is N or CH;
  • R 1 is (C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkyl, or cycloalkyl optionally substituted with 1 to 3 halo;
  • L 2 is CH 2 or CHMe;
  • Cy 2 is bi-cyclic heterocyclyl or bi-cyclic heteroaryl, each of which are optionally substituted with 1 to 3 groups independently selected from halo, (C 1 -C 4 )alkyl, and (C 1 -C 4 )alkoxy, wherein said (C 1 -C 4 )alkyl and (C 1 -C 4 )alkoxy are optionally substituted with 1 to 3 halo;
  • R 7 is hydrogen or —CH 2 OH; and
  • R 9 is —NH(C 1 -C 4 )alkyl, (C 1 -C 4 )alkyl, or (C 1 -C 4 )alkyl substituted with OH.
  • the compound of Formula I is of the Formula VII:
  • the compound of Formula I is of the Formula VIII:
  • Z is a 5- or 6-membered heterocyclyl ring having one or more heteroatoms selected from oxygen or nitrogen; and wherein Z is optionally substituted with (C 1 -C 4 )alkyl or 1 to 3 halo, and wherein the remaining variables are as described above for Formula I and the thirty-sixth or thirty-seventh embodiment.
  • the compound of Formula I is of the Formula IX or X:
  • R 10 and R 11 are each independently hydrogen, (C 1 -C 3 )alkyl, or halo, wherein the remaining variables are as described above for Formula I and the thirty-sixth, thirty-seventh, or thirty-eighth embodiment.
  • the compound of Formula I is of the Formula XI:
  • R 10 and R 11 are each independently hydrogen or halo, wherein the remaining variables are as described above for Formula I and the thirty-sixth, thirty-seventh, thirty-eighth, or thirty-ninth embodiment.
  • R 10 and R 11 in Formulae IX to XI are each halo, wherein the remaining variables are as described above for Formula I and the thirty-sixth, thirty-seventh, thirty-eighth, thirty-ninth, or fortieth embodiment.
  • R 10 and R 11 in Formulae IX to XI are each fluoro, wherein the remaining variables are as described above for Formula I and the thirty-sixth, thirty-seventh, thirty-eighth, thirty-ninth, fortieth, or forty-first embodiment.
  • R 1 in Formulae VI to XI is halo(C 1 -C 4 )alkyl, cyclopropyl, or cyclobutyl, wherein said cyclopropyl and cyclobutyl are each optionally substituted with 1 to 3 halo, wherein the remaining variables are as described above for Formula I and the thirty-sixth, thirty-seventh, thirty-eighth, thirty-ninth, fortieth, forty-first, or forty-second embodiment.
  • R 1 in Formulae VI to XI is CF 3 , CHF 2 , or cyclobutyl, wherein the remaining variables are as described above for Formula I and the thirty-sixth, thirty-seventh, thirty-eighth, thirty-ninth, fortieth, forty-first, forty-second, or forty-third embodiment.
  • R 9 in Formulae VI to XI is (C 1 -C 3 )alkyl, wherein the remaining variables are as described above for Formula I and the thirty-sixth, thirty-seventh, thirty-eighth, thirty-ninth, fortieth, forty-first, forty-second, forty-third, or forty-fourth embodiment.
  • L 2 in Formulae VI to XI is CH 2 , wherein the remaining variables are as described above for Formula I and the thirty-sixth, thirty-seventh, thirty-eighth, thirty-ninth, fortieth, forty-first, forty-second, forty-third, forty-fourth, or forty-fifth embodiment.
  • R 7 in Formulae VI to XI is —CH 2 OH; and A is N, wherein the remaining variables are as described above for Formula I and the thirty-sixth, thirty-seventh, thirty-eighth, thirty-ninth, fortieth, forty-first, forty-second, forty-third, forty-fourth, forty-fifth, or forty-sixth embodiment.
  • the compound of Formula I is of the Formula XII:
  • A is N or CH
  • R 1 is (C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkyl, cyclobutyl optionally substituted with 1 to 3 halo, or cyclopropyl optionally substituted with 1 to 3 halo;
  • L 2 is CH2 or CHMe
  • each R 6 is independently selected from halo, —CN, —OR c , (C 1 -C 4 )alkyl and (C 1 -C 4 )alkyl substituted with halo;
  • n 1 or 2;
  • R 7 is hydrogen or —CH 2 OH
  • R 9 is —NH(C 1 -C 4 )alkyl, (C 1 -C 4 )alkyl, or (C 1 -C 4 )alkyl substituted with OH.
  • the compound of Formula I is selected from any one of the compounds in Table 1 or a pharmaceutically acceptable salt thereof.
  • the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least three X-ray powder diffraction peaks at 2 ⁇ angles selected from 11.20°, 12.60°, 17.86°, 19.04°, 21.12°, and 21.71°.
  • the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least four X-ray powder diffraction peaks at 2 ⁇ angles selected from 11.20°, 12.60°, 17.86°, 19.04°, 21.12°, and 21.71°.
  • the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least five X-ray powder diffraction peaks at 2 ⁇ angles selected from 11.20°, 12.60°, 17.86°, 19.04°, 21.12°, and 21.71°.
  • the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2 ⁇ angles 11.20°, 12.60°, 17.86°, 19.04°, 21.12°, and 21.71°.
  • the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2 ⁇ angles selected from Table 2.
  • the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by an X-ray powder diffraction pattern substantially similar to FIG. 1 .
  • the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least three X-ray powder diffraction peaks at 2 ⁇ angles selected from 11.20°, 12.60°, 17.86°, 19.04°, 21.19°, and 21.71°.
  • the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least four X-ray powder diffraction peaks at 2 ⁇ angles selected from 11.20°, 12.60°, 17.86°, 19.04°, 21.19°, and 21.71°.
  • the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least five X-ray powder diffraction peaks at 2 ⁇ angles selected from 11.20°, 12.60°, 17.86°, 19.04°, 21.19°, and 21.71°.
  • the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2 ⁇ angles 11.200, 12.600, 17.86, 19.04, 21.19, and 21.71.
  • the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2 ⁇ angles selected from Table 2-1.
  • the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is at least 50% pure by weight, at least 75% pure by weight, at least 80% pure by weight, at least 90% pure by weight, at least 95% pure by weight, or at least 98% pure by weight.
  • the crystalline form of the free base of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least three X-ray powder diffraction peaks at 2 ⁇ angles selected from 17.25°, 18.89°, 19.33°, 20.49°, 21.97°, and 23.73°.
  • the crystalline form of the free base of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least four X-ray powder diffraction peaks at 2 ⁇ angles selected from 17.25°, 18.89°, 19.33°, 20.49°, 21.97°, and 23.73°.
  • the crystalline form of the free base of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least five X-ray powder diffraction peaks at 2 ⁇ angles selected from 17.25°, 18.89°, 19.33°, 20.49°, 21.97°, and 23.73°.
  • the crystalline form of the free base of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2 ⁇ angles 17.25°, 18.89°, 19.33°, 20.49°, 21.97°, and 23.73°.
  • the crystalline form of the free base of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 20 angles selected from Table 2a.
  • the crystalline form of the free base of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by an X-ray powder diffraction pattern substantially similar to FIG. 2 .
  • the crystalline form of the free base of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is at least 50% pure by weight, at least 75% pure by weight, at least 80% pure by weight, at least 90% pure by weight, at least 95% pure by weight, or at least 98% pure by weight.
  • crystalline Form I of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least three X-ray powder diffraction peaks at 2 ⁇ angles selected from 15.52°, 17.30°, 19.39°, 21.68°, 23.32°, and 23.82°.
  • crystalline Form I of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least four X-ray powder diffraction peaks at 2 ⁇ angles selected from 15.52°, 17.30°, 19.39°, 21.68°, 23.32°, and 23.82°.
  • crystalline Form I of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least five X-ray powder diffraction peaks at 2 ⁇ angles selected from 15.52°, 17.30°, 19.39°, 21.68°, 23.32°, and 23.82°.
  • crystalline Form I of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2 ⁇ angles 15.52°, 17.30°, 19.39°, 21.68°, 23.32°, and 23.82°.
  • crystalline Form I of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2 ⁇ angles selected from Table 2b.
  • crystalline Form I of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by an X-ray powder diffraction pattern substantially similar to FIG. 3 .
  • crystalline Form I of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is at least 50% pure by weight, at least 75% pure by weight, at least 80% pure by weight, at least 90% pure by weight, at least 95% pure by weight, or at least 98% pure by weight.
  • crystalline Form II of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least three X-ray powder diffraction peaks at 2 ⁇ angles selected from 13.18°, 14.46°, 16.47°, 17.97°, 19.80°, and 26.52°.
  • crystalline Form II of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least four X-ray powder diffraction peaks at 2 ⁇ angles selected from 13.18°, 14.46°, 16.47°, 17.97°, 19.80°, and 26.52°.
  • crystalline Form II of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least five X-ray powder diffraction peaks at 2 ⁇ angles selected from 13.18°, 14.46°, 16.47°, 17.97°, 19.80°, and 26.52°.
  • crystalline Form II of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2 ⁇ angles 13.18°, 14.46°, 16.47°, 17.97°, 19.80°, and 26.52°.
  • crystalline Form II of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2 ⁇ angles selected from Table 2c.
  • crystalline Form II of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by an X-ray powder diffraction pattern substantially similar to FIG. 4 .
  • crystalline Form II of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is at least 50% pure by weight, at least 75% pure by weight, at least 80% pure by weight, at least 90% pure by weight, at least 95% pure by weight, or at least 98% pure by weight.
  • crystalline Form III of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least three X-ray powder diffraction peaks at 2 ⁇ angles selected from 6.62°, 14.48°, 16.53°, 17.96°, 19.89°, and 26.53°.
  • crystalline Form III of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least four X-ray powder diffraction peaks at 2 ⁇ angles selected from 6.62°, 14.48°, 16.53°, 17.96°, 19.89°, and 26.53°.
  • crystalline Form III of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least five X-ray powder diffraction peaks at 2 ⁇ angles selected from 6.62°, 14.48°, 16.53°, 17.96°, 19.89°, and 26.53°.
  • crystalline Form III of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2 ⁇ angles 6.62°, 14.48°, 16.53°, 17.96°, 19.89°, and 26.53°.
  • crystalline Form III of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2 ⁇ angles selected from Table 2d.
  • crystalline Form III of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by an X-ray powder diffraction pattern substantially similar to FIG. 5 .
  • crystalline Form III of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is at least 50% pure by weight, at least 75% pure by weight, at least 80% pure by weight, at least 90% pure by weight, at least 95% pure by weight, or at least 98% pure by weight.
  • the crystalline form of the HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least three X-ray powder diffraction peaks at 2 ⁇ angles selected from 7.67°, 12.60°, 13.35°, 15.39°, 18.86°, and 25.38°.
  • the crystalline form of the HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least four X-ray powder diffraction peaks at 2 ⁇ angles selected from 7.67°, 12.60°, 13.35°, 15.39°, 18.86°, and 25.38°.
  • the crystalline form of the HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least five X-ray powder diffraction peaks at 2 ⁇ angles selected from 7.67°, 12.60°, 13.35°, 15.39°, 18.86°, and 25.38°.
  • the crystalline form of the HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2 ⁇ angles 7.67°, 12.60°, 13.35°, 15.39°, 18.86°, and 25.38°.
  • the crystalline form of the HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 20 angles selected from Table 2e.
  • the crystalline form of the HCl salt (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by an X-ray powder diffraction pattern substantially similar to FIG. 6 .
  • the crystalline form of the HCl salt (R)-1-((2,2-di fluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl) —N-(1-(5-(ethyl sulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is at least 50% pure by weight, at least 75% pure by weight, at least 80% pure by weight, at least 90% pure by weight, at least 95% pure by weight, or at least 98% pure by weight.
  • the crystalline form of(R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least three X-ray powder diffraction peaks at 2 ⁇ angles selected from 12.23°, 14.00°, 15.78°, 16.41°, 17.77°, and 19.70°.
  • the crystalline form of (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least four X-ray powder diffraction peaks at 2 ⁇ angles selected from 12.23°, 14.00°, 15.78°, 16.41°, 17.77°, and 19.70°.
  • the crystalline form of (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least five X-ray powder diffraction peaks at 2 ⁇ angles selected from 12.23°, 14.00°, 15.78°, 16.41°, 17.77°, and 19.70°.
  • the crystalline form of (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2 ⁇ angles 12.23°, 14.00°, 15.78°, 16.41°, 17.77°, and 19.70°.
  • the crystalline form of (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2 ⁇ angles selected from Table 2f.
  • the crystalline form of (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by an X-ray powder diffraction pattern substantially similar to FIG. 7 .
  • the crystalline form of (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is at least 50% pure by weight, at least 75% pure by weight, at least 80% pure by weight, at least 90% pure by weight, at least 95% pure by weight, or at least 98% pure by weight.
  • the present disclosure provides a method of treating a patient (e.g., a human) with a disorder mediated by ROR ⁇ comprising the step of administering to the patient an effective amount of the compound with any compound described herein, or a pharmaceutically acceptable salt or composition thereof.
  • the present disclosure provides a method of treating a subject (e.g., a human) with a disorder mediated by RORY using a composition comprising a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
  • pharmaceutically acceptable carrier refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated.
  • Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this disclosure include, but are not limited to, organic or inorganic carriers, excipients or diluents suitable for pharmaceutical applications.
  • compositions described herein may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • Liquid dosage forms, injectable preparations, solid dispersion forms, and dosage forms for topical or transdermal administration of a compound are included herein.
  • the amount of provided compounds that may be combined with carrier materials to produce a composition in a single dosage form will vary depending upon the patient to be treated and the particular mode of administration.
  • a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, the judgment of the treating physician, and the severity of the particular disease being treated.
  • the amount of a provided compound in the composition will also depend upon the particular compound in the composition.
  • the present disclosure provides a method of treating inflammatory, metabolic and autoimmune diseases or disorders mediated by ROR ⁇ , comprising administering a provided compound or composition. More particularly, the compounds and compositions described herein act as inverse agonists or antagonists of ROR ⁇ .
  • treatment refers to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein.
  • treatment may be administered after one or more symptoms have developed, i.e., therapeutic treatment.
  • treatment may be administered in the absence of symptoms.
  • treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors), i.e., prophylactic treatment. Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.
  • Modulation of ROR ⁇ means that a change or alteration in the activity of ROR ⁇ has occurred from the administration of one or more of the compounds described herein. Modulation may be an upregulation (increase) or a downregulation (decrease) in the magnitude of the activity or function of ROR ⁇ . Exemplary activities and functions include e.g., binding characteristics, enzymatic activity, cell receptor activation, transcriptional activity, and signal transduction.
  • the compounds described herein inhibit ROR ⁇ .
  • the compounds described herein act as agonists, antagonists, or inverse agonists of ROR ⁇ .
  • compounds and compositions described herein are useful for reducing the amount of IL-17 in a subject.
  • methods of reducing the amount of IL-17 in a subject comprising administering an effective amount of a provided compound or composition.
  • ROR ⁇ modulators disclosed in WO 2014/179564, WO 2015/116904, WO 2016/061160, PCT/US2016/045318, PCT/US2016/062422, and U.S. patent publication Nos. US 2016-0122318 and US 2016-0122345 can also be used in such methods.
  • compounds and compositions described herein are useful for inhibiting the synthesis of IL-17 in a subject.
  • methods of inhibiting the synthesis of IL-17 in a subject comprising administering an effective amount of a provided compound or composition.
  • ROR ⁇ modulators disclosed in WO 2014/179564, WO 2015/116904, WO 2016/061160, PCT/US2016/045318, PCT/US2016/062422, and U.S. patent publication Nos. US 2016-0122318 and US 2016-0122345 can also be used in such methods.
  • Diseases and conditions treatable according to the methods herein include, but are not limited to, inflammatory, metabolic and autoimmune diseases or disorders mediated by ROR ⁇ . These diseases and conditions include, for example, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, allergic rhinitis, atopic dermatitis, contact dermatitis, acne, urticaria, hives, angioedema, cystic fibrosis, allograft rejection, multiple sclerosis, Balo's concentric (circular) sclerosis, Balo disease, leukoencephalitis periaxialis concentrica, encephalitis periaxialis concentrica, scleroderma, limited scleroderma, CREST syndrome, arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, reactive arthritis, Reiter's syndrome, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), Hashi
  • an exemplified form of cancer treatable according to the methods herein also includes prostate cancer e.g., (metastatic castration-resistant prostate cancer tumors).
  • an exemplified form of cancer treatable according to the methods herein includes e.g., malignant tumor, angiogenesis glaucoma, infantile hemangioma, multiple myeloma, acute myeloblastic leukemia, chronic sarcoma, chronic myelogenous leukemia, metastasis melanoma, Kaposi's sacroma, vascular proliferation, cachexia, colorectal cancer (e.g., familial colorectal cancer, hereditary nonpolyposis colorectal cancer, and gastrointestinal stromal tumor), lung cancer (e.g., non-small cell lung cancer, small cell lung cancer and malignant mesothelioma), mesothelioma, pancreatic cancer (e.g., pancreatic duct cancer), gastric cancer
  • malignant tumor
  • Diseases and disorders mediated by IL-17 expression also include, e.g., emphysema, lung fibrosis, idiopathic pulmonary fibrosis, retroperitoneal fibrosis, giant cell arteritis, giant cell myocarditis, arteriosclerosis, hepatitis, chronic active hepatitis, alcoholic hepatitis, alcoholic liver fibrosis, alcoholic cirrhosis, viral hepatitis, hepatitis B viral liver disorder, autoimmune hepatitis, cartilage inflammation, bone degradation, juvenile arthritis, pauciarticular juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, spondyloarthritis, juvenile ankylosing spondylitis, juvenile enteropathic arthritis, juvenile reactive arthritis, juvenile Reiter's syndrome, seronegative enthesopathy and arthr
  • diseases or disorders which are implicated by the regulation of the circadian rhythm of individuals and include, e.g., major depression, seasonal affective disorder, post-traumatic stress disorder (PTSD), bipolar disorder, autism, epilepsy, Alzheimer's disease and other central nervous system (CNS) disorders associated with altered sleep and/or circadian rhythms.
  • PTSD post-traumatic stress disorder
  • CNS central nervous system
  • diseases and disorders mediated by IL-17 expression include, e.g., corneal fungal infection; risk of corneal fungal infection; corneal ulcer; corneal ulcer resulting from fungal keratitis; corneal ulcer resulting from fungal infection; corneal fungal infection and related inflammation; keratitis; fungal keratitis; corneal inflammation; corneal disease; ocular disease; fungal-mediated corneal infection, corneal ulcer, corneal inflammation, or ocular ulcer, inflammation or infection; bacterial-mediated corneal infection, corneal ulcer, corneal inflammation, or ocular ulcer, inflammation or infection; microbial disease; bacterial infections; fungal infections; Aspergillus keratitis; Fusarium keratitis; cutaneous T cell lymphoma; lung inflammation; acute kidney ischemia-reperfusion injury; anthrax, including, cutaneous anthrax, inhalation anthrax, gastrointestinal anthrax and injection anthrax
  • Compounds described herein can also be used to treat or reduce the risk of abnormal cortical development or psychiatric disorder, e.g., autism spectrum disorder (ASD), schizophrenia, and/or depression, in a fetus.
  • Compounds described herein can also be used to treat a pregnant female having a hyper-inflammatory condition associated with an infection, such as a viral or bacterial infection, or associated with exposure to an inflammatory or environmental toxin during pregnancy.
  • a fetus is treated in utero in a pregnant female with a compound disclosed herein to decrease the risk of the fetus developing a psychiatric disorder, to reduce inflammation in the pregnant female, to reduce the risk of abnormal cortical development in the fetus, and/or to decrease symptoms of a psychiatric disorder in offspring of a pregnant female.
  • a human patient is treated with a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant, or vehicle, wherein said compound is present in an amount to treat or ameliorate one or more of the diseases and conditions recited above.
  • the diseases and conditions treated or ameliorated by a compound of Formula I include, e.g., asthma, atopic dermatitis, acne, Crohn's disease, regional enteritis, ulcerative colitis, Sjögren's syndrome, uveitis, Behçet's disease, dermatomyositis, multiple sclerosis, ankylosing spondylitis, systemic lupus erythematosus (SLE), scleroderma, psoriasis, psoriatic arthritis (PsA), steroid resistant asthma and rheumatoid arthritis in the patient.
  • SLE systemic lupus erythematosus
  • PsA steroid resistant asthma and rheumatoid arthritis
  • the diseases and conditions treated or ameliorated by a compound of Formula I include e.g., atopic dermatitis, acne, dermatomyositis, scleroderma, psoriasis, psoriatic arthritis (PsA), and rheumatoid arthritis.
  • the present disclosure further relates to a combination therapy for treating or ameliorating a disease or a disorder described herein.
  • the combination therapy comprises administering at least one compound represented by Structural Formula I in combination with one or more agents for treating or ameliorating inflammatory, metabolic and autoimmune diseases or disorders mediated by ROR ⁇ .
  • the combination therapy comprises administering at least one compound represented by Structural Formula I in combination with one or more agents for the treatment of diseases including asthma, chronic obstructive pulmonary disease (COPD), bronchitis, allergic rhinitis, atopic dermatitis, contact dermatitis, acne, cystic fibrosis, allograft rejection, multiple sclerosis, scleroderma, arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), Hashimoto's disease, pancreatitis, autoimmune diabetes, type I diabetes, autoimmune ocular disease, ulcerative colitis, Crohn's disease, regional enteritis, inflammatory bowel disease (IBD), inflammatory bowel syndrome (IBS), Sjögren's syndrome, optic neuritis, obesity, hepatosteatosis, adipose tissue-associated
  • the compounds herein may also be used alone or in combination with immunotherapies for the treatment of a disease or disorder disclosed herein.
  • Combination therapy includes, e.g., co-administration of a compound described herein and one or more other agents, sequential administration of a compound described herein and one or more other agents, administration of a composition containing a compound described herein and one or more other agents, or simultaneous administration of separate compositions containing a compound described herein and one or more other agents.
  • the present disclosure further provides a method of treating a subject, such as a human, suffering from one of the abovementioned disorders or diseases.
  • ROR ⁇ modulators disclosed in WO 2014/179564, WO 2015/116904, WO 2016/061160, PCT/US2016/045318, PCT/US2016/062422, and U.S. patent publication Nos. US 2016-0122318 and US 2016-0122345 can also be used in the methods disclosed herein to treat or ameliorate, in a subject, one or more of the diseases and/or disorders and/or conditions recited herein.
  • a subject is treated with one or more ROR modulators disclosed in WO 2014/179564, WO 2015/116904, WO 2016/061160 PCT/US2016/045318, PCT/US2016/062422, and U.S. patent publication Nos.
  • the one or more ROR ⁇ modulator disclosed in WO 2014/179564, WO 2015/116904, WO 2016/061160 PCT/US2016/045318, PCT/US2016/062422, and U.S. patent publication Nos. US 2016-0122318 and US 2016-0122345 is administered in combination with one or more additional agent for treating the disease or disorder.
  • the present disclosure further relates to the use of provided compounds for the production of pharmaceutical compositions which are employed for the treatment and/or prophylaxis and/or amelioration of the diseases and disorders mentioned herein.
  • Compounds or compositions described herein may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of the diseases and conditions described herein.
  • the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like.
  • Provided compounds are preferably formulated in unit dosage form for ease of administration and uniformity of dosage.
  • the expression “unit dosage form” as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present disclosure will be decided by the attending physician within the scope of sound medical judgment.
  • the specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.
  • compositions of this disclosure can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, creams, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated.
  • provided compounds may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
  • provided compounds are administered topically.
  • compositions which comprise an additional therapeutic agent as described above that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • compositions which comprise an additional therapeutic agent that additional therapeutic agent and the provided compound may act synergistically. Therefore, the amount of additional therapeutic agent in such compositions will be less than that required in a monotherapy utilizing only that therapeutic agent.
  • compositions of this disclosure will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent.
  • the compounds described herein can be readily prepared according to the following reaction schemes and examples, or modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. Many of the reactions can also be carried out under microwave (MW) conditions or using conventional heating or utilizing other technologies such as solid phase reagents/scavengers or flow chemistry. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in the art, but are not mentioned in greater detail. Furthermore, other methods for preparing compounds described herein will be readily apparent to a person of ordinary skill in the art in light of the following reaction schemes and examples.
  • reagents in the reaction schemes are used in equimolar amounts; however, in certain cases it may be desirable to use an excess of one reagent to drive a reaction to completion. This is especially the case when the excess reagent can be readily removed by evaporation or extraction.
  • Bases employed to neutralize HCl in reaction mixtures are generally used in slight to substantial excess (1.05-5 equivalents).
  • a compound of Formula I wherein X ⁇ CONH, is prepared from a benzimidazole carboxylic acid of Formula 100 and an amine of Formula 105, using peptide bond formation reagents such as EDC with HOBt, PyBOP or HATU. Alternatively, the acid chloride of 100 is used.
  • a compound of Formula I wherein X ⁇ NHCO, is prepared from an aminobenzimidazole of Formula 110 and a carboxylic acid of Formula 115, using peptide bond formation reagents such as EDC with HOBt, PyBOP or HATU. Alternatively, the acid chloride of 115 is used.
  • a compound of Formula I is prepared by heating a diamine of Formula 125 with a carboxylic acid of Formula 120.
  • Carboxylic acids of Formula 125 can be purchased or prepared by literature methods.
  • a compound of Formula I is prepared in two steps from a diamine of Formula 125.
  • a carboxylic acid of Formula 120 is reacted with a diamine of Formula 125 using peptide bond formation reagents such as EDC, HOBt or HATU to give a monoamide of Formula 130.
  • the acid chloride of 120 is used.
  • a monoamide of Formula 130 is heated with an acid such as HOAc or TFA to give a compound of Formula I.
  • a diamine of Formula 125 is reacted with an ⁇ , ⁇ -dichloro ester of Formula 135 to give a compound of Formula I in which R 1 is —C( ⁇ O)OR.
  • a diamine of Formula 125 is reacted with a dichloroiminium salt of Formula 140 to give a compound of Formula I, wherein R is NR d R e .
  • a compound of Formula I is prepared by reaction of a benzimidazole of Formula 145 with a compound of Formula 150, wherein R 100 is a leaving group such as iodide, bromide, chloride, methanesulfonate, tosylate or triflate, in the presence of an organic or inorganic base.
  • a compound of Formula I is prepared from another compound of Formula I.
  • Non-limiting examples of this process include: (1)Treatment of a compound of Formula I wherein R 5 or R 6 is OMe with BBr 3 or Me 3 SiI to give a compound of Formula I wherein R 5 or R 6 is OH; (2) Reaction of a compound of Formula I wherein Cy 1 or Cy 2 is azetidinyl, pyrrolidinyl or piperidinyl bearing a free NH with an alkylating agent such as an (C 1 -C 6 )alkyl halide or halo(C 1 -C 6 )alkyl triflate to give a compound of Formula I, wherein R 5 or R 6 is (C 1 -C 6 )alkyl or halo(C 1 -C 6 )alkyl attached to the N of the azetidine, pyrrolidine or piperidine ring; (3) Reaction of a compound of Formula I wherein Cy 1 or
  • benzimidazole carboxylic acids of Formula 100 which are precursors to compounds of Formula I, are prepared in four steps.
  • the nitro group of 165 is reduced using, for example, zinc dust in the presence of NH 4 C 1 , iron powder in HOAc, SnCl 2 , or H 2 in the presence of Pd on C, to give a diaminoester of Formula 170.
  • Diaminoester 170 is converted to benzimidazole ester 175 using procedures described in the third process.
  • the ester in 175 is hydrolyzed using an alkali metal hydroxide to give 100.
  • aminobenzimidazoles of Formula 110 which are precursors to compounds of Formula I, are prepared in four steps.
  • An amine 155 is reacted with a nitrobenzene 180, wherein R 110 is F or C 1 to given a nitroaniline 185.
  • Reduction of 185 using, for example, SnCl 2 gives diamine 190.
  • Diamine 190 is converted to bromobenzimidazole 195 using procedures described in the third process.
  • Bromobenzimidazole 195 is converted to aminobenzimidazole 110 using for example NaN 3 , CuI.
  • diamines of Formula 125 which are precursors to compounds of Formula I, are prepared in three steps.
  • Reaction of 205 with amine of Formula 155 gives nitroanilines of Formula 210 which are reduced using, for example, SnCl 2 to give diamines 125.
  • benzimidazoles of Formula 145 which are precursors of compounds of Formula I, are prepared in three steps.
  • Diaminoester 215 is reacted with carboxylic acids of Formula 120, as described in the third process, to give benzimidazole esters of Formula 220.
  • Treatment of esters 220 with alkali metal hydroxides gives acids of Formula 225 which are reacted with amines of Formula 105 under peptide coupling conditions, mediated by for example HATU, HBTU or EDC, to afford amides of Formula 145.
  • Carboxylic acids AC1-AC6 were purchased:
  • the title compound is prepared from ethyl 2-(4-(ethylthio)phenyl)-2-oxoacetate (Matrix Scientific) following a procedure similar to that described for AC8.
  • This compound is prepared following a procedure analogous to that described for AM5.
  • This compound is prepared following procedures analogous to those described for AM8.1 using methyl iodide in place of EtBr in Step 1 and (S)-2-methylpropane-2-sulfinamide in Step 4.
  • Step 4 (R c ,E)-N-(2-((tert-butyldimethylsilyl)oxy)ethylidene)-2-methylpropane-2-sulfinamide
  • Step 5 (R)—N—((R)-2-((tert-butyldimethylsilyl)oxy)-1-(4-(ethylthio)phenyl)ethyl)-2-methylpropane-2-sulfinamide
  • Step 7 (R)-2-amino-2-(4-(ethylsulfonyl)phenyl)ethanol
  • This compound is prepared following procedures analogous to those described for AM8.1 using (4-bromo-3-fluorophenyl)(ethyl)sulfane in Step 5.
  • This compound is prepared using procedures analogous to those described for AM11.1 using NaSMe in Step 1.
  • This compound is prepared following procedures analogous to those described for AM11.1 using NaSMe in Step 1 and (S,E)-N-(2-((tert-butyldimethylsilyl)oxy)ethylidene)-2-methylpropane-2-sulfinamide in Step 2.
  • Step 2 (R)—N—((R)-2-((tert-butyldimethylsilyl)oxy)-1-(5-(ethylthio)pyridin-2-yl)ethyl)-2-methylpropane-2-sulfinamide
  • Step 4 (R)-2-amino-2-(5-(ethylsulfonyl)pyridin-2-yl)ethanol
  • the racemic was further purified by preparative HPLC (neutral) to give (R)—N—((R)-1-(4-(ethylthio)phenyl)-2-methoxyethyl)-2-methylpropane-2-sulfinamide (18 g, 99% purity, 40%) and (R)—N—((S)-1-(4-(ethylthio)phenyl)-2-methoxyethyl)-2-methylpropane-2-sulfinamide (7.0 g, 99% purity, 10%) as colorless oil.
  • LC-MS Method 2 t R 1.306 min, MS (ESI) m/z 316.2 [M+H] + .
  • Mobile phase A water with 10 mM NH 4 HCO 3
  • Mobile phase B CH 3 CN
  • Flow rate 150 mL/min.
  • Detection UV 220 nm/254 nm
  • a flask was charge with 5-bromo-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole (40 mg, 0.09 mmol), CuI (22 mg, 0.12 mmol), Na 2 CO 3 (15 mg, 0.14 mmol), NaN 3 (15 mg, 0.23 mmol) and DMEDA (17.5 ⁇ L, 0.16 mmol).
  • the flask was sealed with a septum and flushed with N 2 for 5 min. Dry DMSO (1 mL) was introduced using a syringe and the mixture was heated at 110° C. for 1.5 h.
  • benzimidazole carboxylic acid was prepared by procedures analogous to those described above using MeCF 2 CO 2 H and heating to 80° C. in Step 1.
  • benzimidazole carboxylic acids are prepared following procedures analogous to those described in Preparations 35, 36 and 37 using the acid R 1 CO 2 H or the acid chloride R 1 COCl in Step 1.
  • Nozzle Temp 60° C.
  • Mobile phase A water with 0.05% NH 3 H 2 O solution
  • Mobile phase B MeCN Flow rate: 120 mL/min.
  • Mobile phase A water with 0.05% NH 3 H 2 O solution
  • Mobile phase B MeCN Flow rate: 120 mL/min.
  • Seed crystals were obtained by vapor diffusion of ether into a solution of lyophilized I-130.1.HCl salt (3-5 mg) in MeCN (0.25 mL).
  • XRPD analyses were conducted using a Bruker D8 Advance X-Ray diffractometer operating with a Cu radiation source at 40 kV, 40 mA through a Ni filter with a divergence slit of 0.60 mm/2.5°.
  • HATU 10.1 g, 26.7 mmol
  • LC-MS showed that the reaction was completed.
  • the mixture was combined with another 13.2 g batch and washed with water (3 ⁇ 300 mL) and brine (300 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Nozzle Temp 60° C.
  • Mobile phase A water with 10 mM NH 4 HCO 3 solution
  • Mobile phase B MeCN Flow rate: 120 mL/min.
  • Mobile phase A water with 0.05% NH 3 H 2 O solution
  • Mobile phase B MeCN Flow rate: 110 mL/min.
  • Nozzle Temp 60° C.
  • Mobile phase A water (0.05% ammonia hydroxide v/v)-ACN
  • Mobile phase B CH 3 CN
  • Flow rate 150 mL/min.
  • Detection UV 220 nm/254 nm
  • Mobile phase A water (0.05% ammonia hydroxide v/v)-ACN
  • Mobile phase B CH3CN Flow rate: 25 mL/min. Detection: UV 220 nm/254 nm Column: Phenomenex Gemini 150*25 mm*10 um Column temperature: 30° C.
  • Mobile phase A water(0.05% HCl)-ACN
  • Mobile phase B CH 3 CN
  • Flow rate 120 mL/min.
  • Detection UV 220 nm/254 nm
  • the following compound is prepared by a similar procedure, also as a mixture of regioisomers.
  • Mobile phase A water with 0.05% ammonia solution
  • Mobile phase B MeCN Flow rate: 25 mL/min.
  • Methyl (S)-3-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamido)-3-(4-(ethylsulfonyl)phenyl)propanoate is prepared following conditions analogous to those described in Example 2.
  • Mobile phase A water with 10 mM NH 4 HCO 3 solution
  • Mobile phase B CH 3 CN Flow rate: 22 mL/min. Detection: UV 220 nm/254 nm
  • the plate was shaken at 700 rpm for 20 min and incubated for 10 min at rt, after which 40 ⁇ L of poly-Lys YSi SPA beads (PerkinElmer, Cat. #RPNQ0010) were added to achieve 50 pg of the beads per well.
  • the plate was incubated on an orbital shaker for 20 min and then for 10 min without agitation at rt.
  • SPA signal for tritium beta radiation was registered on PerkinElmer Microbeta plate reader. Percent inhibition values were calculated based on the high signal obtained with DMSO control and the low signal observed with 10 ⁇ M standard ROR ⁇ inverse agonist T0901317 (SigmaAldrich, Cat. #T2320). The percent inhibition vs.
  • concentration data were fit into a four-parameter model, and IC50 values were calculated from the fit as the concentrations corresponding to the inflection points on the dose-response curves.
  • Inhibitory constants (Ki) were calculated using the following equation, where [RL] is the concentration in the assay and K D is a dissociation constant of 25-hydroxy [26,27- 3 H]-cholesterol:
  • K i IC 50 ( 1 + [ RL ] K D ) .
  • Jurkat cells (30 million cells) were transfected with 11 pg of EX-T6988-MO2 and 26 pg of the reporter plasmid in OptiMEM® media using Lipofectamine® LTX and PlusTM reagents (Life Technologies, Cat. #15338-100). After 5-6 hrs of incubation at 37° C./5% CO 2 , the cells were collected, resuspended in phenol-red free RPMI media containing 10% (v/v) delipidated FBS (Hyclone, Cat. #SH30855.03) and dispensed into 96-well clear bottom tissue culture plates (CoStar, Cat. #3603), at 80,000 cells per well.
  • OptiMEM® media Lipofectamine® LTX and PlusTM reagents
  • Tested compounds were added to the cells in the same media (final concentration of DMSO was 0.1% (v/v)), and the plates were incubated at 37° C./5% CO 2 for 16-18 hrs. Luciferase activity in the conditioned supernatants was determined with NanoGlo® assay reagents (Promega, Cat. #N1130). Percent inhibition values were calculated based on the fully inhibited and non-inhibited (DMSO) controls, and the values were regressed against concentrations of the tested compounds to derive IC50 values using a four-parameter non-linear fitting model.

Abstract

Provided are novel compounds of Formula I
Figure US20210094940A1-20210401-C00001
pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Description

    RELATED APPLICATIONS
  • This application is a 35 U.S.C. § 371 national stage filing of International Application No. PCT/US2017/015220, filed Jan. 27, 2017, which claims priority to U.S. Provisional Application No. 62/288,487, filed Jan. 29, 2016 and U.S. Provisional Application No. 62/320,893, filed Apr. 11, 2016, the contents of each of which are incorporated herein by reference.
    • TECHNICAL FIELD
  • The present disclosure is directed to novel retinoic acid receptor-related orphan receptor gamma (“RORγ” or “ROR-gamma”) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic, autoimmune and other diseases mediated by RORγ.
    • BACKGROUND
  • Retinoic acid receptor-related orphan receptors (RORs) are a subfamily of transcription factors in the steroid hormone nuclear receptor superfamily (Jetten & Joo (2006) Adv. Dev. Biol. 2006, 16, 313-355). The ROR family consists of ROR alpha (RORα), ROR beta (RORβ) and ROR gamma (RORγ), each encoded by a separate gene (in human: RORA, RORB and RORC, respectively; in mouse: rora, rorb and rorc, respectively). RORs contain four principal domains shared by the majority of nuclear receptors: an N-terminal domain, a highly conserved DNA-binding domain (DBD) consisting of two zinc finger motifs, a hinge domain, and a ligand binding domain (LBD). Each ROR gene generates several isoforms, differing only in their N-terminal domains. RORγ has two isoforms: RORγ1 and RORγ2 (also known as RORγt). RORγ refers to RORγ1 and/or RORγt. RORγ1 is expressed in a variety of tissues including thymus, muscle, kidney and liver, but RORγt is exclusively expressed in the cells of the immune system, has a critical role in thymopoiesis and the development of several secondary lymphoid tissues, and is a key regulator of Thl7 cell differentiation (Jetten, 2009, Nucl. Recept. Signal., 7:e003, doi:10.1621/nrs.07003, Epub 2009 Apr. 3).
  • Thl7 cells are a subset of T helper cells which preferentially produce the pro-inflammatory cytokines IL-17A, IL-17F, IL-21 and IL-22. Thl7 cells and their effector molecules, such as IL-17, IL-21, IL-22, GM-CSF and CCL20, are associated with the pathogenesis of several autoimmune and inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis, inflammatory bowel disease, allergy and asthma (Maddur et al., 2012, Am. J. Pathol., 181:8-18). Recent findings support a role for IL17 and Thl7 cells in the pathogenesis of acne (Thiboutot et al., 2014, J. Invest. Dermatol., 134(2):307-10, doi: 10.1038/jid.2013.400; Agaketal., 2014, J. Invest. Dermatol., 134(2):366-73, doi: 10.1038/jid.2013.334, Epub 2013 Aug. 7). Thl7 cells are also potent inducers of inflammation associated with endometriosis, a chronic inflammatory disease (Hirata et al., 2010, Endocrinol., 151:5468-5476; Hirata et al., 2011, Fertil Steril., July; 96(1):113-7, doi: 10.1016/j.fertnstert.2011.04.060, Epub 2011 May 20). Additionally, Thl7 cells have a key role in the mouse autoimmune models of experimental autoimmune encephalomyelitis (EAE), collagen-induced arthritis (CIA) and adjuvant-induced arthritis (AIA) (Bedoya et al., 2013, Clin. Dev. Immunol., 2013:986789. Epub 2013 Dec. 26. Thl7 cells are activated during inflammatory and autoimmune disease processes and are responsible for recruiting other inflammatory cell types, particularly neutrophils, to mediate pathology in target tissues (Miossec & Kolls, 2012, Nature Rev., 11:763-776; Korn et al., 2009, Annu. Rev. Immunol., 27:485-517). Aberrant Thl7 cell function has been implicated in a variety of autoimmune diseases, including multiple sclerosis and rheumatoid arthritis. Autoimmune disease is believed to arise from the disruption of the equilibrium between effector and regulatory T cells (Solt et al., 2012, ACS Chem. Biol., 7:1515-1519, Epub 2012 Jul. 9). The importance of RORγt to Thl7 cell differentiation and the pathogenic role of Thl7 cells is evidenced by the fact that RORγt-deficient mice have very few Thl7 cells and have a reduction in severity of EAE (Ivanov et al., 2006, Cell, 126:1121-1133).
  • Recently, IL-17-producing neutrophils have been identified as promoting inflammation leading to both microbial clearance and IL-17-associated tissue damage in the cornea and other tissues (Taylor et al., 2014, J. Immunol, 192:3319-3327; Taylor et al., 2014, Nat. Immunol., 15:143-151), supporting a role for compounds that inhibit RORγ activity in the treatment of corneal ulcers and other diseases and disorders associated with IL-17 expressing neutrophils.
  • Circadian rhythms are daily cycles of behavioral and physiological changes that are regulated by endogenous circadian clocks. A number of studies have established links between nuclear receptor (including RORγ) function and expression, the circadian regulatory circuitry, and the regulation of various physiological processes (Jetten (2009) op. cit.).
  • Obstructive sleep apnea syndrome (OSAS) is a chronic inflammatory disease regulated by T lymphocytes. OSAS patients have a significant increase in peripheral Thl7 cell frequency, IL-17 and RORγt levels (Ye et al., 2012, Mediators Inflamm., 815308, doi: 10.1155/2012/815308, Epub 2012 Dec. 31).
  • A number of studies have provided evidence of a role of RORs in cancer. Mice deficient in the expression of RORγ exhibit a high incidence of thymic lymphomas that metastasize frequently to liver and spleen. High expression of Thl7-associated genes (including RORγ) and high levels of Thl7 cells in the tumor microenvironment has been shown to correlate with a poor prognosis in various cancers, including lung, gastric, breast and colon cancer (Tosolini et al., 2011, Cancer Res., 71:1263-1271, doi: 10.1158/0008-5472.CAN-10-2907, Epub 2011 Feb. 8; Su et al., 2014, Immunol. Res., 58:118-124, doi: 10.1007/s12026-013-8483-y, Epub 2014 Jan. 9; Carmi et al., 2011, J. Immunol., 186:3462-3471, doi: 10.4049/jimmunol.1002901, Epub 2011 Feb. 7; Chen et al., 2013, Histopathology, 63:225-233, doi: 10.1111/his.12156, Epub 2013 Jun. 6). Recent evidence also shows that RORγ is overexpressed and amplified in metastatic castration-resistant prostate cancer tumors, and that RORγ antagonists suppressed tumor growth in multiple androgen receptor-expressing xenograft prostate cancer models. See e.g., Nature Medicine, Mar. 28, 2016, advance online publication, doi: 10.1038/nm.4070.
  • RORγ has also been identified to have a regulatory role in lipid/glucose homeostasis, and has been implicated in metabolic syndrome, obesity (Meissburger et al., 2011, EMBO Mol. Med., 3:637-651), hepatosteatosis, insulin resistance and diabetes.
  • Further support for the role of RORγ in the pathogenesis of inflammatory, metabolic, circadian effect, cancer, and autoimmune diseases and disorders can be found in the following references: Chang et al., 2012, J. Exp. Pharmacol., 4:141-148; Jetten et al., 2013, Frontiers Endocrinol., 4:1-8; Huh & Littman, 2012, Eur. J. Immunol., 42:2232-2237; Martinez et al., 2008, Ann. N.Y. Acad. Sci., 1143:188-211; Pantelyushin et al., 2012, J. Clin. Invest., 122:2252-2256; Jetten & Ueda, 2002, Cell Death Differen., 9:1167-1171; Solt et al., 2010, Curr. Opin. Lipidol., 21:204-211.
  • In light of the role that RORγ plays in disease pathogenesis, inhibition of RORγ activity and Thl7 cell differentiation and activity, including IL17 production, is of significant therapeutic benefit. Compounds that inhibit RORγ activity and hence have utility in the treatment of e.g., inflammatory, autoimmune, metabolic, circadian effect, cancer, and other diseases mediated by RORγ are described in WO 2014/179564 and WO 2015/116904. However, there is a continuing need for the development of new and improved drugs that modulate RORγ and are useful in the treatment of disease.
    • SUMMARY
  • It has now been found that compounds described herein, and pharmaceutically acceptable compositions thereof, are effective modulators of RORY (see e.g., Table 3. Such compounds include those of Formula I:
  • Figure US20210094940A1-20210401-C00002
  • or a pharmaceutically acceptable salt thereof, wherein each of Cy1, Cy2, L2, R1, R7, R8, and X are as defined and described herein.
  • The provided compounds can be used alone (i.e., as a monotherapy) or in combination with one or more other therapeutic agent effective for treating any of the indications described herein.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 depicts a powder X-ray diffractogram of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-130.1) HCl salt.
  • FIG. 2 depicts a powder X-ray diffractogram of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-130.1) free base.
  • FIG. 3 depicts a powder X-ray diffractogram of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-11.1) Form I.
  • FIG. 4 depicts a powder X-ray diffractogram of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-11.1) Form II.
  • FIG. 5 depicts a powder X-ray diffractogram of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-11.1) Form III.
  • FIG. 6 depicts a powder X-ray diffractogram of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide (I-131.1) HCl salt.
  • FIG. 7 depicts a powder X-ray diffractogram of (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide (I-132.1) free base.
    •  DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS 1. General Description of Compounds
  • In certain embodiments, the present disclosure provides a compound of Formula I
  • Figure US20210094940A1-20210401-C00003
  • or a pharmaceutically acceptable salt thereof, wherein
  • X is —C(O)NH— or —NHC(O)—;
  • R1 is (C1-C4)alkyl —C(═O)ORc, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, —NRdRe, monocyclic heterocyclyl, or monocyclic cycloalkyl, wherein said (C1-C4)alkyl is optionally substituted with —ORc, said monocyclic heterocyclyl is optionally substituted with (C1-C4)alkyl or ═O, and said monocyclic cycloalkyl is optionally substituted with —C(═O)ORc, —CN, or one or more halo;
  • L2 is CH2, CHMe, or cyclopropyl;
  • Cy1 is aryl, heteroaryl, heterocyclyl, or cycloalkyl, each of which is optionally substituted with 1 to 3 groups independently selected from R5;
  • Cy2 is aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with 1 to 3 groups independently selected from R6;
  • R5 and R6 are each independently selected from halo, —CN, —ORc, —NRdRe, —S(O)kRb, —NRcS(O)2Rc, —S(O)2NRdRe, —C(═O)ORc, —OC(═O)ORc, —OC(═O)Rc, —OC(═S)ORc, —C(═S)ORc, —OC(═S)Rc, —C(═O)NRdRe, —NRcC(═O)Rc, —C(═S)NRdRe, —NRcC(═S)Rc, —NRcC(═O)ORc, —OC(═O)NRdRe, —NR(C═S)ORc, —OC(═S)NRdRe, —NRcC(═O)NRdRe, —NR(C═S)NRdRe, —C(═S)Rc, —C(═O)Re, oxo, (C1-C6)alkyl, cycloalkyl, —(CH2)1-4-cycloalkyl, heterocyclyl, —(CH2)1-4-heterocyclyl, aryl, —NHC(═O)-heterocyclyl, —NHC(═O)-cycloalkyl, —(CH2)1-4-aryl, heteroaryl and —(CH2)1-4-heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl portion present in each of said (C1-C6)alkyl, cycloalkyl, —(CH2)1-4-cycloalkyl, heterocyclyl, —(CH2)1-4-heterocyclyl, aryl, —(CH2)1-4-aryl, heteroaryl and —(CH2)1-4-heteroaryl substituent for R5 and R6 are further optionally substituted with one or more halo, ORc, —NO2, —CN, —NRcC(═O)Rc, —NRdRe, —S(O)kRb, —C(═O)ORc, —C(═O)NRdRe, —C(═O)Rc, (C1-C3)alkyl, halo(C1-C3)alkyl, (C1-C3)alkoxy(C1-C3)alkyl, (C1-C3)alkoxy, or halo(C1-C3)alkoxy;
  • R7 and R8 are each independently hydrogen, ORc, —C(═O)ORc, monocyclic heterocyclyl, halophenyl, or (C1-C3)alkyl, wherein the (C1-C3)alkyl is optionally substituted with ORc, —NRdRe, —O(C1-C3)alkyl-C(═O)ORc, —C(═O)ORc, —C(═O)NRdRe, or halophenyl;
  • k is 0, 1 or 2;
  • each Rb is independently selected from hydrogen and (C1-C3)alkyl optionally substituted with OH, —O(C1-C3)alkyl, —C(O)O(C1-C3)alkyl, —C(O)NH2, —C(O)NH(C1-C3)alkyl, or —C(O)N((C1-C3)alkyl)2;
  • each Rc is independently selected from hydrogen and (C1-C3)alkyl optionally substituted with one or more halo; and
  • each Rd and Re is independently selected from hydrogen and (C1-C3)alkyl.
    • 2. Compounds and Definitions
  • The terms “halo” and “halogen” as used herein refer to an atom selected from fluorine (fluoro, —F), chlorine (chloro, —Cl), bromine (bromo, —Br), and iodine (iodo, —I).
  • The term “alkyl”, used alone or as a part of a larger moiety such as e.g., “haloalkyl”, means a saturated monovalent straight or branched hydrocarbon radical having, unless otherwise specified, 1-10 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl and the like. “Monovalent” means attached to the rest of the molecule at one point.
  • The term “haloalkyl” or “halocycloalkyl” include mono, poly, and perhaloalkyl groups where the halogens are independently selected from fluorine, chlorine, and bromine.
  • The term “cycloalkyl” refers to a cyclic hydrocarbon having from, unless otherwise specified, 3 to 10 carbon ring atoms. Monocyclic cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, and cyclooctyl. It will be understood that when specified, optional substituents on a cycloalkyl or cycloaliphatic group may be present on any substitutable position and, include, e.g., the position at which the cycloalkyl or cycloaliphatic group is attached.
  • The term “aryl” used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to an aromatic carbocyclic ring system having, unless otherwise specified, a total of 6 to 10 ring members. The term “aryl” may be used interchangeably with the term “aryl ring”, “aryl group”, “aryl moiety,” or “aryl radical”. In certain embodiments, “aryl” refers to an aromatic ring system which includes, but is not limited to, phenyl (abbreviated as “Ph”), naphthyl and the like. It will be understood that when specified, optional substituents on an aryl group may be present on any substitutable position and, include, e.g., the position at which the aryl is attached.
  • The term “heteroaryl” used alone or as part of a larger moiety as in “heteroarylalkyl”, “heteroarylalkoxy”, or “heteroarylaminoalkyl”, refers to a 5- to 12-membered aromatic radical containing 1-4 heteroatoms selected from N, O, and S. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring”, “heteroaryl group”, or “heteroaromatic”. A heteroaryl group may be mono- or bi-cyclic. Monocyclic heteroaryl includes, for example, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl,
  • Bi-cyclic heteroaryls include groups in which a monocyclic heteroaryl ring is fused to one or more aryl or heteroaryl rings. Nonlimiting examples include indolyl, benzooxazolyl, benzooxodiazolyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, quinazolinyl, quinoxalinyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyrrolopyridinyl, thienopyridinyl, thienopyrimidinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. It will be understood that when specified, optional substituents on a heteroaryl group may be present on any substitutable position and, include, e.g., the position at which the heteroaryl is attached.
  • The term “heterocyclyl” means a 4- to 12-membered saturated or partially unsaturated heterocyclic ring containing 1 to 4 heteroatoms independently selected from N, O, and S. The terms “heterocycle”, “heterocyclyl”, “heterocyclyl ring”, “heterocyclic group”, “heterocyclic moiety”, and “heterocyclic radical”, are used interchangeably herein. A heterocyclyl ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. A heterocyclyl group may be mono- or bicyclic. Examples of monocyclic saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, morpholinyl, dihydrofuranyl, dihydropyranyl, dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl, and tetrahydropyrimidinyl. Bi-cyclic heterocyclyl groups include, e.g., unsaturated heterocyclic radicals fused to another unsaturated heterocyclic radical, cycloalkyl, or aromatic or heteroaryl ring, such as for example, benzodioxolyl, dihydrobenzodioxinyl, 6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazolyl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyridinyl, 1,2-dihydroquinolinyl, dihydrobenzofuranyl, tetrahydronaphthyridine, indolinone, dihydropyrrolotriazole, quinolinone, dioxaspirodecane. It will be understood that when specified, optional substituents on a heterocyclyl group may be present on any substitutable position and, include, e.g., the position at which the heterocyclyl is attached.
  • As used herein the terms “subject” and “patient” may be used interchangeably, and means a mammal in need of treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, pigs, horses, sheep, goats and the like) and laboratory animals (e.g., rats, mice, guinea pigs and the like). Typically, the subject is a human in need of treatment.
  • Certain of the disclosed compounds may exist in various stereoisomeric forms. Stereoisomers are compounds that differ only in their spatial arrangement. Enantiomers are pairs of stereoisomers whose mirror images are not superimposable, most commonly because they contain an asymmetrically substituted carbon atom that acts as a chiral center. “Enantiomer” means one of a pair of molecules that are mirror images of each other and are not superimposable. Diastereomers are stereoisomers that contain two or more asymmetrically substituted carbon atoms. The symbol “*” in a structural formula represents the presence of a chiral carbon center. “R” and “S” represent the configuration of substituents around one or more chiral carbon atoms. Thus, “R*” and “S*” denote the relative configurations of substituents around one or more chiral carbon atoms.
  • As used herein, a hyphen (“-”) at the beginning or end of a recited group designates the point at which a recited group is attached to a defined group. For example, —SO2—(C1-C3)alkyl-(C2-C6)cycloalkyl means that the group is attached via the sulfonyl.
  • “Racemate” or “racemic mixture” means a compound of equimolar quantities of two enantiomers, wherein such mixtures exhibit no optical activity, i.e., they do not rotate the plane of polarized light.
  • “Geometric isomer” means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Atoms (other than H) on each side of a carbon-carbon double bond may be in an E (substituents are on opposite sides of the carbon-carbon double bond) or Z (substituents are oriented on the same side) configuration. “Rc,” “S,” “S*,” “R*,” “E,” “Z,” “cis,” and “trans,” indicate configurations relative to the core molecule. When a disclosed compound is named or depicted by structure without indicating a particular geometric isomer form, it is to be understood that the name or structure encompasses one geometric isomer free of other geometric isomers, mixtures of geometric isomers, or mixtures of all geometric isomers.
  • The compounds of the herein may be prepared as individual enantiomers by either enantio-specific synthesis or resolved from an enantiomerically enriched mixture. Conventional resolution techniques include forming the salt of a free base of each isomer of an enantiomeric pair using an optically active acid (followed by fractional crystallization and regeneration of the free base), forming the salt of the acid form of each enantiomer of an enantiomeric pair using an optically active amine (followed by fractional crystallization and regeneration of the free acid), forming an ester or amide of each of the enantiomers of an enantiomeric pair using an optically pure acid, amine or alcohol (followed by chromatographic separation and removal of the chiral auxiliary), or resolving an enantiomeric mixture of either a starting material or a final product using various well known chromatographic methods.
  • When the stereochemistry of a disclosed compound is named or depicted by structure, the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight pure relative to all of the other stereoisomers. Percent by weight pure relative to all of the other stereoisomers is the ratio of the weight of one stereoisomer over the weight of the other stereoisomers. When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight optically pure. Percent optical purity by weight is the ratio of the weight of the enantiomer over the weight of the enantiomer plus the weight of its optical isomer.
  • When the stereochemistry of a disclosed compound is named or depicted by structure, and the named or depicted structure encompasses more than one stereoisomer (e.g., as in a diastereomeric pair), it is to be understood that one of the encompassed stereoisomers or any mixture of the encompassed stereoisomers are included. It is to be further understood that the stereoisomeric purity of the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight pure relative to all of the other stereoisomers. The stereoisomeric purity in this case is determined by dividing the total weight in the mixture of the stereoisomers encompassed by the name or structure by the total weight in the mixture of all of the stereoisomers.
  • When a disclosed compound is named or depicted by structure without indicating the stereochemistry, and the compound has one chiral center, it is to be understood that the name or structure encompasses one enantiomer of compound free from the corresponding optical isomer, a racemic mixture of the compound, or mixtures enriched in one enantiomer relative to its corresponding optical isomer.
  • When a disclosed compound is named or depicted by structure without indicating the stereochemistry and e.g., the compound has more than one chiral center (e.g., at least two chiral centers), it is to be understood that the name or structure encompasses one stereoisomer free of other stereoisomers, mixtures of stereoisomers, or mixtures of stereoisomers in which one or more stereoisomers is enriched relative to the other stereoisomer(s). For example, the name or structure may encompass one stereoisomer free of other diastereomers, mixtures of stereoisomers, or mixtures of stereoisomers in which one or more diastereomers is enriched relative to the other diastereomer(s).
  • The compounds of the herein may be present in the form of pharmaceutically acceptable salts. For use in medicines, the salts of the compounds of the invention refer to non-toxic “pharmaceutically acceptable salts.” Pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts.
  • Pharmaceutically acceptable basic/cationic salts include, the sodium, potassium, calcium, magnesium, diethanolamine, n-methyl-D-glucamine, L-lysine, L-arginine, ammonium, ethanolamine, piperazine and triethanolamine salts.
  • Pharmaceutically acceptable acidic/anionic salts include, e.g., the acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, carbonate, citrate, dihydrochloride, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrobromide, hydrochloride, malate, maleate, malonate, mesylate, nitrate, salicylate, stearate, succinate, sulfate, tartrate, and tosylate.
    • 3. Description of Exemplary Compounds
  • In a first embodiment, the present disclosure provides a compound of Formula I
  • Figure US20210094940A1-20210401-C00004
  • or a pharmaceutically acceptable salt thereof, wherein the variables are as described above.
  • In a second embodiment, Cy2 in Formula I is heteroaryl or heterocyclyl, each of which are optionally substituted with 1 to 3 groups independently selected from R6, wherein the remaining variables are as described above for Formula I.
  • In a third embodiment, Cy2 in Formula I is bi-cyclic heterocyclyl or bi-cyclic heteroaryl, each of which are optionally substituted with 1 to 3 groups independently selected from R6, wherein the remaining variables are as described above for Formula I and the second embodiment.
  • In a fourth embodiment, Cy2 in Formula I is selected from:
  • Figure US20210094940A1-20210401-C00005
  • and y each of which are optionally substituted with 1 to 3 groups independently selected from R6, wherein the remaining variables are as described above for Formula I and the second or third embodiment.
  • In a fifth embodiment, Cy2 in Formula I is selected from:
  • Figure US20210094940A1-20210401-C00006
  • each of which are optionally substituted with 1 to 3 groups independently selected from R6, wherein the remaining variables are as described above for Formula I and the second, third, or fourth embodiment.
  • In a sixth embodiment, Cy2 in Formula I is
  • Figure US20210094940A1-20210401-C00007
  • optionally substituted with 1 to 3 groups independently selected from R6, wherein the remaining variables are as described above for Formula I and the second, third, fourth, or fifth embodiment.
  • In a seventh embodiment, Cy2 in Formula I is a monocyclic heteroaryl optionally substituted with 1 to 3 groups independently selected from R6, wherein the remaining variables are as described above for Formula I and the second embodiment.
  • In an eighth embodiment, Cy2 in Formula I is pyridyl or pyrimindinyl, each of which are optionally substituted with 1 to 3 groups independently selected from R6, wherein the remaining variables are as described above for Formula I and the second or seventh embodiment.
  • In a ninth embodiment, Cy2 in Formula I is phenyl, optionally substituted with 1 to 3 groups independently selected from R6, wherein the remaining variables are as described above for Formula I.
  • In a tenth embodiment, L2 in Formula I is CH2 or CHMe, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment.
  • In an eleventh embodiment, the compound of Formula I is of the Formula II:
  • Figure US20210094940A1-20210401-C00008
  • or a pharmaceutically acceptable salt thereof, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, or tenth embodiment.
  • In a twelfth embodiment, the compound of Formula I is of the Formula III:
  • Figure US20210094940A1-20210401-C00009
  • or a pharmaceutically acceptable salt thereof, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, or eleventh embodiment.
  • In a thirteenth embodiment, the compound of Formula I is of the Formula IV:
  • Figure US20210094940A1-20210401-C00010
  • or a pharmaceutically acceptable salt thereof, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, or twelfth embodiment.
  • In a fourteenth embodiment, the compound of Formula I is of the Formula V:
  • Figure US20210094940A1-20210401-C00011
  • or a pharmaceutically acceptable salt thereof, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, or thirteenth embodiment.
  • In a fifteenth embodiment, Cy1 in Formulae I to V is selected from aryl, monocyclic heteroaryl, and monocyclic heterocyclyl, each of which are optionally substituted with 1 to 3 groups independently selected from R5, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth embodiment.
  • In a sixteenth embodiment, Cy1 in Formulae I to V is selected from phenyl, pyridyl, and piperidinyl, each of which are optionally substituted with 1 to 3 groups independently selected from Rc, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, or fifteenth embodiment.
  • In a seventeenth embodiment, Cy1 in Formulae I to V is phenyl or pyridyl optionally substituted with 1 to 3 groups independently selected from Rc, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, or sixteenth embodiment.
  • In an eighteenth embodiment, R7 in Formulae I to V is hydrogen, ORc, or (C1-C3)alkyl optionally substituted with ORc or NRdRe; and R8 when present is hydrogen, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, or seventeenth embodiment.
  • In a nineteenth embodiment, R7 in Formulae I to V is hydrogen or (C1-C3)alkyl optionally substituted with ORc; and R8 when present is hydrogen, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, or eighteenth embodiment.
  • In a twentieth embodiment, R7 in Formulae I to V is hydrogen or —(C1-C3)alkyl-OH; and R8 when present is hydrogen, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, or nineteenth embodiment.
  • In a twenty-first embodiment, R1 in Formulae I to V is selected from (C1-C4)alkyl, halo(C1-C4)alkyl, cyclobutyl, tetrahydrofuranyl, (C1-C4)alkoxy, —N((C1-C3)alkyl)2, —(C1-C3)alkyl-O—(C1-C2)alkyl, —C(O)O(C1-C2)alkyl, and cyclopropyl, wherein said cyclobutyl and cyclopropyl are each optionally substituted with C(═O)OMe, —CN, or 1 to 3 halo, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, or twentieth embodiment.
  • In a twenty-second embodiment, R1 in Formulae I to V is selected from (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, cyclobutyl, and cyclopropyl, wherein said cyclobutyl and cyclopropyl are each optionally substituted with 1 to 3 halo, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, or twenty-first embodiment.
  • In a twenty-third embodiment, R1 in Formulae I to V is halo(C1-C4)alkyl, cyclobutyl, or cyclopropyl, wherein said cyclobutyl and cyclopropyl are optionally substituted with 1 to 3 halo, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first or twenty-second embodiment.
  • In a twenty-fourth embodiment, R1 in Formulae I to V is CF3, CHF2, cyclobutyl, or cyclopropyl, wherein said cyclobutyl and cyclopropyl are optionally substituted with 1 to 2 fluoro, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, or twenty-third embodiment.
  • In a twenty-fifth embodiment, R1 in Formulae I to V is —C(═O)ORe, (C1-C4)alkoxy, halo(C1-C4)alkoxy, —NRdRe, monocyclic heterocyclyl, or monocyclic cycloalkyl, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, or twenty-fourth embodiment.
  • In a twenty-sixth embodiment, R1 in Formulae I to V is cyclobutyl, tetrahydrofuranyl, (C1-C4)alkoxy, —N((C1-C3)alkyl)2, —C(O)O(C1-C2)alkyl, or cyclopropyl, wherein said cyclobutyl and cyclopropyl are each optionally substituted with C(═O)OMe, —CN, or 1 to 3 halo, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, or twenty-fifth embodiment.
  • In a twenty-seventh embodiment, R1 in Formulae I to V is selected from (C1-C4)alkoxy, cyclobutyl, and cyclopropyl, wherein said cyclobutyl and cyclopropyl are each optionally substituted with 1 to 3 halo, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, or twenty-sixth embodiment.
  • In a twenty-eighth embodiment, R5 in Formulae I to V is selected from halo, —CN, —ORc, —NRdRe, —NRcS(O)2Rc, —S(O)2NRdRe, —C(═O)ORc, —C(═O)NRdRe, —NRcC(═O)Rc, —NRcC(═O)ORc, —OC(═S)NRdRe, —C(═O)Rc, —SO2Rc, and (C1-C4)alkyl optionally substituted with 1 to 3 halo, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, or twenty-seventh embodiment.
  • In a twenty-ninth embodiment, R5 in Formulae I to V is selected from —CN, —S(O)2NRdRe and —SO2Rb, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, or twenty-eighth embodiment.
  • In a thirtieth embodiment, R5 in Formulae I to V is selected from —S(O)2NRdRe and —SO2Rb, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, or twenty-ninth embodiment.
  • In a thirty-first embodiment, R5 in Formulae I to V is —SO2(C1-C3)alkyl, —SO2NH2, —SO2NH(C1-C3)alkyl, —SO2(C1-C3)alkyl-OH, —SO2(C1-C3)alkyl-C(O)O(C1-C3)alkyl, —SO2(C1-C3)alkyl-C(O)NH(C1-C3)alkyl, —SO2(C1-C3)alkyl-O(C1-C3)alkyl, and —SO2(C1-C3)alkyl-C(O)NH2, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, or thirtieth embodiment.
  • In a thirty-second embodiment, R5 in Formulae I to V is —SO2(C1-C3)alkyl or —SO2NH(C1-C3)alkyl, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, or thirty-first embodiment.
  • In a thirty-third embodiment, R6 in Formulae I to V is selected from halo, —CN, —ORc, —NRdRe, —NRcS(O)2Rc, —S(O)2NRdRe, —C(═O)ORc, —OC(═O)ORc, —OC(═O)Re, —C(═O)NRdRe, —NRcC(═O)Rc, —C(═S)NRdRe, —NRcC(═S)Rc, —NRcC(═O)ORc, —OC(═O)NRdRe, —NRc(C═S)ORc, —OC(═S)NRdRe, —NRcC(═O)NRdRe, —NR(C═S)NRdRe, —C(═S)Rc, —C(═O)Re, —SO2Rb, and (C1-C4)alkyl optionally substituted with 1 to 3 halo, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first, or twenty-second embodiment.
  • In a thirty-fourth embodiment, R6 in Formulae I to V is selected from halo, —CN, —ORc, (C1-C4)alkyl and (C1-C4)alkyl optionally substituted with 1 to 3 halo, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first, twenty-second, or twenty-third embodiment.
  • In a thirty-fifth embodiment, R6 in Formulae I to V is selected from halo, —CN, —ORc, and (C1-C3)alkyl; and Rc is (C1-C3)alkyl, wherein the remaining variables are as described above for Formula I and the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first, twenty-second, twenty-third, or twenty-fourth embodiment.
  • In a thirty-sixth embodiment, the compound of Formula I is of the Formula VI:
  • Figure US20210094940A1-20210401-C00012
  • or a pharmaceutically acceptable salt thereof, wherein A is N or CH; R1 is (C1-C4)alkyl, halo(C1-C4)alkyl, or cycloalkyl optionally substituted with 1 to 3 halo; L2 is CH2 or CHMe; Cy2 is bi-cyclic heterocyclyl or bi-cyclic heteroaryl, each of which are optionally substituted with 1 to 3 groups independently selected from halo, (C1-C4)alkyl, and (C1-C4)alkoxy, wherein said (C1-C4)alkyl and (C1-C4)alkoxy are optionally substituted with 1 to 3 halo; R7 is hydrogen or —CH2OH; and R9 is —NH(C1-C4)alkyl, (C1-C4)alkyl, or (C1-C4)alkyl substituted with OH.
  • In a thirty-seventh embodiment, the compound of Formula I is of the Formula VII:
  • Figure US20210094940A1-20210401-C00013
  • or a pharmaceutically acceptable salt thereof, wherein the remaining variables are as described above for Formula I and the thirty-sixth embodiment.
  • In a thirty-eighth embodiment, the compound of Formula I is of the Formula VIII:
  • Figure US20210094940A1-20210401-C00014
  • or a pharmaceutically acceptable salt thereof, wherein Z is a 5- or 6-membered heterocyclyl ring having one or more heteroatoms selected from oxygen or nitrogen; and wherein Z is optionally substituted with (C1-C4)alkyl or 1 to 3 halo, and wherein the remaining variables are as described above for Formula I and the thirty-sixth or thirty-seventh embodiment.
  • In a thirty-ninth embodiment, the compound of Formula I is of the Formula IX or X:
  • Figure US20210094940A1-20210401-C00015
  • or a pharmaceutically acceptable salt thereof, wherein R10 and R11 are each independently hydrogen, (C1-C3)alkyl, or halo, wherein the remaining variables are as described above for Formula I and the thirty-sixth, thirty-seventh, or thirty-eighth embodiment.
  • In a fortieth embodiment, the compound of Formula I is of the Formula XI:
  • Figure US20210094940A1-20210401-C00016
  • or a pharmaceutically acceptable salt thereof, wherein R10 and R11 are each independently hydrogen or halo, wherein the remaining variables are as described above for Formula I and the thirty-sixth, thirty-seventh, thirty-eighth, or thirty-ninth embodiment.
  • In a forty-first embodiment, R10 and R11 in Formulae IX to XI are each halo, wherein the remaining variables are as described above for Formula I and the thirty-sixth, thirty-seventh, thirty-eighth, thirty-ninth, or fortieth embodiment.
  • In a forty-second embodiment, R10 and R11 in Formulae IX to XI are each fluoro, wherein the remaining variables are as described above for Formula I and the thirty-sixth, thirty-seventh, thirty-eighth, thirty-ninth, fortieth, or forty-first embodiment.
  • In a forty-third embodiment, R1 in Formulae VI to XI is halo(C1-C4)alkyl, cyclopropyl, or cyclobutyl, wherein said cyclopropyl and cyclobutyl are each optionally substituted with 1 to 3 halo, wherein the remaining variables are as described above for Formula I and the thirty-sixth, thirty-seventh, thirty-eighth, thirty-ninth, fortieth, forty-first, or forty-second embodiment.
  • In a forty-fourth embodiment, R1 in Formulae VI to XI is CF3, CHF2, or cyclobutyl, wherein the remaining variables are as described above for Formula I and the thirty-sixth, thirty-seventh, thirty-eighth, thirty-ninth, fortieth, forty-first, forty-second, or forty-third embodiment.
  • In a forty-fifth embodiment, R9 in Formulae VI to XI is (C1-C3)alkyl, wherein the remaining variables are as described above for Formula I and the thirty-sixth, thirty-seventh, thirty-eighth, thirty-ninth, fortieth, forty-first, forty-second, forty-third, or forty-fourth embodiment.
  • In a forty-sixth embodiment, L2 in Formulae VI to XI is CH2, wherein the remaining variables are as described above for Formula I and the thirty-sixth, thirty-seventh, thirty-eighth, thirty-ninth, fortieth, forty-first, forty-second, forty-third, forty-fourth, or forty-fifth embodiment.
  • In a forty-sixth embodiment, R7 in Formulae VI to XI is —CH2OH; and A is N, wherein the remaining variables are as described above for Formula I and the thirty-sixth, thirty-seventh, thirty-eighth, thirty-ninth, fortieth, forty-first, forty-second, forty-third, forty-fourth, forty-fifth, or forty-sixth embodiment.
  • In a forty-seventh embodiment, the compound of Formula I is of the Formula XII:
  • Figure US20210094940A1-20210401-C00017
  • or a pharmaceutically acceptable salt thereof, wherein
  • A is N or CH;
  • R1 is (C1-C4)alkyl, halo(C1-C4)alkyl, cyclobutyl optionally substituted with 1 to 3 halo, or cyclopropyl optionally substituted with 1 to 3 halo;
  • L2 is CH2 or CHMe;
  • each R6 is independently selected from halo, —CN, —ORc, (C1-C4)alkyl and (C1-C4)alkyl substituted with halo;
  • m is 1 or 2;
  • R7 is hydrogen or —CH2OH; and
  • R9 is —NH(C1-C4)alkyl, (C1-C4)alkyl, or (C1-C4)alkyl substituted with OH.
  • In a forty-eighth embodiment, the compound of Formula I is selected from any one of the compounds in Table 1 or a pharmaceutically acceptable salt thereof.
  • TABLE 1
    Cpd No Name
    I-1 N-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-2-(4-
    (ethylsulfonyl)phenyl)acetamide
    I-2 N-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-2-(4-
    (methylsulfonyl)phenyl)acetamide
    I-3 N-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-2-(4-((2-
    hydroxyethyl)sulfonyl)phenyl)acetamide
    I-4 N-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-2-(4-((2-
    methoxyethyl)sulfonyl)phenyl)acetamide
    I-5 N-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-2-(4-(N-
    methylsulfamoyl)phenyl)acetamide
    I-6 2-(4-cyanophenyl)-N-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-
    yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)acetamide
    I-7 ethyl 2-(4-(2-((1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazol-5-yl)amino)-2-
    oxoethyl)phenyl)acetate
    I-8 2-(4-(2-((1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazol-5-yl)amino)-2-
    oxoethyl)phenyl)acetic acid
    I-9 N-(2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-
    1H-benzo[d]imidazol-5-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide
    I-10 N-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-2-(1-
    (methylsulfonyl)piperidin-4-yl)acetamide
    I-11.1 (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-
    (ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-11.2 (S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-
    (ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-12 (R)-2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-
    (1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-13 (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-
    (1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-14 (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(1,1-
    difluoroethyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-15 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((R)-1-(4-
    (ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-((R)-tetrahydrofuran-2-yl)-
    1H-benzo[d]imidazole-5-carboxamide
    I-16 (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-ethyl-N-(1-(4-
    (ethylsulfonyl)phenyl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-17 (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (difluoromethyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-18 (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-
    (ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(1-fluorocyclopropyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-19 (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-
    (ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(1-fluorocyclobutyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-20.1 (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(2-hydroxy-1-
    (4-(methylsulfonyl)phenyl)ethyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-20.2 (S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(2-hydroxy-1-
    (4-(methylsulfonyl)phenyl)ethyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-21 (R)-2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-
    (2-hydroxy-1-(4-(methylsulfonyl)phenyl)ethyl)-1H-benzo[d]imidazole-
    5-carboxamide
    I-22 (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-
    (2-hydroxy-1-(4-(methylsulfonyl)phenyl)ethyl)-1H-benzo[d]imidazole-
    5-carboxamide
    I-23.1 (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (difluoromethyl)-N-(2-hydroxy-1-(4-(methylsulfonyl)phenyl)ethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-23.2 (S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (difluoromethyl)-N-(2-hydroxy-1-(4-(methylsulfonyl)phenyl)ethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-24 (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(1-
    fluorocyclopropyl)-N-(2-hydroxy-1-(4-(methylsulfonyl)phenyl)ethyl)-
    1H-benzo[d]imidazole-5-carboxamide
    I-25 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    (ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-26 2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    (ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-27 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    (ethylsulfonyl)benzyl)-2-(1-fluorocyclopropyl)-1H-benzo[d]imidazole-
    5-carboxamide
    I-28 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    (ethylsulfonyl)benzyl)-2-(methoxymethyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-29 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-ethyl-N-(4-
    (ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-30 2-(tert-butyl)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    (ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-31 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    (ethylsulfonyl)benzyl)-2-isopropyl-1H-benzo[d]imidazole-5-
    carboxamide
    I-32 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    (ethylsulfonyl)benzyl)-2-methyl-1H-benzo[d]imidazole-5-carboxamide
    I-33 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    (ethylsulfonyl)benzyl)-2-isobutyl-1H-benzo[d]imidazole-5-carboxamide
    I-34 2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    (methylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-35 2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    (N-methylsulfamoyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-36 2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    (ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-37 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-
    (4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-38 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(1,1-difluoroethyl)-
    N-(4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-39.1a (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    (ethylsulfonyl)benzyl)-2-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazole-
    5-carboxamide
    I-39.2b (S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    (ethylsulfonyl)benzyl)-2-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazole-
    5-carboxamide
    I-40 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(1-
    fluorocyclopropyl)-N-(4-(methylsulfonyl)benzyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-41 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(1-
    fluorocyclopropyl)-N-(4-((2-hydroxyethyl)sulfonyl)benzyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-42 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(1-
    fluorocyclopropyl)-N-(4-(N-methylsulfamoyl)benzyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-43 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    (ethylsulfonyl)benzyl)-2-(1-fluorocyclobutyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-44 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-
    (4-((2-hydroxyethyl)sulfonyl)benzyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-45 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-((2-
    hydroxyethyl)sulfonyl)benzyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-46 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(N-
    methylsulfamoyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-47 2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    ((2-hydroxyethyl)sulfonyl)benzyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-48 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    (methylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-49.1 and (S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    I-49.2c (ethylsulfonyl)benzyl)-2-(1-methoxyethyl)-1H-benzo[d]imidazole-5-
    carboxamide and (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-
    N-(4-(ethylsulfonyl)benzyl)-2-(1-methoxyethyl)-1H-benzo[d]imidazole-
    5-carboxamide
    I-50 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-
    (4-(methylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-51 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    sulfamoylbenzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-52 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    (propylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-53 methyl 2-((4-((1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-
    carboxamido)methyl)phenyl)sulfonyl)acetate
    I-54 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    (ethylsulfonyl)benzyl)-2-(2-methoxypropan-2-yl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-55 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-
    (ethylsulfonyl)benzyl)-2-methoxy-1H-benzo[d]imidazole-5-
    carboxamide
    I-56 2-((1S,2R)-2-cyanocyclopropyl)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-
    yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-57 2-((1R,2R)-2-cyanocyclopropyl)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-
    yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-58 methyl(1R,2R)-2-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-5-
    ((4-(ethylsulfonyl)benzyl)carbamoyl)-1H-benzo[d]imidazol-2-
    yl)cyclopropane-1-carboxylate
    I-59 (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-
    (ethylsulfonyl)phenyl)-2-methoxyethyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-60 (R)-2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-
    (1-(4-(ethylsulfonyl)phenyl)-2-methoxyethyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-61 (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-
    (ethylsulfonyl)phenyl)-2-methoxyethyl)-2-(1-fluorocyclopropyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-62 (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-
    (ethylsulfonyl)pyridin-2-yl)-2-methoxyethyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-63 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((5-
    (ethylsulfonyl)pyridin-2-yl)methyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-64 2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((5-
    (ethylsulfonyl)pyridin-2-yl)methyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-65 2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((5-
    (ethylsulfonyl)pyridin-2-yl)methyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-66 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(1,1-difluoroethyl)-
    N-((5-(ethylsulfonyl)pyridin-2-yl)methyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-67 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((5-
    (ethylsulfonyl)pyridin-2-yl)methyl)-2-(1-fluorocyclopropyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-68 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(1-
    fluorocyclopropyl)-N-((5-(methylsulfonyl)pyridin-2-yl)methyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-69 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((5-
    (ethylsulfonyl)pyridin-2-yl)methyl)-2-(1-fluorocyclobutyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-70 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((5-
    (methylsulfonyl)pyridin-2-yl)methyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-71 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((1-
    (methylsulfonyl)piperidin-4-yl)methyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-72 2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((1-
    (methylsulfonyl)piperidin-4-yl)methyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-73 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(1-
    fluorocyclopropyl)-N-((1-(methylsulfonyl)piperidin-4-yl)methyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-74 methyl 2-((4-((1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-
    carboxamido)methyl)piperidin-1-yl)sulfonyl)acetate
    I-75 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((1-((2-
    (methylamino)-2-oxoethyl)sulfonyl)piperidin-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-76 methyl 2-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamido)-2-(1-
    (methylsulfonyl)piperidin-4-yl)acetate
    I-77 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((1-(N-
    methylsulfamoyl)piperidin-4-yl)methyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-78 N-((1-((2-amino-2-oxoethyl)sulfonyl)piperidin-4-yl)methyl)-1-((2,2-
    difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-79 2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((1-
    ((2-(methylamino)-2-oxoethyl)sulfonyl)piperidin-4-yl)methyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-80 (R)-1-((2,3-dihydrobenzofuran-7-yl)methyl)-N-(1-(4-
    (ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-81 (R)-1-(benzo[d][1,3]dioxol-4-ylmethyl)-N-(1-(4-(ethylsulfonyl)phenyl)-
    2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-82 1-(3,5-dimethoxybenzyl)-N-(4-(ethylsulfonyl)benzyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-83 1-(3-cyano-4-methoxybenzyl)-N-(4-(ethylsulfonyl)benzyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-84 N-(4-(ethylsulfonyl)benzyl)-1-(4-(trifluoromethoxy)benzyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-85 1-(4-cyanobenzyl)-N-(4-(ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-86 1-((6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl)methyl)-N-(4-
    (ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-87 N-(4-(ethylsulfonyl)benzyl)-1-((2-methyl-5,6,7,8-
    tetrahydroimidazo[1,2-a]pyridin-8-yl)methyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-88 N-(4-(ethylsulfonyl)benzyl)-1-(3-methoxybenzyl)-2-(trifluoromethyl)-
    1H-benzo[d]imidazole-5-carboxamide
    I-89 N-(4-(ethylsulfonyl)benzyl)-1-((2-methoxypyridin-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-90 1-(3-cyanobenzyl)-N-(4-(ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-91 N-(4-(ethylsulfonyl)benzyl)-1-((2-oxo-1,2-dihydroquinolin-4-
    yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-92 1-(1-(3-cyanophenyl)cyclopropyl)-N-(4-(ethylsulfonyl)benzyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-93.1 (S)-1-(1-(3-cyanophenyl)ethyl)-N-(4-(ethylsulfonyl)benzyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-93.2 (R)-1-(1-(3-cyanophenyl)ethyl)-N-(4-(ethylsulfonyl)benzyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-94 1-(5-cyano-2-fluorobenzyl)-N-(4-(ethylsulfonyl)benzyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-95 1-(benzofuran-4-ylmethyl)-N-(4-(ethylsulfonyl)benzyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-96 1-((2,3-dihydrobenzofuran-7-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-97 1-((1H-indazol-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-98 1-(benzo[d][1,3]dioxol-4-ylmethyl)-N-(4-(ethylsulfonyl)benzyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-99 methyl 3-((5-((4-(ethylsulfonyl)benzyl)carbamoyl)-2-(trifluoromethyl)-
    1H-benzo[d]imidazol-1-yl)methyl)benzoate
    I-100 1-((1H-pyrrolo[2,3-c]pyridin-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-
    2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-101 (R)-2-cyclopropyl-1-((2,2-dimethyl-2,3-dihydrobenzofuran-7-
    yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-102 (R)-2-cyclopropyl-1-((2,3-dihydrobenzofuran-7-yl)methyl)-N-(1-(4-
    (ethylsulfonyl)phenyl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-103 2-cyclopropyl-1-(3,5-dimethoxybenzyl)-N-(4-(ethylsulfonyl)benzyl)-
    1H-benzo[d]imidazole-5-carboxamide
    I-104 2-cyclopropyl-N-(4-(ethylsulfonyl)benzyl)-1-(4-
    (trifluoromethoxy)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-105 2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)methyl)-N-(4-
    (ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-106 2-cyclopropyl-N-(4-(ethylsulfonyl)benzyl)-1-(2-
    (trifluoromethoxy)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-107 tert-butyl (R)-3-((2-cyclopropyl-5-((4-
    (ethylsulfonyl)benzyl)carbamoyl)-1H-benzo[d]imidazol-1-
    yl)methyl)pyrrolidine-1-carboxylate
    I-108 tert-butyl (R)-2-((2-cyclopropyl-5-((4-
    (ethylsulfonyl)benzyl)carbamoyl)-1H-benzo[d]imidazol-1-
    yl)methyl)pyrrolidine-1-carboxylate
    I-109 2-cyclopropyl-N-(4-(ethylsulfonyl)benzyl)-1-(3-
    (trifluoromethoxy)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-110 2-cyclopropyl-N-(4-(ethylsulfonyl)benzyl)-1-(2-methoxy-3-
    (trifluoromethyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-111 2-cyclopropyl-N-(4-(ethylsulfonyl)benzyl)-1-((1-(2,2,2-trifluoroethyl)-
    1H-pyrazol-4-yl)methyl)-1H-benzo[d]imidazole-5-carboxamide
    I-112 1-(3-cyanobenzyl)-2-cyclopropyl-N-(4-(ethylsulfonyl)benzyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-113 2-cyclopropyl-1-(3-(difluoromethoxy)benzyl)-N-(4-
    (ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-114 2-cyclopropyl-N-(4-(ethylsulfonyl)benzyl)-1-((1-(2,2,2-trifluoroethyl)-
    1H-pyrazol-3-yl)methyl)-1H-benzo[d]imidazole-5-carboxamide
    I-115 2-cyclopropyl-N-(4-(ethylsulfonyl)benzyl)-1-(3-methoxy-5-
    (trifluoromethoxy)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-116 (S)-2-cyclopropyl-1-(1-(2,2-difluorobenzo[d][1,3]dioxol-4-yl)ethyl)-N-
    (4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-117 2-cyclopropyl-N-(4-(ethylsulfonyl)benzyl)-1-((6-oxo-1-(2,2,2-
    trifluoroethyl)-1,6-dihydropyridin-3-yl)methyl)-1H-benzo[d]imidazole-
    5-carboxamide
    I-118 2-cyclopropyl-1-((2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)methyl)-N-
    (4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-119 2-cyclopropyl-1-(2,3-dimethoxybenzyl)-N-(4-(ethylsulfonyl)benzyl)-
    1H-benzo[d]imidazole-5-carboxamide
    I-120 2-(4-((1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-
    carboxamido)methyl)cyclohexyl)acetic acid
    I-121 N-((1H-benzo[d][1,2,3]triazol-6-yl)methyl)-1-((2,2-
    difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-122 (R)-N-(1-(4-cyanophenyl)-2-hydroxyethyl)-1-((2,2-
    difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-123 (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-
    (ethylsulfonyl)-2-fluorophenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-
    1H-benzo[d]imidazole-5-carboxamide
    I-124 1-(3,5-dimethoxybenzyl)-N-(4-((2-hydroxyethyl)sulfonyl)benzyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-125.1 (S)-1-(1-(2,2-difluorobenzo[d][1,3]dioxol-4-yl)ethyl)-2-ethyl-N-(4-
    (ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-125.2 (R)-1-(1-(2,2-difluorobenzo[d][1,3]dioxol-4-yl)ethyl)-2-ethyl-N-(4-
    (ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-126 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(ethylsulfonyl)-
    2-hydroxybenzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-127 methyl 2-((4-((1-((1H-indazol-4-yl)methyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamido)methyl)piperidin-1-
    yl)sulfonyl)acetate
    I-128 1-(3,5-dimethoxybenzyl)-N-((5-(ethylsulfonyl)pyridin-2-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-129 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((4-oxo-1,4-
    dihydroquinolin-7-yl)methyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-130.1 (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-
    (ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-130.2 (S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-
    (ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-131.1 (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-
    1H-benzo[d]imidazole-5-carboxamide
    I-131.2 (S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-
    1H-benzo[d]imidazole-5-carboxamide
    I-132.1 (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-
    (1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-132.2 (S)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-
    (1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-133.1 (R)-2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-
    (1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-133.2 (S)-2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-
    (1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-134.1 (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-
    (ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(1-fluorocyclopropyl)-
    1H-benzo[d]imidazole-5-carboxamide
    I-134.2 (S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-
    (ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(1-fluorocyclopropyl)-
    1H-benzo[d]imidazole-5-carboxamide
    I-135 (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(2-hydroxy-1-
    (5-(methylsulfonyl)pyridin-2-yl)ethyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-136 N-(4-(ethylsulfonyl)benzyl)-1-(2-fluoro-3-methoxybenzyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-137 N-(4-(ethylsulfonyl)benzyl)-1-((1-methyl-1H-indazol-7-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-138 N-(4-(ethylsulfonyl)benzyl)-1-((4-methyl-6-(trifluoromethyl)pyrimidin-
    2-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-139 N-(4-(ethylsulfonyl)benzyl)-1-((2-methyl-2H-indazol-7-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-140 1-((1,2-dimethyl-1H-benzo[d]imidazol-7-yl)methyl)-N-(4-
    (ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-141 N-(4-(ethylsulfonyl)benzyl)-1-((1-methyl-1H-indazol-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-142 1-((1H-indazol-7-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-143 N-(4-(ethylsulfonyl)benzyl)-1-((2-methyl-2H-indazol-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-144 N-(4-(ethylsulfonyl)benzyl)-1-((6-oxo-1-(2,2,2-trifluoroethyl)-1,6-
    dihydropyridin-2-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-
    5-carboxamide
    I-145 tert-butyl 4-((5-((4-(ethylsulfonyl)benzyl)carbamoyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazol-1-yl)methyl)piperidine-1-
    carboxylate
    I-146 N-(4-(ethylsulfonyl)benzyl)-1-((1-methyl-2-oxo-1,2-dihydropyridin-3-
    yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-147 1-(benzo[d]oxazol-4-ylmethyl)-N-(4-(ethylsulfonyl)benzyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-148 2-cyclopropyl-1-((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)methyl)-N-(4-
    (ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-149 (R)-2-cyclopropyl-1-(1-(2,2-difluorobenzo[d][1,3]dioxol-4-yl)ethyl)-N-
    (4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-150 1-benzyl-N-(4-(ethylsulfonyl)benzyl)-2-methyl-1H-benzo[d]imidazole-
    5-carboxamide
    I-151 1-(benzo[c][1,2,5]oxadiazol-4-ylmethyl)-N-(4-(ethylsulfonyl)benzyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-152 1-(benzo[d]oxazol-7-ylmethyl)-N-(4-(ethylsulfonyl)benzyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-153 2-cyclopropyl-N-(4-(ethylsulfonyl)benzyl)-1-(3-hydroxy-5-
    (trifluoromethoxy)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-154 2-cyclopropyl-1-(2,3-dihydroxybenzyl)-N-(4-(ethylsulfonyl)benzyl)-
    1H-benzo[d]imidazole-5-carboxamide
    I-155 N-(4-(ethylsulfonyl)benzyl)-1-((1-(2,2,2-trifluoroethyl)piperidin-4-
    yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-156 (S)-2-cyclopropyl-N-(4-(ethylsulfonyl)benzyl)-1-((1-(2,2,2-
    trifluoroethyl)pyrrolidin-3-yl)methyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-157 (R)-2-cyclopropyl-N-(4-(ethylsulfonyl)benzyl)-1-((1-(2,2,2-
    trifluoroethyl)pyrrolidin-2-yl)methyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-158 N-(4-(ethylsulfonyl)benzyl)-1-((1-(5-fluoropyrimidin-2-yl)piperidin-4-
    yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-159 (R)-2-cyclopropyl-N-(4-(ethylsulfonyl)benzyl)-1-((1-(5-
    fluoropyrimidin-2-yl)pyrrolidin-3-yl)methyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-160 (R)-2-cyclopropyl-N-(4-(ethylsulfonyl)benzyl)-1-((1-(5-
    fluoropyrimidin-2-yl)pyrrolidin-2-yl)methyl)-1H-benzo[d]imidazole-5-
    carboxamide
    I-161 2-((1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamido)methyl)-5-
    (ethylsulfonyl)pyridine 1-oxide
    I-162 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(dimethylamino)-N-
    (4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide
    I-163 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((1-((2-
    hydroxyethyl)sulfonyl)piperidin-4-yl)methyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-164.1 and (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(2-hydroxy-1-
    I-164.2c (1-(methylsulfonyl)piperidin-4-yl)ethyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide and (S)-1-((2,2-
    difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(2-hydroxy-1-(1-
    (methylsulfonyl)piperidin-4-yl)ethyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-165 (S)-3-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamido)-3-(4-
    (ethylsulfonyl)phenyl)propanoic acid
    I-166 (R)-2-(2-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamido)-2-(4-
    (ethylsulfonyl)phenyl)ethoxy)acetic acid
    I-167 (S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-
    (ethylsulfonyl)phenyl)-3-(methylamino)-3-oxopropyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-168 (S)-N-(3-amino-1-(4-(ethylsulfonyl)phenyl)-3-oxopropyl)-1-((2,2-
    difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-169 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-((2-
    (methylamino)-2-oxoethyl)sulfonyl)benzyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-170 N-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-2-(4-
    (ethylsulfonyl)phenyl)-2-hydroxyacetamide
    I-170.1 and (S)-N-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    I-170.2c (trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-2-(4-
    (ethylsulfonyl)phenyl)-2-hydroxyacetamide and
    (R)-N-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-2-(4-
    (ethylsulfonyl)phenyl)-2-hydroxyacetamide
    I-171 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((4-methyl-1-
    (methylsulfonyl)-1,4-diazepan-5-yl)methyl)-2-(trifluoromethyl)-1H-
    benzo[d]imidazole-5-carboxamide
    I-172 1-((2,3-dihydrobenzofuran-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-
    (trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
    I-173 methyl 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-5-((4-
    (ethylsulfonyl)benzyl)carbamoyl)-1H-benzo[d]imidazole-2-carboxylate
    I-174 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(2-(4-
    (ethylsulfonyl)phenyl)-1,3-dihydroxypropan-2-yl)-2-(trifluoromethyl)-
    1H-benzo[d]imidazole-5-carboxamide
    aThe compound was prepared from (R)-tetrahydrofuran-2-carboxylic acid but the integrity of the stereocenter in the product was not established.
    bThe compound was prepared from (S)-tetrahydrofuran-2-carboxylic acid but the integrity of the stereocenter in the product was not established.
    cThe isomers were separated by chromatography on a chiral column. The stereochemical configuration of the isomers was not determined.
  • Further provided is a crystalline hydrochloride salt form of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (1-130.1). See Example 3 below.
  • In one aspect, the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least three X-ray powder diffraction peaks at 2θ angles selected from 11.20°, 12.60°, 17.86°, 19.04°, 21.12°, and 21.71°. Alternatively, the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least four X-ray powder diffraction peaks at 2θ angles selected from 11.20°, 12.60°, 17.86°, 19.04°, 21.12°, and 21.71°. In another alternative, the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least five X-ray powder diffraction peaks at 2θ angles selected from 11.20°, 12.60°, 17.86°, 19.04°, 21.12°, and 21.71°. In yet another alternative, the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2θ angles 11.20°, 12.60°, 17.86°, 19.04°, 21.12°, and 21.71°. In yet another embodiment, the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2θ angles selected from Table 2. In yet another embodiment, the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by an X-ray powder diffraction pattern substantially similar to FIG. 1.
  • TABLE 2
    2-Theta d Value Intensity Rel. Intensity (%)
    7.31 12.08 235 12
    7.75 11.4 433 22.1
    8.95 9.87 386 19.7
    10.86 8.14 304 15.5
    11.2 7.879 1960 100
    12.1 7.31 947 48.3
    12.60 7.02 1590 81.2
    13.43 6.63 576 29.4
    14.79 5.98 634 32.4
    15.42 5.74 964 49.2
    17.39 5.10 349 17.8
    17.90 4.96 1201 61.3
    18.4 4.82 414 21.1
    19.04 4.66 1887 96.3
    19.44 4.56 959 48.9
    20.27 4.38 282 14.4
    20.60 4.31 532 27.1
    21.19 4.19 1018 51.9
    21.71 4.09 1456 74.3
    22.79 3.90 693 35.4
    23.14 3.84 529 27.0
    23.90 3.72 725 37.0
    24.86 3.58 614 31.3
    25.11 3.54 511 26.1
    25.67 3.47 511 26.1
    26.46 3.37 307 15.6
    26.71 3.33 464 23.7
    27.59 3.23 270 13.8
    28.26 3.16 604 30.8
    29.55 3.02 398 20.3
    30.86 2.90 285 14.5
    31.34 2.85 49 2.5
    32.90 2.72 182 9.3
    33.62 2.66 138 7.0
    33.68 2.67 137 7.0
    33.83 2.65 138 7.0
    33.81 2.65 119 6.0
    34.84 2.57 57 2.9
    38.75 2.32 118 6.0
  • In one aspect, the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least three X-ray powder diffraction peaks at 2θ angles selected from 11.20°, 12.60°, 17.86°, 19.04°, 21.19°, and 21.71°. Alternatively, the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least four X-ray powder diffraction peaks at 2θ angles selected from 11.20°, 12.60°, 17.86°, 19.04°, 21.19°, and 21.71°. In another alternative, the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least five X-ray powder diffraction peaks at 2θ angles selected from 11.20°, 12.60°, 17.86°, 19.04°, 21.19°, and 21.71°. In yet another alternative, the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2θ angles 11.200, 12.600, 17.86, 19.04, 21.19, and 21.71. In yet another embodiment, the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2θ angles selected from Table 2-1.
  • TABLE 2-1
    2-Theta d Value Intensity Rel. Intensity (%)
    7.31 12.08 235 12.0
    7.75 11.40 433 22.1
    8.95 9.87 386 19.7
    10.86 8.14 304 15.5
    11.20 7.89 1960 100
    12.10 7.31 947 48.3
    12.60 7.02 1590 81.2
    13.34 6.63 576 29.4
    14.79 5.98 634 32.4
    15.42 5.74 964 49.2
    17.39 5.10 349 17.8
    17.86 4.96 1201 61.3
    18.40 4.82 414 21.1
    19.04 4.66 1887 96.3
    19.44 4.56 959 48.9
    20.27 4.38 282 14.4
    20.60 4.31 532 27.1
    21.19 4.19 1018 51.9
    21.71 4.09 1456 74.3
    22.79 3.90 693 35.4
    23.14 3.84 529 27.0
    23.90 3.72 725 37.0
    24.86 3.58 614 31.3
    25.11 3.54 511 26.1
    25.67 3.47 511 26.1
    26.46 3.37 307 15.6
    26.71 3.33 464 23.7
    27.59 3.23 270 13.8
    28.26 3.16 604 30.8
    29.55 3.02 398 20.3
    30.86 2.90 285 14.5
    31.34 2.85 49 2.5
    32.90 2.72 182 9.3
    33.62 2.66 138 7.0
    33.68 2.66 137 7.0
    33.83 2.65 138 7.0
    33.81 2.65 119 6.0
    34.84 2.57 57 2.9
    38.75 2.32 118 6.0
  • In one aspect, the crystalline HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is at least 50% pure by weight, at least 75% pure by weight, at least 80% pure by weight, at least 90% pure by weight, at least 95% pure by weight, or at least 98% pure by weight.
  • Further provided is a crystalline form of the free base of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-130.1). See Example 3 below.
  • In one aspect, the crystalline form of the free base of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least three X-ray powder diffraction peaks at 2θ angles selected from 17.25°, 18.89°, 19.33°, 20.49°, 21.97°, and 23.73°. Alternatively, the crystalline form of the free base of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least four X-ray powder diffraction peaks at 2θ angles selected from 17.25°, 18.89°, 19.33°, 20.49°, 21.97°, and 23.73°. In another alternative, the crystalline form of the free base of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least five X-ray powder diffraction peaks at 2θ angles selected from 17.25°, 18.89°, 19.33°, 20.49°, 21.97°, and 23.73°. In yet another alternative, the crystalline form of the free base of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2θ angles 17.25°, 18.89°, 19.33°, 20.49°, 21.97°, and 23.73°. In yet another embodiment, the crystalline form of the free base of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 20 angles selected from Table 2a. In yet another embodiment, the crystalline form of the free base of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by an X-ray powder diffraction pattern substantially similar to FIG. 2.
  • TABLE 2a
    2-Theta d Value Intensity Rel. Intensity (%)
    7.55 11.70 197 4.1
    8.56 10.33 408 8.4
    10.81 8.18 1733 35.7
    13.78 6.42 599 12.3
    15.47 5.72 2115 43.6
    15.94 5.56 398 8.2
    17.25 5.14 3538 72.9
    17.81 4.98 621 12.8
    18.48 4.80 1280 26.4
    18.89 4.69 2407 49.6
    19.33 4.59 3149 64.9
    19.51 4.55 1838 37.9
    20.06 4.42 1841 37.9
    20.49 4.33 2492 51.3
    21.37 4.15 1160 23.9
    21.97 4.04 4853 100
    23.27 3.82 358 7.4
    23.73 3.75 4074 83.9
    24.00 3.70 714 14.7
    24.61 3.61 1852 38.2
    25.35 3.51 1043 21.5
    25.64 3.47 667 13.7
    25.84 3.45 772 15.9
    26.54 3.36 277 5.7
    26.95 3.31 943 19.4
    27.10 3.29 264 5.4
    27.74 3.21 306 6.3
    27.90 3.20 570 11.7
    28.28 3.15 238 4.9
    29.69 3.01 294 6.1
    29.93 2.98 305 6.3
    30.28 2.95 976 20.1
    30.90 2.89 146 3
    31.37 2.85 360 7.4
    31.88 2.80 516 10.6
    32.39 2.76 114 2.3
    33.51 2.67 61.4 1.3
    34.22 2.62 356 7.3
    34.78 2.58 783 16.1
    35.79 2.51 247 5.1
    36.17 2.48 299 6.2
    37.05 2.42 260 5.4
    37.39 2.40 187 3.8
    37.85 2.38 61.6 1.3
    38.60 2.33 181 3.7
    39.13 2.30 173 3.6
    39.73 2.27 205 4.2
  • In one aspect, the crystalline form of the free base of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is at least 50% pure by weight, at least 75% pure by weight, at least 80% pure by weight, at least 90% pure by weight, at least 95% pure by weight, or at least 98% pure by weight.
  • Further provided is a crystalline Form I of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-11.1) See Example 2 below.
  • In one aspect, crystalline Form I of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least three X-ray powder diffraction peaks at 2θ angles selected from 15.52°, 17.30°, 19.39°, 21.68°, 23.32°, and 23.82°. Alternatively, crystalline Form I of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least four X-ray powder diffraction peaks at 2θ angles selected from 15.52°, 17.30°, 19.39°, 21.68°, 23.32°, and 23.82°. In another alternative, crystalline Form I of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least five X-ray powder diffraction peaks at 2θ angles selected from 15.52°, 17.30°, 19.39°, 21.68°, 23.32°, and 23.82°. In yet another alternative, crystalline Form I of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2θ angles 15.52°, 17.30°, 19.39°, 21.68°, 23.32°, and 23.82°. In yet another embodiment, crystalline Form I of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2θ angles selected from Table 2b. In yet another embodiment, crystalline Form I of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by an X-ray powder diffraction pattern substantially similar to FIG. 3.
  • TABLE 2b
    2-Theta Rel. Intensity (%)
    3.92 26.88
    8.69 7.61
    10.94 27.24
    11.54 3.51
    13.94 29.53
    15.52 50.94
    16.04 2.49
    17.30 100.00
    18.01 7.41
    18.49 24.12
    18.99 7.41
    19.11 19.74
    19.39 46.72
    19.59 17.66
    20.07 29.29
    20.85 23.01
    21.45 19.91
    21.68 60.81
    21.88 10.16
    22.09 8.61
    22.82 6.22
    23.32 39.18
    23.82 37.88
    24.22 20.39
    24.86 29.02
    25.17 16.01
    25.55 5.45
    26.59 4.17
    27.10 7.44
    27.41 9.68
    28.02 18.93
    29.29 4.98
    29.63 3.95
    29.95 18.31
    30.44 4.74
    31.07 20.50
    32.00 4.22
    33.93 10.91
    34.57 4.98
    34.92 7.18
    35.93 2.79
    36.85 4.56
    37.60 6.58
    38.26 6.78
    38.59 5.34
    38.85 2.44
    39.21 2.45
    39.88 1.63
    41.67 2.22
    42.29 3.29
    42.58 2.65
    43.97 1.59
    44.95 2.20
    46.16 3.31
    47.35 1.26
    47.99 5.28
    48.68 3.52
    49.67 1.37
    52.34 2.43
    54.12 0.61
    56.58 1.12
  • In one aspect, crystalline Form I of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is at least 50% pure by weight, at least 75% pure by weight, at least 80% pure by weight, at least 90% pure by weight, at least 95% pure by weight, or at least 98% pure by weight.
  • Further provided is a crystalline Form II of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-11.1) See Example 2 below.
  • In one aspect, crystalline Form II of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least three X-ray powder diffraction peaks at 2θ angles selected from 13.18°, 14.46°, 16.47°, 17.97°, 19.80°, and 26.52°. Alternatively, crystalline Form II of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least four X-ray powder diffraction peaks at 2θ angles selected from 13.18°, 14.46°, 16.47°, 17.97°, 19.80°, and 26.52°. In another alternative, crystalline Form II of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least five X-ray powder diffraction peaks at 2θ angles selected from 13.18°, 14.46°, 16.47°, 17.97°, 19.80°, and 26.52°. In yet another alternative, crystalline Form II of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2θ angles 13.18°, 14.46°, 16.47°, 17.97°, 19.80°, and 26.52°. In yet another embodiment, crystalline Form II of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2θ angles selected from Table 2c. In yet another embodiment, crystalline Form II of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by an X-ray powder diffraction pattern substantially similar to FIG. 4.
  • TABLE 2c
    2-Theta Rel. Intensity (%)
    6.61 34.38
    8.58 7.82
    9.69 10.60
    9.88 12.74
    11.64 2.61
    13.18 34.62
    14.46 69.36
    16.47 48.21
    16.84 29.84
    17.45 8.77
    17.97 100.00
    18.32 28.19
    18.97 6.41
    19.36 19.02
    19.80 98.44
    20.24 22.84
    20.56 10.60
    21.21 7.35
    21.74 15.98
    22.84 5.81
    23.21 5.27
    23.57 5.57
    23.96 5.24
    24.89 0.99
    25.47 24.01
    25.78 32.32
    26.52 61.94
    26.96 12.84
    27.29 9.18
    27.70 6.09
    28.31 5.59
    29.49 5.66
    31.00 2.23
    31.92 12.31
    32.97 3.25
    33.29 5.23
    33.91 0.92
    34.45 2.32
    34.92 6.63
    35.86 1.37
    36.30 0.99
    38.44 0.31
    39.91 0.50
    41.11 3.30
    41.90 2.17
    42.31 3.38
    43.11 3.55
    43.61 0.98
    44.37 1.88
    46.39 1.44
    48.54 0.71
  • In one aspect, crystalline Form II of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is at least 50% pure by weight, at least 75% pure by weight, at least 80% pure by weight, at least 90% pure by weight, at least 95% pure by weight, or at least 98% pure by weight.
  • Further provided is a crystalline Form III of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-11.1) See Example 2 below.
  • In one aspect, crystalline Form III of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least three X-ray powder diffraction peaks at 2θ angles selected from 6.62°, 14.48°, 16.53°, 17.96°, 19.89°, and 26.53°. Alternatively, crystalline Form III of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least four X-ray powder diffraction peaks at 2θ angles selected from 6.62°, 14.48°, 16.53°, 17.96°, 19.89°, and 26.53°. In another alternative, crystalline Form III of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least five X-ray powder diffraction peaks at 2θ angles selected from 6.62°, 14.48°, 16.53°, 17.96°, 19.89°, and 26.53°. In yet another alternative, crystalline Form III of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2θ angles 6.62°, 14.48°, 16.53°, 17.96°, 19.89°, and 26.53°. In yet another embodiment, crystalline Form III of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2θ angles selected from Table 2d. In yet another embodiment, crystalline Form III of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by an X-ray powder diffraction pattern substantially similar to FIG. 5.
  • TABLE 2d
    2-Theta Rel. Intensity (%)
    5.44 1.17
    6.62 52.21
    8.54 16.72
    9.68 11.14
    9.90 10.29
    10.52 2.38
    11.01 2.30
    11.58 1.62
    12.33 1.67
    13.23 34.69
    13.56 1.54
    13.78 1.82
    14.48 74.59
    14.57 4.82
    16.53 39.88
    16.93 30.23
    17.07 14.59
    17.53 12.30
    17.96 100.00
    18.36 25.05
    19.02 7.37
    19.36 18.85
    19.89 84.77
    20.27 33.31
    20.61 17.14
    21.19 14.50
    21.74 31.45
    22.35 2.94
    22.91 5.82
    23.26 7.72
    23.61 7.76
    23.96 12.80
    24.79 2.30
    25.42 29.67
    25.76 35.78
    26.53 55.30
    26.92 22.87
    27.28 12.20
    27.68 7.61
    28.23 5.41
    29.68 6.84
    31.18 1.92
    31.73 4.74
    32.02 12.59
    33.03 7.60
    33.37 4.33
    33.97 1.63
    34.94 11.41
    35.76 2.60
    36.28 1.64
    36.90 1.08
    38.40 1.53
    40.18 1.64
    41.14 4.85
    41.94 3.51
    42.33 3.68
    43.31 5.00
    43.96 1.80
    44.38 3.09
    44.91 1.28
    46.46 1.94
    47.38 0.58
    48.55 1.12
    54.94 0.73
  • In one aspect, crystalline Form III of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide is at least 50% pure by weight, at least 75% pure by weight, at least 80% pure by weight, at least 90% pure by weight, at least 95% pure by weight, or at least 98% pure by weight.
  • Further provided is a crystalline form of the HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide (I-131.1). See Example 4 below.
  • In one aspect, the crystalline form of the HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least three X-ray powder diffraction peaks at 2θ angles selected from 7.67°, 12.60°, 13.35°, 15.39°, 18.86°, and 25.38°. Alternatively, the crystalline form of the HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least four X-ray powder diffraction peaks at 2θ angles selected from 7.67°, 12.60°, 13.35°, 15.39°, 18.86°, and 25.38°. In another alternative, the crystalline form of the HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least five X-ray powder diffraction peaks at 2θ angles selected from 7.67°, 12.60°, 13.35°, 15.39°, 18.86°, and 25.38°. In yet another alternative, the crystalline form of the HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2θ angles 7.67°, 12.60°, 13.35°, 15.39°, 18.86°, and 25.38°. In yet another embodiment, the crystalline form of the HCl salt of (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 20 angles selected from Table 2e. In yet another embodiment, the crystalline form of the HCl salt (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by an X-ray powder diffraction pattern substantially similar to FIG. 6.
  • TABLE 2e
    2-Theta d Value Intensity Rel. Intensity (%)
    6.28 14.06 121 4.1
    7.67 11.52 962 32.2
    8.81 10.03 265 8.8
    10.86 8.14 269 9
    11.01 8.03 135 4.5
    11.98 7.38 216 7.2
    12.60 7.02 2992 100
    13.35 6.63 1883 62.9
    14.67 6.03 581 19.4
    15.39 5.75 1714 57.3
    16.73 5.29 132 4.4
    17.70 5.01 583 19.5
    18.32 4.84 738 24.7
    18.86 4.70 962 32.2
    19.45 4.56 552 18.4
    20.37 4.36 326 10.9
    21.33 4.16 276 9.2
    21.66 4.10 821 27.4
    22.45 3.96 268 8.9
    22.66 3.92 423 14.1
    23.15 3.84 451 15.1
    23.81 3.73 509 17
    24.73 3.60 641 21.4
    25.38 3.51 1014 33.9
    26.27 3.39 406 13.6
    26.65 3.34 262 8.7
    27.46 3.25 274 9.2
    28.11 3.17 429 14.3
    29.24 3.05 114 3.8
    30.90 2.89 324 10.8
    32.21 2.78 106 3.5
    32.95 2.72 211 7.1
    34.10 2.63 77.6 2.6
    34.63 2.59 138 4.6
    35.67 2.51 70.1 2.3
    38.81 2.32 90.9 3
    39.69 2.27 48.9 1.6
  • In one aspect, the crystalline form of the HCl salt (R)-1-((2,2-di fluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl) —N-(1-(5-(ethyl sulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is at least 50% pure by weight, at least 75% pure by weight, at least 80% pure by weight, at least 90% pure by weight, at least 95% pure by weight, or at least 98% pure by weight.
  • Further provided is a crystalline form of (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide (I-132.1). See Example 5 below.
  • In one aspect, the crystalline form of(R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least three X-ray powder diffraction peaks at 2θ angles selected from 12.23°, 14.00°, 15.78°, 16.41°, 17.77°, and 19.70°. Alternatively, the crystalline form of (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least four X-ray powder diffraction peaks at 2θ angles selected from 12.23°, 14.00°, 15.78°, 16.41°, 17.77°, and 19.70°. In another alternative, the crystalline form of (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by at least five X-ray powder diffraction peaks at 2θ angles selected from 12.23°, 14.00°, 15.78°, 16.41°, 17.77°, and 19.70°. In yet another alternative, the crystalline form of (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2θ angles 12.23°, 14.00°, 15.78°, 16.41°, 17.77°, and 19.70°. In yet another embodiment, the crystalline form of (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by X-ray powder diffraction peaks at 2θ angles selected from Table 2f. In yet another embodiment, the crystalline form of (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is characterized by an X-ray powder diffraction pattern substantially similar to FIG. 7.
  • TABLE 2f
    2-Theta d Value Intensity Rel. Intensity (%)
    7.74 11.41 260 22.5
    8.11 10.90 137 11.8
    8.75 10.09 74 6.4
    10.25 8.62 145 12.5
    10.53 8.40 234 20.2
    11.95 7.40 240 20.8
    12.23 7.23 735 63.6
    13.57 6.52 558 48.3
    14.00 6.32 635 54.9
    15.78 5.61 738 63.8
    16.41 5.40 924 79.9
    17.77 4.99 1156 100
    18.64 4.76 472 40.8
    19.70 4.50 853 73.8
    20.59 4.31 511 44.2
    21.27 4.17 602 52.1
    22.08 4.02 352 30.5
    23.56 3.77 284 24.6
    24.90 3.57 156 13.5
    26.32 3.38 113 9.8
    29.02 3.07 142 12.2
    29.54 3.02 129 11.1
  • In one aspect, the crystalline form of (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide is at least 50% pure by weight, at least 75% pure by weight, at least 80% pure by weight, at least 90% pure by weight, at least 95% pure by weight, or at least 98% pure by weight.
  • Unless otherwise indicated, the XRPD patterns/assignments for the crystalline forms defined herein are not to be construed as absolute and can vary 0.2 degrees.
  • Specific examples of compounds are provided in the EXEMPLIFICATION. Pharmaceutically acceptable salts as well as the neutral forms of these compounds are included herein.
  • In certain embodiments, the present disclosure provides a method of treating a patient (e.g., a human) with a disorder mediated by RORγ comprising the step of administering to the patient an effective amount of the compound with any compound described herein, or a pharmaceutically acceptable salt or composition thereof.
    • 4. Uses, Formulation and Administration
  • Pharmaceutically Acceptable Compositions
  • According to another embodiment, the present disclosure provides a method of treating a subject (e.g., a human) with a disorder mediated by RORY using a composition comprising a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
  • The term “pharmaceutically acceptable carrier” refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this disclosure include, but are not limited to, organic or inorganic carriers, excipients or diluents suitable for pharmaceutical applications.
  • Compositions described herein may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term “parenteral” as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Liquid dosage forms, injectable preparations, solid dispersion forms, and dosage forms for topical or transdermal administration of a compound are included herein.
  • The amount of provided compounds that may be combined with carrier materials to produce a composition in a single dosage form will vary depending upon the patient to be treated and the particular mode of administration.
  • It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, the judgment of the treating physician, and the severity of the particular disease being treated. The amount of a provided compound in the composition will also depend upon the particular compound in the composition.
  • Uses of Compounds and Pharmaceutically Acceptable Compositions
  • Compounds and compositions described herein are generally useful for modulating RORγ. Thus, in some embodiments, the present disclosure provides a method of treating inflammatory, metabolic and autoimmune diseases or disorders mediated by RORγ, comprising administering a provided compound or composition. More particularly, the compounds and compositions described herein act as inverse agonists or antagonists of RORγ.
  • As used herein, the terms “treatment,” “treat,” and “treating” refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed, i.e., therapeutic treatment. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors), i.e., prophylactic treatment. Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.
  • Modulation of RORγ (or to modulate RORγ), means that a change or alteration in the activity of RORγ has occurred from the administration of one or more of the compounds described herein. Modulation may be an upregulation (increase) or a downregulation (decrease) in the magnitude of the activity or function of RORγ. Exemplary activities and functions include e.g., binding characteristics, enzymatic activity, cell receptor activation, transcriptional activity, and signal transduction. In one aspect, the compounds described herein inhibit RORγ. In further aspects, the compounds described herein act as agonists, antagonists, or inverse agonists of RORγ.
  • In another aspect, compounds and compositions described herein are useful for reducing the amount of IL-17 in a subject. Thus, in some embodiments, provided herein are methods of reducing the amount of IL-17 in a subject comprising administering an effective amount of a provided compound or composition. RORγ modulators disclosed in WO 2014/179564, WO 2015/116904, WO 2016/061160, PCT/US2016/045318, PCT/US2016/062422, and U.S. patent publication Nos. US 2016-0122318 and US 2016-0122345 can also be used in such methods.
  • In another aspect, compounds and compositions described herein are useful for inhibiting the synthesis of IL-17 in a subject. Thus, in some embodiments, provided herein are methods of inhibiting the synthesis of IL-17 in a subject comprising administering an effective amount of a provided compound or composition. RORγ modulators disclosed in WO 2014/179564, WO 2015/116904, WO 2016/061160, PCT/US2016/045318, PCT/US2016/062422, and U.S. patent publication Nos. US 2016-0122318 and US 2016-0122345 can also be used in such methods.
  • Diseases and conditions treatable according to the methods herein include, but are not limited to, inflammatory, metabolic and autoimmune diseases or disorders mediated by RORγ. These diseases and conditions include, for example, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, allergic rhinitis, atopic dermatitis, contact dermatitis, acne, urticaria, hives, angioedema, cystic fibrosis, allograft rejection, multiple sclerosis, Balo's concentric (circular) sclerosis, Balo disease, leukoencephalitis periaxialis concentrica, encephalitis periaxialis concentrica, scleroderma, limited scleroderma, CREST syndrome, arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, reactive arthritis, Reiter's syndrome, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), Hashimoto's disease, pancreatitis, autoimmune diabetes, type I diabetes, autoimmune ocular disease, ulcerative colitis, Crohn's disease, regional enteritis, inflammatory bowel disease (IBD), inflammatory bowel syndrome (IBS), Sjögren's syndrome, optic neuritis, obesity, hepatosteatosis, adipose tissue-associated inflammation, insulin resistance, type II diabetes, neuromyelitis optica, myasthenia gravis, age related macular degeneration, dry eye, uveitis, Guillain-Barré syndrome, psoriasis, plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, psoriatic epidermal hyperplasia, epidermal hyperplasia, psoriatic arthritis (PsA), steroid resistant asthma, Graves' disease, scleritis, endometriosis, obstructive sleep apnea syndrome (OSAS), Behçet's disease, dermatomyositis, polymyocitis, graft versus host disease, chronic graft versus host disease, acute graft versus host disease, primary biliary cirrhosis, liver fibrosis, non-alcoholic fatty liver disease (NAFLD), sarcoidosis, primary sclerosing cholangitis, autoimmune thyroid disease, autoimmune polyendocrine syndrome type I, autoimmune polyendocrine syndrome type II, celiac disease, celiac sprue, neuromyelitis, juvenile idiopathic arthritis, systemic sclerosis, myocardial infarction, pulmonary hypertension, osteoarthritis, cutaneous leishmaniasis, sinonasal polyposis, and cancer, including but not limited to lung cancer, gastric cancer, breast cancer and colon cancer. In one aspect, an exemplified form of cancer treatable according to the methods herein also includes prostate cancer e.g., (metastatic castration-resistant prostate cancer tumors). In another aspect, an exemplified form of cancer treatable according to the methods herein includes e.g., malignant tumor, angiogenesis glaucoma, infantile hemangioma, multiple myeloma, acute myeloblastic leukemia, chronic sarcoma, chronic myelogenous leukemia, metastasis melanoma, Kaposi's sacroma, vascular proliferation, cachexia, colorectal cancer (e.g., familial colorectal cancer, hereditary nonpolyposis colorectal cancer, and gastrointestinal stromal tumor), lung cancer (e.g., non-small cell lung cancer, small cell lung cancer and malignant mesothelioma), mesothelioma, pancreatic cancer (e.g., pancreatic duct cancer), gastric cancer (e.g., papillary adenocarcinoma, mucinous adenocarcinoma and adenosquamous carcinoma), breast cancer (e.g., invasive ductal carcinoma, ductal carcinoma in situ, inflammatory breast cancer and metastatic breast cancer), ovarian cancer (e.g., ovarian epithelial carcinoma, extragonadal germ cell tumor, ovarian germ cell tumor, and ovarian low malignant potential tumor), hormone-dependent prostate cancer, non-hormone dependent prostate cancer, liver cancer (e.g., primary liver cancer and extrahepatic bile duct cancer), thyroid cancer (e.g., medullary thyroid carcinoma), kidney cancer (e.g., renal cell carcinoma, and transitional cell carcinoma in kidney and urinary duct), uterine cancer, endometrial cancer, brain tumor (e.g., pineal astrocytoma, pilocytic astrocytoma, diffuse astrocytoma and anaplastic astrocytoma), melanoma, sarcoma, urinary bladder cancer, hematologic cancer, hypophyseal adenoma, glioma, acoustic neurinoma, retinoblastoma, head and neck cancer, head and neck squamous cell carcinoma, pharyngeal cancer, laryngeal cancer, cancer of the tongue, thymoma, esophagus cancer, duodenal cancer, colorectal cancer, rectal cancer, hepatoma, pancreatic endocrine tumor, cancer of the bile duct, gallbladder cancer, penile cancer, urinary duct cancer, testis tumor, vulvar cancer, cervical cancer, endometrial cancer, uterus sarcoma, vaginal cancer, skin cancer, fungoid mycosis, basal cell tumor, soft tissue sarcoma, malignant lymphoma, Hodgkin's disease, myelodysplastic syndrome, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, malignant myeloma, adult T cell leukemia, chronic bone marrow proliferative disease, pancreatic endocrine tumor, fibrous histiocytoma, leiomyosarcoma, rhabdomyosarcoma, cancer of unknown primary, cancer-driven myelopoiesis, tumor growth, and metastasis.
  • Diseases and disorders mediated by IL-17 expression, and which are treatable using the compounds described herein also include, e.g., emphysema, lung fibrosis, idiopathic pulmonary fibrosis, retroperitoneal fibrosis, giant cell arteritis, giant cell myocarditis, arteriosclerosis, hepatitis, chronic active hepatitis, alcoholic hepatitis, alcoholic liver fibrosis, alcoholic cirrhosis, viral hepatitis, hepatitis B viral liver disorder, autoimmune hepatitis, cartilage inflammation, bone degradation, juvenile arthritis, pauciarticular juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, spondyloarthritis, juvenile ankylosing spondylitis, juvenile enteropathic arthritis, juvenile reactive arthritis, juvenile Reiter's syndrome, seronegative enthesopathy and arthropathy (SEA) syndrome, juvenile dermatomyositis, juvenile psoriatic arthritis, juvenile scleroderma, juvenile systemic lupus erythematosus, juvenile vasculitis, pauciarticular rheumatoid arthritis, polyarticular rheumatoid arthritis, systemic onset rheumatoid arthritis, enteropathic arthritis, vasculitis, leukocytoclastic vasculitis, myositis, juvenile myositis, polymyositis, autoimmune myositis, osteoarthritis, polyarteritis nodosa, arteritis, Takayasu's arteritis, temporal arteritis, giant cell arteritistesticular autoimmunity, polymyalgia rheumatica, rheumatic fever, sclerosis, primary biliary sclerosis, primary biliary cirrhosis, sclerosing cholangitis, primary sclerosing cholangitis, enthesitis, enthesopathy, dermatitis, dermatitis herpetiformis, progesterone dermatitis, atopic eczema, contact eczema, eczema, atherosclerosis, Still's disease, Addison's disease, Raynaud's phenomenon, erythrodermic psoriasis, noninfectious uveitis, peripheral uveitis, Dressler's syndrome, eosinophilic esophagitis, eosinophilic fasciitis, erythema nodosum, experimental allergic encephalomyelitis, Evans syndrome, fibrosing alveolitis, Vogt-Koyanagi-Harada syndrome, mucosal leishmaniasis, Kawasaki disease or syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, thrombocytopenic purpura, immune thrombocytopenic purpura (also known as immune thrombocytopenia, idiopathic immune thrombocytopenia, idiopathic thrombocytopenic thrombotic purpura, primary immune thrombocytopenia, idiopathic thrombocytopenic purpura (ITP), primary immune thrombocytopenic purpura, or autoimmune thrombocytopenic purpura), agammaglobulinemia, kidney inflammation, interstitial kidney inflammation, kidney disease, chronic kidney disease, renal failure, acute renal failure, end stage kidney disease, acute kidney injury, cisplatin induced acute renal failure, sepsis induced acute renal failure, anti-glomerular basement membrane (GBM) nephritis, anti-tubular basement membrane (TBM) nephritis, antiphospholipid syndrome (APS), nephritis, nephrotoxic nephritis, glomerulonephritis, acute glomerulonephritis, antineutrophil cytoplasmic autoantibody (ANCA) associated vasculitis, microscopic polyangiitis, granulomatosis with polyangiitis (GPA), Wegener's granulomatosis, amyotrophic lateral sclerosis, lupus nephritis, allergic eczema, transplant rejection, non-radiographic spondyloarthropathy, ophthalmic disorders, organ allograft rejection, fibroid lung, renal insufficiency, diabetic complications, diabetic nephropathy, diabetic retinopathy, diabetic retinitis, diabetic microangiopathy, insulitis, tuberculosis, invasive staphylococcia, invasive Staphylococcus aureus infection, inflammation after cataract surgery, allergic conjunctivitis, alopecia, alopecia areata, chronic urticaria, allergic asthma, neutrophilic asthma, periodontal diseases, periodonitis, gingivitis, gum disease, cardiomyopathy, diastolic cardiomyopathies, cardiac infarction, myocarditis, chronic heart failure, congenital heart block, coxsackie myocarditis, postmyocardial infarction syndrome, postpericardiotomy syndrome, endocarditis, subacute bacterial endocarditis (SBE), angiostenosis, restenosis, reperfusion disorders, autoimmune pancreatitis, acute pancreatitis, chronic pancreatitis, asthma, bronchial asthma, acute respiratory distress syndrome, adult respiratory distress syndrome, inflammatory bone disease, inflammatory pulmonary disease, ischemic attack, transient ischemic attack, systemic inflammatory response syndrome, glaucoma, orbital cellulitis, sudden orbital inflammation, postoperative inflammation, posttraumatic inflammation, allergic inflammation, intestinal inflammation, mucosal inflammation, prostate inflammation, prostatitis, chronic pelvic pain syndrome, testicular inflammation, chronic testicular inflammation, orchitis, orchitis mediated infertility, liver disorder, liver injury, hepatoxicity, pneumonia, meningitis, cystitis, interstitial cystitis, pharyngolaryngitis, gastric mucosal injury, chronic pneumonia, pulmonary infarction, silicosis, sarcoidosis, pulmonary sarcoidosis, autoimmune angioedema, autoimmune dysautonomia, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune aplastic anemia, autoimmune anemia, autoimmune hemolytic anemia, hemolytic anemia, autoimmune retinopathy, autoimmune thrombocytopenic purpura (ATP), autoimmune thyroid disease, autoimmune urticaria, Goodpasture's syndrome, sinusitis, chronic hypertrophic rhinitis, chronic inflammatory demyelinating polyneuropathy, mixed connective tissue disease, undifferentiated connective tissue disease (UCTD), cognitive impairment, cognitive impairment in Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, spinal cerebellar atrophy, progressive supranuclear palsy, Fisher syndrome, dicoid lupus, central nervous system lupus, neuromyelitis optica (NMO; also known as Devic's disease or Devic's syndrome), encephalomyelitis, acute disseminated encephalomyelitis (ADEM), transverse myelitis, acute necrotizing hemorrhagic leukoencephalitis, multiple system atrophy, Huntington's disease, cerebrovascular dementia, diffuse Lewy body disease, amyloidosis, cerebrovascular disorder, cerebral infarction, transient ischemic attack, intracerebral hemorrhage, vascular disease of the spinal cord, spinal cord infarction, Lambert-Eaton syndrome, muscular dystrophy, metabolic myopathy, inflammatory myopathy, Chagas disease, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic recurrent multifocal ostomyelitis (CRMO), Churg-Strauss syndrome, Cogan's syndrome, cold agglutinin disease, essential mixed cryoglobulinemia, demyelinating neuropathies, inclusion body myositis, encephalitis, pemphigoid, bullous pemphigoid, pemphigus, pemphigus vulgaris, pemphigus foliaceus, cicatricial pemphigoid, ocular cicatricial pemphigoid, benign mucosal pemphigoid, Castleman disease (also known as giant or angiofollicular lymph node hyperplasia, lymphoid hamartoma, and angiofollicular lymph node hyperplasia), profundus lupus erythematosus, chronic thyroiditis, autoimmune gastritis, sepsis, burn injury, axonal and neuronal neuropathies, pain, neuropathy, peripheral neuropathy, chronic pain, optic neuritis, optic neuropathy, traumatic optic neuropathy, ischemic brain injury, deep venous thrombosis, neutropenia, autoimmune neutropenia, thrombocytopenia, abnormal immunoresponse, radiodermatitis, osteoporosis, parasitic infection, clonorchiasis, Cryptosporidium infection, Streptococcus pneumoniae carriage, chronic pneumococcal carriage, an immune disorder associated with or arising from activity of pathogenic lymphocytes, Henoch-Schonlein purpura, herpes gestationis, hypogammaglobulinemia, IgA nephropathy, IgG4-related sclerosing disease, immunoregulatory lipoproteins, Lambert-Eaton syndrome, lichen planus, lichen sclerosus, ligneous conjunctivitis, linear IgA disease (LAD), chronic Lyme disease, Meniere's disease, microscopic polyangiitis, mixed connective tissue disease (MCTD), Mooren's ulcer, Mucha-Habermann disease, narcolepsy, palindromic rheumatism, pediatric autoimmune neuropsychiatric disorders associated with Streptococcus (PANDAS), paraneoplastic cerebellar degeneration, paroxysmal nocturnal hemoglobinuria (PNH), Parry-Romberg syndrome, Parsonnage-Turner syndrome, pars planitis, perivenous encephalomyelitis, pernicious anemia, POEMS syndrome, type I autoimmune polyglandular syndrome, type II autoimmune polyglandular syndrome, type III autoimmune polyglandular syndrome, pyoderma gangrenosum, pure red cell aplasia, reflex sympathetic dystrophy, relapsing polychondritis, restless legs syndrome, Schmidt syndrome, sperm autoimmunity, stiff person syndrome, Susac's syndrome, sympathetic ophthalmia, Tolosa-Hunt syndrome, vesiculobullous dermatosis, and vitiligo.
  • Also included are diseases or disorders which are implicated by the regulation of the circadian rhythm of individuals and include, e.g., major depression, seasonal affective disorder, post-traumatic stress disorder (PTSD), bipolar disorder, autism, epilepsy, Alzheimer's disease and other central nervous system (CNS) disorders associated with altered sleep and/or circadian rhythms.
  • Further included are diseases and disorders mediated by IL-17 expression, including STAT3-mediated IL-17 expression, in neutrophils, and include, e.g., corneal fungal infection; risk of corneal fungal infection; corneal ulcer; corneal ulcer resulting from fungal keratitis; corneal ulcer resulting from fungal infection; corneal fungal infection and related inflammation; keratitis; fungal keratitis; corneal inflammation; corneal disease; ocular disease; fungal-mediated corneal infection, corneal ulcer, corneal inflammation, or ocular ulcer, inflammation or infection; bacterial-mediated corneal infection, corneal ulcer, corneal inflammation, or ocular ulcer, inflammation or infection; microbial disease; bacterial infections; fungal infections; Aspergillus keratitis; Fusarium keratitis; cutaneous T cell lymphoma; lung inflammation; acute kidney ischemia-reperfusion injury; anthrax, including, cutaneous anthrax, inhalation anthrax, gastrointestinal anthrax and injection anthrax; aspergillosis, including, pulmonary aspergillosis, chronic pulmonary aspergillosis (CPA), chronic aspergillosis, chronic cavitary pulmonary aspergillosis (CCPA), allergic bronchopulmonary aspergillosis (ABPA), allergic Aspergillus sinusitis, aspergilloma, invasive aspergillosis, chronic necrotizing aspergillosis and cutaneous (skin) aspergillosis; and histoplasmosis, including, systemic histoplasmosis. In particular embodiments, the fungus or fungal infection meditating the disease or disorder described above includes one or more of Aspergillus, Fusarium, Alternaria, Candida, Curvularia or Histoplasma.
  • Compounds described herein can also be used to treat or reduce the risk of abnormal cortical development or psychiatric disorder, e.g., autism spectrum disorder (ASD), schizophrenia, and/or depression, in a fetus. Compounds described herein can also be used to treat a pregnant female having a hyper-inflammatory condition associated with an infection, such as a viral or bacterial infection, or associated with exposure to an inflammatory or environmental toxin during pregnancy. In particular embodiments, a fetus is treated in utero in a pregnant female with a compound disclosed herein to decrease the risk of the fetus developing a psychiatric disorder, to reduce inflammation in the pregnant female, to reduce the risk of abnormal cortical development in the fetus, and/or to decrease symptoms of a psychiatric disorder in offspring of a pregnant female.
  • In one embodiment, a human patient is treated with a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant, or vehicle, wherein said compound is present in an amount to treat or ameliorate one or more of the diseases and conditions recited above. In an alternative embodiment, the diseases and conditions treated or ameliorated by a compound of Formula I include, e.g., asthma, atopic dermatitis, acne, Crohn's disease, regional enteritis, ulcerative colitis, Sjögren's syndrome, uveitis, Behçet's disease, dermatomyositis, multiple sclerosis, ankylosing spondylitis, systemic lupus erythematosus (SLE), scleroderma, psoriasis, psoriatic arthritis (PsA), steroid resistant asthma and rheumatoid arthritis in the patient. In an alternative embodiment, the diseases and conditions treated or ameliorated by a compound of Formula I include e.g., atopic dermatitis, acne, dermatomyositis, scleroderma, psoriasis, psoriatic arthritis (PsA), and rheumatoid arthritis.
  • The present disclosure further relates to a combination therapy for treating or ameliorating a disease or a disorder described herein. In some embodiments, the combination therapy comprises administering at least one compound represented by Structural Formula I in combination with one or more agents for treating or ameliorating inflammatory, metabolic and autoimmune diseases or disorders mediated by RORγ. In some embodiments, the combination therapy comprises administering at least one compound represented by Structural Formula I in combination with one or more agents for the treatment of diseases including asthma, chronic obstructive pulmonary disease (COPD), bronchitis, allergic rhinitis, atopic dermatitis, contact dermatitis, acne, cystic fibrosis, allograft rejection, multiple sclerosis, scleroderma, arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), Hashimoto's disease, pancreatitis, autoimmune diabetes, type I diabetes, autoimmune ocular disease, ulcerative colitis, Crohn's disease, regional enteritis, inflammatory bowel disease (IBD), inflammatory bowel syndrome (IBS), Sjögren's syndrome, optic neuritis, obesity, hepatosteatosis, adipose tissue-associated inflammation, insulin resistance, type II diabetes, neuromyelitis optica, myasthenia gravis, age related macular degeneration, dry eye, uveitis, Guillain-Barré syndrome, psoriasis, psoriatic arthritis (PsA), steroid resistant asthma, Graves' disease, scleritis, major depression, seasonal affective disorder, PTSD, bipolar disorder, autism, epilepsy, Alzheimer's, CNS disorders associated with altered sleep and/or circadian rhythms, endometriosis, obstructive sleep apnea syndrome (OSAS), Behçet's disease, dermatomyositis, polymyocitis, graft versus host disease, primary biliary cirrhosis, liver fibrosis, non-alcoholic fatty liver disease (NAFLD), sarcoidosis, primary sclerosing cholangitis, autoimmune thyroid disease, autoimmune polyendocrine syndrome type I, autoimmune polyendocrine syndrome type II, celiac disease, neuromyelitis, juvenile idiopathic arthritis, systemic sclerosis, myocardial infarction, pulmonary hypertension, osteoarthritis, cutaneous leishmaniasis, sinonasal polyposis, and cancer, including but not limited to, lung cancer, gastric cancer, breast cancer and colon cancer.
  • The compounds herein may also be used alone or in combination with immunotherapies for the treatment of a disease or disorder disclosed herein.
  • Combination therapy includes, e.g., co-administration of a compound described herein and one or more other agents, sequential administration of a compound described herein and one or more other agents, administration of a composition containing a compound described herein and one or more other agents, or simultaneous administration of separate compositions containing a compound described herein and one or more other agents.
  • The present disclosure further provides a method of treating a subject, such as a human, suffering from one of the abovementioned disorders or diseases.
  • In one aspect, RORγ modulators disclosed in WO 2014/179564, WO 2015/116904, WO 2016/061160, PCT/US2016/045318, PCT/US2016/062422, and U.S. patent publication Nos. US 2016-0122318 and US 2016-0122345 can also be used in the methods disclosed herein to treat or ameliorate, in a subject, one or more of the diseases and/or disorders and/or conditions recited herein. In one embodiment, a subject is treated with one or more ROR modulators disclosed in WO 2014/179564, WO 2015/116904, WO 2016/061160 PCT/US2016/045318, PCT/US2016/062422, and U.S. patent publication Nos. US 2016-0122318 or US 2016-0122345 and a pharmaceutically acceptable carrier, adjuvant, or vehicle, wherein said RORγ modulator is present in an amount to treat or ameliorate a disease or disorder selected from corneal fungal infection; risk of corneal fungal infection; corneal ulcer; corneal ulcer resulting from fungal keratitis; corneal ulcer resulting from fungal infection; corneal fungal infection and related inflammation; keratitis; fungal keratitis; corneal inflammation; corneal disease; ocular disease; fungal-mediated corneal infection, corneal ulcer, corneal inflammation, or ocular ulcer, inflammation or infection; bacterial-mediated corneal infection, corneal ulcer, corneal inflammation, or ocular ulcer, inflammation or infection; microbial disease; bacterial infections; fungal infections; Aspergillus keratitis; Fusarium keratitis; cutaneous T cell lymphoma; lung inflammation; acute kidney ischemia-reperfusion injury; anthrax, including, cutaneous anthrax, inhalation anthrax, gastrointestinal anthrax and injection anthrax; aspergillosis, including, pulmonary aspergillosis, chronic pulmonary aspergillosis (CPA), chronic aspergillosis, chronic cavitary pulmonary aspergillosis (CCPA), allergic bronchopulmonary aspergillosis (ABPA), allergic Aspergillus sinusitis, aspergilloma, invasive aspergillosis, chronic necrotizing aspergillosis and cutaneous (skin) aspergillosis; histoplasmosis, including, systemic histoplasmosis; and prostate cancer. In some embodiments, the one or more RORγ modulator disclosed in WO 2014/179564, WO 2015/116904, WO 2016/061160 PCT/US2016/045318, PCT/US2016/062422, and U.S. patent publication Nos. US 2016-0122318 and US 2016-0122345 is administered in combination with one or more additional agent for treating the disease or disorder.
  • The present disclosure further relates to the use of provided compounds for the production of pharmaceutical compositions which are employed for the treatment and/or prophylaxis and/or amelioration of the diseases and disorders mentioned herein.
  • Compounds or compositions described herein may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of the diseases and conditions described herein. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like. Provided compounds are preferably formulated in unit dosage form for ease of administration and uniformity of dosage. The expression “unit dosage form” as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present disclosure will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.
  • Pharmaceutically acceptable compositions of this disclosure can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, creams, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, provided compounds may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
  • In other embodiments, provided compounds are administered topically.
  • The amount of both, a provided compound and additional therapeutic agent (in those compositions which comprise an additional therapeutic agent as described above) that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • In those compositions which comprise an additional therapeutic agent, that additional therapeutic agent and the provided compound may act synergistically. Therefore, the amount of additional therapeutic agent in such compositions will be less than that required in a monotherapy utilizing only that therapeutic agent.
  • The amount of additional therapeutic agent present in the compositions of this disclosure will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent.
    • EXEMPLIFICATION
  • As depicted in the Examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures. It will be appreciated that, although the general methods depict the synthesis of certain compounds herein, the following general methods, and other methods known to one of ordinary skill in the art, can be applied to all compounds and subclasses and species of each of these compounds, as described herein.
    • General Description of Synthesis
  • The compounds described herein can be readily prepared according to the following reaction schemes and examples, or modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. Many of the reactions can also be carried out under microwave (MW) conditions or using conventional heating or utilizing other technologies such as solid phase reagents/scavengers or flow chemistry. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in the art, but are not mentioned in greater detail. Furthermore, other methods for preparing compounds described herein will be readily apparent to a person of ordinary skill in the art in light of the following reaction schemes and examples. In cases where synthetic intermediates and final products contain potentially reactive functional groups, for example amino, hydroxy, thiol and carboxylic acid groups, that may interfere with the desired reaction, it may be advantageous to employ protected forms of the intermediate. Methods for the selection, introduction and subsequent removal of protecting groups are well known to those skilled in the art. In the discussion below variables have the meanings indicated above unless otherwise indicated. The abbreviations used in these experimental details are listed below and additional ones should be known to a person skilled in the art of synthesis. In addition, one can refer to the following references for suitable methods of synthesis as described in March, Advanced Organic Chemistry, 3rd edition, John Wiley & Sons, 1985, Greene and Wuts, Protective Groups in Organic Synthesis, 2nd edition, John Wiley & Sons, 1991, and Richard Larock, Comprehensive Organic Transformations, 4th edition, VCH publishers Inc., 1989.
  • Generally, reagents in the reaction schemes are used in equimolar amounts; however, in certain cases it may be desirable to use an excess of one reagent to drive a reaction to completion. This is especially the case when the excess reagent can be readily removed by evaporation or extraction. Bases employed to neutralize HCl in reaction mixtures are generally used in slight to substantial excess (1.05-5 equivalents).
  • Where NMR data are presented, spectra were obtained on a Varian 400 (400 MHz) or 300 (300 MHz) and are reported as ppm downfield from tetramethylsilane with number of proton, multiplicities and coupling constants indicated parenthetically along with reference to deuterated solvent.
  • The invention is illustrated by way of the following examples, in which the following abbreviations may be employed.
  • Abbreviation Meaning
    ACN, MeCN, CH3CN acetonitrile
    AIBN azobisisobutyronitrile
    aq aqueous
    Boc tert-butoxycarbonyl or t-butoxycarbonyl
    brine saturated aqueous NaCl
    c-Bu cyclobutyl
    Cbz benzyloxy carbonyl
    CeCl3 ceric chloride
    Cs2CO3 cesium carbonate
    CuI cuprous iodide
    c-Pr cyclopropyl
    DCM or CH2Cl2 methylene chloride
    DIEA, i-Pr2NEt diisopropyl ethyl amine
    DMF dimethyl formamide
    DMS/Me2S dimethyl sulfide
    DMSO dimethyl sulfoxide
    EDCI, EDC 1-(3-dimethylaminopropyl)-3-ethylcarbodiiimide
    hydrochloride
    EtI ethyl iodide
    Et ethyl
    Et2O ethyl ether
    Et3SiH triethylsilane
    Et3N triethylamine
    EtOAc, EA, AcOEt ethyl acetate
    EtOH ethanol
    FeCl3 ferric chloride
    h, hr hour(s)
    HATU O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-
    tetramethyluronium-hexafluorophosphate
    HBTU O-benzotriazole-1-yl-N,N,N′,N′-
    tetramethyluronium-hexafluorophosphate
    HCl hydrochloric acid
    H2O water
    H2O2 hydrogen peroxide
    HOAc acetic acid
    HOBt N-hydroxybenzotriazole
    HPLC high performance liquid chromatography
    i-BuOCOCl iso-butoxycarbonyl chloride
    ICl iodochloride
    K2CO3 potassium carbonate
    K3PO4 tripotassium phosphate
    LC-MS liquid chromatography-mass spectrometry
    LDA lithium diiisopropylamide
    LiCl lithium chloride
    LiOH lithium hydroxide
    MCPBA, m-CPBA meta-chloroperoxybenzoic acid
    MeOH methanol
    MeI methyl iodide
    Me methyl
    mg milligram
    MgSO4 magnesium sulfate (anhydrous)
    min minute(s)
    mL milliliters
    mmol millimoles
    mp, m.p. melting point
    MS mass spectrometry
    MW, uwave microwave
    NaBH4 sodium borohydride
    NaBH3CN sodium cyanoborohydride
    NaH sodium hydride
    NaHCO3 sodium bicarbonate
    NaOH sodium hydroxide
    NaOMe sodium methoxide
    Na2S2O3 sodium thiosulfate
    Na2S2O5 sodium dithionate
    Na2SO4 sodium sulfate
    NH4OH ammonium hydroxide
    (NH4)2CO3 ammonium carbonate
    NH4Cl ammonium chloride
    Na2CO3 sodium carbonate
    NaH sodium hydride
    NBS N-bromosuccinimide
    n-BuLi n-butyllithium
    NMM N-methyl-morpholine
    NMP N-methyl-pyrrolidin-2-one
    OTf trifluoromethanesulfonate
    OTs tosylate
    oxone potassium peroxymonosulfate
    PdCl2dppf [1,1-bis(diphenylphosphino)ferrocene]
    dichloropalladium(ii)
    Pd2(dba)3 tris(dibenzylideneacetone)dipalladium(0)
    PE petroleum ether
    rt room temperature
    sat., satd saturated
    SFC supercritical fluid chromatography
    t-BuOK potassium tert butoxide
    t-BuLi tert butyl lithium
    t-BuOOH tert butyl peroxide
    TBAF tetrabutylammonium fluoride
    TFA trifluoroacetic acid
    THF tetrahydrofuran
    TLC thin layer chromatography
    Ti(OEt)4 titanium tetra ethoxide
    μmol micromoles
    Zn zinc
    Zn(CN)2 zinc cyanide
    • Preparation of Compounds of Formula I
  • Compounds of Formula I were prepared according to the general procedures outlined below.
  • In a first process, a compound of Formula I, wherein X═CONH, is prepared from a benzimidazole carboxylic acid of Formula 100 and an amine of Formula 105, using peptide bond formation reagents such as EDC with HOBt, PyBOP or HATU. Alternatively, the acid chloride of 100 is used.
  • Figure US20210094940A1-20210401-C00018
  • In a second process, a compound of Formula I, wherein X═NHCO, is prepared from an aminobenzimidazole of Formula 110 and a carboxylic acid of Formula 115, using peptide bond formation reagents such as EDC with HOBt, PyBOP or HATU. Alternatively, the acid chloride of 115 is used.
  • Figure US20210094940A1-20210401-C00019
  • In a third process, a compound of Formula I is prepared by heating a diamine of Formula 125 with a carboxylic acid of Formula 120. Carboxylic acids of Formula 125 can be purchased or prepared by literature methods.
  • Figure US20210094940A1-20210401-C00020
  • In an alternative to the third process, a compound of Formula I is prepared in two steps from a diamine of Formula 125. In the first step, a carboxylic acid of Formula 120 is reacted with a diamine of Formula 125 using peptide bond formation reagents such as EDC, HOBt or HATU to give a monoamide of Formula 130. Alternatively, the acid chloride of 120 is used. In the second step, a monoamide of Formula 130 is heated with an acid such as HOAc or TFA to give a compound of Formula I.
  • Figure US20210094940A1-20210401-C00021
  • In a fourth process, a diamine of Formula 125 is reacted with an α,α-dichloro ester of Formula 135 to give a compound of Formula I in which R1 is —C(═O)OR.
  • Figure US20210094940A1-20210401-C00022
  • In a fifth process, a diamine of Formula 125 is reacted with a dichloroiminium salt of Formula 140 to give a compound of Formula I, wherein R is NRdRe.
  • Figure US20210094940A1-20210401-C00023
  • In a sixth process, a compound of Formula I is prepared by reaction of a benzimidazole of Formula 145 with a compound of Formula 150, wherein R100 is a leaving group such as iodide, bromide, chloride, methanesulfonate, tosylate or triflate, in the presence of an organic or inorganic base.
  • Figure US20210094940A1-20210401-C00024
  • In a seventh process, a compound of Formula I is prepared from another compound of Formula I. Non-limiting examples of this process include: (1)Treatment of a compound of Formula I wherein R5 or R6 is OMe with BBr3 or Me3SiI to give a compound of Formula I wherein R5 or R6 is OH; (2) Reaction of a compound of Formula I wherein Cy1 or Cy2 is azetidinyl, pyrrolidinyl or piperidinyl bearing a free NH with an alkylating agent such as an (C1-C6)alkyl halide or halo(C1-C6)alkyl triflate to give a compound of Formula I, wherein R5 or R6 is (C1-C6)alkyl or halo(C1-C6)alkyl attached to the N of the azetidine, pyrrolidine or piperidine ring; (3) Reaction of a compound of Formula I wherein Cy1 or Cy2 is azetidinyl, pyrrolidinyl or piperidinyl bearing a free NH with an heteroaryl halide such as an optionally substituted 2-chloropyridine, 2-chloropyrimidine or 4-chloropyrimidine to give a compound of Formula I, wherein R5 or R6 is a heteroaryl group such as an optionally substituted pyridinyl or pyrimidinyl group attached to the N of the azetidine, pyrrolidine or piperidine ring; (4) Oxidation of compound of Formula I in which Cy1 or Cy2 is a pyridine ring with a peracid, such as m-CPBA, to the corresponding pyridine N-oxide of Formula I; (5) Reduction of a compound of Formula I, wherein R5, R6, R7 or R8 is —C(═O)ORe, or (C1-C2)alkyl substituted by —C(═O)ORc, with a hydride reducing agent such as NaBH4, NaBH4/CaCl2 or LiBH4 to give a compound of Formula I in which R5, R6, R7 or R8 is (C1-C3)alkyl substituted by OH; (6) Hydrolysis of a compound of Formula I, wherein R5, R6, R7 or R8 is —C(═O)ORe, or (C1-C3)alkyl substituted —C(═O)ORc and Rc is (C1-C3)alkyl with an alkali metal hydroxide to provide a compound of Formula I, wherein R5, R6, R7 or R8 is —C(═O)OH, or (C1-C3)alkyl substituted —C(═O)OH; (7) Reaction of a compound of Formula I, wherein R5, R6, R7 or R8 is —C(═O)OH, or (C1-C3)alkyl substituted —C(═O)OH with an amine RdReNH under peptide coupling conditions to give a compound of Formula I, wherein R5, R6, R7 or R8 is —C(═O)NRdRe, or (C1-C3)alkyl substituted —C(═O)NRdRe; (8) Oxidation of a compound of Formula I, in which Cy1 and/or Cy2 is substituted with R5 or R6 which is —SRb, with a peracid, such as m-CPBA, to give a compound of Formula I wherein R5 and/or R6 is —S(O)kRb in which k is 1 or 2.
  • In an eighth process, benzimidazole carboxylic acids of Formula 100, which are precursors to compounds of Formula I, are prepared in four steps. An amine of Formula 155 and a halonitroester of Formula 160, wherein R110 is F or Cl, are reacted in the presence of an organic base, such as i-Pr2NEt, to give a nitroaniline of Formula 165. The nitro group of 165 is reduced using, for example, zinc dust in the presence of NH4C1, iron powder in HOAc, SnCl2, or H2 in the presence of Pd on C, to give a diaminoester of Formula 170. Diaminoester 170 is converted to benzimidazole ester 175 using procedures described in the third process. Finally, the ester in 175 is hydrolyzed using an alkali metal hydroxide to give 100.
  • Figure US20210094940A1-20210401-C00025
  • In a ninth process, aminobenzimidazoles of Formula 110, which are precursors to compounds of Formula I, are prepared in four steps. An amine 155 is reacted with a nitrobenzene 180, wherein R110 is F or C1 to given a nitroaniline 185. Reduction of 185 using, for example, SnCl2 gives diamine 190. Diamine 190 is converted to bromobenzimidazole 195 using procedures described in the third process. Bromobenzimidazole 195 is converted to aminobenzimidazole 110 using for example NaN3, CuI.
  • Figure US20210094940A1-20210401-C00026
  • In a tenth process, diamines of Formula 125, which are precursors to compounds of Formula I, are prepared in three steps. Reaction of benzoic acids of Formula 200 with amines of Formula 105 under peptide coupling conditions, mediated by for example HATU, HBTU or EDC, gives amides of Formula 205. Reaction of 205 with amine of Formula 155 gives nitroanilines of Formula 210 which are reduced using, for example, SnCl2 to give diamines 125.
  • Figure US20210094940A1-20210401-C00027
  • In an eleventh process, benzimidazoles of Formula 145, which are precursors of compounds of Formula I, are prepared in three steps. Diaminoester 215 is reacted with carboxylic acids of Formula 120, as described in the third process, to give benzimidazole esters of Formula 220. Treatment of esters 220 with alkali metal hydroxides gives acids of Formula 225 which are reacted with amines of Formula 105 under peptide coupling conditions, mediated by for example HATU, HBTU or EDC, to afford amides of Formula 145.
  • Figure US20210094940A1-20210401-C00028
  • Exemplary LC-MS Methods Include:
  • Method 1
  • HPLC System: Waters ACQUITY
  • Column: Waters ACQUITY CSH™ C18 1.7 uM
  • Guard column: Waters Assy. Frit, 0.2 uM, 2.1 mm.
  • Column temp: 40° C.
  • Mobile Phase:
      • A: TFA:Water (1:1000, v:v)
      • B: TFA: ACN (1:1000, v:v)
  • Gradient Program:
  • Time (min) B %
    0 5
    1.9 95
    2.20 95
    2.21 5
  • Flow Rate: 0.65 mL/min
  • Mass Spectrometer Parameters
  • Mass Spectrometer Waters SQD
  • Ionization Positive Electrospray Ionization (ESI)
  • Mode Scan (100-1400 m/z in every 0.2 second)
  • ES Capilary Voltage: 3.5 kv
  • ES Cone Voltage: 25 v
  • Source Temperature 120° C.
  • Disolvation Temperature: 500° C.
  •
    Desolvation Gas Flow: Nitrogen Setting 650 (L/hr)
    Cone Gas Flow: Nitrogen Setting 50 (L/hr)
  • Method 2
  • 10-80AB_2 MIN
    Column Xtimate C18 2.1*30 mm, 3 um
    Mobile Phase A: water(4 L) + TFA(1.5 mL)
    B: acetonitrile(4 L) + TFA(0.75 mL)
    TIME(min) B %
    0 10
    0.9 80
    1.5 80
    1.51 10
    2 10
    Flow Rate 1.2 mL/min
    wavelength UV 220 nm
    Oven Temp
    50° C.
  • Method 3
  • 5-95AB_1.5 MIN
    Column MERCK, RP-18e 25-2 mm
    Mobile Phase A: water(4 L) + TFA(1.5 mL)
    B: acetonitrile(4 L) + TFA(0.75 mL)
    TIME(min) B %
    0 5
    0.7 95
    1.1 95
    1.11 5
    1.5 5
    Flow Rate 1.5 mL/min
    wavelength UV 220 nm
    Oven Temp
    50° C.
    MS ionization ESI
    • Preparations of Precursors to Compounds of Formula I
  • Carboxylic acids AC1-AC6 were purchased:
  • Figure US20210094940A1-20210401-C00029
    • Preparation 1 2-(1-(methylsulfonyl)piperidin-4-yl)acetic Acid (AC7)
  • Figure US20210094940A1-20210401-C00030
  • Step 1
  • To a mixture of tert-butyl 4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate (100 mg, 0.39 mmol) in anhydrous CH2Cl2 (3 mL), HCl/dioxane (1 mL, 4 N) was added dropwise. The mixture was stirred at 10° C. for 2 h. TLC showed the starting material was consumed. The mixture was concentrated under reduced pressure to afford crude methyl 2-(piperidin-4-yl)acetate HCl salt (75 mg, 99%) as a white solid, which was used for the next step directly without further purification.
  • Step 2
  • To a mixture of crude methyl 2-(piperidin-4-yl)acetate HCl salt (34 mg, 0.18 mmol) in anhydrous CH2Cl2 (2 mL) was added Et3N (88 mg, 0.88 mmol). The mixture was stirred at 0° C. under N2 for 10 min. MsCl (30 mg, 0.26 mmol) was added. The mixture was stirred at 0° C. for 2 h. TLC (petroleum ether/EtOAc=1/2) showed a new spot was observed. The mixture was quenched with H2O (10 mL) and extracted with CH2Cl2 (3×10 mL). The combined organic layers were washed with H2O (10 mL) and brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford crude methyl 2-(1-(methylsulfonyl)piperidin-4-yl)acetate (41 mg, 99%) as a white solid, which was used for the next step directly without further purification. 1H NMR (CDCl 3 400 MHz): δ 3.80 (d, J=12.4 Hz, 2H), 3.69 (s, 3H), 2.78 (s, 3H), 2.71-2.65 (m, 2H), 2.30 (d, J=7.2 Hz, 2H), 1.92-1.90 (m, 1H), 1.85 (d, J=14.0 Hz, 2H), 1.42-1.33 (m, 2H)
  • Step 3
  • To a mixture of crude methyl 2-(1-(methylsulfonyl)piperidin-4-yl)acetate (20 mg, 0.085 mmol) in MeOH/H2O/CH2Cl2 (2 mL, v/v/v=1/1/1) was added LiOH H2O (18 mg, 0.43 mmol). The mixture was stirred at rt for 4 h. TLC (petroleum ether/EtOAc=1/5) showed the starting material was consumed. The mixture was concentrated under reduced pressure. The residue was neutralized with 2 N HCl solution (5 mL) and extracted with CH2Cl2 (3×5 mL). The combined organic layers were washed with H2O (5 mL) and brine (5 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford crude 2-(1-(methylsulfonyl)piperidin-4-yl)acetic acid (15 mg, 80%) as a white solid, which was used for next step directly without further purification. 1H NMR (CDCl 3 400 MHz): δ 3.81 (d, J=12.0 Hz, 2H), 3.78 (s, 3H), 2.72-2.66 (m, 2H), 2.34 (d, J=6.4 Hz, 2H), 1.98-1.85 (m, 3H), 1.42-1.30 (m, 2H).
    • Preparation 2 2-(4-(2-ethoxy-2-oxoethyl)phenyl)acetic Acid (AC8) and 2,2′-(1,4-phenylene)diacetic Acid (AC9)
  • Figure US20210094940A1-20210401-C00031
  • To a stirred solution of diethyl 2,2′-(1,4-phenylene)diacetate (950 mg, 3.8 mmol) in 3:1:1 EtOH/THF/H2O (50 mL) was added LiOH.H2O (200 mg, 4.7 mmol). The mixture was stirred overnight and concentrated. The aq residue was diluted with water (10 mL), washed with ether (60 mL) and acidified with conc HCl. The acidic solution was extracted with ether (2×50 mL). These ether extracts were combined, washed with brine (10 mL), dried over Na2SO4 and concentrated to leave a white solid. 1H NMR indicated a ˜2:1 mixture of the desired monoester (AC8, R=Et) and diacid (AC9, R═H) which was used without further purification.
    • Preparation 3 2-(4-(ethylthio)phenyl)-2-oxoacetic Acid (AC10)
  • Figure US20210094940A1-20210401-C00032
  • The title compound is prepared from ethyl 2-(4-(ethylthio)phenyl)-2-oxoacetate (Matrix Scientific) following a procedure similar to that described for AC8.
  • The following amines were purchased.
  • Figure US20210094940A1-20210401-C00033
    Figure US20210094940A1-20210401-C00034
    • Preparation 4 (4-(propylsulfonyl)phenyl)methanamine (AM3)
  • Figure US20210094940A1-20210401-C00035
  • Step 1
  • To a mixture of 4-fluorobenzonitrile (1.1 g, 9 mmol) in anhydrous DMF (20 mL) was added sodium propane-1-thiolate (1 g, 10 mmol). The mixture was stirred at 0° C. for 2 h. The mixture was diluted with water (20 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with water (3×20 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford crude 4-(propylthio)benzonitrile (1.6 g, 100%) as a colorless oil, which was used for next step directly without further purification. 1H NMR (CDCl 3 400 MHz): δ 7.51 (d, J=4.8 Hz, 2H), 7.28 (d, J=4.8 Hz, 2H), 2.95 (t, J=7.6 Hz, 2H), 1.76-1.69 (m, 2H), 1.06 (t, J=4.0 Hz, 3H).
  • Step 2
  • To a mixture of crude 4-(propylthio)benzonitrile (1 g, 5.6 mmol) in MeOH (10 mL) and H2O (2 mL) was added oxone (6.9 g, 11.2 mmol). The mixture was stirred at 16° C. for 2 h. TLC (petroleum ether/EtOAc=1/1) showed that the reaction was completed. The mixture was lyophilized directly. Then the mixture was dissolved in CH2Cl2 (30 mL) and filtered. The filtrate was concentrated under reduced pressure to afford crude 4-(propylsulfonyl)benzonitrile (500 mg, 42%) as a white solid, which was used for next step directly without further purification. 1H NMR (CDCl 3 400 MHz): δ 8.04 (d, J=6.8 Hz, 2H), 7.88 (d, J=5.2 Hz, 2H), 3.11 (t, J=5.4 Hz, 2H), 1.78-1.72 (m, 2H), 1.02 (t, J=7.2 Hz, 3H).
  • Step 3
  • To a mixture of crude 4-(propylsulfonyl)benzonitrile (100 mg, 0.48 mmol) in anhydrous THE (5 mL) was added LiAlH4 (0.95 mL, 0.95 mmol, 1 M in THF) at 0° C. under N2. The mixture was stirred at rt for 2 h. TLC (EtOAc) showed that the reaction was completed. The mixture was quenched with water (0.04 mL) and aq. NaOH solution (0.04 mL, 10%) at 0° C. The mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC (EtOAc) to afford (4-(propylsulfonyl)phenyl)methanamine (25 mg, 24%) as a yellow oil.
    • Preparation 5 (5-(methylsulfonyl)pyridin-2-yl)methanamine (AM4)
  • Figure US20210094940A1-20210401-C00036
  • This compound is prepared following a procedure analogous to that described for AM5.
    • Preparation 6 (5-(ethylsulfonyl)pyridin-2-yl)methanamine (AM5)
  • Figure US20210094940A1-20210401-C00037
  • Step 1
  • To a flame dried flask equipped with a stir bar were added tert-butyl ((5-bromopyridin-2-yl)methyl)carbamate (2.92 g, 10.2 mmol), ethane sulfinic acid sodium salt (2.36 g, 20.3 mmol), L-proline (234 mg, 2.03 mmol), copper (I) iodide (194 mg, 1.02 mmol) and sodium hydroxide (81.3 mg, 2.03 mmol). The flask was purged with N2, then DMSO (35 mL) was added. The reaction mixture was heated to 110° C. and stirred for 15 h. The flask was then cooled to rt and the mixture was partitioned between EtOAc (150 mL) and satd aq NH4Cl (150 mL). The organic phase was separated, washed with brine (50 mL), dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with 35% EtOAc in hexanes, gradient to 60%) to afford 1.81 g tert-butyl ((5-bromopyridin-2-yl)methyl)carbamate (59%). LC-MS tR=0.74 min in 1 min chromatography, MS (ESI) m/z 301.4 [M+H]+. 1H NMR (CDCl3, 400 MHz): δ 9.02 (dd, J=0.8 Hz, 2.0 Hz, 1H), 8.15 (dd, J=2.4 Hz, 8.4 Hz, 1H), 7.49 (dd, J=0.8 Hz, 8.4 Hz, 1H), 5.49 (broad s, 1H), 4.55 (d, J=7.0 Hz, 2H), 3.15 (q, J=7.2 Hz, 2H), 1.47 (s, 9H), 1.31 (t, J=7.2 Hz, 3H).
  • Step 2
  • To a solution of tert-butyl ((5-bromopyridin-2-yl)methyl)carbamate (1.81 g, 6.03 mmol) in MeOH (40 mL) at 0° C. was added acetyl chloride (4.30 mL, 60.3 mmol) dropwise over 5 min. The solution was allowed to warm to rt and was stirred for 3 h. The mixture was concentrated under reduced pressure to yield 1.64 g (5-(ethylsulfonyl)pyridin-2-yl)methanamine bishydrochloride (100%). LC-MS tR=0.25 min in 1 min chromatography, MS (ESI) m/z 201.2 [M+H]+. 1H NMR (CD3OD, 400 MHz): δ 9.09 (d, J=1.2 Hz, 1H), 8.35 (dd, J=2.4 Hz, 8.4 Hz, 1H), 7.49 (d, J=8.4 Hz, 1H), 4.45 (s, 2H), 3.31 (q, J=7.2 Hz, 2H), 1.26 (t, J=7.2 Hz, 3H).
    • Preparation 7 (R)-2-amino-2-(4-(methylsulfonyl)phenyl)ethanol (AM7.1)
  • Figure US20210094940A1-20210401-C00038
  • This compound is prepared using procedures analogous to those described for AM8.1, substituting Mel for EtBr in Step 1.
    • Preparation 8 (S)-2-amino-2-(4-(methylsulfonyl)phenyl)ethanol (AM7.2)
  • Figure US20210094940A1-20210401-C00039
  • This compound is prepared following procedures analogous to those described for AM8.1 using methyl iodide in place of EtBr in Step 1 and (S)-2-methylpropane-2-sulfinamide in Step 4.
    • Preparation 9 (R)-2-amino-2-(4-(ethylsulfonyl)phenyl)ethanol (AM8.1)
  • Figure US20210094940A1-20210401-C00040
    • Step 1: (4-bromophenyl)(ethyl)sulfane
  • A mixture of 4-bromobenzenethiol (50 g, 0.26 mol), bromoethane (58 g, 0.53 mol) and triethylamine (78 g, 0.78 mol) in acetonitrile (1 L) was stirred at reflux for 17 h. The mixture was cooled to rt and filtered. The filtrate was concentrated under vacuum. The residue was purified by silica gel chromatography (eluting with petroleum ether) to give (4-bromophenyl)(ethyl)sulfane (55 g, 96%) as an oil. 1H NMR (CDC3, 400 MHz): δ 7.40-7.42 (dd, J=6.4, 2.0 Hz, 2H), 7.18-7.20 (dd, J=6.4, 2.0 Hz, 2H), 2.91-2.96 (q, J=7.2 Hz, 2H), 1.30-1.33 (t, J=7.2 Hz, 3H).
    • Step 2: 2-((tert-butyldimethylsilyl)oxy)ethanol
  • To a solution of ethane-1,2-diol (110 g, 1.77 mol) in anhydrous CH2Cl2 (1.1 L) was added triethylamine (215.2 g, 296 mL, 2.13 mol) at rt. The mixture was cooled to 0° C., then tert-butylchlorodimethylsilane (267.1 g, 1.77 mol) dissolved in CH2Cl2 (300 mL) was added dropwise over 1 h. The mixture was stirred at rt overnight. The reaction mixture was quenched with satd aq NH4Cl solution (400 mL) and separated. The aqueous phase was extracted with MTBE (2×400 mL). The combined organic layers were concentrated under vacuum and the residue was redissolved in MTBE (400 mL). The MTBE layer was washed with water (2×500 mL) and brine (500 mL), dried over anhydrous Na2SO4, filtered and concentrated under vacuum to give 2-((tert-butyldimethylsilyl)oxy)ethanol (280 g, 90%) as a slight oil, which was used for the next step directly without further purification. 1H NMR (CDC3, 400 MHz): δ 3.64-3.66 (m, 2H), 3.57-3.60 (m, 2H), 0.85 (s, 9H), 0.02 (s, 6H).
    • Step 3: 2-((tert-butyldimethylsilyl)oxy)acetaldehyde
  • To a solution of CH2Cl2 (1.8 L) cooled to −30° C. was added oxalyl chloride (79.2 g, 52.8 mL, 624 mmol) dropwise. The mixture was cooled to −78° C., then DMSO (62.5 g, 88.5 mL, 1.25 mmol) was added dropwise. After addition, the mixture was stirred at −78° C. for 30 min. A solution of 2-((tert-butyldimethylsilyl)oxy)ethanol (100 g, 567 mmol) dissolved in CH2Cl2 (200 mL) was added slowly at −78° C. The reaction mixture was stirred at −78° C. for 1 h. Triethylamine (287 g, 395 mL, 2.84 mmol) was added dropwise at −78° C. The mixture was stirred at −78° C. for 30 min and then rt overnight. The reaction mixture was washed with water (1 L), 1 N HCl (2×1 L), satd aq NaHCO3 solution (1 L) and brine (1 L). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under vacuum to give 2-((tert-butyldimethylsilyl)oxy)acetaldehyde (98.5 g, 99.8%) as a brown oil, which was used for the next step directly without further purification. 1H NMR (CDCl3, 400 MHz): δ 9.70 (s, 1H), 4.22 (s, 2H), 0.93 (s, 9H), 0.11 (s, 6H).
    • Step 4: (Rc,E)-N-(2-((tert-butyldimethylsilyl)oxy)ethylidene)-2-methylpropane-2-sulfinamide
  • A mixture of 2-((tert-butyldimethylsilyl)oxy)acetaldehyde (93.5 g, 0.54 mol), (R)-2-methylpropane-2-sulfinamide (78.8 g, 0.65 mol) and copper (II) sulfate (215 g, 1.35 mol) in anhydrous CH2Cl2 (1.5 L) was stirred at rt for 16 h. The mixture was quenched with H2O (800 mL) and separated. The aqueous phase was extracted with CH2Cl2 (2×1 L). The combined organic layers were washed with water (1 L) and brine (1 L), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (eluting with petroleum ether:EtOAc=8:1) to give (Rc,E)-N-(2-((tert-butyldimethylsilyl)oxy)ethylidene)-2-methylpropane-2-sulfinamide (38.5 g, 26%) as a yellow oil. 1H NMR (CDCl3, 400 MHz): δ 7.96-7.97 (t, J=3.2 Hz, 1H), 4.44-4.45 (d, J=2.8 Hz, 2H), 1.11 (s, 9H), 0.00 (s, 6H).
    • Step 5: (R)—N—((R)-2-((tert-butyldimethylsilyl)oxy)-1-(4-(ethylthio)phenyl)ethyl)-2-methylpropane-2-sulfinamide
  • To a solution of (4-bromophenyl)(ethyl)sulfane (28.9 g, 133.1 mmol) in anhydrous THE (500 mL) was added dropwise n-butyllithium (73 mL, 181.5 mmol, 2.5 M in hexanes) at −78° C. The mixture was stirred at −78° C. for 30 min. A solution of (Rc,E)-N-(2-((tert-butyldimethylsilyl)oxy)ethylidene)-2-methylpropane-2-sulfinamide (33.5 g, 121 mmol) in anhydrous THE (100 mL) was added to the mixture at −78° C. The mixture was stirred at −78° C. for 2 h, then allowed to warm to rt and stirred for 2 h. The mixture was quenched with satd aq NH4Cl solution (200 mL) and extracted with EtOAc (3×300 mL). The combined organic layer was washed with water (200 mL) and brine (200 mL), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (eluting with petroleum ether:EtOAc=15:1) three times to afford (R)—N—((R)-2-((tert-butyldimethylsilyl)oxy)-1-(4-(ethylthio)phenyl)ethyl)-2-methylpropane-2-sulfinamide (22 g, 44%) as a yellow oil. 1H NMR (CDCl3, 400 MHz): δ 7.21-7.24 (d, J=7.2 Hz, 2H), 7.18-7.21 (d, J=8.4 Hz, 2H), 4.42-4.45 (dd, J=8.8, 2.4 Hz, 1H), 4.21 (brs, 1H), 3.69-3.73 (dd, J=10.4, 4.4 Hz, 1H), 3.51-3.56 (t, J=9.6 Hz, 1H), 2.87-2.92 (q, J=7.6 Hz, 2H), 1.25-1.29 (t, J=7.2 Hz, 3H), 1.18 (s, 9H), 0.88 (s, 9H), 0.02 (s, 6H). LC-MS Method 3 tR=1.010 min MS (ESI) m/z 437.9 [M+Na]+. Isomer SFC tR=3.607 and 4.014 min in 12 min chromatography (AD-H_5_5_40_2.3 5 ML), ee=90.85%.
    • Step 6: (R)-2-amino-2-(4-(ethylthio)phenyl)ethanol
  • To a solution of (R)—N—((R)-2-((tert-butyldimethylsilyl)oxy)-1-(4-(ethylthio)phenyl)ethyl)-2-methylpropane-2-sulfinamide (22 g, 52.9 mmol) in CH2Cl2 (250 mL) was added HCl (26.5 mL, 4 N in dioxane) at 0° C. The mixture was stirred at rt for 2 h. LC-MS showed no starting material remaining. The mixture was concentrated under reduced pressure to afford crude (R)-2-amino-2-(4-(ethylthio)phenyl)ethanol HCl salt (12.3 g, 100%) as a brown solid, which was used for the next step directly without further purification. LC-MS tR=1.226 min in 0-30AB_2 min chromatography (Xtimate 3 um, C18, 2.1*30 mm), MS (ESI) m/z 180.9 [M-OH]+.
    • Step 7: (R)-2-amino-2-(4-(ethylsulfonyl)phenyl)ethanol
  • To a mixture of (R)-2-amino-2-(4-(ethylthio)phenyl)ethanol (15.2 g, 65.0 mmol) in methanol (200 mL) was added dropwise a solution of oxone reagent (80.0 g, 130.0 mmol) in water (200 mL) at 0° C. The mixture was stirred at rt for 1.5 h; LC-MS showed no starting material remaining. The mixture was filtered and methanol was removed under reduced pressure. The aqueous phase was extracted with EtOAc (2×80 mL), then the aqueous layer was basified to pH=8-9 with solid sodium carbonate portionwise at 0° C., then this solution was lyophilized (contained the Na2CO3). The solid was dissolved in CH2Cl2:MeOH (3:1, 600 mL) and stirred for 30 min, filtered, then concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with CH2Cl2:MeOH=1:0 to 4:1) to give (R)-2-amino-2-(4-(ethylsulfonyl)phenyl)ethanol (11.5 g, 77%) as a white solid. LC-MS tR=0.738 min in 0-30CD_POS chromatography (Xtimate ODS 2.1*30 mm, 3 um), MS (ESI) m/z 230.1 [M+H]+. Isomer SFC tR=6.99 min in 30 min chromatography (CD-PH_10-80_B_08 ML), ee=97.42%. 1H NMR (D2O, 400 MHz): δ 7.82-7.84 (d, J=8.0 Hz, 2H), 7.54-7.56 (d, J=8.4 Hz, 2H), 4.33-4.35 (t, J=6.4 Hz, 1H), 3.72-3.78 (m, 2H), 3.19-3.25 (q, J=7.6 Hz, 2H), 1.03-1.07 (t, J=7.6 Hz, 3H).
    • Preparation 10 Alternate Preparation of AM8.1
  • Figure US20210094940A1-20210401-C00041
    • Step 1: 4-(ethylsulfonyl)benzaldehyde
  • To a solution of 4-fluorobenzaldehyde (24.6 g, 198 mmol) in dimethylsulfoxide (60 mL) was added sodium ethanesulfinate (46 g, 396 mmol). The resulting mixture was stirred at 125° C. for 20 h. After cooling to rt, the reaction mixture was triturated with 350 mL of H2O. The product was filtered, washed with two 10-mL portions of EtOH and dried under vacuum to afford 4-(ethylsulfonyl)benzaldehyde as a light yellow solid (31.2 g, 80% yield). LC-MS tR=1.19 min in 2 min chromatography, MS (ESI) m/z 199.1 [M+H]+. 1H NMR (CDCl3) δ 10.14 (s, 1H), 8.09 (s, 4H), 3.16 (q, J=7.2 Hz, 2H), 1.30 (t, J=7.2 Hz, 3H).
    • Step 2: 2-(4-(ethylsulfonyl)phenyl)oxirane
  • To a solution of 4-(ethylsulfonyl)benzaldehyde (10 g, 50.5 mmol) in DMF (85 mL) at rt was added trimethylsulfonium iodide (11.9 g, 58.1 mmol) followed by potassium hydroxide powder (5.66 g, 101 mmol). The reaction mixture was stirred at rt for 20 min before quenching with H2O (50 mL). The mixture was carefully neutralized with 1 N HCl solution (55 mL) and extracted with EtOAc (3×100 mL). The combined organic phase was washed with brine, dried over anhydrous Na2SO4, and passed through a pad of silica gel (eluting with EtOAc). It was concentrated under reduced pressure to afford crude 2-(4-(ethylsulfonyl)phenyl)oxirane as yellow oil, which was used directly for the next step without further purification. LC-MS tR=1.13 min in 2 min chromatography, MS (ESI) m/z 213.2 [M+H]+.
    • Step 3: 2-amino-2-(4-(ethylsulfonyl)phenyl)ethan-1-ol
  • To a solution of crude 2-(4-(ethylsulfonyl)phenyl)oxirane (50.5 mmol) in CH3CN (200 mL) at 0° C. was slowly added concentrated sulfuric acid (5.4 mL, 101 mmol). The mixture was allowed to stir at rt for 1.5 h. LC-MS showed the starting material was consumed. H2O (15 mL) was added to the reaction mixture. Stirring continued at rt for 8 h, then at 45° C. for 10 h. After cooling to rt, the pH of the reaction mixture was adjusted to 3-4 by addition of 1 N NaOH solution (90 mL). The mixture was extracted with EtOAc (100 mL). The organic phase was then extracted with H2O (2×30 mL). The combined aqueous layers were then basified with 1 N NaOH solution (110 mL) to pH=9 and extracted with 1-butanol (5×60 mL). The combined organic layer (consisting of 1-butanol extracts) was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. It was dried under high vacuum to afford crude 2-amino-2-(4-(ethylsulfonyl)phenyl)ethan-1-ol as an off-white solid. 4 g, 35% yield over 3 steps. Intermediate 4-(4-(ethylsulfonyl)phenyl)-2-methyl-4,5-dihydrooxazole: LC-MS tR=0.77, 0.81 min in 2 min chromatography, MS (ESI) m/z 254.26 [M+H]+. 2-amino-2-(4-(ethylsulfonyl)phenyl)ethan-1-ol: LC-MS tR=0.61 min in 2 min chromatography, MS (ESI) m/z 230.21 [M+H]+. 1H NMR (CD3OD): δ 7.88 (d, J=8.4 Hz, 2H), 7.64 (d, J=8.4 Hz, 2H), 4.16-4.12 (m, 1H), 3.76-3.72 (m, 1H), 3.66-3.61 (m, 1H), 3.17 (q, J=7.2 Hz, 2H), 1.19 (t, J=7.2 Hz, 3H).
    • Step 4: 2-amino-2-(4-(ethylsulfonyl)phenyl)ethan-1-ol mono-mandelate salt
  • To a solution of 2-amino-2-(4-(ethylsulfonyl)phenyl)ethan-1-ol (238 mg, 1.0 mmol) in MeOH (3 mL) at 50° C. was added a solution of (R)-Mandelic acid (76 mg, 0.5 mmol) in MeOH (1 mL). The resulting solution was allowed to cool down to ambient temperature slowly. After stirring for 1 day, the resulting crystals were collected by vacuum filtration and dried under high vacuum, providing the mono-mandelate salt as a white crystal, 107 mg (28% yield), 92.5% ee. 1H NMR (CD3OD): δ 7.97 (d, J=8.0 Hz, 2H), 7.71 (d, J=8.4 Hz, 2H), 7.46 (d, J=8.0 Hz, 2H), 7.46 (d, J=8.0 Hz, 2H), 7.31-7.27 (m, 2H), 7.25-7.22 (m, 1H), 4.42-4.42 (m, 1H), 3.92-3.89 (m, 1H), 3.81-3.77 (m, 1H), 3.21 (q, J=7.2 Hz, 2H), 1.21 (t, J=7.2 Hz, 3H).
    • Preparation 11 (S)-2-amino-2-(4-(ethylsulfonyl)phenyl)ethanol (AM8.2)
  • Figure US20210094940A1-20210401-C00042
  • This compound is prepared following procedures analogous to those described for AM8.1 using (S)-2-methylpropane-2-sulfinamide in Step 4
    • Preparation 12 (R)-2-amino-2-(4-(ethylsulfonyl)-2-fluorophenyl)ethan-1-ol (AM9.1)
  • Figure US20210094940A1-20210401-C00043
  • This compound is prepared following procedures analogous to those described for AM8.1 using (4-bromo-3-fluorophenyl)(ethyl)sulfane in Step 5.
    • Preparation 13 (R)-2-amino-2-(5-(methylsulfonyl)pyridin-2-yl)ethanol (AM10.1)
  • Figure US20210094940A1-20210401-C00044
  • This compound is prepared using procedures analogous to those described for AM11.1 using NaSMe in Step 1.
    • Preparation 14 (S)-2-amino-2-(5-(methylsulfonyl)pyridin-2-yl)ethanol (AM10.2)
  • Figure US20210094940A1-20210401-C00045
  • This compound is prepared following procedures analogous to those described for AM11.1 using NaSMe in Step 1 and (S,E)-N-(2-((tert-butyldimethylsilyl)oxy)ethylidene)-2-methylpropane-2-sulfinamide in Step 2.
    • Preparation 15 (R)-2-amino-2-(5-(ethylsulfonyl)pyridin-2-yl)ethanol (AM11.1)
  • Figure US20210094940A1-20210401-C00046
    • Step 1: 2-bromo-5-(ethylthio)pyridine
  • To a mixture of 2-bromo-5-fluoropyridine (6.28 g, 35.66 mmol) in anhydrous DMF (60 mL) was added sodium ethanethiolate (3 g, 35.66 mmol). The mixture was stirred at 100° C. for 3 h. TLC (petroleum ether/EtOAc 10/1) showed that the starting material was not consumed completely. Additional sodium ethanethiolate (0.9 g, 9.56 mmol) was added to the mixture. The mixture was stirred at 100° C. for 12 h. The mixture was quenched with H2O (150 mL) and extracted with EtOAc (3×150 mL). The combined organic layers were washed with brine (400 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with petroleum ether/EtOAc 80/1) to afford 2-bromo-5-(ethylthio)pyridine (7.0 g, 90%) as a colorless oil. LC-MS Method 3 tR=0.717 min, MS (ESI) m/z 217.6 [M+H]+.
    • Step 2: (R)—N—((R)-2-((tert-butyldimethylsilyl)oxy)-1-(5-(ethylthio)pyridin-2-yl)ethyl)-2-methylpropane-2-sulfinamide
  • To a solution of toluene (60 mL) was added n-BuLi (10.6 mL, 26.48 mmol, 2.5 M in hexanes) dropwise at −78° C.; the internal temperature did not exceed −50° C. A solution of 2-bromo-5-(ethylthio)pyridine (3.85 g, 17.65 mmol) in toluene (10 mL) was then added to the reaction mixture at −78° C.; the internal temperature did not exceed −65° C. The mixture was stirred at −78° C. for 1 h. A solution of (Rc,E)-N-(2-((tert-butyldimethylsilyl)oxy)ethylidene)-2-methylpropane-2-sulfinamide (4.90 g, 17.65 mmol) in toluene (10 mL) was added to the reaction mixture at −78° C.; the internal temperature did not exceed −60° C. The mixture was stirred at −78° C. for another 2 h. The mixture was quenched with brine (150 mL) at −78° C. and extracted with EtOAc (3×150 mL). The combined organic layers were washed with brine (400 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with petroleum ether/EtOAc 10/1 to 3/1) to afford (R)—N—((R)-2-((tert-butyldimethylsilyl)oxy)-1-(5-(ethylthio)pyridin-2-yl)ethyl)-2-methylpropane-2-sulfinamide (3.0 g, 41%) as a pale yellow oil. LC-MS Method 3 tR=1.014 min, MS (ESI) m/z 417.2 [M+H]+.
    • Step 3: (R)-2-amino-2-(5-(ethylthio)pyridin-2-yl)ethanol
  • A procedure analogous to that in Preparation 9 Step 6 is employed.
    • Step 4: (R)-2-amino-2-(5-(ethylsulfonyl)pyridin-2-yl)ethanol
  • A procedure analogous to that in Preparation 9 Step 7 is employed. 1H NMR (CD3OD, 400 MHz): δ 9.08 (s, 1H), 8.35 (dd, J=2.0, 8.4 Hz, 1H), 7.79 (d, J=8.4 Hz, 1H), 4.70 (t, J=5.6 Hz, 1H), 4.03 (dd, J=4.8, 12.0 Hz, 1H), 3.91 (dd, J=4.8, 11.6 Hz, 1H), 3.29 (q, J=7.2 Hz, 2H), 1.25 (t, J=7.2 Hz, 3H).
    • Preparation 16 (S)-2-amino-2-(5-(ethylsulfonyl)pyridin-2-yl)ethanol (AM11.2)
  • Figure US20210094940A1-20210401-C00047
  • This compound was prepared using procedures analogous to those described for AM11.1 using (S,E)-N-(2-((tert-butyldimethylsilyl)oxy)ethylidene)-2-methylpropane-2-sulfinamide in Step 2.
    • Preparation 17 Methyl 2-((4-(aminomethyl)piperidin-1-yl)sulfonyl)acetate (AM13)
  • Figure US20210094940A1-20210401-C00048
  • Step 1
  • To a mixture of tert-butyl (piperidin-4-ylmethyl)carbamate (100 mg, 0.469 mmol) in CH2Cl2 (2 mL) was added methyl 2-(chlorosulfonyl)acetate (89 mg, 0.516 mmol) and Et3N (95 mg, 0.938 mmol). The mixture was stirred at rt for 16 h. TLC (petroleum ether/EtOAc=1/1) showed that a new spot was observed and TLC (CH2Cl2/MeOH=10/1) showed that the starting material was consumed completely. The mixture was quenched with H2O (20 mL) and extracted with CH2Cl2 (3×20 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by preparative TLC with petroleum ether/EtOAc=1/1 to afford methyl 2-((4-(((tert-butoxycarbonyl)amino)methyl)piperidin-1-yl)sulfonyl)acetate (100 mg, 61%) as a white solid. 1H NMR (CDCl 3 400 MHz): δ 4.70-4.59 (m, 1H), 3.93 (s, 2H), 3.85 (d, J=12.4 Hz, 2H), 3.80 (s, 3H), 3.04 (t, J=6.0 Hz, 2H), 2.86 (dt, J=2.0, 12.0 Hz, 2H), 1.78 (d, J=10.4 Hz, 2H), 1.70-1.53 (m, 1H), 1.44 (s, 9H), 1.38-1.24 (m, 2H).
  • Step 2
  • A solution of methyl 2-((4-(((tert-butoxycarbonyl)amino)methyl)piperidin-1-yl)sulfonyl)acetate (60 mg, 0.33 mmol) in dioxane (1 mL) was added HCl/dioxane (3 mL, 4 M) and then stirred at rt for 2 h. TLC (petroleum ether/EtOAc=1/1) showed that the reaction was completed. The mixture was concentrated under reduced pressure to afford crude methyl 2-((4-(aminomethyl)piperidin-1-yl)sulfonyl)acetate HCl salt (36 mg, 73%) as a yellow oil, which was used for the next step directly without further purification.
    • Preparation 18 (R)-1-(4-(ethylsulfonyl)phenyl)-2-methoxyethan-1-amine (AM16)
  • Figure US20210094940A1-20210401-C00049
  • Step 1
  • NaH (87 g, 2179.08 mmol, 60% in mineral oil) in anhydrous THE (600 mL) was added (E)-but-2-ene-1,4-diol (80 g, 907.95 mmol) in anhydrous THE (200 mL) dropwise via dropping funnel over 20 min under N2 with an ice-water bath. The reaction mixture was stirred at 0-5° C. for 1 h. Then CH3I (758 g, 5340.28 mmol) was added dropwise over 30 min. The resulting mixture was stirred at 16-19° C. for 16 h. TLC (petroleum ether:EtOAc=5:1) showed the starting material was consumed. The reaction was cooled with an ice-water bath, quenched with water (100 mL), diluted with EtOAc (1.5 L). The mixture was washed with brine (3×500 mL), dried over anhydrous Na2SO4, filtered and the filtrate was concentrated under reduced pressure to afford (E)-1,4-dimethoxybut-2-ene (94.9 g crude, 90% purity, 90%) as a colorless oil which was used for the next step directly without further purification. 1H NMR (CDC3, 400 MHz): δ 5.71 (t, J=3.6 Hz, 2H), 4.00 (d, J=4.4 Hz, 4H), 3.33 (s, 6H).
  • Step 2
  • A solution of (E)-1,4-dimethoxybut-2-ene (86.9 g, 748.28 mmol) in anhydrous CH2Cl2 (1 L) and anhydrous MeOH (0.5 L) was bubbled with Ozone at −78° C. After the reaction mixture was stirred at −78° C. for 1 h and the reaction mixture turn blue. Excess Ozone was removed by bubbling argon through the reaction mixture. TLC (petroleum ether:EtOAc=5:1) showed the starting material was consumed. The 2-methoxyacetaldehyde (crude in CH2Cl2 and MeOH, 100%) was used for the next step directly without further purification.
  • Step 3
  • To a solution of above 2-methoxyacetaldehyde (crude in CH2Cl2 and MeOH, 748.28 mmol) was add a solution of (R)-2-methylpropane-2-sulfinamide (109 g, 897.93 mmol) in anhydrous CH2Cl2 (500 mL) and CuSO4 (179 g, 1127.42 mmol) in anhydrous CH2Cl2 (1.5 L) under N2. The reaction mixture was stirred at 18-20° C. for 20 h. TLC (petroleum ether:EtOAc=5:1) showed the reaction was completed. The reaction mixture was filtered and the filter cake was washed with CH2Cl2 (3×1.5 L). The combined organic layers were concentrated under reduced pressure, purified by column chromatograph on silica gel (eluting with petroleum ether: EtOAc=20:1-3:1) to give (Rc,E)-N-(2-methoxyethylidene)-2-methylpropane-2-sulfinamide (47 g, 92% purity, 35%) as a brown oil. 1H NMR (CDCl 3 400 MHz): δ 8.08 (t, J=2.8 Hz, 1H), 4.32 (t, J=3.6 Hz, 2H), 3.45 (s, 3H), 1.20 (s, 9H).
  • Step 4
  • To a solution of (4-bromophenyl)(ethyl)sulfane (51.2 g, 235.8 mmol) in anhydrous THE (1 L) was added n-BuLi (128.6 mL, 321.55 mmol, 2.5 M in hexane) dropwise via dropping funnel over 30 min at −78° C. under N2. After addition, the reaction mixture was stirred at −78° C. for 30 min. Then a solution of (Rc,E)-N-(2-methoxyethylidene)-2-methylpropane-2-sulfinamide (38 g, 214.37 mmol) in anhydrous THE (300 mL) was added dropwire via dropping funnel over 30 min. The reaction mixture was stirred at −78° C. for 1 h. TLC (petroleum ether:EtOAc=2:1) showed the starting material was consumed. The mixture was quenched with satd aq NH4Cl solution (100 mL). The mixture was added with EtOAc (1.2 L), washed with brine (3×500 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure, purified by column chromatograph on silica gel (eluting with petroleum ether:EtOAc=10:1-2:3) to afford (R)—N—((R)-1-(4-(ethylthio)phenyl)-2-methoxyethyl)-2-methylpropane-2-sulfinamide (9 g, 93% purity), and the mixture of racemic (R)—N—((R)-1-(4-(ethylthio)phenyl)-2-methoxyethyl)-2-methylpropane-2-sulfinamide and (R)—N—((S)-1-(4-(ethylthio)phenyl)-2-methoxyethyl)-2-methylpropane-2-sulfinamide (35 g). The racemic was further purified by preparative HPLC (neutral) to give (R)—N—((R)-1-(4-(ethylthio)phenyl)-2-methoxyethyl)-2-methylpropane-2-sulfinamide (18 g, 99% purity, 40%) and (R)—N—((S)-1-(4-(ethylthio)phenyl)-2-methoxyethyl)-2-methylpropane-2-sulfinamide (7.0 g, 99% purity, 10%) as colorless oil. LC-MS Method 2 tR=1.306 min, MS (ESI) m/z 316.2 [M+H]+.
  • Neutral Preparative HPLC Method
  • Mobile phase A: water with 10 mM NH4HCO3
    Mobile phase B: CH3CN
    Flow rate: 150 mL/min.
    Detection: UV 220 nm/254 nm
    Column: Phenomenex luna C18 250*77 mm*10 um
    Column temperature: 30° C.
  • Time in min % A % B
    0.00 80 20
    30.00 36 64
    31.00 0 100
    40.00 0 100
  • Step 5
  • To a solution of (R)—N—((R)-1-(4-(ethylthio)phenyl)-2-methoxyethyl)-2-methylpropane-2-sulfinamide (18.0 g, 57.05 mmol) in anhydrous CH2Cl2 (400 mL) was added HCl/dioxane (28.5 mL, 114.10 mmol, 4.0 M in 1,4-dioxane) dropwise via dropping funnel over 10 min under N2. Then the reaction was stirred at rt for 16 h. TLC (petroleum ether:EtOAc=1:3) showed the starting material was consumed. The solvent was removed under reduced pressure to afford crude (R)-1-(4-(ethylthio)phenyl)-2-methoxyethanamine HCl salt (20 g crude, 89.48% purity, 100%) as a brown solid, which was used for the next step directly without further purification. LC-MS: tR=1.225 min in 0-60AB_2.0 min chromatography (A: Xtimate ODS 2.1*30 mm, B: XBrige Shield RP18 2.1*50 mm), MS (ESI) m/z 195.2 [M-NH3]+.
  • Step 6
  • To a solution of (R)-1-(4-(ethylthio)phenyl)-2-methoxyethanamine (20 g crude, 57.05 mmol) in MeOH (300 mL) was added a solution of oxone (63 g, 102.69 mmol) in H2O (500 mL) dropwise via dropping funnel over 30 min at 0-5° C. with an ice-water bath. Then the reaction mixture was stirred at rt for 2 h. LC-MS showed the starting material was consumed. The mixture was cooled down to 0-5° C. with an ice-water bath for 10 min, quenched with sat. Na2SO3 solution (300 mL), basified to pH=12-14 with 10% w/w NaOH solution, extracted with EtOAc (3×1 L). The combined organic layers were washed with brine (3×1.2 L), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatograph on silica gel (eluting with CH2Cl2: MeOH=50:1 to 10:1) to give (R)-1-(4-(ethylsulfonyl)phenyl)-2-methoxyethanamine (12.5 g, 97% purity, 90%) as a brown oil. LC-MS: tR=1.428 min in 0-60CD_POS_3.0 min chromatography (A: Xtimate ODS 2.1*30 mm, B: XBrige Shield RP18 2.1*50 mm), MS (ESI) m/z 244.1 [M+H]+.
    • Preparation 19 (R)-1-(5-(ethylsulfonyl)pyridin-2-yl)-2-methoxyethan-1-amine (AM17)
  • Figure US20210094940A1-20210401-C00050
  • This compound was prepared using procedures analogous to those described for AM 17
    • Preparation 20 4-(aminomethyl)-N-methylpiperidine-1-sulfonamide (AM18)
  • Figure US20210094940A1-20210401-C00051
  • Step 1
  • To a mixture of tert-butyl (piperidin-4-ylmethyl)carbamate (30 mg, 0.141 mmol) in CH2Cl2 (1 mL) was added methylsulfamoyl chloride (21 mg, 0.155 mmol) and Et3N (43 mg, 0.423 mmol). The mixture was stirred at rt for 16 h under N2. TLC (petroleum ether/EtOAc=1/2) showed that a new major spot was observed. The mixture was diluted with CH2Cl2 (20 mL) and washed with brine (20 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by preparative TLC with petroleum ether/EtOAc=1/2 to afford tert-butyl ((1-(N-methylsulfamoyl)piperidin-4-yl)methyl)carbamate (35 mg, 81%) as a yellow oil. 1H NMR (CDCl 3 400 MHz): δ 4.66-4.55 (m, 1H), 4.00-3.92 (m, 1H), 3.96 (d, J=4.8 Hz, 2H), 3.03 (t, J=6.4 Hz, 2H), 2.80-2.69 (m, 5H), 1.76 (d, J=13.2 Hz, 2H), 1.62-1.55 (m, 1H), 1.43 (s, 9H), 1.33-1.20 (m, 2H).
  • Step 2
  • To a solution of tert-butyl ((1-(N-methylsulfamoyl)piperidin-4-yl)methyl)carbamate (35 mg, 0.114 mmol) in dioxane (1 mL) was added HCl/dioxane (3 mL, 4 M). The mixture was stirred at rt for 2 h. TLC (petroleum ether/EtOAc=1/2) showed that the starting material was consumed completely. The mixture was concentrated under reduced pressure to afford crude 4-(aminomethyl)-N-methylpiperidine-1-sulfonamide HCl salt (28 mg, 100%) as a pale yellow oil, which was used for the next step directly without further purification.
    • Preparation 21 2-((4-(aminomethyl)piperidin-1-yl)sulfonyl)-N-methylacetamide(AM19)
  • Figure US20210094940A1-20210401-C00052
  • Step 1
  • To a mixture of tert-butyl (piperidin-4-ylmethyl)carbamate (100 mg, 0.469 mmol) in CH2Cl2 (2 mL) was added methyl 2-(chlorosulfonyl)acetate (89 mg, 0.516 mmol) and Et3N (95 mg, 0.938 mmol). The mixture was stirred at rt for 16 h. TLC (petroleum ether/EtOAc=1/1) showed that the desired spot was observed and TLC (CH2C2/MeOH=10/1) showed that the starting material was consumed completely. The mixture was quenched with H2O (20 mL) and extracted with CH2Cl2 (3×20 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by preparative TLC with petroleum ether/EtOAc=1/1 to afford methyl 2-((4-(((tert-butoxycarbonyl)amino)methyl)piperidin-1-yl)sulfonyl)acetate (100 mg, 61%) as a white solid. 1H NMR (CDCl 3 400 MHz): δ 4.70-4.59 (m, 1H), 3.93 (s, 2H), 3.85 (d, J=12.4 Hz, 2H), 3.80 (s, 3H), 3.04 (t, J=6.0 Hz, 2H), 2.86 (dt, J=2.0, 12.0 Hz, 2H), 1.78 (d, J=10.4 Hz, 2H), 1.70-1.53 (m, 1H), 1.44 (s, 9H), 1.38-1.24 (m, 2H).
  • Step 2
  • To a mixture of methyl 2-((4-(((tert-butoxycarbonyl)amino)methyl)piperidin-1-yl)sulfonyl)acetate (100 mg, 0.286 mmol) in MeOH (5 mL) was added LiOH H2O (120 mg, 2.86 mmol) and H2O (1 mL). The mixture was stirred at rt for 5 h. TLC (EtOAc) showed that the reaction was completed. The mixture was concentrated under reduced pressure. The residue was diluted with H2O (10 mL) and adjusted to pH=4-5 with 1 NHCl solution. The aqueous layer was extracted with EtOAc (3×15 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford crude 2-((4-(((tert-butoxycarbonyl)amino)methyl)piperidin-1-yl)sulfonyl)acetic acid (96 mg, 100%) as a pale yellow solid, which was used for the next step directly without further purification.
  • Step 3
  • To a mixture of crude 2-((4-(((tert-butoxycarbonyl)amino)methyl)piperidin-1-yl)sulfonyl)acetic acid (96 mg, 0.286 mmol) in DMF (5 mL) was added MeNH2.HCl (38 mg, 0.572 mmol), HATU (217 mg, 0.572 mmol) and Et3N (58 mg, 0.572 mmol). The mixture was stirred at rt for 16 h under N2. TLC (EtOAc) showed that a new spot was observed. The mixture was diluted with EtOAc (30 mL) and washed with brine (3×30 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by preparative TLC with EtOAc to afford tert-butyl ((1-((2-(methylamino)-2-oxoethyl)sulfonyl)piperidin-4-yl)methyl)carbamate (65 mg, 65%) as a pale yellow solid. 1H NMR (CDCl 3 400 MHz): δ 6.47-6.39 (m, 1H), 4.60-4.50 (m, 1H), 3.80-3.70 (m, 4H), 3.03-2.94 (m, 2H), 2.82-2.70 (m, 5H), 1.75-1.68 (m, 2H), 1.61-1.57 (m, 1H), 1.37 (s, 9H), 1.30-1.16 (m, 2H).
  • Step 4
  • To a mixture of tert-butyl ((1-((2-(methylamino)-2-oxoethyl)sulfonyl)piperidin-4-yl)methyl)carbamate (35 mg, 0.1 mmol) in dioxane (0.5 mL) was added HCl/dioxane (2 mL, 4 M). The mixture was stirred at rt for 2 h. TLC (EtOAc) showed that the reaction was completed. The mixture was concentrated under reduced pressure to afford crude 2-((4-(aminomethyl)piperidin-1-yl)sulfonyl)-N-methylacetamide HCl salt (28 mg, 100%) as a yellow oil, which was used for the next step directly without further purification.
    • Preparation 22 Methyl 2-amino-2-(1-(methylsulfonyl)piperidin-4-yl)acetate (AM21)
  • Figure US20210094940A1-20210401-C00053
  • Step 1
  • To a solution of methyl 2-((tert-butoxycarbonyl)amino)-2-(piperidin-4-yl)acetate (0.3 g, 1.1 mmol) in anhydrous CH2Cl2 (6 mL) was added Et3N (0.33 g, 3.3 mmol) at 0° C. under N2. Then MsCl (0.13 mL, 1.7 mmol) was added dropwise at 0° C. under N2. Then the mixture was stirred at 0° C. for 1.5 h. TLC (CH2Cl2/MeOH=15/1) showed the reaction was completed. The mixture was added with ice-water (10 mL) at 0° C. The mixture was extracted with CH2Cl2 (3×10 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford crude methyl 2-((tert-butoxycarbonyl)amino)-2-(1-(methylsulfonyl)piperidin-4-yl)acetate (360 mg, 93%) as a white solid, which was used for the next step directly without further purification.
  • Step 2
  • A procedure analogous to that used in Step 2 of the preparation of AM26 is employed.
    • Preparation 23 2-((4-(aminomethyl)piperidin-1-yl)sulfonyl)acetamide (AM22)
  • Figure US20210094940A1-20210401-C00054
  • The title compound is prepared following procedures analogous to those used for AM19, substituting NH4Cl for MeNH2.HCl in Step 3.
    • Preparation 24 Methyl (S)-3-amino-3-(4-(ethylsulfonyl)phenyl)propanoate (AM25)
  • Figure US20210094940A1-20210401-C00055
  • Step 1
  • To a stirred solution of (S)-3-(4-bromophenyl)-3-((tert-butoxycarbonyl)amino)propanoic acid (AstaTech, 990 mg, 2.88 mmol) in MeOH (5 mL) and ether (5 mL) was added 2 M Me3SiCHN2 in hexanes (5 mL in 1 mL aliquots at 2 minute intervals, 10 mmol) until a persistent yellow solution was obtained. The solution was stirred for 15 min and glacial HOAc was added dropwise until the yellow color was quenched and gas evolution ceased. The solution was concentrated and the residue was purified by chromatography on a 12-g silica cartridge eluted with a 0-50% EtOAc in hexanes gradient to afford methyl (S)-3-(4-bromophenyl)-3-((tert-butoxycarbonyl)amino)propanoate (890 mg, 86%) as a waxy solid. LC-MS 1.5 minute method tR=0.97 min, m/z=360, 358, 304, 302.
  • Step 2
  • A flask was charged with methyl (S)-3-(4-bromophenyl)-3-((tert-butoxycarbonyl)amino)propanoate (890 mg, 2.5 mmol), NaSO2Et (1.16 g, 10.0 mmol), CuI (95 mg, 0.5 mmol) and L-proline sodium salt (137 mg, 1.0 mmol). The flask was capped with a septum and flushed with dry N2 for 10 min. Dry DMSO (6 mL) was introduced by syringe and the mixture was heated at 100° C. for 1 day. The mixture was cooled, diluted with EtOAc (100 mL), washed with water (3×10 mL) and brine (10 mL), and dried over Na2SO4. Removal of the solvent left an oil (909 mg). Chromatography on a 12-g silica cartridge eluted with a 0-80% EtOAc in hexanes gradient afforded methyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4-(ethylsulfonyl)phenyl)propanoate (494 mg, 53%). LC-MS 1.5 minute method tR=0.80 min, m/z=316. Unreacted starting material (147 mg, 16%) was also recovered.
  • Step 3
  • A procedure analogous to that used in Step 2 of the preparation of AM26 is employed.
    • Preparation 25 2-amino-2-(1-(methylsulfonyl)piperidin-4-yl)ethan-1-ol (AM26)
  • Figure US20210094940A1-20210401-C00056
  • Step 1
  • To a solution of CaCl2) (158 mg, 1.42 mmol) in THF/EtOH (1 mL, VTHF/VEtOH=1/1) was added NaBH4 (108 mg, 2.84 mmol) at 0° C. under N2. The mixture was stirred at 0° C. for 1 h under N2. Then a solution of crude methyl 2-((tert-butoxycarbonyl)amino)-2-(1-(methylsulfonyl)piperidin-4-yl)acetate (50 mg, 0.14 mmol) in THF/EtOH (1 mL, VTHF/VEtOH=1/1) was added to the reaction mixture at 0° C. The mixture was allowed to warm to rt and stirred at rt overnight under N2. The mixture was quenched with water (10 mL) slowly at 0° C. The mixture was lyophilized directly and then EtOAc (30 mL) was added. The mixture was stirred at 25° C. for 1 hand filtered. The filter cake was washed with EtOAc (2×10 mL). The combined organic layers were concentrated under reduced pressure to afford crude tert-butyl (2-hydroxy-1-(1-(methylsulfonyl)piperidin-4-yl)ethyl)carbamate (45 mg, 98%) as a white solid, which was used for the next step directly without further purification. 1H NMR (CDCl 3 400 MHz): δ 4.92 (d, J=9.2 Hz, 1H), 3.90-3.75 (m, 2H), 3.73-3.60 (m, 2H), 3.55-3.40 (m, 1H), 2.83 (brs, 1H), 2.77 (s, 3H), 2.68-2.55 (m, 2H), 1.95-1.76 (m, 2H), 1.75-1.66 (m, 1H), 1.42 (s, 9H), 1.42-1.30 (m, 2H).
  • Step 2
  • To a solution of crude tert-butyl (2-hydroxy-1-(1-(methylsulfonyl)piperidin-4-yl)ethyl)carbamate (45 mg, 0.14 mmol) in dry CH2Cl2 (2 mL) was added HCl/dixoane (2 mL, 4 M) at rt. The mixture was stirred for 1 h. The solvent was removed under reduced pressure and water (5 mL) was added. The mixture was extracted with MTBE (3×5 mL). The aqueous layer was lyophilized directly to give crude 2-amino-2-(1-(methylsulfonyl)piperidin-4-yl)ethanol HCl salt (36 mg, 100%) as a colorless oil, which was used for the next step directly without further purification. 1H NMR (CD3OD 400 MHz): δ 3.90-3.80 (m, 2H), 3.75-3.70 (m, 2H), 3.20-3.05 (m, 1H), 2.86 (s, 3H), 2.85-2.70 (m, 2H), 1.95-1.80 (m, 3H), 1.60-1.40 (m, 2H).
    • Preparation 26 Methyl 2-((4-(aminomethyl)phenyl)sulfonyl)acetate (AM27)
  • Figure US20210094940A1-20210401-C00057
  • To a solution of methyl 2-((4-cyanophenyl)sulfonyl)acetate (10 mg, 0.042 mmol) in anhydrous THE (1 mL) was added Raney Ni (20 mg). The mixture was stirred at rt for 2 h under H2 (30 psi). TLC (petroleum ether/EtOAc=3/1) showed the reaction was completed. The mixture was added with CH2Cl2 (10 mL) and filtered. The filtrate was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford crude methyl 2-((4-(aminomethyl)phenyl)sulfonyl) acetate (10 mg, 100%) as a pale yellow oil, which was used for next step directly without further purification. LC-MS tR=1.702 min in 0-30 CD_3.0 min chromatography (Xtimate ODS 2.1*30 mm,3 um), MS (ESI) m/z 244.0 [M+H]+
    • Preparation 27 Ethyl (R)-2-(2-amino-2-(4-(ethylsulfonyl)phenyl)ethoxy)acetate (AM28)
  • Figure US20210094940A1-20210401-C00058
  • Step 1
  • To a solution of (R)—N—((R)-1-(4-(ethylthio)phenyl)-2-hydroxyethyl)-2-methylpropane-2-sulfinamide (500 mg, 1.65 mmol) and ethyl 2-bromoacetate (551 mg, 3.30 mmol) in anhydrous THF (10 mL) was added NaH (200 mg, 4.95 mmol, 60% in mineral oil) at 0° C. under N2. After addition, the mixture was stirred at 70° C. for 4 h. LC-MS showed that the starting material was consumed completely and the ratio of product:byproduct (2-((R)-2-((R)-1,1-dimethylethylsulfinamido)-2-(4-(ethylthio)phenyl)ethoxy)acetic acid) was 3:5. The mixture was added with sat. NH4Cl solution (6 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with water (20 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with petroleum ether/EtOAc=1/1 to afford ethyl 2-((R)-2-((R)-1,1-dimethylethylsulfinamido)-2-(4-(ethylthio)phenyl)ethoxy)acetate (150 mg, 23.5%) as a pale brown oil. LC-MS Method 3 tR=0.780 min, MS (ESI) m/z 387.9 [M+H]+
  • Step 2
  • To a solution of ethyl 2-((R)-2-((R)-1,1-dimethylethylsulfinamido)-2-(4-(ethylthio)phenyl)ethoxy)acetate (150 mg, 0.088 mmol) in anhydrous CH2Cl2 (1 mL) was added HCl/dioxane (1 mL, 4 M). The mixture was stirred at 14° C. for 2 h. TLC (petroleum ether/EtOAc=1/1) showed that the reaction was completed. The mixture was concentrated under reduced pressure to afford crude (R)-ethyl 2-(2-amino-2-(4-(ethylthio)phenyl)ethoxy)acetate HCl salt (150 mg, >100%) as a brown oil, which was used for next step directly without further purification.
  • Step 3
  • To a solution of crude (R)-ethyl 2-(2-amino-2-(4-(ethylthio)phenyl)ethoxy)acetate HCl salt (crude 150 mg, 0.088 mmol) in H2O/MeOH (4 mL/2 mL) was added Oxone (475 mg, 0.773 mmol). The mixture was stirred at 13° C. for 2 h. LC-MS showed that most was the desired MS. The mixture was added with H2O (15 mL) and Na2SO3 (95 mg, 0.773 mmol), then dry-freezing directly to afford crude (R)-ethyl 2-(2-amino-2-(4-(ethylsulfonyl)phenyl)ethoxy)acetate (670 mg, >100%, containing a lot of salts) as a white solid, which was used for next step directly without further purification. LC-MS Method 3 tR=0.471 min, MS (ESI) m/z 315.9 [M+H]+
    • Preparation 28 4-benzyl 1-(tert-butyl) 5-(aminomethyl)-1,4-diazepane-1,4-dicarboxylate (AM29)
  • Figure US20210094940A1-20210401-C00059
    • Preparation 29 2-(aminomethyl)-5-(ethylsulfonyl)phenol (AM30)
  • Figure US20210094940A1-20210401-C00060
    • Diamine Preparations Preparation 30 4-bromo-N1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)benzene-1,2-diamine
  • Figure US20210094940A1-20210401-C00061
  • Step 1
  • A solution of (2,2-difluorobenzo[d][1,3]dioxol-4-yl)methanamine (265 mg, 1.4 mmol), 4-bromo-1-fluoro-2-nitrobenzene (0.17 mL, 1.4 mmol) and i-Pr2NEt (0.53 mL, 2.9 mmol) in EtOH (7 mL) was stirred at rt for 2 h and at 50° C. for 17 h. The mixture was concentrated. The residue was taken up in EtOAc (90 mL), washed with 5% aq HCl (10 mL) and brine (10 mL), and dried over Na2SO4. Removal of the solvent left crude 4-bromo-N-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-nitroaniline (820 mg) as a yellow solid.
  • Step 2
  • A stirred mixture of crude 4-bromo-N-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-nitroaniline (820 mg, <1.4 mmol) and SnCl2 (1.08 g, 5.7 mmol) in dry DMF (10 mL) was heated at 80° C. for 2 h. Additional SnCl2 (1.08 g, 5.7 mmol) was added and heating was continued for 0.5 h. After cooling, satd aq NaHCO3 (10 mL) was added, followed by Celite. The mixture was stirred for 15 min and filtered through additional Celite, washing with EtOAc. The filtrate was washed with brine, dried over Na2SO4 and rotovaped to leave a brown oil. Chromatography on 12 g silica cartridge, eluted with a 0-100% EtOAc in hexanes gradient, afforded 4-bromo-N1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)benzene-1,2-diamine (305 mg, 60% over two steps). LC-MS Method 1 tR=1.89 min, m/z=359, 357.
    • Preparation 31 Methyl 3-amino-4-(((2,2-difluorobenzo[d][1,3]dioxol-4-yl) methyl) amino) benzoate
  • Figure US20210094940A1-20210401-C00062
  • Step 1
  • To a stirred solution of (2,2-difluorobenzo[d][1,3]dioxol-4-yl)methanamine (PharmaBlock, 2.98 g, 15.9 mmol) and methyl 4-fluoro-3-nitrobenzoate (CombiBlocks, 3.33 g, 16.7 mmol) in MeOH (80 mL) was added i-Pr2NEt (6 mL, 33.5 mmol). The mixture was stirred at rt for 2 days. A thick yellow ppt formed. The mixture was concentrated and the residue was taken up in 5% aq HCl (50 mL) and EtOAc (100 mL). The aqueous layer was separated and extracted with EtOAc (100 mL). The combined EtOAc layer was was washed with brine (20 mL), dried over Na2SO4 and concentrated to leave crude methyl 4-(((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)amino)-3-nitrobenzoate (6.07 g, 104%) as a yellow solid. LC-MS 2.5 min method tR=1.88 min, m/z=367.
  • Step 2
  • A solution of methyl 4-(((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)amino)-3-nitrobenzoate (5.88 g, 16.1 mmol) in 2:1 EtOAc/EtOH (150 mL) was stirred under H2 (1 atm, balloon) in the presence of 10% Pd on C (250 mg) for 4 h. The mixture was filtered through Celite, washing with EtOAc. The filtrate was concentrated to leave a solid (6.69 g). Chromatography on an 80 g silica cartridge, eluted with a 0-60% EtOAc in hexanes gradient, gave methyl 3-amino-4-(((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)amino)benzoate (4.75 g, 87%) as an off-white solid. LC-MS 2.5 min method tR=1.56 min, m/z=337.
  • Alternative Step 2
  • To a solution of methyl 4-(((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)amino)-3-nitrobenzoate (7.2 g, 19.7 mmol) in H2O/MeOH/THF (120 mL, V/V/V=1:1:1) was added Zn (12.8 g, 197 mmol) and NH4Cl (10.4 g, 197 mmol). The mixture was stirred at 22° C. for 45 min. TLC (petroleum ether/EtOAc=5/1) showed the reaction was completed. The mixture was added with CH2Cl2 (100 mL) and filtered. The filtrate was dried over anhydrous Na2SO4, filterer and concentrated under reduced pressure to afford methyl 3-amino-4-(((2,2-difluorobenzo[d][1,3]dioxol-4-yl) methyl) amino) benzoate (6.6 g, 99%) as a yellow solid, which was used for next step directly without further purification. LC-MS Method 3 tR=0.708 min, MS (ESI) m/z 336.9 [M+H]+
  • The diamines listed below are prepared following analogous procedures using the appropriate amine Cy2-L2-NH2 in place of (2,2-difluorobenzo[d][1,3]dioxol-4-yl)methanamine in Step 1.
  • Figure US20210094940A1-20210401-C00063
    L2 Cy2
    CH2 2,3-dihydrobenzofuran-7-yl
    CH2 benzo[d][1,3]dioxol-4-yl
    CH2 3,5-dimethoxyphenyl
    CH2 4-methoxy-3-cyanophenyl
    CH2 4-(trifluoromethoxy)phenyl
    CH2 4-cyanophenyl
    CH2 6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl
    CH2 2-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-8-yl
    CH2 3-methoxyphenyl
    CH2 2-methoxypyridin-4-yl
    CH2 3-cyanophenyl
    CH2 2-oxo-1,2-dihydroquinolin-4-yl
    Figure US20210094940A1-20210401-C00064
         		3-cyanophenyl
    (S)—CHMe 3-cyanophenyl
    (R)—CHMe 3-cyanophenyl
    CH2 2-fluoro-5-cyanophenyl
    CH2 benzofuran-4-yl
    CH2 1H-indazol-4-yl
    CH2 3-(methoxycarbonyl)phenyl
    CH2 1H-pyrrolo[2,3-c]pyridin-4-yl
    CH2 2,2-dimethyl-2,3-dihydrobenzofuran-7-yl
    CH2 2,2-difluorobenzo[d][1,3]dioxol-5-yl
    CH2 2-(trifluoromethoxy)phenyl
    CH2 (3R)-1-(t-butoxycarbonyl)pyrrolidin-3-yl
    CH2 (2R)-1-(t-butoxycarbonyl)pyrrolidin-3-yl
    CH2 3-(trifluoromethoxy)phenyl
    CH2 2-methoxy-3-(trifluoromethyl)phenyl
    CH2 1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl
    CH2 3-cyanophenyl
    CH2 3-(difluoromethoxy)phenyl
    CH2 1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl
    CH2 3-(trifluoromethoxy)-5-methoxyphenyl
    (S)—CHMe 2,2-difluorobenzo[d][1,3]dioxol-4-yl
    CH2 6-oxo-1-(2,2,2-trifluoroethyl)-1,6-dihydropyridin-3-yl
    CH2 2,3-dimethoxyphenyl
    (R)—CHMe 2,2-difluorobenzo[d][1,3]dioxol-4-yl
    • Preparation 32 3-amino-N-(4-(ethylsulfonyl)benzyl)-4-((2-fluoro-3-methoxybenzyl)amino)benzamide
  • Figure US20210094940A1-20210401-C00065
  • Step 1
  • To a stirred solution of 4-fluoro-3-nitrobenzoic acid (0.47 g, 2.5 mmol), AM2 (0.47 g, 2.4 mmol) and i-Pr2NEt (1.4 mL, 7.8 mmol) in CH2Cl2 (20 mL) was added solid HATU (1.5 g, 3.9 mmol). The mixture was stirred at rt for 2 h and concentrated. The residue was taken up in EtOAc (90 mL), washed with 5% aq HCl (2×10 mL), satd aq NaHCO3 (10 mL) and brine (10 mL), and dried over Na2SO4. Removal of the solvent left a yellow foam (1.72 g). Chromatography on a 40 g silica cartridge, eluted with a 20-100% EtOAc in hexanes gradient, afforded N-(4-(ethylsulfonyl)benzyl)-4-fluoro-3-nitrobenzamide (1.08 g, %) as a sticky solid. LC-MS Method 1 tR=1.44 min, m/z=367.
  • Step 2
  • A mixture of N-(4-(ethylsulfonyl)benzyl)-4-fluoro-3-nitrobenzamide (99 mg, 0.27 mmol), 2-fluoro-3-methoxybenzylamine (52 mg, 0.34 mmol), i-Pr2NEt (0.15 mL,).82 mmol) and i-PrOH (1 mL) was heated in a 60° C. oil bath for 16 h. The mixture was diluted with EtOAc (90 mL), washed with 5% aq HCl (10 mL) and 1:1 satd aq NaHCO3/brine (10 mL), and dried over Na2SO4. Concentration provided crude N-(4-(ethylsulfonyl)benzyl)-4-((2-fluoro-3-methoxybenzyl)amino)-3-nitrobenzamide (130 mg) as a yellow oil. LC-MS Method 1 tR=1.67 min, m/z=502.
  • Step 3
  • A solution of crude N-(4-(ethylsulfonyl)benzyl)-4-((2-fluoro-3-methoxybenzyl)amino)-3-nitrobenzamide (26 mg, 52 mol) in EtOAc (10 mL) was stirred under H2 (1 atm balloon) in the presence of 10% Pd on C (cat qty) for 45 min. The solution was filtered and concentrated to leave crude 3-amino-N-(4-(ethylsulfonyl)benzyl)-4-((2-fluoro-3-methoxybenzyl)amino)benzamide (16 mg) as a yellow oil. LC-MS Method 1 tR=1.36 min, m/z=472.
  • The following compounds are prepared following analogous procedures using the appropriate amine Cy2-L2-NH2 in place of 2-fluoro-3-methoxybenzylamine in Step 2.
  • Figure US20210094940A1-20210401-C00066
    L2 Cy2
    CH2 1-methyl-1H-indazol-7-yl
    CH2 4-methyl-6-(trifluoromethyl)pyrimidin-2-yl
    CH2 2-methyl-2H-indazol-7-yl
    CH
    2 1,2-dimethyl-1H-benzo[d]imidazol-7-yl
    CH2 1-methyl-1H-indazol-4-yl
    CH2 1H-indazol-7-yl
    CH2 2-methyl-2H-indazol-4-yl
    CH2 6-oxo-1-(2,2,2-trifluoroethyl)-1,6-dihydropyridin-3-yl
    CH2 1-(t-butoxycarbonyl)piperidin-4-yl
    CH2 1-methyl-2-oxo-1,2-dihydropyridin-3-yl
    CH2 benzo[d]oxazol-4-yl
    CH2 2,3-dihydrobenzo[b][1,4]dioxin-5-yl
    (R)-CHMe 2,2-difluorobenzo[d][1,3]dioxol-4-yl
    CH2 phenyl
    • Benzimidazole Preparations Preparation 33 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazol-5-amine
  • Figure US20210094940A1-20210401-C00067
  • Step 1
  • A solution of 4-bromo-N1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)benzene-1,2-diamine (305 mg, 0.85 mmol) in TFA (5 mL) was heated at 70° C. for 2 h and concentrated. The residue was taken up in EtOAc (90 mL), washed with satd aq NaHCO3 (10 mL) and brine (10 mL), dried over Na2SO4 and concentrated to leave an oil (283 mg). Chromatography on a 12 g silica cartridge, eluted with a 0-100% EtOAc in hexanes gradient, afforded 5-bromo-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole (138 mg, 37%) as an oil. LC-MS Method 1 tR=2.03 min, m/z=437, 435.
  • Step 2
  • A flask was charge with 5-bromo-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole (40 mg, 0.09 mmol), CuI (22 mg, 0.12 mmol), Na2CO3 (15 mg, 0.14 mmol), NaN3 (15 mg, 0.23 mmol) and DMEDA (17.5 μL, 0.16 mmol). The flask was sealed with a septum and flushed with N2 for 5 min. Dry DMSO (1 mL) was introduced using a syringe and the mixture was heated at 110° C. for 1.5 h. After cooling, the mixture was diluted with EtOAc (80 mL), washed with water (10 mL) and brine (10 mL), and dried over Na2SO4. Removal of the solvent left an oil (37 mg) which was purified by chromatography on a 12 g silica cartridge, eluted with a 0-100% EtOAc in hexanes gradient, to afford 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazol-5-amine (27 mg, 79%) as an oil. LC-MS Method 1 tR=1.48 min, m/z=372.
    • Preparation 34 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxylic Acid
  • Figure US20210094940A1-20210401-C00068
  • Step 1
  • A stirred solution of methyl 3-amino-4-(((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)amino)benzoate (290 mg, 0.86 mmol) in CF3CO2H (5 mL) at 70° C. for 2 h. The mixture was concentrated. The residue was taken up in CH2Cl2 (70 mL), washed with 9:1 brine/satd aq NaHCO3 (10 mL) and dried over Na2SO4. Removal of the solvent left an oil (368 mg). Chromatography on a 12 g silica cartridge, eluted with a 0-100% EtOAc in hexanes gradient, afforded methyl 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxylate (292 mg, 82%) as a colorless oil. LC-MS Method 1 tR=1.81 min, m/z=415.
  • Step 2
  • To a stirred solution of methyl 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxylate (292 mg, 0.70 mmol) in 2:1:1 MeOH/THF/H2O (8 mL) was added LiOH.H2O (93 mg, 2.2 mmol). After stirring overnight, the mixture was concentrated. The residue was partitioned between EtOAc (90 mL) and 5% aq HCl (10 mL). The organic layer was dried over Na2SO4 and concentrated to leave crude 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxylic acid (306 mg, 108%) as a solid, which was used without further purification. LC-MS Method 1 tR=1.63 min, m/z=401.
  • The following benzimidazole carboxylic acids are prepared by analogous procedures.
  • Figure US20210094940A1-20210401-C00069
    L2 Cy2
    CH2 2,3-dihydrobenzofuran-7-yl
    CH2 benzo[d][1,3]dioxol-4-yl
    CH2 3,5-dimethoxyphenyl
    CH2 4-methoxy-3-cyanophenyl
    CH2 4-(trifluoromethoxy)phenyl
    CH2 4-cyanophenyl
    CH2 6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl
    CH2 2-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-8-yl
    CH2 3-methoxyphenyl
    CH2 2-methoxypyridin-4-yl
    CH2 3-cyanophenyl
    CH2 2-oxo-1,2-dihydroquinolin-4-yl
    Figure US20210094940A1-20210401-C00070
         		3-cyanophenyl
    (S)-CHMe 3-cyanophenyl
    (R)-CHMe 3-cyanophenyl
    CH2 2-fluoro-5-cyanophenyl
    CH2 benzofuran-4-yl
    CH2 1H-indazol-4-yl
    CH2 3-(methoxycarbonyl)phenyl
    CH2 1H-pyrrolo[2,3-c]pyridin-4-yl
    CH2 2,2-dimethyl-2,3-dihydrobenzofuran-7-yl
  • The following benzimidazole carboxylic acid was prepared by procedures analogous to those described above using MeCF2CO2H and heating to 80° C. in Step 1.
  • Figure US20210094940A1-20210401-C00071
    • Preparation 35 2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-1H-benzo[d]imidazole-5-carboxylic Acid
  • Figure US20210094940A1-20210401-C00072
  • Step 1
  • A mixture of methyl 3-amino-4-(((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)amino)benzoate (6.6 g, 19.6 mmol), cyclobutanecarboxylic acid (3.94 g, 39.3 mmol), Et3N (6.0 g, 58.9 mmol) and HATU (8.2 mg, 21.6 mmol) in anhydrous CH2Cl2 (150 mL) was stirred at 22° C. under N2 for 2 h. LC-MS showed the reaction was completed. The mixture was added with CH2Cl2 (100 mL) and washed with water (200 mL×3), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with petroleum ether:EtOAc=10:1-5:1 to afford methyl 3-(cyclobutanecarboxamido)-4-(((2,2-difluorobenzo[d][1,3]dioxol-4-yl) methyl)amino)benzoate (8.2 g, 99%) as a pale yellow solid. LC-MS Method 3 tR=0.789 min, MS (ESI) m/z 419.0 [M+H]+
  • Step 2
  • To a solution of methyl 3-(cyclobutanecarboxamido)-4-(((2,2-difluorobenzo[d][1,3]dioxol-4-yl) methyl) amino)benzoate (8.2 g, 19.6 mmol) in TFA (80 mL) was stirred at 70° C. for 8 h under N2. LC-MS showed the reaction was completed. The mixture was concentrated under reduced pressure. The mixture was added with water (20 mL). The aqueous layer was adjusted to pH=6-7 with sat.NaHCO3 solution and extracted with CH2Cl2 (3×50 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with petroleum ether:EtOAc=10:1-5:1 to afford methyl 2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-1H-benzo[d]imidazole-5-carboxylate (6.7 g, 85%) as a pale yellow oil. LC-MS Method 3 tR=0.701 min, MS (ESI) m/z 401.1 [M+H]+ 1H NMR (CDCl 3 400 MHz): δ 8.53 (s, 1H), 7.97 (d, J=8.4 Hz, 1H), 7.24 (d, J=8.4 Hz, 1H), 7.01 (d, J=8.0 Hz, 1H), 6.95 (t, J=8.0 Hz, 1H), 6.45 (d, J=8.0 Hz, 1H), 5.32 (s, 2H), 3.95 (s, 3H), 3.79-3.66 (m, 1H), 2.67-2.58 (m, 2H), 2.46-2.32 (m, 2H), 2.19-1.99 (m, 2H).
  • Step 3
  • To a solution of methyl 2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-1H-benzo[d]imidazole-5-carboxylate (8.0 g, 20 mmol) in H2O/MeOH (100 mL, V/V=1:5) was added LiOH H2O (4.2 g, 100 mmol). The mixture was stirred at 22° C. for 16 h and 40° C. for 3 h. LC-MS showed the reaction was completed. The mixture was concentrated under reduced pressure. The residue was added with H2O (50 mL) and adjusted to pH=3-4 with 1N HCl solution to give a precipitate. After filtered, the filter cake was dissolved in MeOH (500 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford crude 2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-1H-benzo[d]imidazole-5-carboxylic acid (7.68 g, 99%) as a yellow solid, which was used for next step directly without further purification. LC-MS Method 3 tR=0.653 min, MS (ESI) m/z 387.0 [M+H]+
    • Preparation 36 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-1H-benzo[d]imidazole-5-carboxylic Acid
  • Figure US20210094940A1-20210401-C00073
  • Step 1
  • A mixture of methyl 3-amino-4-(((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)amino)benzoate (16 g, 47.62 mmol), 2,2-difluoroacetic acid (9.1 g, 95.24 mmol), HOt (12.9 g, 95.24 mmol) and EDCI (18.4 g, 95.24 mmol) in anhydrous CH2C2 (360 mL) was added Et3N (24 g, 0.24 mol) at 0° C. The mixture was stirred at 12-21° C. for 16 h under N2. LC-MS showed that 10% of starting material was still remained. The mixture was added with water (600 mL) and a lot of precipitate was found. After filtered, the filtered cake was washed with petroleum ether (3×50 mL), then dissolved with CH2Cl2/MeOH (8.1, 400 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford crude methyl 3-(2,2-difluoroacetamido)-4-(((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)amino)benzoate (14.4 g, 730%) as a white solid, which was used for next step directly without further purification. LC-MS Method 3tR=0.888 min, MS (ESI) m/z 414.9 [M+H]+.
  • Step 2
  • A mixture of methyl 3-(2,2-difluoroacetamido)-4-(((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)amino)benzoate (15 g, 36.23 mmol) in TFA (50 mL) was stirred at 70° C. for 3h. TLC showed that the reaction was completed. The mixture was concentrated under reduced pressure. The residue was added with sat. NaHCO3 solution to adjust pH=7-8 and extracted with EtOAc (2×100 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with petroleum ether/EtOAc=7/3 to afford methyl 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-1H-benzo[d]imidazole-5-carboxylate (9.38 g, 65) as a white solid. LC-MS Method 3 tR=min, MS (ESI) m/z 396.9 [M+H]+.
  • Step 3
  • To a mixture of methyl 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-1H-benzo[d]imidazole-5-carboxylate (15 g, 37.78 mmol) in MeOH/H2O (3/1, 180 mL) was added LiOH H2O (7.9 g, 0.19 mol). The mixture was stirred at 15-19° C. for 16 h and 50° C. for 3 h. LC-MS showed that the reaction was completed. The mixture was concentrated under reduced pressure to remove MeOH. The residue was adjusted to pH=4-5 with 2N HCl solution. The aqueous layer was extracted with EtOAc (3×100 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford crude 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-1H-benzo[d]imidazole-5-carboxylic acid (14.5 g, 100%) as a white solid, which was used for the next step directly without further purification. LC-MS Method 3 tR=0.717 min, MS (ESI) m/z 382.9 [M+H]+.
    • Preparation 37 2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-1H-benzo[d]imidazole-5-carboxylic Acid
  • Figure US20210094940A1-20210401-C00074
  • Step 1
  • A stirred solution of methyl 3-amino-4-(((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)amino)benzoate (252 mg, 0.75 mmol) and pyridine (0.13 mL, 1.5 mmol) in CH2Cl2 (10 mL) was cooled to −70° C. and cyclopropanecarbonyl chloride (65 μL, 0.71 mmol) was added. The dry ice bath was allowed to expire. After 2.5 h, the mixture had reached rt and water (5 mL) was added. The mixture was concentrated. The aqueous residue was diluted with EtOAc (90 mL), washed with water (5 mL), satd aq NaHCO3 (10 mL) and brine (10 mL), and dried over Na2SO4. Removal of the solvent left crude methyl 3-(cyclopropanecarboxamido)-4-(((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)amino)benzoate (307 mg) as an oil which was used without further purification.
  • Step 2
  • Crude methyl 3-(cyclopropanecarboxamido)-4-(((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)amino)benzoate (307 mg) was dissolved in HOAc (2 mL) and heated at 100° C. for 2 h. The mixture was concentrated. The residue was taken up in CH2Cl2 (3 mL) and applied to a 10-mL Chem Elut cartridge that had been prewetted with satd aq NaHCO3 (5 mL). The cartridge was eluted with EtOAc (80 mL). The eluate was concentrated to leave a brown oil (261 mg). Chromatography on a 12-g silica cartridge eluted with a 0-100% EtOAc in hexanes gradient afforded methyl 2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-1H-benzo[d]imidazole-5-carboxylate (63 mg, 22% over two steps) as an oil. LC-MS Method 1 tR=1.29 min, m/z=387.
  • Step 3
  • A solution of methyl 2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-1H-benzo[d]imidazole-5-carboxylate (63 mg, 0.16 mmol) and LiOH.H2O (75 mg, 1.8 mmol) in 2:1:1 MeOH/THF/H2O (2 mL) was stirred overnight at rt and concentrated to remove organic solvents. The aqueous residue was residue was acidified with 5% aq HCl (10 mL) and extracted with EtOAc (80 mL). The organic layer was separated, washed with brine (10 mL), dried over Na2SO4 and concentrated to provide the title compound (70 mg, quant). LC-MS Method 1 tR=1.11 min, m/z=373.
  • The following benzimidazole carboxylic acids are prepared following procedures analogous to those described in Preparations 35, 36 and 37 using the acid R1CO2H or the acid chloride R1COCl in Step 1.
  • Figure US20210094940A1-20210401-C00075
    R1 L2 Cy2
    (R)-tetrahydrofuran-2-yl CH2 2,2-difluorobenzo[d][1,3]dioxol-4-yl
    Et CH2 2,2-difluorobenzo[d][1,3]dioxol-4-yl
    1-fluorocyclopropyl CH2 2,2-difluorobenzo[d][1,3]dioxol-4-yl
    1-fluorocyclobutyl CH2 2,2-difluorobenzo[d][1,3]dioxol-4-yl
    t-Bu CH2 2,2-difluorobenzo[d][1,3]dioxol-4-yl
    i-Pr CH2 2,2-difluorobenzo[d][1,3]dioxol-4-yl
    Me CH2 2,2-difluorobenzo[d][1,3]dioxol-4-yl
    i-Bu CH2 2,2-difluorobenzo[d][1,3]dioxol-4-yl
    (S)-tetrahydrofuran-2-yl CH2 2,2-difluorobenzo[d][1,3]dioxol-4-yl
    1-methoxyethyl CH2 2,2-difluorobenzo[d][1,3]dioxol-4-yl
    2-methoxy-2-propyl CH2 2,2-difluorobenzo[d][1,3]dioxol-4-yl
    cis-2-cyanocyclopropyl CH2 2,2-difluorobenzo[d][1,3]dioxol-4-yl
    trans-2-cyancyclopropyl CH2 2,2-difluorobenzo[d][1,3]dioxol-4-yl
    cis-2- CH2 2,2-difluorobenzo[d][1,3]dioxol-4-yl
    (methoxycarbonyl)cyclopropyl
    cyclopropyl CH2 2,2-dimethyl-2,3-dihydrobenzofuran-7-yl
    cyclopropyl CH2 2,3-dihydrobenzofuran-7-yl
    cyclopropyl CH2 3,5-dimethoxyphenyl
    cyclopropyl CH2 4-(trifluoromethoxy)phenyl
    cyclopropyl CH2 2-(trifluoromethoxy)phenyl
    cyclopropyl CH2 (3R)-1-(t-butoxycarbonyl)pyrrolidin-3-yl
    cyclopropyl CH2 (2R)-1-(t-butoxycarbonyl)pyrrolidin-3-yl
    cyclopropyl CH2 3-(trifluoromethoxy)phenyl
    cyclopropyl CH2 2-methoxy-3-(trifluoromethyl)phenyl
    cyclopropyl CH2 1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl
    cyclopropyl CH2 3-cyanophenyl
    cyclopropyl CH2 3-(difluoromethoxy)phenyl
    cyclopropyl CH2 1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl
    cyclopropyl CH2 3-(trifluoromethoxy)-5-methoxyphenyl
    cyclopropyl (S)- 2,2-difluorobenzo[d][1,3]dioxol-4-yl
    CHMe
    cyclopropyl CH2 6-oxo-1-(2,2,2-trifluoroethyl)-1,6-dihydropyridin-3-yl
    cyclopropyl CH2 2,2-dimethyl-2,3-dihydrobenzofuran-7-yl
    cyclopropyl CH2 2,3-dimethoxyphenyl
    Et (R)- 2,2-difluorobenzo[d][1,3]dioxol-4-yl
    CHMe
    Et (S)- 2,2-difluorobenzo[d][1,3]dioxol-4-yl
    CHMe
    • Preparation 38 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-methoxy-1H-benzo[d]imidazole-5-carboxylic Acid
  • Figure US20210094940A1-20210401-C00076
  • Step 1
  • To a stirred, ice cold solution of methyl 3-amino-4-(((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)amino)benzoate (66 mg, 0.2 mmol) in 2:1 THF/CH2Cl2 (6 mL) was added Et3N (4 eq), followed by a solution of triphosgene (0.5 eq) in CH2Cl2 (3 mL) dropwise. After 15 min, the cooling bath was removed and the mixture was stirred at rt for 3 h. Aqueous work up afforded methyl 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate (66 mg, 93%). LC-MS Method 1 tR=1.42 min, m/z=363.
  • Step 2
  • A solution of methyl 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate (66 mg, 0.18 mmol) in POCl3 (4 mL) was heated at 120° C. for 2.5 h. The mixture was cooled and poured onto crushed ice. After the ice had melted, the aqueous mixture was extracted with EtOAc (3×). The combined organic layer was washed with water and brine, and dried over Na2SO4. Removal of the solvent left crude methyl 2-chloro-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-1H-benzo[d]imidazole-5-carboxylate (21 mg) which was used without further purification. LC-MS Method 1 tR=1.73 min, m/z=381.
  • Step 3
  • A mixture of crude methyl 2-chloro-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-1H-benzo[d]imidazole-5-carboxylate (21 mg, 0.055 mmol), 25 wt % NaOMe in MeOH (0.5 mL) and MeOH (3 mL) was stirred at rt overnight. Satd aq NH4Cl was added and the mixture concentrated to remove MeOH. The aq residue was diluted with EtOAc, washed with 1% aq HCl, water and brine, dried over Na2SO4 and concentrated. The residue was purified by chromatography on a 4-g silica cartridge, eluted with a 10-50% EtOAc in hexanes gradient, to afford methyl 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-methoxy-1H-benzo[d]imidazole-5-carboxylate (7.5 mg). LC-MS Method 1 tR=1.69 min, m/z=377.
  • Step 4
  • Methyl 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-methoxy-1H-benzo[d]imidazole-5-carboxylate (7.5 mg) was reacted with LiOH using a procedure analogous to that described in Preparation 37, Step 3 to afford the title compound. LC-MS Method 1 tR=1.36 min, m/z=363.
    • Preparation 39 N-(4-(ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide
  • Figure US20210094940A1-20210401-C00077
  • Step 1
  • A mixture of methyl 3,4-diaminobenzoate (2.93 g, 17.6 mmol) and TFA (10 mL) was heated at reflux for 2.5 h and concentrated. The residue was partitioned between EtOAc (175 mL) and satd aq NaHCO3 (40 mL). The organic layer was separated, washed with satd aq NaHCO3 (20 mL) and brine (20 mL), and dried over Na2SO4. Removal of the solvent left a dark solid (4.38 g). Chromatography on a 40-g silica cartridge, eluted with a 0-100% EtOAc in hexanes gradient, afforded methyl 2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxylate (3.06 g, 71%). LC-MS Method 1 tR=1.38 min, m/z=245.
  • Step 2
  • A stirred solution of methyl 2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxylate (278 mg, 1.1 mmol), LiOH.H2O (198 mg, 4.7 mmol) in 3:1 MeOH/H2O (8 mL) was heated at 40° C. for 2 days and concentrated. The residue was taken up in 5% aq HCl (5 mL) and MeCN (5 mL) and concentrated again to leave crude 2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxylic acid.
  • Step 3
  • Half of the crude 2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxylic acid from Step 2 (<0.55 mmol), AM2 (150 mg, 0.75 mmol) and i-Pr2NEt (0.36 mL, 2.0 mmol) were stirred in 5:1 CH2Cl2/DMF (6 mL) and solid HATU (285 mg, 0.75 mmol) was added. After stirring for 2 h, the mixture was diluted with EtOAc (90 mL), washed with 5% aq HCl (10 mL), satd aq NaHCO3 (10 mL) and brine (10 mL), and dried over Na2SO4. Removal of the solvent left an oil (348 mg). Chromatography on a 12 g silica cartridge, eluted with a 0-100% EtOAc in hexanes gradient, afforded N-(4-(ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (127 mg, 62%) as an oil. LC-MS Method 1 tR=1.35 min, m/z=412.
    • Preparation 40 3-(4-(ethylthio)phenyl)oxetan-3-amine
  • Figure US20210094940A1-20210401-C00078
  • Step 1
  • A stirred solution of (4-bromophenyl)(ethyl)sulfane (1.05 g, 4.8 mmol) in dry THE (20 mL) was cooled to −70° C. and 2.2 M n-BuLI in cyclohexane (2.8 mL, 6.1 mmol) was added dropwise over 5 min. The mixture was stirred at −70° C. for 1 h. A solution of 2-methyl-N-(oxetan-3-ylidene)propane-2-sulfinamide (936 mg, 5.3 mmol) in dry THE (2 mL) was added dropwise over 2 min. The mixture was stirred at −70° C. for 0.5 h, removed from the cooling bath and quenched with satd aq NH4Cl (20 mL) and water (10 mL). The mixture was extracted with EtOAc (2×40 mL). The combined organic layer was washed with brine (10 mL), dried over Na2SO4 and concentrated to leave a yellow oil (1.66 g). Chromatography on a 12 g silica cartridge, eluted with a 10-100% EtOAc in hexanes gradient, afforded N-(3-(4-(ethylthio)phenyl)oxetan-3-yl)-2-methylpropane-2-sulfinamide (1.07 g, 71%) as an oil. LC-MS Method 1 tR=1.33 min, m/z=314.
  • Step 2
  • To a stirred, ice cold solution of N-(3-(4-(ethylthio)phenyl)oxetan-3-yl)-2-methylpropane-2-sulfinamide (1.07 g, 3.4 mmol) in MeOH (5 mL) was added 4 M HCl in dioxane (1.3 mL, 5.1 mmol). The mixture was stirred for 2 min and concentrated to leave the title compound as its HCl salt. LC-MS Method 1 tR=0.65 min, m/z=193 [M-NH2]+
    • Preparation of Compounds of Formula I Example 1 N-(1-((2,2-difluoro-3a,7a-dihydrobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide (I-1)
  • Figure US20210094940A1-20210401-C00079
  • To a stirred solution of 1-((2,2-difluoro-3a,7a-dihydrobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazol-5-amine (13.5 mg, 36 μmol), ACl (13 mg, 58 μmol) and i-Pr2NEt (26 μL, 0.14 mmol) in CH2Cl2 (2 mL) was added solid HATU (40 mg, 0.11 mmol). The mixture was stirred at rt for 0.5 h and concentrated. The residue was purified by prep HPLC to afford N-(1-((2,2-difluoro-3a,7a-dihydrobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide (16 mg, %). 1H NMR (d4-MeOH) δ 1.20 (t, 3H), 3.18 (q, 2H), 3.84 (s, 2H), 5.72 (s, 2H), 6.77 (d, 1H), 7.04-7.18 (m, 2H), 7.47 (d, 1H), 7.59 (d, 1H), 7.62 (d, 2H), 7.86 (d, 2H), 8.19 (s, 1H). LC-MS Method 1 tR=1.80 min, m/z=582.
  • The following compounds are prepared following a similar procedure using the appropriate acid p-R6—C6H4CH2CO2H selected from AC1 to AC9:
  • Figure US20210094940A1-20210401-C00080
    Cpd.
    No. R1 R5
    I-2 CF3 SO2Me
    1-3 CF3 SO2CH2CH2OH
    1-4 CF3 SO2CH2CH2OMe
    1-5 CF3 SO2NHMe
    1-6 CF3 CN
    I-7 CF3 CH2CO2Et
    I-8 CF3 CH2CO2H
    I-9 c-Pr SO2Et
  • Compound I-10 was prepared by an analogous procedure:
  • Figure US20210094940A1-20210401-C00081
    • Example 2 (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-11.1)
  • Figure US20210094940A1-20210401-C00082
  • To a stirred solution of crude 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxylic acid (17 mg, 42 μmol), (R)-2-amino-2-(4-(ethylsulfonyl)phenyl)ethan-1-ol (AM8.1, 12.7 mg, 64 μmol) and i-Pr2NEt (30 uL, 0.17 mmol) in CH2Cl2 (2 mL) was added solid HATU (25 mg, 65 μmol). The mixture was stirred overnight and concentrated. The residue was purified by prep HPLC to afford (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (22 mg, 84%) as an oil. 1H NMR (d4-MeOH) δ 1.24 (t, 3H), 3.23 (q, 2H), 3.99 (d, 2H), 5.38 (t, 1H), 5.86 (s, 2H), 6.88 (d, 1H), 7.13-7.22 (m, 2H), 7.70 (d, 1H), 7.77 (d, 2H), 7.95 (d, 2H), 8.03 (d, 1H), 8.48 (s, 1H). LC-MS 2.5 min method tR=1.47 min, m/z=612.
  • A solution of I-11.1 (100 mg) in CH2Cl2 (2 mL) was diluted with n-Pr2O (4 mL). Additional CH2Cl2 (0.5 mL) was added to dissolve precipitate and a seed crystal of I-130.1 was added. The mixture was allowed to stand in a closed vial for 36 days, filtered and dried in vacuo to give I-11.1 (64 mg) with mp 134-136° C. This material gave the X-ray powder diffraction pattern shown in FIG. 3.
  • A solution of I-11.1 (150 mg) in i-PrOAc (2 mL) was diluted with CCl4 (8 mL). The mixture was allowed to stand overnight and filtered. The white solid collected was dried in vacuo to give I-11.1 (106 mg) which softened at 97-102° C. and melted at 135-137° C. This material gave the X-ray powder diffraction pattern shown in FIG. 4.
  • A solution of I-11.1 (100 mg) in t-BuOAc (1 mL) was diluted with benzene (2 mL). The solution was seeded with solid prepared as described immediately above and allowed to stand overnight. The white solid was collected and dried in vacuo to give I-11.1 (77 mg) which softened at 97° C. and melted −105° C. This material gave the X-ray powder diffraction pattern shown in FIG. 5.
  • Compound I-11.2, the enantiomer of I-11.1, is prepared using a similar procedure using AM8.2.
  • Figure US20210094940A1-20210401-C00083
  • The compounds listed below are prepared following procedures analogous to those described for I-11.1 using the appropriate benzimidazole carboxylic acid in place of 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxylic acid.
  • Figure US20210094940A1-20210401-C00084
    Cpd. No. R1
    I-12 c-Pr
    I-13 c-Bu
    1-14 CF2Me
    1-15 2-tetrahydrofuranyl
    I-16 Et
    I-17 CHF2
    I-18 1-fluorocyclopropyl
    I-19 1-fluorocyclobutyl
  • The compounds listed below are prepared following similar procedures using amines AM7.1 and AM7.2.
  • Figure US20210094940A1-20210401-C00085
    Cpd.
    No. * R1
    I-20.1 R CF3
    I-20.2 S CF3
    I-21 R c-Pr
    I-22 R c-Bu
    I-23.1 R CF2H
    I-23.2 S CF2H
    I-24 R 1-fluorocyclopropyl
  • The following compounds are prepared following similar procedures.
  • Figure US20210094940A1-20210401-C00086
    Cpd. No. R1 Rb
    I-25 CF3 Et
    I-26 c-Pr Et
    I-27 1-fluorocyclopropyl Et
    I-28 MeOCH2 Et
    1-29 Et Et
    I-30 t-Bu Et
    I-31 i-Pr Et
    I-32 Me Et
    I-33 i-Bu Et
    I-34 c-Pr Me
    I-35 c-Pr NHMe
    I-36 c-Bu Et
    I-37 CF2H Et
    I-38 CF2Me Et
    I-39.1a (R)-2-tetrahydrofuranyl Et
    I-39.2a (S)-2-tetrahydrofuranyl Et
    I-40 1-fluorocyclopropyl Me
    I-41 1-fluorocyclopropyl CH2CH2OH
    I-42 1-fluorocyclopropyl NHMe
    I-43 1-fluorocyclobutyl Et
    I-44 CF2H CH2CH2OH
    I-45 CF3 CH2CH2OH
    I-46 CF3 NHMe
    I-47 c-Pr CH2CH2OH
    I-48 CF3 Me
    I-49.1b MeOCHMe Et
    I-49.2b MeOCHMe Et
    I-50 CF2H Me
    I-51 CF3 NH2
    I-52 CF3 n-Pr
    I-53 CF3 CH2CO2Me
    I-54 MeOC(Me2) Et
    I-55 MeO Et
    I-56 cis-2-cyanocyclopropyl Et
    I-57 trans-2-cyanocyclopropyl Et
    I-58 trans-2- Et
    (MeO2C)cyclopropyl
    aPrepared from the corresponding chiral tetrahydrofuran-2-carboxylic acids. The stereochemical integrity of the chiral center in the final products was not confirmed.
    bThe enantiomers were separated by chromatography on a chiral column.
  • The following compounds are prepared following similar procedures.
  •
    Figure US20210094940A1-20210401-C00087
    Cpd. No. R1 A
    I-59 CF3 CH
    I-60 c-Pr CH
    I-61 1-fluorocyclopropyl CH
    I-62 CF3 N
  • The following compounds are prepared following similar procedures.
  • Figure US20210094940A1-20210401-C00088
    Cpd.
    No. R1 Rb
    I-63 CF3 Et
    I-64 c-Pr Et
    I-65 c-Bu Et
    I-66 CF2Me Et
    I-67 1-fluorocyclopropyl Et
    I-68 1-fluorocyclopropyl Me
    I-69 1-fluorocyclobutyl Et
    I-70 CF3 Me
  • The following compounds are prepared following similar procedures.
  • Figure US20210094940A1-20210401-C00089
    Cpd. No. R1 R7 Rb
    I-71 CF3 H Me
    I-72 c-Pr H Me
    I-73 1- H Me
    fluorocyclopropyl
    I-74 CF3 H CH2CO2Me
    I-75 CF3 H CH2CONHMe
    I-76 CF3 CO2Me Me
    I-77 CF3 H NHMe
    I-78 CF3 H CH2CONH2
    I-79 c-Pr H CH2CONHMe
    I-164.1a CF3 CH2OH Me
    I-164.2a CF3 CH2OH Me
    aThe isomers were separated by chromatography on a chiral column. The stereochemical configuration of the isomers was not established.
  • The following compounds are prepared following similar procedures.
  • Figure US20210094940A1-20210401-C00090
    Cpd. No. L2 Cy2 R7
    I-80 CH2 2,3-dihydro7-benzofuranyl CH2OH
    I-81 CH2 benzo[d][1,3]dioxol-4-yl CH2OH
    I-82 CH2 3,5-dimethoxyphenyl H
    I-83 CH2 4-methoxy-3-cyanophenyl H
    I-84 CH2 4-(trifluoromethoxy)phenyl H
    I-85 CH2 4-cyanophenyl H
    I-86 CH2 6,7-dihydro-5H-pyrrolo H
    [2,1-c][1,2,4]triazol-3-yl
    I-87 CH2 2-methyl-5,6,7,8-tetrahydroimidazo H
    [1,2-a]pyridin-8-yl
    I-88 CH2 3-methoxyphenyl H
    I-89 CH2 2-methoxy-4-pyridyl H
    I-90 CH2 3-cyanophenyl H
    I-91 CH2 2-oxo-1,2-dihydroquinolin-4-yl H
    I-92 c-Pr 3-cyanophenyl H
    I-93.1 (S)-CHMe 3-cyanophenyl H
    I-93.2 (R)-CHMe 3-cyanophenyl H
    I-94 CH2 2-fluoro-5-cyanophenyl H
    I-95 CH2 4-benzofuranyl H
    I-96 CH2 2,3-dihydro-4-benzofuranyl H
    I-97 CH2 4-indazolyl H
    I-98 CH2 benzo[d][1,3]dioxol-4-yl H
    I-99 CH2 3-(methoxycarbonyl)phenyl H
    I-100 CH2 1H-pyrrolo[2,3-c]pyridin-4-yl H
  • Figure US20210094940A1-20210401-C00091
    Cpd.
    No. L2 Cy2 R7
    I-101 CH2 2,2-dimethyl-2,3-dihydrobenzofuran-7-yl CH2OH
    I-102 CH2 2,3-dihydrobenzofuran-7-yl CH2OH
    I-103 CH2 3,5-dimethoxyphenyl H
    I-104 CH2 4-(trifluoromethoxy)phenyl H
    I-105 CH2 2,2-difluorobenzo[d][1,3]dioxol-5-yl H
    I-106 CH2 2-(trifluoromethoxy)phenyl H
    I-107 CH2 (3R)-1-(tert-butoxycarbonyl) H
    pyrrolidin-3-yl
    I-108 CH2 (2R)-1-(tert-butoxycarbonyl) H
    pyrrolidin-2-yl
    I-109 CH2 3-(trifluoromethoxy)phenyl H
    I-110 CH2 2-methoxy-3-(trifluoromethyl)phenyl H
    I-111 CH2 1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl H
    I-112 CH2 3-cyanophenyl H
    I-113 CH2 3-(difluoromethoxy)phenyl H
    I-114 CH2 1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl H
    I-115 CH2 3-(trifluoromethoxy)-5-methoxyphenyl H
    I-116 (s)-CHMe 2,2-difluorobenzo[d][1,3]dioxol-4-yl H
    I-117 CH2 6-oxo-1-(2,2,2-trifluoroethyl)-1,6- H
    dihydropyridin-3-yl
    I-118 CH2 2,2-dimethyl-2,3-dihydrobenzofuran-7-yl H
    I-119 CH2 2,3-dimethoxyphenyl H
  • Figure US20210094940A1-20210401-C00092
    Figure US20210094940A1-20210401-C00093
    Figure US20210094940A1-20210401-C00094
    • Example 3 (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-130.1) and (S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-130.2)
  • Figure US20210094940A1-20210401-C00095
  • To a mixture of 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxylic acid (5.4 g, 13.5 mmol) and (R)-2-amino-2-(5-(ethylsulfonyl)pyridin-2-yl)ethanol HCl salt (5.4 g, 20.2 mmol) in anhydrous DCM (120 mL) was added Et3N (8.2 g, 81.0 mmol). Then the mixture solution was cooled to 0° C. and HATU (6.7 g, 17.6 mmol) was added in several portions. The mixture was stirred at 25° C. for 4 h under N2. LC-MS showed that the reaction was completed. The mixture was combined with another 3.6 g batch and diluted with DCM (100 mL), washed with water (2×100 mL) and brine (200 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with petroleum ether/EtOAc=¼ to give the racemic compound (12.4 g, 90%). The racemic compound was separated by SFC separation (AD), basic preparative HPLC separation, then freeze-drying to afford (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-301.1, 6.73 g, 49%, EE=99.54%) and (S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-130.2, 1.17 g, 9%, EE=98.84%) as white solids.
  • Before SFC separation: Isomer SFC tR=4.83 and 5.37 min in 10 min chromatography (Column: AD-H; Method Name: AD3_IPA_DEA_5_40_25ML, ee=66%)
  • SFC separation condition:
    • Instrument: Thar 80
  • Column: AD 250 mm*30 mm, 10 um
    Mobile phase: A: Supercritical CO2, B: IPA (0.05% NH3.H2O), A: B=70:30 at 200 mL/min
    • Column Temp: 38° C. Nozzle Pressure: 100Bar Nozzle Temp: 60° C. Evaporator Temp: 20° C. Trimmer Temp: 25° C. Wavelength: 220 nm
  • Cpd No I-130.1 (6.73 g, 48.8%, EE=99.54%) as a white solid LC-MS Method 3 tR=0.729 min, MS (ESI) m/z 613.0 [M+H]+. 1H NMR (CDCl3 400 MHz): δ 9.05 (s, 1H), 8.43 (s, 1H), 8.22 (dd, J=2.0, 8.4 Hz, 1H), 7.96 (d, J=8.8 Hz, 1H), 7.86 (d, J=6.8 Hz, 1H), 7.73 (d, J=8.0 Hz, 1H), 7.42 (d, J=8.8 Hz, 1H), 7.10-6.92 (m, 2H), 6.59 (d, J=8.0 Hz, 1H), 5.62 (s, 2H), 5.52-5.40 (m, 1H), 4.35-4.15 (m, 1H), 4.08-3.90 (m, 1H), 3.51-3.44 (m, 1H), 3.18 (q, J=7.6 Hz, 2H), 1.35 (t, J=7.6 Hz, 3H). Isomer SFC tR=5.395 min in 10 min chromatography (Column: AD-3; Method Name: AD_3_IPA_DEA_5_40_25 mL_10 min.met, ee=99.54%)
  • Basic Preparative HPLC Method:
  • Mobile phase A: water with 0.05% NH3H2O solution
    Mobile phase B: MeCN
    Flow rate: 120 mL/min.
    • Detection: UV 220 nm
  • Column: Phenomenex Gemini 150*25 mm*10 um
    Column temperature: 40° C.
  • Time in min % A % B
    0.00 62 38
    19.00 32 68
    19.20 0 100
    21.00 0 100
  • Cpd No I-130.2 (1.17 g, 8.5%, EE=98.84%) as a white solid LC-MS Method 3 tR=0.728 min, MS (ESI) m/z 613.0 [M+H]+. 1H NMR (CDCl3 400 MHz): δ 9.05 (s, 1H), 8.43 (s, 1H), 8.21 (dd, J=2.4, 8.0 Hz, 1H), 7.96 (d, J=8.4 Hz, 1H), 7.87 (d, J=7.2 Hz, 1H), 7.73 (d, J=8.0 Hz, 1H), 7.42 (d, J=8.8 Hz, 1H), 7.07-6.97 (m, 2H), 6.59 (d, J=8.0 Hz, 1H), 5.62 (s, 2H), 5.51-5.43 (m, 1H), 4.27-4.20 (m, 1H), 4.10-4.04 (m, 1H), 3.55-3.46 (m, 1H), 3.18 (q, J=7.6 Hz, 2H), 1.34 (t, J=7.6 Hz, 3H). Isomer SFC tR=4.840 min in 10 min chromatography (Column: AD-3; Method Name: AD_3_IPA_DEA_5_40_25 mL_10 min.met, ee=98.84%)
  • Basic Preparative HPLC Method:
  • Mobile phase A: water with 0.05% NH3H2O solution
    Mobile phase B: MeCN
    Flow rate: 120 mL/min.
    • Detection: UV 220 nm Column: Gemini 150*25 5u
  • Column temperature: 40° C.
  • Time in min % A % B
    0.00 59 41
    17.00 29 71
    17.20 0 100
    19.00 0 100
  • A solution of Cpd No I-130.1 (0.5 g) in MeCN (5 mL) was diluted with 5% aq HCl (˜20 mL) until the solution became milky and immediately frozen in a dry ice/acetone bath. The resulting solid was lyophilized to afford I-130.1.HCl salt as a tan solid. 1H NMR (CD3OD 400 MHz): δ 9.20 (s, 1H), 8.79 (d, 1H), 8.48 (s, 1H), 8.24 (d, 1H), 8.03 (d, 1H), 7.67 (d, 1H), 7.10-7.21 (m, 2H), 6.89 (d, 1H), 5.82 (s, 2H), 5.43 (m, 1H), 4.15 (m, 2H), 3.40 (q, 2H), 1.27 (t, 3H).
  • Seed crystals were obtained by vapor diffusion of ether into a solution of lyophilized I-130.1.HCl salt (3-5 mg) in MeCN (0.25 mL).
  • A solution of lyophilized I-130.1.HCl salt (1.80 g) in MeCN (36 mL) was diluted with Et2O (12 mL) and a seed crystal was added. After standing overnight, the solid was collected by filtration and dried under high vacuum to afford I-130.1.HCl salt (1.39 g) as a white solid, mp 139-142° C. This material gave the X-ray powder diffraction pattern shown in FIG. 1.
  • XRPD analyses were conducted using a Bruker D8 Advance X-Ray diffractometer operating with a Cu radiation source at 40 kV, 40 mA through a Ni filter with a divergence slit of 0.60 mm/2.5°.
  • A solution of the free base of I-130.1 (0.30 g) in EtOAc (3 mL) was diluted with hexanes (7 mL) and allowed to stand loosely covered for 5 days. Filtration provided a solid (224 mg) with mp 149-152° C. This material gave the X-ray powder diffraction pattern shown in FIG. 2.
    • Example 4 (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide (I-131.1) and (S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide (I-131.2)
  • Figure US20210094940A1-20210401-C00096
  • To a mixture of 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-1H-benzo[d]imidazole-5-carboxylic acid (8.5 g, 22.25 mmol) and Et3N (6.7 g, 66.75 mmol) in CH2Cl2 (350 mL) was added (R)-2-amino-2-(5-(ethylsulfonyl)pyridin-2-yl)ethanol HCl salt (7.7 g, 28.83 mmol) at 0° C. Then the mixture was stirred at 0° C. for 5 min. HATU (10.1 g, 26.7 mmol) was added in portions. The mixture was stirred at 0-16° C. for 3 h. LC-MS showed that the reaction was completed. The mixture was combined with another 13.2 g batch and washed with water (3×300 mL) and brine (300 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with petroleum ether/EtOAc=1/4-0/1, separated by SFC (AD), preparative HPLC separation and dry-freezing to afford (R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide (I-131.1, 7.96 g, 28%, neutral preparative HPLC separation) and (S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide (I-131.2, 1.71 g, 6%, basic preparative HPLC separation) as white solids.
  • Before SFC separation: Isomer SFC tR=0.556 and 0.760 min in 3 min chromatography (Column: AD-H; Method Name: AD-H_3UM_4_40_4ML_3MIN.M, ee=68%)
  • SFC separation condition:
    • Instrument: Thar 80
  • Column: AD 250 mm*30 mm, 10 um
    Mobile phase: A: Supercritical CO2, B: IPA (0.05% NH3.H2O), A:B=60:40 at 200 mL/min
    • Column Temp: 38° C. Nozzle Pressure: 100Bar Nozzle Temp: 60° C. Evaporator Temp: 20° C. Trimmer Temp: 25° C. Wavelength: 220 nm
  • Cpd No I-131.1 (7.96 g, 25%) as a white solid LC-MSMethod 3 tR=0.713 min, MS (ESI) m/z 595.1 [M+H]+. 1H NMR (CDCl 3 400 MHz): δ 9.04 (d, J=2.0 Hz, 1H), 8.37 (s, 1H), 8.21 (dd, J=2.4, 8.0 Hz, 1H), 7.90 (d, J=8.8 Hz, 1H), 7.84 (d, J=6.8 Hz, 1H), 7.72 (d, J=8.4 Hz, 1H), 7.38 (d, J=8.4 Hz, 1H), 7.02 (t, J=52.4 Hz, 1H), 7.04-6.96 (m, 2H), 6.64 (d, J=8.0 Hz, 1H), 5.66 (s, 2H), 5.49-5.46 (m, 1H), 4.23 (dd, J=4.0, 11.2 Hz, 1H), 4.23 (dd, J=4.0, 11.6 Hz, 1H), 3.17 (q, J=7.6 Hz, 2H), 1.34 (t, J=7.6 Hz, 3H). Isomer SFC tR=0.814 min in 3 min chromatography (Column: AD-H; Method Name: AD-H_3UM_4_40_4ML_3MIN.M, ee=99.47%)
  • Neutral Preparative HPLC Method:
  • Mobile phase A: water with 10 mM NH4HCO3 solution
    Mobile phase B: MeCN
    Flow rate: 120 mL/min.
    • Detection: UV 220 nm
  • Column: Phenomenex luna C18 250*50 mm*10 um
    Column temperature: 40° C.
  • Time in min % A % B
    0.00 77 23
    21.00 38 62
    24.00 0 100
    30.00 0 100
  • Cpd No I-131.2 (1.71 g, 5%) as a white solid LC-MS Method 3 tR=0.719 min, MS (ESI) m/z 595.0 [M+H]+. 1H NMR (CDCl 3 400 MHz): δ 9.04 (s, 1H), 8.36 (s, 1H), 8.18 (d, J=8.4 Hz, 1H), 7.89 (d, J=8.4 Hz, 1H), 7.87-7.84 (m, 1H), 7.71 (d, J=8.0 Hz, 1H), 7.38 (d, J=8.4 Hz, 1H), 7.01 (t, J=52.4 Hz, 1H), 7.03-6.95 (m, 2H), 6.64 (d, J=8.0 Hz, 1H), 5.65 (s, 2H), 5.49-5.45 (m, 1H), 4.25-4.21 (m, 1H), 4.06-4.03 (m, 1H), 3.16 (q, J=7.6 Hz, 2H), 1.33 (t, J=7.6 Hz, 3H). Isomer SFC tR=0.577 min in 3 min chromatography (Column: AD-H; Method Name: AD-H_3UM_4_40_4ML_3MIN.M, ee=95.60%)
  • Basic Preparative HPLC Method:
  • Mobile phase A: water with 0.05% NH3H2O solution
    Mobile phase B: MeCN
    Flow rate: 110 mL/min.
    • Detection: UV 220 nm
  • Column: Phenomenex Synergi Max-RP 250*50 mm*10 um
    Column temperature: 40° C.
  • Time in min % A % B
    0.00 85 15
    25.00 35 65
    28.00 0 100
    31.00 0 100
  • A solution of lyophilized I-131.1.HCl salt (2.03 g) in MeCN (36 mL) was diluted with Et2O (12 mL) and a seed crystal of I-130.1 HCl salt was added. After standing over the weekend, the mixture was placed in the freezer for 2 weeks. The white solid was collected by filtration and dried under high vacuum to afford I-131.1.HCl salt (1.30 g), mp 129-134° C. This material gave the X-ray powder diffraction pattern shown in FIG. 6.
    • Example 5 (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide (I-132.1) and (S)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide (I-132.2)
  • Figure US20210094940A1-20210401-C00097
  • To a mixture of 2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-1H-benzo[d]imidazole-5-carboxylic acid (3.6 g, 9.32 mmol) in anhydrous CH2Cl2 (150 mL) was added (R)-2-amino-2-(5-(ethylsulfonyl)pyridin-2-yl)ethanol HCl salt (3.2 g, 12.0 mmol), Et3N (2.83 g, 28 mmol) and HATU (4.6 g, 12.12 mmol) in portions at 0° C. under N2. The mixture was stirred at 22° C. for 1 h. LC-MS showed the reaction was completed. The mixture (together with another 5.5 g batch) was added with water (300 mL) and washed with CH2Cl2 (3×300 mL). The combined organic layers were washed with brine (500 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with CH2Cl2: MeOH=50:1-25:1 to give 2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridine-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide (11.72 g), which was separated by SFC separation (cellulose-2) to give (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide (I-132.1, 6.2 g+2.4 g), and (S)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl) methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide (I-132.2, 1.6 g) as yellow solids.
  • I-132.1 (6.2 g) was purified by basic preparative HPLC separation and dry-freezing to afford (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide (I-132.1, 4.88 g, 35%) as a white solid.
  • I-132.2 (1.6 g) was purified by basic preparative HPLC separation and dry-freezing to afford (S)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide (I-132.2, 784 mg, 6%) as a white solid.
  • I-132.1 (2.4 g) was purified by HCl preparative HPLC separation and dry-freezing to afford (R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide (I-132.1, 1.29 g, 9%) as a white solid.
  • Before SFC separation: Isomer SFC tR=7.525 and 10.107 min in 12 min chromatography (Column: CELLULOSE-2; Method Name: CELLULOSE-2_ETOH(DEA)_40_2_12 min.met, ee=67.57%).
  • SFC separation condition:
    • Instrument: Berger MultiGram™ SFC, Mettler Toledo Co, Ltd
  • Column: C2 250 mm*50 mm, 10 um
    Mobile phase: A: Supercritical CO2, B: EtOH (0.05% NH4OH), A:B=60:40 at 200 mL/min
    • Column Temp: 40° C. Nozzle Pressure: 100Bar Nozzle Temp: 60° C. Evaporator Temp: 20° C. Trimmer Temp: 25° C. Wavelength: 220 nm
  • Cpd No I-132.1 (4.88 g, free base) as a white solid LC-MS Method 3 tR=0.649 min, MS (ESI) m/z 599.1 [M+H]+ 1H NMR (CDCl 3 400 MHz): δ 9.01 (s, 1H), 8.34 (s, 1H), 8.07-7.97 (m, 2H), 7.84 (d, J=12.4 Hz, 1H), 7.67 (d, J=8.0 Hz, 1H), 7.29 (s, 1H), 7.03 (d, J=7.6 Hz, 1H), 6.97 (t, J=8.0 Hz, 1H), 6.46 (d, J=8.0 Hz, 1H), 5.52-5.35 (m, 1H), 5.35 (s, 2H), 4.60-4.36 (m, 1H), 4.31-4.25 (m, 1H), 4.11-4.05 (m, 1H), 3.76-3.68 (m, 1H), 3.16 (q, J=7.6 Hz, 2H), 2.61-2.50 (m, 2H), 2.48-2.31 (m, 2H), 2.19-2.08 (m, 1H), 2.07-1.98 (m, 1H), 1.33 (t, J=7.2 Hz, 3H). Isomer SFC tR=10.480 min in 14 min chromatography (Column: CELLULOSE-2; Method Name: CELLULOSE-2_ETOH(DEA)_40_2,5M-14 min.met, ee=99.66%).
  • Basic Preparative HPLC Method
  • Mobile phase A: water (0.05% ammonia hydroxide v/v)-ACN
    Mobile phase B: CH3CN
    Flow rate: 150 mL/min.
    Detection: UV 220 nm/254 nm
    Column: Phenomenex Synergi Max-RP 250*50 mm*10 um
    Column temperature: 30° C.
  • Time in min % A % B
    0.00 70 30
    10.00 45 55
    12.00 0 100
    13.00 0 100
  • A solution of the free base of I-132.1 (0.25 g) in EtOAc (3 mL) was diluted with hexanes (3 mL) and allowed stand loosely covered. Filtration and drying under vacuum provided I-132.1 (177 mg) as a solid with mp 96-110° C. This material gave the X-ray powder diffraction pattern shown in FIG. 7.
  • Cpd No I-132.2 (0.784 g, free base) as a white solid LC-MS Method 3 tR=0.653 min, MS (ESI) m/z 599.2 [M+H]+ 1H NMR (CDCl3 400 MHz): δ 8.91 (s, 1H), 8.37 (s, 1H), 8.16 (d, J=7.6 Hz, 1H), 7.87-7.78 (m, 2H), 7.57 (d, J=8.0 Hz, 1H), 7.23 (d, J=8.4 Hz, 1H), 6.98 (d, J=7.6 Hz, 1H), 6.92 (t, J=8.0 Hz, 1H), 6.42 (d, J=8.0 Hz, 1H), 5.52-5.41 (m, 1H), 5.35-5.20 (m, 2H), 5.15-4.93 (m, 1H), 5.34 (dd, J=3.6, 11.6 Hz, 1H), 4.10-4.02 (m, 1H), 3.71-3.62 (m, 1H), 3.08 (q, J=7.6 Hz, 2H), 2.61-2.52 (m, 2H), 2.49-2.21 (m, 2H), 2.15-1.91 (m, 2H), 1.26 (t, J=7.6 Hz, 3H). Isomer SFC tR=7.466 min in 13 min chromatography (Column: CELLULOSE-2; Method Name: CELLULOSE-2_ETOH(DEA)_40_2,5M-13 min.met, ee=95.17%).
  • Basic Preparative HPLC Method
  • Mobile phase A: water (0.05% ammonia hydroxide v/v)-ACN
    Mobile phase B: CH3CN
    Flow rate: 25 mL/min.
    Detection: UV 220 nm/254 nm
    Column: Phenomenex Gemini 150*25 mm*10 um
    Column temperature: 30° C.
  • Time in min % A % B
    0.00 59 41
    10.00 29 71
    12.00 0 100
    13.00 0 100
  • Cpd No I-132.1 (1.29 g, HCl salt) as a white solid LC-MS Method 3 tR=0.663 min, MS (ESI) m/z 599.1 [M+H]+ 1H NMR (CD3OD 400 MHz): δ 9.05 (s, 1H), 8.43-8.36 (m, 1H), 8.35-8.22 (m, 1H), 8.16 (d, J=7.2 Hz, 1H), 7.88 (d, J=8.8 Hz, 1H), 7.83-7.22 (m, 1H), 7.27-7.21 (m, 2H), 7.17 (d, J=7.2 Hz, 1H), 5.88 (s, 2H), 5.43 (t, J=6.0 Hz, 1H), 4.39-4.31 (m, 1H), 4.12-4.03 (m, 2H), 3.29-3.27 (m, 2H), 2.66-2.51 (m, 4H), 2.36-2.26 (m, 1H), 2.17-2.06 (m, 1H), 1.28 (t, J=7.2 Hz, 3H). Isomer SFC tR=9.673 min in 13 min chromatography (Column: CELLULOSE-2; Method Name: CELLULOSE-2_ETOH(DEA)_40_2,5M-13 min.met, ee=99.77%).
  • HCl Preparative HPLC Method
  • Mobile phase A: water(0.05% HCl)-ACN
    Mobile phase B: CH3CN
    Flow rate: 120 mL/min.
    Detection: UV 220 nm/254 nm
    Column: Phenomenex Synergi Max-RP 250*50 mm*10 um
    Column temperature: 30° C.
  • Time in min % A % B
    0.00 95 5
    10.00 60 40
    12.00 0 100
    13.00 0 100
  • The following compounds are prepared using procedures analogous to those in Examples 3, 4 and 5.
  •
    Figure US20210094940A1-20210401-C00098
    Cpd No R1 * Rb
    I-133.1 c-Pr R Et
    I-133.2 c-Pr S Et
    I-134.1 1-fluorocyclopropyl R Et
    I-134.2 1-fluorocyclopropyl S Et
    I-135 CF3 R Me
    • Example 6 N-(4-(ethylsulfonyl)benzyl)-1-(2-fluoro-3-methoxybenzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-136)
  • Figure US20210094940A1-20210401-C00099
  • A solution of 3-amino-N-(4-(ethylsulfonyl)benzyl)-4-((2-fluoro-3-methoxybenzyl)amino)benzamide (16.5 mg, mol) in TFA (2 mL) was stirred at 70° C. for 3 h. After concentration, the residue was purified by prep HPLC to provide the title compound (6 mg, 31%) as an oil. 1H NMR (d4-MeOH) δ 1.20 (s, 3H), 3.19 (q, 2H), 3.87 (s, 3H), 4.71 (s, 2H), 5.75 (s, 2H), 6.34-6.42 (m, 1H), 6.96-7.10 (m, 2H), 7.58-7.64 (m, 3H), 7.88 (d, 2H), 7.97 (d, 1H), 8.38 (s, 1H). LC-MS Method 1 tR=1.63 min, m/z=550.
  • The following compounds are prepared using an analogous procedure
  • Figure US20210094940A1-20210401-C00100
    Cpd No Cy2
    I-137 1-methyl-1H-indazol-7-yl
    I-138 4-methyl-6-(trifluoromethyl)pyrimidin-2-yl
    I-139 2-methyl-2H-indazol-7-yl
    I-140 1,2-dimethyl-1H-benzo[d]imidazol-7-yl
    I-141 1-methyl-1H-indazol-4-yl
    I-142 1H-indazol-7-yl
    I-143 2-methyl-2H-indazol-4-yl
    I-144 6-oxo-1-(2,2,2-trifluoroethyl)-1,6-dihydropyridin-3-yl
    I-145a 1-(t-butoxycarbonyl)piperidin-4-yl
    I-146 1-methyl-2-oxo-1,2-dihydropyridin-3-yl
    I-147 benzo[d]oxazol-4-yl
    aThe crude product was treated with Boc2O to reintroduce the Boc group.
  • The following compounds are prepared by similar procedures.
  • Figure US20210094940A1-20210401-C00101
    • Example 7 1-(benzo[c]1,2,5 oxadiazol-4-ylmethyl)-N-(4-(ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1-benzo[d]imidazole-5-carboxamide (I-151)
  • Figure US20210094940A1-20210401-C00102
  • A stirred mixture of N-(4-(ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (37 mg, 90 μmol), benzo[c][1,2,5]oxadiazol-4-ylmethyl methanesulfonate (31 mg, 135 μmol), powdered NaHCO3 (23 mg, 0.27 mmol) and dry DMF (2 mL) was heated at 60° C. for 3 h. The mixture was diluted with EtOAc (90 mL), washed with water (10 mL) and brine (10 mL), and dried over Na2SO4. Removal of the solvent left an oil (111 mg) which was purified by prep HPLC to afford the title compound as a 1:1 mixture with the regioisomer shown. LC-MS Method 1 tR=1.56 min, m/z=545.
  • The following compound is prepared by a similar procedure, also as a mixture of regioisomers.
  • Figure US20210094940A1-20210401-C00103
    • Example 8 2-cyclopropyl-N-(4-(ethylsulfonyl)benzyl)-1-(3-hydroxy-5-(trifluoromethoxy)benzyl)-1H-benzo[d]imidazole-5-carboxamide (I-153)
  • Figure US20210094940A1-20210401-C00104
  • To a stirred, ice-cold solution of 2-cyclopropyl-N-(4-(ethylsulfonyl)benzyl)-1-(3-methoxy-5-(trifluoromethoxy)benzyl)-1H-benzo[d]imidazole-5-carboxamide (28 mg, 48 mol) in CH2Cl2 (2 mL) was added 1M BBr3 in CH2Cl2 (0.25 mL, 0.25 mmol). The mixture was allowed to warm to rt, stirred overnight and treated with MeOH (5 mL). The mixture was concentrated and the residue was purified by prep HPLC to give 2-cyclopropyl-N-(4-(ethylsulfonyl)benzyl)-1-(3-hydroxy-5-(trifluoromethoxy)benzyl)-1H-benzo[d]imidazole-5-carboxamide (11 mg, 40%) as its TFA salt. 1H NMR (CD3OD, 400 MHz) δ 8.15 (s, 1H), 8.05 (d, 1H), 7.82 (d, 2H), 7.72 (d, 1H), 7.57 (d, 2H), 6.57-6.65 (m, 2H), 6.54 (s, 1H), 5.72 (s, 2H), 4.66 (s, 2H), 3.10 (q, 2H), 2.37-2.47 (m, 1H), 1.25-1.45 (m, 4H), 1.13 (t, 3H). LC-MS Method 1 tR=1.26 min, m/z=574.
  • The following compound is prepared from Cpd No I-119 using an analogous procedure:
  • Figure US20210094940A1-20210401-C00105
    • Example 9 N-(4-(ethylsulfonyl)benzyl)-1-((1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-155)
  • Figure US20210094940A1-20210401-C00106
  • Step 1
  • A solution of tert-butyl 4-((5-((4-(ethylsulfonyl)benzyl)carbamoyl)-2-(trifluoromethyl)-1H-benzo[d]imidazol-1-yl)methyl)piperidine-1-carboxylate (42 mg, 69 μmol) in 4:1 CH2Cl2/TFA (5 mL) was stirred at rt for 2 h and concentrated to leave crude N-(4-(ethylsulfonyl)benzyl)-1-(piperidin-4-ylmethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide as its TFA salt (53 mg, quant). LC-MS Method 1 tR=0.74 min, m/z=509.
  • Step 2
  • To a stirred solution of N-(4-(ethylsulfonyl)benzyl)-1-(piperidin-4-ylmethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide TFA salt (18 mg, 29 μmol) and i-Pr2NEt (21 μL, 0.12 mmol) in MeCN (1 mL) was added 2,2,2-trifluoroethyl trifluoromethanesulfonate (5 L, 35 μmol). The mixture was stirred overnight at rt and purified by prep HPLC to give the title compound as its TFA salt (8 mg, 39%). 1H NMR (CD3OD, 400 MHz) δ 8.38 (s, 1H), 8.03 (d, 1H), 7.82-7.95 (m, 3H), 7.62 (d, 2H), 4.71 (s, 2H), 4.40 (d, 2H), 3.68 (q, 2H), 3.36 (m, 2H), 3.19 (q, 2H), 2.78 (t, 2H), 2.15-2.30 (m, 1H), 1.60-1.78 (m, 2H), 1.18 (t, 3H). LC-MS Method 1 tR=1.26 min, m/z=591.
  • The following compounds are prepared using analogous procedures.
  • Figure US20210094940A1-20210401-C00107
    • Example 10 N-(4-(ethylsulfonyl)benzyl)-1-((1-(5-fluoropyrimidin-2-yl)piperidin-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-158)
  • Figure US20210094940A1-20210401-C00108
  • A solution of N-(4-(ethylsulfonyl)benzyl)-1-(piperidin-4-ylmethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide TFA salt (18 mg, 29 μmol), 2-chloro-5-fluoropyrimidine(11.5 mg, 86 μmol) and i-Pr2NEt (21 μL, 0.12 mmol) in MeCN (1 mL) was heated in the microwave at 100° C. for 3 h. Prep HPLC gave the title compound as its TFA salt (5 mg, 23%). 1H NMR (CD3OD, 400 MHz) δ 8.40 (s, 1H), 8.28 (s, 2H), 8.08 (d, 1H), 7.86-7.98 (m, 3H), 7.68 (d, 2H), 4.77 (s, 2H), 4.41 (d, 2H), 3.15-3.40 (m, 4H), 2.78-2.90 (m, 2H), 2.28-2.42 (m, 1H), 1.58-1.68 (m, 2H), 1.35-1.50 (m, 2H), 1.25 (t, 3H). LC-MS Method 1 tR=1.54 min, m/z=605.
  • The following compounds are prepared using analogous procedures.
  • Figure US20210094940A1-20210401-C00109
    • Example 11 2-((1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamido)methyl)-5-(ethylsulfonyl)pyridine 1-oxide (I-161)
  • Figure US20210094940A1-20210401-C00110
  • To a stirred solution of 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((5-(ethylsulfonyl)pyridin-2-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (28 mg, 49 μmol) in CH2Cl2 (2 mL) was added m-CPBA (16 mg, 65 μmol assuming 70% purity). The mixture was stirred overnight at rt, concentrated and the residue purified by prep HPLC to give the title compound (5.6 mg, 19%). 1H NMR (CD3OD, 400 MHz) δ 8.78 (s, 1H), 8.46 (s, 1H), 8.03 (d, 1H), 7.93 (d, 1H), 7.75 (d, 1H), 7.68 (d, 1H), 7.08-7.21 (m, 2H), 6.86 (d, 1H), 5.83 (s, 2H), 4.83 (s, 2H), 3.35 (q, 2H), 1.25 (t, 3H). LC-MS Method 1 tR=1.43 min, m/z=599. Starting material (14 mg, 50%) was also recovered.
    • Example 12 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(dimethylamino)-N-(4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide (I-162)
  • Figure US20210094940A1-20210401-C00111
  • A mixture of 3-amino-4-(((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)amino)-N-(4-(ethylsulfonyl)benzyl)benzamide (52 mg, 0.1 mmol), phosgene iminium chloride (34 mg, 0.21 mmol), i-Pr2NEt (0.3 mL, 1.7 mmol) and 1,2-dichloroethane (1 mL) was stirred at rt for 4 h. The mixture was diluted with EtOAc (90 mL), washed with water (10 mL), satd aq NaHCO3 (5 mL) and brine (5 mL), and dried over Na2SO4. Removal of the solvent left an oil (50 mg). Prep HPLC gave the title compound (5 mg, 7%) as an oil. 1H NMR (CD3OD, 400 MHz) δ 7.99 (s, 1H), 7.82-7.88 (m, 3H), 7.62 (d, 2H), 7.47 (d, 1H), 7.15-7.27 (m, 2H), 7.08 (d, 1H), 5.72 (s, 2H), 4.68 (d, 2H), 3.30 (s, 6H), 3.18 (q, 2H), 1.20 (t, 3H). LC-MS Method 1 tR=1.30 min, m/z=557.
    • Example 13 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((1-((2-hydroxyethyl)sulfonyl)piperidin-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-163)
  • Figure US20210094940A1-20210401-C00112
  • To a mixture of methyl 2-((4-((1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamido)methyl)piperidin-1-yl)sulfonyl)acetate (Cpd No I-74, 25 mg, 0.0396 mmol) in MeOH (1 mL) was added NaBH4 (8 mg, 0.1978 mmol). The mixture was stirred at rt for 2 h under N2. LC-MS showed that 63% of product was observed. The mixture was quenched with satd aq NH4Cl solution (15 mL) and extracted with EtOAc (3×15 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by preparative TLC with CH2Cl2/acetone=2/1 and basic preparative HPLC separation, then freeze dried directly to afford 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((1-((2-hydroxyethyl)sulfonyl)piperidin-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-163, 9.90 mg, 41%) as a white solid. LC-MS Method 3 tR=0.731 min, MS (ESI) m/z 605.0 [M+H]+. 1H NMR (CDCl 3 400 MHz): δ 8.26 (s, 1H), 7.90 (d, J=8.8 Hz, 1H), 7.39 (d, J=8.8 Hz, 1H), 7.06-6.96 (m, 2H), 6.57 (d, J=8.0 Hz, 1H), 6.45-6.38 (m, 1H), 5.59 (s, 2H), 4.11-4.04 (m, 2H), 3.83 (d, J=12.4 Hz, 2H), 3.41 (t, J=5.6 Hz, 2H), 3.13 (t, J=5.6 Hz, 2H), 2.90-2.75 (m, 3H), 1.93-1.81 (m, 3H), 1.45-1.32 (m, 2H).
  • Basic Preparative HPLC Method:
  • Mobile phase A: water with 0.05% ammonia solution
    Mobile phase B: MeCN
    Flow rate: 25 mL/min.
    • Detection: UV 220 nm Column: Gemini 150*25 5u
  • Column temperature: 40° C.
  • Time in min % A % B
    0.00 65 35
    10.00 35 65
    10.20 0 100
    12.00 0 100
    • Example 14 (S)-3-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamido)-3-(4-(ethylsulfonyl)phenyl)propanoic Acid (I-165)
  • Figure US20210094940A1-20210401-C00113
  • Step 1
  • Methyl (S)-3-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamido)-3-(4-(ethylsulfonyl)phenyl)propanoate is prepared following conditions analogous to those described in Example 2.
  • Step 2
  • Hydrolysis of the methyl ester to give I-165 is accomplished under conditions analogous to those described in Preparation 21, Step 2. 1H NMR (CDCl 3 400 MHz): δ 8.49 (s, 1H), 8.24 (s, 1H), 7.78 (d, J=8.4 Hz, 1H), 7.57 (d, J=8.0 Hz, 2H), 7.45 (d, J=8.0 Hz, 2H), 7.23 (d, J=8.8 Hz, 1H), 6.90-6.80 (m, 2H), 6.45 (d, J=7.6 Hz, 1H), 5.55-5.41 (m, 3H), 4.85-4.70 (m, 2H), 2.95-2.75 (m, 3H), 1.00 (t, J=7.2 Hz, 3H).
  • The compounds shown below are prepared following an analogous procedure.
  • Figure US20210094940A1-20210401-C00114
    • Example 15 (S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-3-(methylamino)-3-oxopropyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-167)
  • Figure US20210094940A1-20210401-C00115
  • The title compound is prepared from I-165 following a procedure analogous to Example 2. 1H NMR (CDCl 3 400 MHz): δ 9.24 (d, J=7.2 Hz, 1H), 8.53 (s, 1H), 7.98 (d, J=8.4 Hz, 1H), 7.85 (d, J=8.4 Hz, 2H), 7.56 (d, J=8.4 Hz, 2H), 7.40 (d, J=8.4 Hz, 1H), 7.06-6.98 (m, 2H), 6.58 (d, J=8.0 Hz, 1H), 5.62 (s, 2H), 5.57-5.51 (m, 2H), 3.09 (q, J=7.6 Hz, 2H), 2.92 (dd, J=4.8, 14.4 Hz, 1H), 2.73 (d, J=4.4 Hz, 3H), 2.63 (dd, J=4.4, 14.8 Hz, 1H), 1.28 (t, J=7.6 Hz, 3H).
  • The following compounds are prepared by an analogous procedure.
  • Figure US20210094940A1-20210401-C00116
    • Example 16 N-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-2-(4-(ethylsulfonyl)phenyl)-2-hydroxyacetamide (I-170)
  • Figure US20210094940A1-20210401-C00117
  • Step 1
  • A procedure analogous to that in Example 1 was followed. LC-MS Method 1 tR=2.03 min, m/z=564 (M+H).
  • Step 2
  • A 0.05 M solution of the thioether in 1:1 MeCN/H2O was treated with oxone (3 equivs) and stirred overnight at rt. The mixture was concentrated. The aqueous residue was extracted with EtOAc (2×). The combined EtOAc layer was washed with brine, dried over Na2SO4 and concentrated to leave the crude sulfone. LC-MS Method 1 tR=1.79 min, m/z=596 (M+H).
  • Step 3
  • A procedure analogous to that in Example 13 was followed to give I-170. 1H NMR (CD3OD, 400 MHz) δ 8.20 (s, 1H), 7.92 (d, 2H), 7.85 (d, 2H), 7.63 (d, 1H), 7.50 (d, 1H), 7.07-7.18 (m, 2H), 6.80 (d, 1H), 5.76 (s, 2H), 5.32 (s, 1H), 3.20 (q, 2H), 1.30 (t, 3H). The enantiomers (I-170.1 and I-170.2) were separated by chromatography on a chiral column.
    • Example 17 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((4-methyl-1-(methylsulfonyl)-1,4-diazepan-5-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-171)
  • Figure US20210094940A1-20210401-C00118
    • Example 18 1-((2,3-dihydrobenzofuran-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-172)
  • Figure US20210094940A1-20210401-C00119
  • A solution I-95 (8 mg) in 4:2:1 EtOH/H2O/HOAc (3.5 mL) was stirred under H2 (1 atm, balloon) in the presence of Pd(OH)2 (cat qty) overnight at rt. Prep HPLC afforded the title compound (1.1 mg). 1H NMR (CD3OD, 400 MHz) δ 8.40 (s, 1H), 7.94 (d, 1H), 7.87 (d, 2H), 7.64 (d, 2H), 7.50 (d, 1H), 6.99 (t, 1H), 7.68 (d, 2H), 6.19 (d, 1H), 5.66 (s, 2H), 4.73 (d, 2H), 4.55 (t, 2H), 3.19 (q, 2H), 3.05 (t, 2H), 1.20 (t, 3H).
    • Example 19 Methyl 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-5-((4-(ethylsulfonyl)benzyl)carbamoyl)-1H-benzo[d]imidazole-2-carboxylate (I-173)
  • Figure US20210094940A1-20210401-C00120
  • Step 1
  • To a mixture of 3-amino-4-(((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)amino)-N-(4-(ethylsulfonyl)benzyl)benzamide (47 mg, 0.093 mmol), DIPEA (72 mg, 0.56 mmol) and DMAP (5.7 mg, 0.047 mmol) in DCE (4 mL) was added methyl 2,2-dichloro-2-methoxyacetate (48 mg, 0.28 mmol) at 18° C. After stirring at 18° C. for 0.5 h, 40° C. for 1 h and 60° C. for 0.5 h, LC-MS showed that most was product. The mixture was diluted with H2O (25 mL) and DCM (30 mL). After partition, the organic layer was dried over Na2SO4, filtered, concentrated under reduced pressure, purified by neutral preparative HPLC separation and freeze dried to afford the title compound (11.60 mg, 23%) as a white solid.
  • LC-MS Method 3 tR=0.725 min, MS (ESI) m/z 572.0 [M+H]+. 1H NMR (CDCl 3 400 MHz): δ 8.08 (d, J=2.0 Hz, 1H), 7.87 (d, J=8.0 Hz, 3H), 7.55 (d, J=8.0 Hz, 2H), 7.32 (d, J=8.4 Hz, 1H), 7.00-6.98 (m, 2H), 6.92-6.91 (m, 1H), 6.70-6.69 (m, 1H), 5.58 (s, 2H), 4.77 (d, J=6.0 Hz, 2H), 4.15 (s, 3H), 3.11 (q, J=7.6 Hz, 2H), 1.28 (t, J=7.6 Hz, 3H).
  • Neutral Preparative HPLC Method:
  • Mobile phase A: water with 10 mM NH4HCO3 solution
    Mobile phase B: CH3CN
    Flow rate: 22 mL/min.
    Detection: UV 220 nm/254 nm
    • Column: Phenomenex Synergi C18 150*25*10 um
  • Column temperature: 30° C.
  • Time in min % A % B
    0.00 62 38
    12.00 32 68
    12.20 0 100
    14.50 0 100
    • Example 20 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(2-(4-(ethylsulfonyl)phenyl)-1,3-dihydroxypropan-2-yl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (I-174)
  • Figure US20210094940A1-20210401-C00121
  • Step 1
  • To a stirred solution of 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxylic acid (137 mg, 0.34 mmol), 3-(4-(ethylthio)phenyl)oxetan-3-amine HCl salt (126 mg, 0.51 mmol) and i-Pr2NEt (0.25 mL, 1.4 mmol) in CH2Cl2 (5 mL) was added solid HATU (0.26 g, 0.69 mmol). The mixture was stirred for 1 h, diluted with EtOAc (90 mL), washed with 5% aq HCl (10 mL), satd aq NaHCO3 (10 mL) and brine (10 mL), and dried over Na2SO4. Removal of the solvent left an oil (570 mg). Chromatography on a 12 g silica cartridge, eluted with a 0-100% EtOAc in hexanes gradient gave an oil (142 mg). A 23 mg portion of this oil was purified by prep HPLC (MeCN in H2O gradient, 0.1% TFA) to afford crude 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(2-(4-(ethylthio)phenyl)-1,3-dihydroxypropan-2-yl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (16 mg) as a solid. LC-MS Method 1 tR=1.26 min, m/z=610.
  • Step 2
  • To a stirred, ice-cold solution of crude 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(2-(4-(ethylthio)phenyl)-1,3-dihydroxypropan-2-yl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide (16 mg, 26 μmol) in CH2Cl2 (2 mL) was added m-CPBA (<77% pure, 12 mg, <53 μmol). The mixture was stirred in the ice bath for 1 h and a second aliquot of m-CPBA (<77%, 16 mg, <70 μmol) was added. The mixture was stirred for 2 h at rt, diluted with CH2Cl2 (40 mL), washed with 1 M aq NaOH (5 mL), dried over Na2SO4 and concentrated to leave an oil (19 mg). Prep HPLC afforded the title compound (10 mg, 59%) as an oil. LC-MS Method 1 tR=1.11 min, m/z=642. 1H NMR (CD3OD, 400 MHz): δ 8.43 (s, 1H), 8.02-8.08 (m, 3H), 7.63 (d, 2H), 7.63 (d, 1H), 7.10-7.20 (m, 2H), 6.87 (d, 1H), 5.81 (s, 2H), 5.0 (d, 1H), 4.91 (d, 1H), 4.15 (d, 1H), 4.04 (d, 1H), 3.21 (q, 2H), 1.16 (t, 3H).
  • LC-MS data
    LC-MS
    Cpd No Method tR (min) m/z
    I-1 1 1.80 582 (M + H)
    I-2 1 1.71 568 (M + H)
    I-3 1 1.64 598 (M + H)
    I-4 1 1.68 612 (M + H)
    I-5 3 0.782 582.9 (M + H)
    I-6 1 1.83 515 (M + H)
    I-7 1 1.86 576 (M + H)
    I-8 1 1.69 548 (M + H)
    I-9 1 1.28 554 (M + H)
    I-10 2 1.134 575.1 (M + H)
    I-11.1 3 0.77 612.0 (M + H)
    I-11.2 1 1.63 612 (M + H)
    I-12 1 1.10 584 (M + H)
    I-13 1 1.31 598 (M + H)
    I-14 1 1.62 608 (M + H)
    I-15 1 1.07 573 (M + H)
    I-16 1 1.23 572 (M + H)
    I-17 3 0.73 593.9 (M + H)
    I-18 1 1.55 602 (M + H)
    I-19 1 1.61 616 (M + H)
    I-20.1 3 0.745 597.9 (M + H)
    I-20.2 3 0.747 597.8 (M + H)
    I-21 3 0.628 570.0 (M + H)
    I-22 3 0.776 584.1 (M + H)
    I-23.1 3 0.715 579.9 (M + H)
    I-23.2 3 0.719 579.9 (M + H)
    I-24 3 0.734 587.9 (M + H)
    I-25 2 1.25 582.0 (M + H)
    I-26 1 1.19 554 (M + H)
    I-27 1 1.49 572 (M + H)
    I-28 1 1.47 558 (M + H)
    I-29 1 1.11 542 (M + H)
    I-30 1 1.28 570 (M + H)
    I-31 1 1.20 556 (M + H)
    I-32 1 1.06 528 (M + H)
    I-33 1 1.25 570 (M + H)
    I-34 1 1.14 540 (M + H)
    I-35 1 1.16 555 (M + H)
    I-36 1 1.24 568 (M + H)
    I-37 1 1.62 564 (M + H)
    I-38 1 1.71 578 (M + H)
    I-39.1 1 1.57 584 (M + H)
    I-39.2 1 1.52 584 (M + H)
    I-40 1 1.71 558 (M + H)
    I-41 1 1.54 588 (M + H)
    I-42 1 1.62 573 (M + H)
    I-43 1 1.67 586 (M + H)
    I-44 1 1.43 614 (M + H)
    I-45 1 1.70 598 (M + H)
    I-46 1 1.60 583 (M + H)
    I-47 1 1.27 570 (M + H)
    I-48 3 0.893 568.0 (M + H)
    I-49.1 3 0.695 572.0 (M + H)
    I-49.2 3 0.695 572.0 (M + H)
    I-50 3 0.740 549.9 (M + H)
    I-51 3 0.758 569.1 (M + H)
    I-52 3 0.79 596.0 (M + H)
    I-53 3 0.793 625.8 (M + H)
    I-54 3 0.758 586.0 (M + H)
    I-55 1 1.54 544 (M + H)
    I-56 1 1.30 579 (M + H)
    I-57 1 1.36 579 (M + H)
    I-58 1 1.36 612 (M + H)
    I-59 3 0.917 626.0 (M + H)
    I-60 3 0.692 597.9 (M + H)
    I-61 3 0.790 615.9 (M + H)
    I-62 2 1.128 627.1 (M + H)
    I-63 1 1.64 583 (M + H)
    I-64 1 1.12 555 (M + H)
    I-65 1 1.18 569 (M + H)
    I-66 1 1.65 579 (M + H)
    I-67 1 1.56 573 (M + H)
    I-68 1 1.5 559 (M + H)
    I-69 1 1.65 587 (M + H)
    I-70 3 0.737 569.0 (M + H)
    I-71 3 0.764 574.9 (M + H)
    I-72 1 1.11 547 (M + H)
    I-73 1 1.65 565 (M + H)
    I-74 3 0.773 633.0 (M + H)
    I-75 3 0.753 632.0 (M + H)
    I-76 3 0.776 632.9 (M + H)
    I-77 3 0.763 590.0 (M + H)
    I-78 3 0.865 618.1 (M + H)
    I-79 3 0.678 604.1 (M + H)
    I-80 1 1.66 574 (M + H)
    I-81 3 0.842 576.0 (M + H)
    I-82 1 1.46 562.2 (M + H)
    I-83 1 1.62 557 (M + H)
    I-84 1 1.59 586 (M + H)
    I-85 1 1.35 527 (M + H)
    I-86 1 0.94 533 (M + H)
    I-87 1 0.78 560 (M + H)
    I-88 1 1.45 532 (M + H)
    I-89 1 1.31 533 (M + H)
    I-90 1 1.35 527 (M + H)
    I-91 1 1.18 569 (M + H)
    I-92 1 1.43 553 (M + H)
    I-93.1 1 1.41 541 (M + H)
    I-93.2 1 1.59 542 (M + H)
    I-94 1 1.55 545 (M + H)
    I-95 1 1.63 542 (M + H)
    I-96 1 1.75 544 (M + H)
    I-97 1 1.40 542 (M + H)
    I-98 3 0.754 546.0 (M + H)
    I-99 3 0.728 560.0 (M + H)
    I-100 1 0.79 542 (M + H)
    I-101 1 1.34 574 (M + H)
    I-102 1 1.05 546 (M + H)
    I-103 1 1.05 534.5 (M + H)
    I-104 1 1.22 558 (M + H)
    I-105 1 1.17 554 (M + H)
    I-106 1 1.21 558 (M + H)
    I-107 1 1.03 567 (M + H)
    I-108 1 1.00 567 (M + H)
    I-109 1 1.22 558 (M + H)
    I-110 1 1.23 572 (M + H)
    I-111 1 0.89 546 (M + H)
    I-112 1 0.99 499 (M + H)
    I-113 1 1.11 540 (M + H)
    I-114 1 0.94 546 (M + H)
    I-115 1 1.25 588 (M + H)
    I-116 1 1.21 568 (M + H)
    I-117 1 1.45 586 (M + H)
    I-118 1 1.39 544 (M + H)
    I-119 1 1.09 534 (M + H)
    I-120 3 0.9 554.1 (M + H)
    I-121 1 1.57 531 (M + H)
    I-122 1 1.60 545 (M + H)
    I-123 3 0.89 629.9 (M + H)
    I-124 1 1.34 578.3 (M + H)
    I-125.1 1 1.13 556 (M + H)
    I-125.2 1 1.13 556 (M + H)
    I-126 1 1.66 598 (M + H)
    I-127 3 0.663 593.0 (M + H)
    I-128 1 1.39 563.3 (M + H)
    I-129 1 1.48 557 (M + H)
    I-130.1 3 0.729 613.0 (M + H)
    I-130.2 3 0.754 612.9 (M + H)
    I-131.1 3 0.713 595.1 (M + H)
    I-131.2 3 0.704 595.0 (M + H)
    I-132.1 3 0.649 599.1 (M + H)
    I-132.2 3 0.653 599.2 (M + H)
    I-133.1 3 0.660 584.9 (M + H)
    I-133.2 3 0.664 584.9 (M + H)
    I-134.1 3 0.846 603.0 (M + H)
    I-134.2 3 0.846 603.0 (M + H)
    I-135 3 0.865 599.0 (M + H)
    I-136 1 1.63 550 (M + H)
    I-137 1 1.67 556 (M + H)
    I-138 1 1.66 586 (M + H)
    I-139 1 1.42 556 (M + H)
    I-140 1 0.93 570 (M + H)
    I-141 1 1.44 556 (M + H)
    I-142 1 1.33 542 (M + H)
    I-143 1 1.30 556 (M + H)
    I-144 1 1.33 601 (M + H)
    I-145 1 0.98 553 (M − 56 + H)
    I-146 1 1.09 533 (M + H)
    I-147 1 1.51 543 (M + H)
    I-148 1 1.01 532 (M + H)
    I-149 1 1.20 568 (M + H)
    I-150 3 0.730 448.2 (M + H)
    I-151 1 1.56 544 (M + H)
    I-152 1 1.48 543 (M + H)
    I-153 1 1.26 574 (M + H)
    I-154 1 1.05 506 (M + H)
    I-155 1 1.26 591 (M + H)
    I-156 1 0.88 549 (M + H)
    I-157 1 1.03 549 (M + H)
    I-158 1 1.54 605 (M + H)
    I-159 1 0.93 563 (M + H)
    I-160 1 0.95 563 (M + H)
    I-161 1 1.43 599 (M + H)
    I-162 1 1.30 557 (M + H)
    I-163 3 0.731 605.0 (M + H)
    I-164.1 3 0.732 604.9 (M + H)
    I-164.2 3 0.732 604.9 (M + H)
    I-165 3 0.748 639.9 (M + H)
    I-166 3 0.759 669.9 (M + H)
    I-167 3 0.752 652.9 (M + H)
    I-168 3 0.739 638.9 (M + H)
    I-169 3 0.751 624.9 (M + H)
    I-170 1 1.72 598 (M + H)
    I-170.1 3 0.785 597.9 (M + H)
    I-170.2 3 0.779 597.9 (M + H)
    I-171 1 1.12 604 (M + H)
    I-172 1 1.53 544 (M + H)
    I-173 3 0.725 572.0 (M + H)
    I-174 1 1.11 642 (M + H)
  • 1H NMR data of selected compounds
  • Cpd Solvent Resonances
    Figure US20210094940A1-20210401-C00122
         		I-11.1 CDCl3 8.56 (s, 1H), 8.04 (d, J = 8.8 Hz, 1H), 7.71 (d, J = 8.0 Hz, 2H), 7.66 (d, J = 7.2 Hz, 1H), 7.58 (d, J = 8.0 Hz, 2H), 7.46 (d, J = 8.8 Hz, 1H), 7.07-7.03 (m, 2H), 6.65 (d, J = 1.6 Hz, 1H), 5.65 (d, J = 4.8 Hz, 2H), 5.42-5.40 (m, 1H), 4.18-4.14 (m, 2H), 3.42-3.40 (brs, 1H), 3.07 (q, J = 7.6 Hz, 2H), 1.28 (t, J = 7.6 Hz, 3H).
    Figure US20210094940A1-20210401-C00123
         		I-14 CD3OD 8.38 (s, 1H), 7.93 (d, 1H), 7.89 (d, 2H), 7.72 (d, 2H), 7.63 (d, 1H), 7.00- 7.20 (m, 2H), 6.75 (d, 1H), 5.80 (s, 2H), 5.31 (m, 1H), 3.92 (d, 2H), 3.19 (q, 2H), 2.25 (t, 3H), 1.20 (t, 3H)
    Figure US20210094940A1-20210401-C00124
         		I-17 CD3OD 8.39 (s, 1H), 7.93 (dd, J = 1.2, 8.8 Hz, 1H), 7.89 (d, J = 8.4 Hz, 2H), 7.70 (d, J = 8.4 Hz, 2H), 7.59 (d, J = 8.8 Hz, 1H), 7.23 (t, 52.0 Hz, 1H), 7.15- 7.09 (m, 2H), 6.85 (d, J = 7.6 Hz, 1H), 5.82 (s, 2H), 5.30 (t, J = 6.0 Hz, 1H), 3.92 (d, J = 6.4 Hz, 2H), 3.19 (q, J = 7.2 Hz, 2H), 1.20 (t, J = 12 Hz, 3H).
    Figure US20210094940A1-20210401-C00125
         		I-18 CD3OD 8.33 (s, 1H), 7.92-7.98 (m, 3H), 7.77 (d, 2H), 7.63 (d, 1H), 7.10-7.25 (m, 2H), 6.92 (d, 1H), 5.92 (s, 2H), 5.38 (m, 1H), 3.99 (d, 2H), 3.23 (q, 2H), 1.57-1.67 (m, 2H), 1.43-1.53 (2H), 1.25 (t, 3H)
    Figure US20210094940A1-20210401-C00126
         		I-20.1 CDCl3 8.43 (s, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.81 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.4 Hz, 2H), 7.45-7.40 (m, 2H), 7.05- 6.95 (m, 2H), 6.60 (d, J = 7.6 Hz, 1H), 5.61 (s, 2H), 5.38-5.30 (m, 1H), 4.15- 4.00 (m, 2H), 3.00 (s, 3H), 2.96 (s, 1H).
    Figure US20210094940A1-20210401-C00127
         		I-24 CDCl3 8.26 (s, 1H), 7.92 (d, J = 8.4 Hz, 2H), 7.89 (d, J = 8.4 Hz, 1H), 7.60 (d, J = 8.0 Hz, 2H), 7.36 (d, J = 8.4 Hz, 1H), 7.20 (d, J = 8.4 Hz, 1H), 7.01 (t, J = 5.6 Hz, 1H), 6.98 (d, J = 8.0 Hz, 1H), 6.67 (d, J = 8.0 Hz, 1H), 5.69 (s, 2H), 5.34 (t, J = 7.2 Hz, 1H), 4.12-4.02 (m, 2H), 3.04 (s, 3H), 2.42 (brs, 1H), 1.56 (t, J = 4.0 Hz, 2H), 1.52 (t, J = 6.4 Hz, 2H).
    Figure US20210094940A1-20210401-C00128
         		I-25 CDCl3 8.39 (d, J = 1.2 Hz, 1H), 7.97 (dd, J = 1.2, 10.0 Hz, 1H), 7.69 (dd, J = 1.6, 6.8 Hz, 2H), 7.45-7.39 (m, 4H), 7.03- 6.99 (m, 2H), 6.60 (d, J = 7.2 Hz, 1H), 5.61 (s, 2H), 4.74 (d, J = 6.0 Hz, 2H), 3.07 (q, J = 7.2 Hz, 2H), 1.23 (t, J = 7.2 Hz, 3H).
    Figure US20210094940A1-20210401-C00129
         		I-27 CD3OD 8.24 (s, 1H), 7.84-7.92 (m, 3H), 7.63 (d, 2H), 7.57 (d, 1H), 7.05-7.17(m, 2H), 6.83 (d, 1H), 5.84 (s, 2H), 4.70 (s, 2H), 3.18 (q, 2H), 1.48-1.60 (m, 2H), 1.35-1.45 (2H), 1.19 (t, 3H)
    Figure US20210094940A1-20210401-C00130
         		I-37 CD3OD 8.42 (s, 1H), 8.02 (d, 1H), 7.96-7.92 (d, 2H), 7.70 (d, 2H), 7.62 (d, 1H), 7.14 (t, 1H), 7.05-7.12 (m, 2H), 6.80 (d, 1H), 5.82 (s, 2H), 4.78 (s, 2H), 3.23 (q, 2H), 1.23 (t, 3H)
    Figure US20210094940A1-20210401-C00131
         		I-48 CDCl3 8.33 (s, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.89 (d, J = 8.0 Hz, 2H), 7.54 (d, J = 8.0 Hz, 2H), 7.42 (d, J = 8.4 Hz, 1H), 7.05-6.97 (m, 2H), 6.73 (t, J = 5.6 Hz, 1H), 6.59 (d, J = 8.0 Hz, 1H), 5.61 (s, 2H), 4.77 (d, J = 6.0 Hz, 2H), 3.04 (s, 3H).
    Figure US20210094940A1-20210401-C00132
         		I-52 CDCl3 8.35 (s, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.84 (d, J = 6.4 Hz, 2H), 7.53 (d, 8.4 Hz, 2H), 7.42 (d, J = 8.8 Hz, 1H), 7.03-7.00 (m, 2H), 6.78 (t, J = 8.8 Hz, 1H), 6.59 (d, J = 6.8 Hz, 1H), 5.61 (s, 2H), 4.78 (d, J = 5.6 Hz, 2H), 3.05 (t, J = 8.0 Hz, 2H), 1.76-1.71 (m, 2H), 0.99 (t, J = 7.2 Hz, 3H).
    Figure US20210094940A1-20210401-C00133
         		I-59 CD3OD 1H NMR (CD3OD 400 MHz): δ 9.09 (d, J = 7.6 Hz, 1H), 8.42 (s, 1H), 7.98 (d, J = 9.2 Hz, 1H), 7.90 (d, J = 8.0 Hz, 2H), 7.71 (d, J = 8.4 Hz, 2H), 7.67 (d, J = 8.8 Hz, 1H), 7.18 (d, J = 6.8 Hz, 1H), 7.13 (t, J = 8.0 Hz, 1H), 6.86 (d, J = 12 Hz, 1H), 5.84 (s, 2H), 5.46- 5.44 (m, 1H), 3.84-3.80 (m, 1H), 3.77- 3.73 (m, 1H), 3.42 (s, 3H), 3.20 (q, J = 7.6 Hz, 2H), 1.21 (t, J = 7.6 Hz, 3H).
    Figure US20210094940A1-20210401-C00134
         		I-60 CDCl3 8.15 (s, 1H), 7.86 (d, J = 8.0 Hz, 2H), 7.79 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 8.0 Hz, 2H), 7.33 (d, J = 8.4 Hz, 1H), 7.15 (d, J = 7.6 Hz, 1H), 7.05-6.95 (m, 2H), 6.63 (d, J = 1.6 Hz, 1H), 5.53 (s, 2H), 5.40-5.33 (m, 1H), 3.85-3.65 (m, 2H), 3.39 (s, 3H), 3.09 (q, J = 12 Hz, 2H), 2.05-0.95 (m, 1H), 1.28 (t, J = 7.2 Hz, 5H), 1.18-1.07 (m, 2H).
    Figure US20210094940A1-20210401-C00135
         		I-61 CDCl3 8.24 (s, 1H), 7.88-7.83 (m, 3H), 7.61 (d, J = 8.4 Hz, 2H), 7.36 (d, J = 8.8 Hz, 1H), 7.15 (d, J = 6.8 Hz, 1H), 7.02 (d, J = 7.6 Hz, 1H), 7.00 (t, J = 7.6 Hz, 1H), 6.66 (d, J = 8.0 Hz, 1H), 5.69 (s, 2H), 5.38 (d, J = 3.2 Hz, 1H), 3.83- 3.73 (m, 2H), 3.39 (s, 3H), 3.09 (q, J = 6.8 Hz, 2H), 1.59-1.49 (m, 4H), 1.28 (t, J = 7.2 Hz, 3H).
    Figure US20210094940A1-20210401-C00136
         		I-62 CD3OD 9.04 (d, J = 2.0 Hz, 1H), 8.45 (s, 1H), 8.30 (dd, J = 2.0, 6.0 Hz, 1H), 8.00 (dd, J = 1.2, 8.8 Hz, 1H), 7.78 (d, J = 8.4 Hz, 1H), 7.68 (d, J = 9.2 Hz, 1H), 7.20-7.12 (m, 2H), 6.87 (d, J = 7.6 Hz, 1H), 5.84 (s, 2H), 5.23 (t, J = 6.4 Hz, 1H), 3.94-3.90 (m, 2H), 3.39 (s, 3H), 3.29 (q, J = 7.2 Hz, 2H), 1.26 (t, J = 7.2 Hz, 3H).
    Figure US20210094940A1-20210401-C00137
         		I-63 CD3OD 8.99 (s, 1H), 8.44 (s, 1H), 8.27 (d, 1H), 8.03 (d, 1H), 7.64-7.74 (m, 2H), 7.12-7.22 (m, 2H), 6.86 (d, 1H), 5.82 (s, 2H), 4.82 (d, 2H), 3.26 (q, 2H), 1.25 (t, 3H)
    Figure US20210094940A1-20210401-C00138
         		I-66 CD3OD 8.97 (s, 1H), 8.39 (s, 1H), 8.25 (d, 1H), 7.93 (d, 1H), 7.64 (d, 1H), 7.53 (d, 1H), 7.02-7.17 (m, 2H), 6.62 (d, 1H), 5.81 (s, 2H), 4.82 (d, 2H), 3.26 (q, 2H), 2.25 (t, 1H), 1.23 (t, 3H)
    Figure US20210094940A1-20210401-C00139
         		I-81 CDCl3 8.45 (s, 1H), 7.94 (dd, J = 1.2, 8.8 Hz, 1H), 7.74 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 8.4 Hz, 2H), 7.51 (d, J = 6.8 Hz, 1H), 7.45 (d, J = 8.8 Hz, 1H), 6.80- 6.71 (m, 2H), 6.44 (d, J = 6.8 Hz, 1H), 5.97 (dd, J = 1.2, 5.2 Hz, 2H), 5.53 (d, J = 2.8 Hz, 2H), 5.39-5.33 (m, 1H), 4.18-4.03 (m, 2H), 3.21 (brs, 1H), 3.06 (q, J = 7.6 Hz, 2H), 1.25 (t, J = 1.6 Hz, 3H).
    Figure US20210094940A1-20210401-C00140
         		I-95 CD3OD 9.22 (m, 1H), 8.41 (s, 1H), 7.75-7.95 (m, 4H), 7.63 (d, 2H), 7.47 (d, 2H), 7.20 (t, 1H), 6.76 (s, 1H), 6.66 (d, 1H), 5.96 (s, 2H), 4.70 (d, 2H), 3.17 (q, 2H), 1.19 (t, 3H)
    Figure US20210094940A1-20210401-C00141
         		I-123 CDCl3 8.51 (s, 1H), 7.99 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 8.8 Hz, 1H), 7.51 (d, J = 6.8 Hz, 2H), 7.42 (d, J = 8.8 Hz, 1H), 7.30 (d, J = 8.0 Hz, 1H), 7.03-7.00 (m, 2H), 6.61 (d, J = 8.0 Hz, 1H), 5.61 (d, J = 2.8 Hz, 2H), 4.13 (s, 2H), 3.61 (s, 1H), 3.05 (q, J = 7.2 Hz, 2H), 1.25 (t, J = 7.2 Hz, 3H).
    Figure US20210094940A1-20210401-C00142
         		I-134.1 CD3OD 9.04 (s, 1H), 8.42 (s, 1H), 8.34 (d, J = 8.4 Hz, 1H), 8.16 (d, J = 8.8 Hz, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.82 (d, J = 8.4 Hz, 1H), 7.23 (t, J = 7.6 Hz, 1H), 7.18 (d, J = 8.0 Hz, 1H), 7.08 (d, J = 8.0 Hz, 1H), 6.05 (s, 2H), 5.40 (t, J = 6.4 Hz, 1H), 4.08 (q, J = 3.2 Hz, 2H), 3.28 (q, J = 7.6 Hz, 2H), 1.87-1.83 (m, 2H), 1.67-1.63 (m, 2H), 1.25 (t, J = 7.2 Hz, 3H).
    • Biological Assays Radio-Ligand RORγ Binding Assay (Assay 1)
  • Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL), 25-hydroxy [26,27-3H]-cholesterol (PerkinElmer, Cat. #NET674250UC), for a ligand binding site on a recombinant RORγ Ligand Binding Domain (LBD) protein expressed as a 6×His-Glutathione-S-Transferase (GST) fusion. The assay was performed in 96-well SPA plates (PerkinElmer, Cat. #1450-401) in 50 mM HEPES buffer, pH 7.4, containing 150 mM NaCl, 5 mM MgCl2, 10% (v/v) glycerol, 2 mM CHAPS, 0.5 mM β-octylglucopyranoside and 5 mM DTT. Tested compounds were dissolved in DMSO, and semi-log (3.162×) serial dilutions of the compounds were prepared in the same solvent. Two μL of the DMSO solutions were mixed with 28 μL of 8.6 nM 25-hydroxy [26,27-3H]-cholesterol and 50 μL of 24 nM RORγ LBD. The plate was shaken at 700 rpm for 20 min and incubated for 10 min at rt, after which 40 μL of poly-Lys YSi SPA beads (PerkinElmer, Cat. #RPNQ0010) were added to achieve 50 pg of the beads per well. The plate was incubated on an orbital shaker for 20 min and then for 10 min without agitation at rt. SPA signal for tritium beta radiation was registered on PerkinElmer Microbeta plate reader. Percent inhibition values were calculated based on the high signal obtained with DMSO control and the low signal observed with 10 μM standard RORγ inverse agonist T0901317 (SigmaAldrich, Cat. #T2320). The percent inhibition vs. concentration data were fit into a four-parameter model, and IC50 values were calculated from the fit as the concentrations corresponding to the inflection points on the dose-response curves. Inhibitory constants (Ki) were calculated using the following equation, where [RL] is the concentration in the assay and KD is a dissociation constant of 25-hydroxy [26,27-3H]-cholesterol:
  • K i = IC 50 ( 1 + [ RL ] K D ) .
    • RORγt 5×RORE Assay in Jurkat Cells (Assay 2)
  • Compounds described herein were tested for RORγ inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanoluc® luciferase was used as a reporter for transcriptional activity of the full-length RORγt in Jurkat cells (ATCC, Cat. #TIB-152). A reporter plasmid was constructed by inserting 5 repeats of the ROR Response Element (RORE) AAAGTAGGTCA (SEQ ID NO:1) into a commercially available promoterless plasmid pNL1.3[secNluc] (Promega, Cat. #N1021) using KpnI and HindIII restriction sites. The expression plasmid for RORγt was purchased (Geneocopoeia, Cat. #EX-T6988-M02). Jurkat cells (30 million cells) were transfected with 11 pg of EX-T6988-MO2 and 26 pg of the reporter plasmid in OptiMEM® media using Lipofectamine® LTX and Plus™ reagents (Life Technologies, Cat. #15338-100). After 5-6 hrs of incubation at 37° C./5% CO2, the cells were collected, resuspended in phenol-red free RPMI media containing 10% (v/v) delipidated FBS (Hyclone, Cat. #SH30855.03) and dispensed into 96-well clear bottom tissue culture plates (CoStar, Cat. #3603), at 80,000 cells per well. Tested compounds were added to the cells in the same media (final concentration of DMSO was 0.1% (v/v)), and the plates were incubated at 37° C./5% CO2 for 16-18 hrs. Luciferase activity in the conditioned supernatants was determined with NanoGlo® assay reagents (Promega, Cat. #N1130). Percent inhibition values were calculated based on the fully inhibited and non-inhibited (DMSO) controls, and the values were regressed against concentrations of the tested compounds to derive IC50 values using a four-parameter non-linear fitting model.
  • The results of assays 1 and 2 are shown in Table 3 below.
  • TABLE 3
    Assay 1 Assay 2
    Cpd No Ki (nM) IC50 (nM)
    I-1 +++ +++
    I-2 +++ +++
    I-3 +++ +++
    I-4 +++ +++
    I-5 +++ +++
    I-6 +++ +
    I-7 ++ nt
    I-8 ++ nt
    I-9 +++ +++
    I-10 +++ +
    I-11.1 +++ +++
    I-11.2 +++ +++
    I-12 +++ +++
    I-13 +++ +++
    I-14 +++ +++
    I-15 +++ +++
    I-16 +++ +++
    I-17 +++ +++
    I-18 +++ +++
    I-19 +++ +++
    I-20.1 +++ +++
    I-20.2 +++ +++
    I-21 +++ +++
    I-22 +++ +++
    I-23.1 +++ +++
    I-23.2 +++ ++
    I-24 +++ +++
    I-25 +++ +++
    I-26 +++ +++
    I-27 +++ +++
    I-28 +++ +++
    I-29 +++ +++
    I-30 +++ +++
    I-31 +++ +++
    I-32 +++ +
    I-33 +++ +++
    I-34 +++ +++
    I-35 +++ +++
    I-36 +++ +++
    I-37 +++ +++
    I-38 +++ +++
    I-39.1 +++ +++
    I-39.2 +++ +++
    I-40 +++ +++
    I-41 +++ +++
    I-42 +++ +++
    I-43 +++ +++
    I-44 +++ +++
    I-45 +++ +++
    I-46 +++ +++
    I-47 +++ +++
    I-48 +++ +++
    I-49.1 +++ +++
    I-49.2 +++ +++
    I-50 +++ +++
    I-51 +++ ++
    I-52 +++ +++
    I-53 +++ ++
    I-54 +++ +++
    I-55 +++ ++
    I-56 ++ nt
    I-57 +++ +++
    I-58 +++ ++
    I-59 +++ +++
    I-60 +++ +++
    I-61 +++ +++
    I-62 +++ +++
    I-63 +++ +++
    I-64 +++ +++
    I-65 +++ +++
    I-66 +++ +++
    I-67 +++ +++
    I-68 +++ +++
    I-69 +++ +++
    I-70 +++ +++
    I-71 +++ +++
    I-72 +++ +++
    I-73 +++ +++
    I-74 +++ +++
    I-75 +++ +++
    I-76 +++ +++
    I-77 +++ +++
    I-78 +++ +++
    I-79 +++ ++
    I-80 +++ ++
    I-81 +++ +++
    I-82 +++ +
    I-83 +++ ++
    I-84 +++ ++
    I-85 +++ +
    I-86 + nt
    I-87 ++ nt
    I-88 +++ +++
    I-89 +++ ++
    I-90 +++ +++
    I-91 ++ nt
    I-92 +++ ++
    I-93.1 +++ +++
    I-93.2 +++ +++
    I-94 +++ ++
    I-95 +++ +++
    I-96 +++ +
    I-97 +++ +++
    I-98 +++ +++
    I-99 +++ ++
    I-100 +++ ++
    I-101 +++ +
    I-102 +++ +++
    I-103 +++ ++
    I-104 +++ +
    I-105 ++ nt
    I-106 +++ ++
    I-107 + nt
    I-108 + nt
    I-109 +++ +++
    I-110 ++ +
    I-111 + nt
    I-112 ++ nt
    I-113 +++ +++
    I-114 + nt
    I-115 +++ +++
    I-116 +++ +++
    I-117 + nt
    I-118 +++ +
    I-119 +++ +++
    I-120 +++ ++
    I-121 ++ nt
    I-122 +++ +++
    I-123 +++ +++
    I-124 +++ +
    I-125.1 +++ +
    I-125.2 +++ +++
    I-126 +++ +++
    I-127 +++ +++
    I-128 +++ +
    I-129 ++ nt
    I-130.1 +++ +++
    I-130.2 +++ +++
    I-131.1 +++ +++
    I-131.2 +++ ++
    I-132.1 +++ +++
    I-132.2 +++ +++
    I-133.1 +++ +++
    I-133.2 ++ nt
    I-134.1 +++ +++
    I-134.2 +++ +++
    I-135 ++ nt
    I-136 +++ +++
    I-137 +++ +++
    I-138 +++ ++
    I-139 +++ +++
    I-140 ++ nt
    I-141 + ++
    I-142 ++ nt
    I-143 +++ ++
    I-144 ++ nt
    I-145 ++ nt
    I-146 ++ nt
    I-147 +++ ++
    I-148 +++ +
    I-149 +++ +++
    I-150 ++ +
    I-151 +++ +++
    I-152 +++ +++
    I-153 +++ +++
    I-154 +++ +
    I-155 ++ nt
    I-156 + nt
    I-157 + nt
    I-158 +++ +
    I-159 + nt
    I-160 ++ nt
    I-161 +++ +++
    I-162 +++ +++
    I-163 +++ +++
    I-164.1 +++ +++
    I-164.2 +++ +++
    I-165 +++ +
    I-166 +++ +
    I-167 +++ +++
    I-168 +++ +++
    I-169 +++ +++
    I-170 +++ +++
    I-170.1 +++ +++
    I-170.2 +++ +++
    I-171 ++ nt
    I-172 +++ +++
    I-173 +++ ++
    I-174 +++ nt
    nt = not tested;
    + means >1000 nM;
    ++ means 100 nM-1000 nM;
    +++ means <100 nM.
  • While we have described a number of embodiments, it is apparent that our basic examples may be altered to provide other embodiments that utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments that have been represented by way of example.
  • The contents of all references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated herein in their entireties by reference. Unless otherwise defined, all technical and scientific terms used herein are accorded the meaning commonly known to one with ordinary skill in the art.

Claims (22)

1-54. (canceled)
55. A method of treating a disease or disorder selected from asthma, chronic obstructive pulmonary disease (COPD), bronchitis, allergic rhinitis, atopic dermatitis, contact dermatitis, acne, cystic fibrosis, allograft rejection, multiple sclerosis, scleroderma, arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), Hashimoto's disease, pancreatitis, autoimmune diabetes, type I diabetes, autoimmune ocular disease, ulcerative colitis, Crohn's disease, regional enteritis, inflammatory bowel disease (IBD), inflammatory bowel syndrome (IBS), Sjögren's syndrome, optic neuritis, obesity, hepatosteatosis, adipose tissue-associated inflammation, insulin resistance, type II diabetes, neuromyelitis optica, myasthenia gravis, age related macular degeneration, dry eye, uveitis, Guillain-Barré syndrome, psoriasis, psoriatic arthritis (PsA), steroid resistant asthma, Graves' disease, scleritis, major depression, seasonal affective disorder, PTSD, bipolar disorder, autism, epilepsy, Alzheimer's, CNS disorders associated with altered sleep and/or circadian rhythms, endometriosis, obstructive sleep apnea syndrome (OSAS), Behçet's disease, dermatomyositis, polymyocitis, graft versus host disease, primary biliary cirrhosis, liver fibrosis, non-alcoholic fatty liver disease (NAFLD), sarcoidosis, primary sclerosing cholangitis, autoimmune thyroid disease, autoimmune polyendocrine syndrome type I, autoimmune polyendocrine syndrome type II, celiac disease, neuromyelitis, juvenile idiopathic arthritis, systemic sclerosis, myocardial infarction, pulmonary hypertension, osteoarthritis, cutaneous leishmaniasis, sinonasal polyposis, and cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the Formula VI:
Figure US20210094940A1-20210401-C00143
or a pharmaceutically acceptable salt thereof, wherein
A is N or CH;
R1 is (C1-C4)alkyl, halo(C1-C4)alkyl, or cycloalkyl optionally substituted with 1 to 3 halo;
L2 is CH2 or CHMe;
Cy2 is bi-cyclic heterocyclyl or bi-cyclic heteroaryl, each of which are optionally substituted with 1 to 3 groups independently selected from halo, (C1-C4)alkyl, and (C1-C4)alkoxy, wherein said (C1-C4)alkyl and (C1-C4)alkoxy are optionally substituted with 1 to 3 halo;
R7 is hydrogen or —CH2OH; and
R9 is —NH(C1-C4)alkyl, (C1-C4)alkyl, or (C1-C4)alkyl substituted with OH.
56. The method of claim 55, wherein the compound is of the Formula VIII:
Figure US20210094940A1-20210401-C00144
or a pharmaceutically acceptable salt thereof, wherein Z is a 5- or 6-membered heterocyclyl ring having one or more heteroatoms selected from oxygen or nitrogen; and wherein Z is optionally substituted with (C1-C4)alkyl or 1 to 3 halo.
57. The method of claim 56, wherein the compound is of the Formula XI:
Figure US20210094940A1-20210401-C00145
or a pharmaceutically acceptable salt thereof, wherein R10 and R11 are each independently hydrogen or halo.
58. The method of claim 57, wherein R1 is halo(C1-C4)alkyl, cyclopropyl, or cyclobutyl, wherein said cyclopropyl and cyclobutyl are each optionally substituted with 1 to 3 halo.
59. The method of claim 57, wherein L2 is CH2.
60. The method of claim 57, wherein R7 is —CH2OH; and A is N.
61. The method of claim 57, wherein R10 and R11 are each fluoro.
62. A method of treating a disease or disorder selected from asthma, chronic obstructive pulmonary disease (COPD), bronchitis, allergic rhinitis, atopic dermatitis, contact dermatitis, acne, cystic fibrosis, allograft rejection, multiple sclerosis, scleroderma, arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), Hashimoto's disease, pancreatitis, autoimmune diabetes, type I diabetes, autoimmune ocular disease, ulcerative colitis, Crohn's disease, regional enteritis, inflammatory bowel disease (IBD), inflammatory bowel syndrome (IBS), Sjögren's syndrome, optic neuritis, obesity, hepatosteatosis, adipose tissue-associated inflammation, insulin resistance, type II diabetes, neuromyelitis optica, myasthenia gravis, age related macular degeneration, dry eye, uveitis, Guillain-Barré syndrome, psoriasis, psoriatic arthritis (PsA), steroid resistant asthma, Graves' disease, scleritis, major depression, seasonal affective disorder, PTSD, bipolar disorder, autism, epilepsy, Alzheimer's, CNS disorders associated with altered sleep and/or circadian rhythms, endometriosis, obstructive sleep apnea syndrome (OSAS), Behçet's disease, dermatomyositis, polymyocitis, graft versus host disease, primary biliary cirrhosis, liver fibrosis, non-alcoholic fatty liver disease (NAFLD), sarcoidosis, primary sclerosing cholangitis, autoimmune thyroid disease, autoimmune polyendocrine syndrome type I, autoimmune polyendocrine syndrome type II, celiac disease, neuromyelitis, juvenile idiopathic arthritis, systemic sclerosis, myocardial infarction, pulmonary hypertension, osteoarthritis, cutaneous leishmaniasis, sinonasal polyposis, and cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the formula:
Figure US20210094940A1-20210401-C00146
Figure US20210094940A1-20210401-C00147
or a pharmaceutically acceptable salt of any of the foregoing formulae.
63. The method of claim 62, wherein the compound is of the formula:
Figure US20210094940A1-20210401-C00148
or a pharmaceutically acceptable salt thereof.
64. The method of claim 62, wherein the compound is of the formula:
Figure US20210094940A1-20210401-C00149
or a pharmaceutically acceptable salt thereof.
65. The method of claim 62, wherein the compound is of the formula:
Figure US20210094940A1-20210401-C00150
or a pharmaceutically acceptable salt thereof.
66. The method of claim 62, wherein the compound is of the formula:
Figure US20210094940A1-20210401-C00151
or a pharmaceutically acceptable salt thereof.
67. The method of claim 62, wherein the compound is of the formula:
Figure US20210094940A1-20210401-C00152
or a pharmaceutically acceptable salt thereof.
68. The method of claim 62, wherein the compound is of the formula:
Figure US20210094940A1-20210401-C00153
or a pharmaceutically acceptable salt thereof.
69. A method of treating a disease or disorder selected from asthma, chronic obstructive pulmonary disease (COPD), bronchitis, allergic rhinitis, atopic dermatitis, contact dermatitis, acne, cystic fibrosis, allograft rejection, multiple sclerosis, scleroderma, arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), Hashimoto's disease, pancreatitis, autoimmune diabetes, type I diabetes, autoimmune ocular disease, ulcerative colitis, Crohn's disease, regional enteritis, inflammatory bowel disease (IBD), inflammatory bowel syndrome (IBS), Sjögren's syndrome, optic neuritis, obesity, hepatosteatosis, adipose tissue-associated inflammation, insulin resistance, type II diabetes, neuromyelitis optica, myasthenia gravis, age related macular degeneration, dry eye, uveitis, Guillain-Barré syndrome, psoriasis, psoriatic arthritis (PsA), steroid resistant asthma, Graves' disease, scleritis, major depression, seasonal affective disorder, PTSD, bipolar disorder, autism, epilepsy, Alzheimer's, CNS disorders associated with altered sleep and/or circadian rhythms, endometriosis, obstructive sleep apnea syndrome (OSAS), Behçet's disease, dermatomyositis, polymyocitis, graft versus host disease, primary biliary cirrhosis, liver fibrosis, non-alcoholic fatty liver disease (NAFLD), sarcoidosis, primary sclerosing cholangitis, autoimmune thyroid disease, autoimmune polyendocrine syndrome type I, autoimmune polyendocrine syndrome type II, celiac disease, neuromyelitis, juvenile idiopathic arthritis, systemic sclerosis, myocardial infarction, pulmonary hypertension, osteoarthritis, cutaneous leishmaniasis, sinonasal polyposis, and cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound selected from:
N-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
N-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-2-(4-(methylsulfonyl)phenyl)acetamide;
N-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-2-(4-((2-hydroxyethyl)sulfonyl)phenyl)acetamide;
N-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-2-(4-((2-methoxyethyl)sulfonyl)phenyl)acetamide;
N-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-2-(4-(N-methylsulfamoyl)phenyl)acetamide;
2-(4-cyanophenyl)-N-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)acetamide;
ethyl 2-(4-(2-((1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)amino)-2-oxoethyl)phenyl)acetate;
2-(4-(2-((1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)amino)-2-oxoethyl)phenyl)acetic acid;
N-(2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-1H-benzo[d]imidazol-5-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
N-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-2-(1-(methylsulfonyl)piperidin-4-yl)acetamide;
(R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
(S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(1,1-difluoroethyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N—((R)-1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-((R)-tetrahydrofuran-2-yl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-ethyl-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(1-fluorocyclopropyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(1-fluorocyclobutyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(2-hydroxy-1-(4-(methylsulfonyl)phenyl)ethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
(S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(2-hydroxy-1-(4-(methylsulfonyl)phenyl)ethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(2-hydroxy-1-(4-(methylsulfonyl)phenyl)ethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(2-hydroxy-1-(4-(methylsulfonyl)phenyl)ethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(2-hydroxy-1-(4-(methylsulfonyl)phenyl)ethyl)-1H-benzo[d]imidazole-5-carboxamide;
(S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(2-hydroxy-1-(4-(methylsulfonyl)phenyl)ethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(1-fluorocyclopropyl)-N-(2-hydroxy-1-(4-(methylsulfonyl)phenyl)ethyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-(1-fluorocyclopropyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-(methoxymethyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-ethyl-N-(4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
2-(tert-butyl)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-isopropyl-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-methyl-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-isobutyl-1H-benzo[d]imidazole-5-carboxamide;
2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(methylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(N-methylsulfamoyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(1,1-difluoroethyl)-N-(4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(1-fluorocyclopropyl)-N-(4-(methylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(1-fluorocyclopropyl)-N-(4-((2-hydroxyethyl)sulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(1-fluorocyclopropyl)-N-(4-(N-methylsulfamoyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-(1-fluorocyclobutyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(4-((2-hydroxyethyl)sulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-((2-hydroxyethyl)sulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(N-methylsulfamoyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-((2-hydroxyethyl)sulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(methylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
(S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-(1-methoxyethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-(1-methoxyethyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(4-(methylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-sulfamoylbenzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(propylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
methyl 2-((4-((1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamido)methyl)phenyl)sulfonyl)acetate;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-(2-methoxypropan-2-yl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-methoxy-1H-benzo[d]imidazole-5-carboxamide;
2-((1S,2R)-2-cyanocyclopropyl)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
2-((1Rc,2R)-2-cyanocyclopropyl)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
methyl (1Rc,2R)-2-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-5-((4-(ethylsulfonyl)benzyl)carbamoyl)-1H-benzo[d]imidazol-2-yl)cyclopropane-1-carboxylate;
(R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-methoxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-methoxyethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-methoxyethyl)-2-(1-fluorocyclopropyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-methoxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((5-(ethylsulfonyl)pyridin-2-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((5-(ethylsulfonyl)pyridin-2-yl)methyl)-1H-benzo[d]imidazole-5-carboxamide;
2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((5-(ethylsulfonyl)pyridin-2-yl)methyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(1,1-difluoroethyl)-N-((5-(ethylsulfonyl)pyridin-2-yl)methyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((5-(ethylsulfonyl)pyridin-2-yl)methyl)-2-(1-fluorocyclopropyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(1-fluorocyclopropyl)-N-((5-(methylsulfonyl)pyridin-2-yl)methyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((5-(ethylsulfonyl)pyridin-2-yl)methyl)-2-(1-fluorocyclobutyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((5-(methylsulfonyl)pyridin-2-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((1-(methylsulfonyl)piperidin-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((1-(methylsulfonyl)piperidin-4-yl)methyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(1-fluorocyclopropyl)-N-((1-(methylsulfonyl)piperidin-4-yl)methyl)-1H-benzo[d]imidazole-5-carboxamide;
methyl 2-((4-((1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamido)methyl)piperidin-1-yl)sulfonyl)acetate;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((1-((2-(methylamino)-2-oxoethyl)sulfonyl)piperidin-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
methyl 2-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamido)-2-(1-(methylsulfonyl)piperidin-4-yl)acetate;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((1-(N-methylsulfamoyl)piperidin-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
N-((1-((2-amino-2-oxoethyl)sulfonyl)piperidin-4-yl)methyl)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((1-((2-(methylamino)-2-oxoethyl)sulfonyl)piperidin-4-yl)methyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-1-((2,3-dihydrobenzofuran-7-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-1-(benzo[d][1,3]dioxol-4-ylmethyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
N-(4-(ethylsulfonyl)benzyl)-1-((2-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-8-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
N-(4-(ethylsulfonyl)benzyl)-1-((2-oxo-1,2-dihydroquinolin-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
1-(benzofuran-4-ylmethyl)-N-(4-(ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,3-dihydrobenzofuran-7-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((1H-indazol-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
1-(benzo[d][1,3]dioxol-4-ylmethyl)-N-(4-(ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((1H-pyrrolo[2,3-c]pyridin-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-2-cyclopropyl-1-((2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-2-cyclopropyl-1-((2,3-dihydrobenzofuran-7-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide;
2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
(S)-2-cyclopropyl-1-(1-(2,2-difluorobenzo[d][1,3]dioxol-4-yl)ethyl)-N-(4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
2-cyclopropyl-1-((2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
2-(4-((1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamido)methyl)cyclohexyl)acetic acid;
N-((1H-benzo[d][1,2,3]triazol-6-yl)methyl)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)—N-(1-(4-cyanophenyl)-2-hydroxyethyl)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)-2-fluorophenyl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
(S)-1-(1-(2,2-difluorobenzo[d][1,3]dioxol-4-yl)ethyl)-2-ethyl-N-(4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-1-(1-(2,2-difluorobenzo[d][1,3]dioxol-4-yl)ethyl)-2-ethyl-N-(4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-(ethylsulfonyl)-2-hydroxybenzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
methyl 2-((4-((1-((1H-indazol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamido)methyl)piperidin-1-yl)sulfonyl)acetate;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((4-oxo-1,4-dihydroquinolin-7-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
(S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide;
(S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(difluoromethyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide;
(S)-2-cyclobutyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide;
(S)-2-cyclopropyl-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(1-fluorocyclopropyl)-1H-benzo[d]imidazole-5-carboxamide;
(S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(5-(ethylsulfonyl)pyridin-2-yl)-2-hydroxyethyl)-2-(1-fluorocyclopropyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(2-hydroxy-1-(5-(methylsulfonyl)pyridin-2-yl)ethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
N-(4-(ethylsulfonyl)benzyl)-1-((1-methyl-1H-indazol-7-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
N-(4-(ethylsulfonyl)benzyl)-1-((2-methyl-2H-indazol-7-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((1,2-dimethyl-1H-benzo[d]imidazol-7-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
N-(4-(ethylsulfonyl)benzyl)-1-((1-methyl-1H-indazol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((1H-indazol-7-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
N-(4-(ethylsulfonyl)benzyl)-1-((2-methyl-2H-indazol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
1-(benzo[d]oxazol-4-ylmethyl)-N-(4-(ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
2-cyclopropyl-1-((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-2-cyclopropyl-1-(1-(2,2-difluorobenzo[d][1,3]dioxol-4-yl)ethyl)-N-(4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
1-(benzo[c][1,2,5]oxadiazol-4-ylmethyl)-N-(4-(ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
1-(benzo[d]oxazol-7-ylmethyl)-N-(4-(ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
2-((1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamido)methyl)-5-(ethylsulfonyl)pyridine 1-oxide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(dimethylamino)-N-(4-(ethylsulfonyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((1-((2-hydroxyethyl)sulfonyl)piperidin-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
(R)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(2-hydroxy-1-(1-(methylsulfonyl)piperidin-4-yl)ethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
(S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(2-hydroxy-1-(1-(methylsulfonyl)piperidin-4-yl)ethyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
(S)-3-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamido)-3-(4-(ethylsulfonyl)phenyl)propanoic acid;
(R)-2-(2-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamido)-2-(4-(ethylsulfonyl)phenyl)ethoxy)acetic acid;
(S)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(1-(4-(ethylsulfonyl)phenyl)-3-(methylamino)-3-oxopropyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
(S)—N-(3-amino-1-(4-(ethylsulfonyl)phenyl)-3-oxopropyl)-1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(4-((2-(methylamino)-2-oxoethyl)sulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
N-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-2-(4-(ethylsulfonyl)phenyl)-2-hydroxyacetamide;
(R)—N-(1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-2-(4-(ethylsulfonyl)phenyl)-2-hydroxyacetamide;
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-((4-methyl-1-(methylsulfonyl)-1,4-diazepan-5-yl)methyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
1-((2,3-dihydrobenzofuran-4-yl)methyl)-N-(4-(ethylsulfonyl)benzyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide;
methyl 1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-5-((4-(ethylsulfonyl)benzyl)carbamoyl)-1H-benzo[d]imidazole-2-carboxylate; and
1-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-N-(2-(4-(ethylsulfonyl)phenyl)-1,3-dihydroxypropan-2-yl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxamide, or a pharmaceutically acceptable salt of any of the foregoing.
70. The method of claim 55, wherein the disease or disorder is selected from asthma, atopic dermatitis, acne, Crohn's disease, regional enteritis, ulcerative colitis, Sjögren's syndrome, uveitis, Behçet's disease, dermatomyositis, multiple sclerosis, ankylosing spondylitis, systemic lupus erythematosus (SLE), scleroderma, psoriasis, psoriatic arthritis (PsA), steroid resistant asthma, and rheumatoid arthritis.
71. The method of claim 62, wherein the disease or disorder is selected from asthma, atopic dermatitis, acne, Crohn's disease, regional enteritis, ulcerative colitis, Sjögren's syndrome, uveitis, Behçet's disease, dermatomyositis, multiple sclerosis, ankylosing spondylitis, systemic lupus erythematosus (SLE), scleroderma, psoriasis, psoriatic arthritis (PsA), steroid resistant asthma, and rheumatoid arthritis.
72. The method of claim 69, wherein the disease or disorder is selected from asthma, atopic dermatitis, acne, Crohn's disease, regional enteritis, ulcerative colitis, Sjögren's syndrome, uveitis, Behçet's disease, dermatomyositis, multiple sclerosis, ankylosing spondylitis, systemic lupus erythematosus (SLE), scleroderma, psoriasis, psoriatic arthritis (PsA), steroid resistant asthma, and rheumatoid arthritis.
73. The method of claim 70, wherein the disease or disorder is selected from atopic dermatitis, acne, dermatomyositis, scleroderma, psoriasis, psoriatic arthritis (PsA), and rheumatoid arthritis.
74. The method of claim 71, wherein the disease or disorder is selected from atopic dermatitis, acne, dermatomyositis, scleroderma, psoriasis, psoriatic arthritis (PsA), and rheumatoid arthritis.
75. The method of claim 72, wherein the disease or disorder is selected from atopic dermatitis, acne, dermatomyositis, scleroderma, psoriasis, psoriatic arthritis (PsA), and rheumatoid arthritis.
US17/023,871 2016-01-29 2020-09-17 Modulators of ror-gamma Abandoned US20210094940A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/023,871 US20210094940A1 (en) 2016-01-29 2020-09-17 Modulators of ror-gamma

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662288487P 2016-01-29 2016-01-29
US201662320893P 2016-04-11 2016-04-11
PCT/US2017/015220 WO2017132432A1 (en) 2016-01-29 2017-01-27 Benzimidazole derivatives as modulators of ror-gamma
US201816073503A 2018-07-27 2018-07-27
US17/023,871 US20210094940A1 (en) 2016-01-29 2020-09-17 Modulators of ror-gamma

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US16/073,503 Division US10829481B2 (en) 2016-01-29 2017-01-27 Benzimidazole derivatives as modulators of ROR-gamma
PCT/US2017/015220 Division WO2017132432A1 (en) 2016-01-29 2017-01-27 Benzimidazole derivatives as modulators of ror-gamma

Publications (1)

Publication Number Publication Date
US20210094940A1 true US20210094940A1 (en) 2021-04-01

Family

ID=57966225

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/073,503 Active US10829481B2 (en) 2016-01-29 2017-01-27 Benzimidazole derivatives as modulators of ROR-gamma
US17/023,871 Abandoned US20210094940A1 (en) 2016-01-29 2020-09-17 Modulators of ror-gamma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US16/073,503 Active US10829481B2 (en) 2016-01-29 2017-01-27 Benzimidazole derivatives as modulators of ROR-gamma

Country Status (15)

Country Link
US (2) US10829481B2 (en)
EP (2) EP3939974A1 (en)
JP (2) JP6948333B2 (en)
KR (1) KR20180100697A (en)
CN (2) CN114230523A (en)
AU (1) AU2017212577B2 (en)
BR (1) BR112018015273A2 (en)
CA (1) CA3011838A1 (en)
MA (2) MA55328A (en)
MX (1) MX2018009257A (en)
RU (2) RU2021133444A (en)
SA (1) SA518392101B1 (en)
TW (2) TWI757266B (en)
UY (1) UY37098A (en)
WO (1) WO2017132432A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11535614B2 (en) 2014-02-03 2022-12-27 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
CN113121497A (en) 2015-05-15 2021-07-16 奥瑞基尼探索技术有限公司 Substituted tetrahydroquinolinone compounds as ROR gamma modulators
WO2017024018A1 (en) 2015-08-05 2017-02-09 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
CN108463458B (en) 2015-11-20 2022-02-01 生命医药有限责任公司 Modulators of ROR-gamma
TWI757266B (en) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 Modulators of ror-gamma
WO2019023207A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibitors of rorϒ
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibitors of ror gamma
CN109593068B (en) * 2017-09-30 2022-12-27 广东东阳光药业有限公司 Intermediate of ROR gamma inhibitor and preparation method thereof
ES2949366T3 (en) * 2018-05-03 2023-09-28 Jiangsu Hengrui Pharmaceuticals Co Ltd Benzimidazole derivatives as modulators of the retinoid-related orphan gamma receptor (rory) and pharmaceutical uses thereof
CN110483437B (en) * 2018-05-14 2022-12-06 嘉兴维眸生物科技有限公司 Five-membered ring-containing compound and preparation and application thereof
CN112601745B (en) * 2018-10-24 2023-06-27 上海和誉生物医药科技有限公司 Azaaryl amide derivative and preparation method and application thereof
CA3156332A1 (en) * 2019-10-31 2021-05-06 Jiangsu Hengrui Medicine Co., Ltd. Acid addition salt of ror.gamma. regulator
CN112745268B (en) * 2019-10-31 2022-09-16 江苏恒瑞医药股份有限公司 Crystal form of benzimidazole derivative and preparation method thereof
TW202136237A (en) 2020-01-06 2021-10-01 大陸商廣東東陽光藥業有限公司 ROR[gamma]T inhibitor, preparation method therefor and use thereof
CN111333552B (en) * 2020-04-09 2021-07-20 广州安岩仁医药科技有限公司 Synthesis method of beta-benzo amino acid compound
CN111606868B (en) * 2020-06-23 2023-02-17 温州大学新材料与产业技术研究院 Preparation method of bidentate oxazoline chiral ligand
CN113912563A (en) * 2020-07-10 2022-01-11 中国科学院广州生物医药与健康研究院 Benzo five-membered nitrogen heterocyclic compound and application thereof
EP4301357A1 (en) * 2021-03-03 2024-01-10 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3233464A1 (en) * 2021-10-04 2023-04-13 Bolt Biotherapeutics, Inc. Asymmetric bis-benzimidazole sting agonist immunoconjugates and uses thereof

Family Cites Families (257)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE128129T1 (en) 1986-07-28 1995-10-15 American Cyanamid Co 5(AND/OR6) SUBSTITUTED 2-(2-IMIDAZOLINE-2-YL) NICOTINIC ACIDS, ESTERS AND SALTS USABLE AS HERBICIDAL AGENTS AND INTERMEDIATE COMPOUNDS FOR THE PRODUCTION OF THESE NICOTINIC ACIDS, ESTERS AND SALTS.
FR2624698A1 (en) 1987-12-18 1989-06-23 Bernard Lyon I Universite Clau HETEROCYCLIC DERIVATIVES OF N-CARBAMOYL-, N-THIOCARBAMOYL- OR N-AMIDINO-AMINOMALONYL OR AMINOSUCCINYL AMIDES USEFUL AS SULFURING AGENTS
WO1990009787A1 (en) 1989-02-27 1990-09-07 The Du Pont Merck Pharmaceutical Company Novel sulfonamides as radiosensitizers
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
GB8927872D0 (en) 1989-12-08 1990-02-14 Beecham Group Plc Pharmaceuticals
JP2807577B2 (en) 1990-06-15 1998-10-08 エーザイ株式会社 Cyclic amide derivative
EP0520573A1 (en) 1991-06-27 1992-12-30 Glaxo Inc. Cyclic imide derivatives
DE4121214A1 (en) 1991-06-27 1993-01-14 Bayer Ag 7-AZAISOINDOLINYL CHINOLONE AND NAPHTHYRIDONE CARBONIC ACID DERIVATIVES
US5416099A (en) 1991-10-29 1995-05-16 Merck & Co., Inc. Fibrinogen receptor antagonists
US5389631A (en) 1991-10-29 1995-02-14 Merck & Co., Inc. Fibrinogen receptor antagonists
US5272158A (en) 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
US5238950A (en) 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
US5364869A (en) 1992-03-09 1994-11-15 Abbott Laboratories Heterocycle-substituted benzyaminopyridine angiotensin II receptor antagonists
US5326760A (en) 1992-06-29 1994-07-05 Glaxo, Inc. Aminobutanoic acid compounds having metalloprotease inhibiting properties
JPH06236056A (en) 1993-02-10 1994-08-23 Fuji Xerox Co Ltd Electrophotographic sensitive body
JP3760474B2 (en) 1993-04-22 2006-03-29 ダイキン工業株式会社 Method and apparatus for generating electric energy, and compound having NF bond used therefor
CA2134192A1 (en) 1993-11-12 1995-05-13 Michael L. Denney 5, 6-bicyclic glycoprotein iib/iiia antagonists
DE4343922A1 (en) 1993-12-22 1995-06-29 Basf Ag Pyridine-2,3-dicarboximides, process for their preparation and their use in combating undesirable plant growth
KR970007419B1 (en) 1993-12-30 1997-05-08 한솔제지 주식회사 Subliming type dye for thermal transfer printing
FR2725946A1 (en) 1994-10-24 1996-04-26 Lohr Ind Vehicle chock, for use on transporters with perforated carrying surfaces,
US5719144A (en) 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
US5770590A (en) 1995-03-24 1998-06-23 Takeda Chemical Industries, Ltd. Cyclic compounds, their prudiction and use
TW394773B (en) 1995-03-24 2000-06-21 Takeda Chemical Industries Ltd Cyclic compounds for antagonizing tachykinin receptor, substance p receptor and neurokinin a receptor, their production and pharmaceutical composition
AU722514B2 (en) * 1995-12-28 2000-08-03 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
DE19608791A1 (en) 1996-03-07 1997-09-11 Hoechst Ag Process for the preparation of fluorinated aromatics and fluorinated nitrogen-containing heteroaromatics
DE19702282C2 (en) 1997-01-23 1998-11-19 Hoechst Ag Catalyst for Halex reactions
US6177443B1 (en) 1997-03-07 2001-01-23 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use
WO1998040385A1 (en) 1997-03-07 1998-09-17 Novo Nordisk A/S 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
KR19980074060A (en) 1997-03-21 1998-11-05 김윤배 Novel substituted 3,4-dialkoxyphenyl derivatives
JPH1143489A (en) 1997-05-30 1999-02-16 Takeda Chem Ind Ltd Heterocyclic compound, its production and agent
US20020132817A1 (en) 1998-03-19 2002-09-19 Hideaki Natsugari Heterocyclic compounds, their production and use
AU751114B2 (en) 1998-03-19 2002-08-08 Takeda Chemical Industries Ltd. Heterocyclic compounds, their production and use as tachykinin receptor antagonists
FR2778662B1 (en) 1998-05-12 2000-06-16 Adir NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP2000007661A (en) 1998-06-23 2000-01-11 Nippon Nohyaku Co Ltd Heterocyclic diamide dicarboxylate derivative, its intermediate and herbicide
EP1101758A4 (en) 1998-07-28 2002-04-03 Nihon Nohyaku Co Ltd Fused-heterocycle dicarboxylic diamide derivatives or salts thereof, herbicides and usage thereof
US6348032B1 (en) * 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
AU1409100A (en) 1998-11-27 2000-06-19 Takeda Chemical Industries Ltd. Drugs
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
RU2261248C2 (en) 1999-06-23 2005-09-27 Авентис Фарма Дойчланд Гмбх Substituted benzimidazoles and medicinal agent based on thereof
JP2003505388A (en) 1999-07-21 2003-02-12 アストラゼネカ・アクチエボラーグ New compound
MXPA02000828A (en) 1999-08-02 2002-07-30 Hoffmann La Roche Retinoids for the treatment of emphysema.
ATE500257T1 (en) 1999-11-09 2011-03-15 Abbott Lab HYDROMORPHINONE COMPOSITIONS
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
CZ20013424A3 (en) 1999-12-27 2002-02-13 Japan Tobacco Inc. Compounds with fused rings and their use as medicaments
WO2001051128A1 (en) 2000-01-12 2001-07-19 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU5275901A (en) 2000-04-25 2001-11-12 Samsung Electronics Co., Ltd. Biphenyl butyric acid derivative as a matrix metalloproteinase inhibitor
CA2354606C (en) 2000-08-03 2005-12-06 Pfizer Products Inc. Azabicycloalkane derivatives and therapeutic uses thereof
US6884782B2 (en) 2000-11-08 2005-04-26 Amgen Inc. STAT modulators
US6677365B2 (en) 2001-04-03 2004-01-13 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
WO2002081447A1 (en) 2001-04-06 2002-10-17 Daewoong Pharmaceutical Co., Ltd. 3-cyclopentyloxy-4-methoxyphenyl-isothiazolinone derivatives and the use thereof
EP1767525A1 (en) 2001-04-09 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists
US7244730B2 (en) 2001-04-19 2007-07-17 Eisai Co., Ltd 2-iminopyrrolidine derivatives
IL158512A0 (en) 2001-05-24 2004-05-12 Lilly Co Eli Novel pyrrole derivatives as pharmaceutical agents
EP1408041A4 (en) 2001-07-16 2005-08-17 Shionogi & Co Process for preparation of amidine derivatives
WO2003029254A1 (en) 2001-09-28 2003-04-10 Takeda Chemical Industries, Ltd. Process for preparation of tricyclic compounds
JP2003171380A (en) 2001-09-28 2003-06-20 Takeda Chem Ind Ltd Method for producing tricyclic compound
GEP20063814B (en) 2001-10-02 2006-05-10 Upjohn Co Azabicyclic-Substituted Fused-Heteroaryl Compounds for Treatment of DiseaseAzabicyclic-Substituted Fused-Heteroaryl Compounds for Treatment of Disease
DE10156719A1 (en) 2001-11-19 2003-05-28 Bayer Ag New N-(aza-bicycloalkyl)-benzo-heterocyclic carboxamides, useful as Alpha-7-nicotinic acetylcholine receptor ligands for e.g. improving attention, concentration, learning and/or memory performance
TWI263640B (en) 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
CN100383124C (en) 2002-02-04 2008-04-23 霍夫曼-拉罗奇有限公司 Quinoline derivatives as NPY antagonists
DE10207037A1 (en) 2002-02-20 2003-08-28 Bayer Cropscience Gmbh New 2-amino-4-(bicyclic substituted amino)-1,3,5-triazine derivatives, useful as pre- or post-emergence, total or selective herbicides or as plant growth regulators
AU2003213266A1 (en) 2002-03-06 2003-09-22 Smithkline Beecham Corporation Condensed heterocyclic compounds as calcitonin agonists
AU2003237492A1 (en) 2002-06-10 2003-12-22 Acadia Pharmaceuticals Inc. Urotensin ii receptor modulators
AU2003250482A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
ATE370139T1 (en) 2002-09-17 2007-09-15 Lilly Co Eli PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA INHIBITORS FOR THE TREATMENT OF CANCER
EP1578765A4 (en) 2002-11-05 2008-04-23 Isis Pharmaceuticals Inc Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
JP2004203791A (en) 2002-12-25 2004-07-22 Dai Ichi Seiyaku Co Ltd Aromatic compound
CN1212674C (en) 2003-01-08 2005-07-27 东南大学 Transverse buffer P-type MOS transistors
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
GB0308025D0 (en) 2003-04-07 2003-05-14 Glaxo Group Ltd Compounds
TW200505442A (en) 2003-05-19 2005-02-16 Genomics Inst Of The Novartis Res Foundation Immunosuppressant compounds and compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
AU2004249664A1 (en) 2003-05-19 2004-12-29 Irm Llc Immunosuppressant compounds and compositions
CN1816544B (en) 2003-05-19 2011-06-08 Irm有限责任公司 Immunosuppressant compounds and compositions
EP1628661A2 (en) 2003-06-05 2006-03-01 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
CN1566099A (en) 2003-06-13 2005-01-19 中国科学院上海药物研究所 Isoquinoline-1,3,4-trione compounds, preparation method and uses thereof
EP1660454A1 (en) 2003-07-07 2006-05-31 Vernalis (R&D) Limited Azacyclic compounds as inhibitors of sensory neurone specific channels
FR2857966A1 (en) 2003-07-24 2005-01-28 Aventis Pharma Sa New piperazine and tetrahydropyridine derivatives are tubulin polymerization inhibitors used for treating cancer and disaggregating cell masses derived from vascular tissue
BRPI0413245A (en) 2003-08-01 2006-10-03 Pfizer Prod Inc 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders
AU2004274403A1 (en) 2003-09-03 2005-03-31 Aventis Pharmaceuticals Inc. 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds
AP2006003559A0 (en) 2003-09-05 2006-04-30 Neurogen Corp Ventis Pharmaceuticals Inc Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF 1 receptor ligands
WO2005025504A2 (en) 2003-09-12 2005-03-24 Kemia, Inc. Modulators of calcitonin and amylin activity
WO2005039564A1 (en) 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
BRPI0416692A (en) 2003-11-19 2007-01-30 Array Biopharma Inc heterocyclic mek inhibitors and methods of using these
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US20050203151A1 (en) 2003-12-19 2005-09-15 Kalypsys, Inc. Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions
BRPI0418092A (en) 2003-12-23 2007-04-17 Pfizer Prod Inc therapeutic combination for cognitive improvement and psychotic disorders
JP2007531744A (en) 2004-04-05 2007-11-08 武田薬品工業株式会社 6-azaindole compounds
WO2005100334A1 (en) 2004-04-14 2005-10-27 Pfizer Products Inc. Dipeptidyl peptidase-iv inhibitors
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
UA91027C2 (en) 2004-09-22 2010-06-25 Янссен Фармацевтика Н.В. Inhibitors of the interaction between mdm2 and p53
US20060128710A1 (en) 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
WO2006065842A2 (en) 2004-12-13 2006-06-22 Synta Pharmaceuticals Corp. 5,6,7,8-tetrahydroquinolines and related compounds and uses thereof
AU2006203828B2 (en) 2005-01-07 2009-12-03 Emory University CXCR4 antagonists for the treatment of medical disorders
JP4647670B2 (en) 2005-02-07 2011-03-09 エフ．ホフマン−ラ ロシュ アーゲー Heterocyclyl-substituted phenylmethanones as inhibitors of glycine transporter 1
GB0504556D0 (en) 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
DE102005012872A1 (en) * 2005-03-19 2006-09-28 Sanofi-Aventis Deutschland Gmbh Substituted, bicyclic 8-pyrrolidino-benzimidazoles, process for their preparation and their use as medicaments
AU2006235735C1 (en) 2005-04-13 2013-10-31 Astex Therapeutics Limited Hydroxybenzamide derivatives and their use as inhibitors of Hsp90
WO2007050124A1 (en) 2005-05-19 2007-05-03 Xenon Pharmaceuticals Inc. Fused piperidine derivatives and their uses as therapeutic agents
WO2007007054A1 (en) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
US20070093515A1 (en) 2005-08-16 2007-04-26 Arrington Mark P Phosphodiesterase 10 inhibitors
DE602006021044D1 (en) 2005-09-29 2011-05-12 Glaxo Group Ltd PYRAZOLOÄ3,4-BÜPYRIDIN COMPOUNDS AND THEIR USE AS PDE4 INHIBITORS
JP4371164B2 (en) 2005-11-10 2009-11-25 萬有製薬株式会社 Aza-substituted spiro derivatives
AR059037A1 (en) 2006-01-17 2008-03-12 Schering Corp COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
WO2007084815A2 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica, N.V. Substituted thienopyrimidine kinase inhibitors
WO2007087231A2 (en) 2006-01-25 2007-08-02 Merck & Co., Inc. Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP1986652B1 (en) 2006-02-15 2013-03-20 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
AU2007220039A1 (en) 2006-02-27 2007-09-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of the unfolded protein response and methods for their use
AU2007228784B2 (en) 2006-03-22 2012-03-08 Janssen Pharmaceutica N.V. Cyclic-alkylaminederivatives as inhibitors of the interaction between MDM2 and p53
US7977351B2 (en) 2006-03-22 2011-07-12 Allergan, Inc. Heteroaryl dihydroindolones as kinase inhibitors
EP2023919A4 (en) 2006-05-08 2010-12-22 Molecular Neuroimaging Llc Compounds and amyloid probes thereof for therapeutic and imaging uses
EA200802210A1 (en) 2006-05-16 2009-06-30 Бёрингер Ингельхайм Интернациональ Гмбх SUBSTITUTED PROLINAMIDES, THEIR RECEIVING AND THEIR USE AS MEDICINES
CN1869036A (en) 2006-06-30 2006-11-29 中国药科大学 7-substituted-3-chloro pyrrolo [3,4-b] pyridine compound
DE102006032824A1 (en) 2006-07-14 2008-01-17 Bayer Healthcare Ag Substituted indazoles
AU2007275816A1 (en) 2006-07-17 2008-01-24 Merck Sharp & Dohme Corp. 1-hydroxy naphthyridine compounds as anti-HIV agents
CA2658887C (en) 2006-07-28 2016-08-23 University Of Connecticut Fatty acid amide hydrolase inhibitors
US8389739B1 (en) 2006-10-05 2013-03-05 Orphagen Pharmaceuticals Modulators of retinoid-related orphan receptor gamma
JP5518478B2 (en) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド Pharmaceutical compounds
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
US8779132B2 (en) 2006-10-12 2014-07-15 Astex Therapeutics Limited Pharmaceutical compounds
JP5721949B2 (en) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ Compound drug
PE20080888A1 (en) 2006-10-18 2008-08-26 Novartis Ag HETEROCYCLIC COMPOUNDS AS ACIL-TRANSFERASE INHIBITORS OF ACIL-CoA-DIACIL-GLYCEROL 1 (DGAT1)
KR20090098877A (en) 2006-12-11 2009-09-17 노파르티스 아게 Method of preventing or treating myocardial ischemia
WO2008083070A1 (en) 2006-12-29 2008-07-10 Neurogen Corporation Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties
KR20090101372A (en) 2007-01-08 2009-09-25 페노믹스 코포레이션 Macrocyclic hepatitis c protease inhibitors
WO2009004496A2 (en) 2007-04-13 2009-01-08 University Of Manitoba Bisanthrapyrazoles as anti-cancer agents
US20110189167A1 (en) 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
US20100129933A1 (en) 2007-04-26 2010-05-27 Forschungszentrum Karlsruhe Gmbh Method for detecting the binding between mdm2 and the proteasome
WO2008135524A2 (en) 2007-05-02 2008-11-13 Boehringer Ingelheim International Gmbh Substituted anthranilamides and analogues, manufacturing and use thereof as medicaments
TW200902533A (en) 2007-05-02 2009-01-16 Boehringer Ingelheim Int Carboxylic acid amides, manufacturing and use thereof as medicaments
SI2152794T1 (en) 2007-05-10 2014-07-31 Constar International Llc Oxygen scavenging molecules, articles containing same, and methods of their use
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
GB0710844D0 (en) 2007-06-06 2007-07-18 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
DE102007034620A1 (en) 2007-07-25 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg New B1 antagonists
WO2009026248A2 (en) 2007-08-17 2009-02-26 The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Hydrazide, amide, phthalimide and phthalhydrazide analogs as inhibitors of retroviral integrase
SG183733A1 (en) 2007-09-17 2012-09-27 Abbott Lab Uracil or thymine derivative for treating hepatitis c
US20090076275A1 (en) 2007-09-19 2009-03-19 David Robert Bolin Diacylglycerol acyltransferase inhibitors
EP2217068A4 (en) 2007-10-11 2011-09-14 Glaxosmithkline Llc NOVEL sEH INHIBITORS AND THEIR USE
CA2702946A1 (en) 2007-10-16 2009-04-23 Northeastern University Monoacylglycerol lipase inhibitors for modulation of cannabinoid activity
EP2211862A2 (en) 2007-10-18 2010-08-04 Novartis AG Csf-1r inhibitors for treatment of cancer and bone diseases
ATE539054T1 (en) 2007-11-29 2012-01-15 Hoffmann La Roche METHOD FOR PRODUCING DIHYDROPYRROL DERIVATIVES AS INTERMEDIATE PRODUCTS
WO2009073788A1 (en) 2007-12-07 2009-06-11 Firestone Leigh H Compositions and methods for treating menopausal females
JP2011506600A (en) * 2007-12-18 2011-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Tetrahydrocyclopenta [b] indol-3-ylcarboxylic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
EP2078711A1 (en) 2007-12-28 2009-07-15 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor
GB0800035D0 (en) * 2008-01-02 2008-02-13 Glaxo Group Ltd Compounds
FR2926554B1 (en) 2008-01-22 2010-03-12 Sanofi Aventis AZABICYCLIC CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
CN101225070B (en) 2008-01-31 2010-04-14 上海交通大学 Antineoplastic medicament
WO2009097972A1 (en) 2008-02-05 2009-08-13 Sanofi-Aventis Sf5 derivatives as par1 inhibitors, production thereof, and use as medicaments
WO2009112445A1 (en) 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
GB0804702D0 (en) 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
GB0804701D0 (en) 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
WO2009124755A1 (en) 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Compounds with novel medical uses and method of identifying such compounds
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
GB0809776D0 (en) 2008-05-29 2008-07-09 Amura Therapeutics Ltd Compounds
MX2010014565A (en) 2008-07-01 2011-03-04 Genentech Inc Isoindolone derivatives as mek kinase inhibitors and methods of use.
US8143259B2 (en) 2008-08-19 2012-03-27 Janssen Pharmaceutica, Nv Cold menthol receptor antagonists
WO2010024258A1 (en) 2008-08-29 2010-03-04 塩野義製薬株式会社 Ring-fused azole derivative having pi3k-inhibiting activity
EP2334183A4 (en) 2008-09-16 2012-06-06 Merck Sharp & Dohme Sulfonamide derivative metabotropic glutamate r4 ligands
WO2010056195A1 (en) 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 575
WO2010056194A1 (en) 2008-11-14 2010-05-20 Astrazeneca Ab 5h-pyrrolo [ 3, 4-b] pyridin derivatives and their use
CN101455661B (en) 2008-11-19 2012-10-10 中国科学院上海有机化学研究所 Use of 3-substituted phthalide and the analogue
JP5752601B2 (en) 2008-12-08 2015-07-22 ブイエム ファーマ エルエルシー Composition of protein receptor tyrosine kinase inhibitor
CN102300852B (en) 2009-01-28 2015-04-22 拜尔农科股份公司 Fungicide N-cycloalkyl-N-bicyclicmethylene-carboxamide derivatives
WO2011078143A1 (en) 2009-12-22 2011-06-30 塩野義製薬株式会社 Pyrimidine derivatives and pharmaceutical composition containing same
WO2011078984A1 (en) * 2009-12-23 2011-06-30 Sanofi [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
EP2563124A4 (en) 2010-01-19 2013-10-16 Res Triangle Inst Kappa opioid receptor binding ligands
CA2787785C (en) 2010-01-28 2018-03-06 President And Fellows Of Harvard College Compositions and methods for enhancing proteasome activity
EP2368886A1 (en) 2010-03-01 2011-09-28 Phenex Pharmaceuticals AG Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease
CN102241621A (en) 2010-05-11 2011-11-16 江苏恒瑞医药股份有限公司 5,5-disubstituted-2-iminopyrrolidine derivatives, preparation method thereof, and medical applications thereof
EP2571876B1 (en) 2010-05-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
ES2526124T3 (en) 2010-06-16 2015-01-07 Cymabay Therapeutics, Inc. GPR120 receptor agonists and their uses
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
CN103384668B (en) 2010-09-03 2017-05-31 福马Tm有限责任公司 Compound and composition for suppressing NAMPT
JP5998142B2 (en) 2010-09-27 2016-09-28 アボット ゲーエムベーハー ウント カンパニー カーゲー Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
JP2013253019A (en) 2010-09-28 2013-12-19 Kowa Co New piperidine derivative and pharmaceutical containing the same
AU2011326071A1 (en) 2010-11-08 2013-05-23 Lycera Corporation N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of RORy activity and the treatment of diseases
TW201305139A (en) 2010-11-10 2013-02-01 Gruenenthal Gmbh Substituted heteroaromatic carboxamide and urea derivatives as vanilloid receptor ligands
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
WO2012100734A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
CN102180780A (en) 2011-03-07 2011-09-14 中国科学技术大学 Indenone derivative and applications thereof as developing agent and aggregation inhibitor of amyloid protein deposit and neurofibrillary tangle
JP5781636B2 (en) 2011-03-14 2015-09-24 インパクト セラピューティックス インコーポレイテッド Quinazolinedione and uses thereof
CN103635458B (en) 2011-03-25 2016-10-19 艾伯维公司 TRPV1 antagonist
US9469667B2 (en) 2011-04-04 2016-10-18 Merck Patent Gmbh Metal complexes
EP2511263A1 (en) 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
SG194526A1 (en) 2011-04-28 2013-12-30 Japan Tobacco Inc Amide compound and pharmaceutical application therefor
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US20140315881A1 (en) * 2011-07-29 2014-10-23 Tempero Pharmaceuticals, Inc. Compounds and methods
EP2736329A4 (en) 2011-07-29 2015-03-25 Tempero Pharmaceuticals Inc Compounds and methods
WO2013019626A1 (en) 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
US20140256740A1 (en) 2011-07-29 2014-09-11 Tempero Pharmaceuticals, Inc. Compounds and methods
JP6054869B2 (en) 2011-07-29 2016-12-27 武田薬品工業株式会社 Heterocyclic compounds
WO2013029338A1 (en) 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
EP2759533B1 (en) 2011-09-22 2017-08-02 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
GB201116641D0 (en) 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
WO2013067036A1 (en) 2011-10-31 2013-05-10 Rutgers, The State University Of New Jersey Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
WO2013064231A1 (en) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
WO2013078233A1 (en) * 2011-11-22 2013-05-30 Ripka Amy S N-benzylbenzimidazole modulators of pparg
WO2013078240A1 (en) * 2011-11-22 2013-05-30 Ripka Amy S N-biphenylmethylbenzimidazole modulators of pparg
EP2800745B1 (en) 2011-12-02 2020-02-12 Phenex Pharmaceuticals AG Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
WO2013092460A1 (en) 2011-12-20 2013-06-27 Syngenta Participations Ag Cyclic bisoxime microbicides
JP6124187B2 (en) 2011-12-21 2017-05-10 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Compounds acting at multiple prostaglandin receptors that confer general anti-inflammatory responses
US9216988B2 (en) 2011-12-22 2015-12-22 Genentech, Inc. Benzyl sulfonamide derivatives as RORc modulators
US20130190356A1 (en) 2011-12-22 2013-07-25 Genentech, Inc. Benzyl sulfonamide derivatives as rorc modulators
WO2013100027A1 (en) 2011-12-28 2013-07-04 武田薬品工業株式会社 Heterocyclic compound
WO2013159095A1 (en) 2012-04-20 2013-10-24 Anderson Gaweco Ror modulators and their uses
GB201207406D0 (en) 2012-04-27 2012-06-13 Glaxo Group Ltd Novel compounds
TWI593678B (en) 2012-04-27 2017-08-01 葛蘭素集團有限公司 Compounds useful as retinoid-related orphan receptor gamma (ror γ) modulators, the pharmaceutical compositions and use thereof
US9708268B2 (en) 2012-04-30 2017-07-18 Innov17 Llc ROR modulators and their uses
JP6236068B2 (en) 2012-05-08 2017-11-22 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Tetrahydronaphthyridine and related bicyclic compounds for inhibiting RORγ activity and treating diseases
EP2847198B1 (en) 2012-05-08 2016-12-14 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ror-gamma and the treatment of disease
RU2014149149A (en) 2012-05-08 2016-07-10 Мерк Шарп И Доум Корп. BICYCLIC SULPHONE COMPOUNDS FOR INHIBITING ROR Gamma ACTIVITY AND TREATMENT OF DISEASE
UY34832A (en) 2012-05-31 2013-12-31 Phenex Pharmaceuticals Ag TIAZOLS REPLACED BY CARBOXAMIDE OR SULFONAMIDE AND RELATED DERIVATIVES AS MODULATORS FOR THE NURLEAR RECEPTOR HUÉRFANO RORy (lambda)
WO2014008214A1 (en) 2012-07-02 2014-01-09 Biogen Idec Ma Inc. Biaryl-containing compounds as inverse agonists of ror-gamma receptors
AR092348A1 (en) 2012-07-11 2015-04-15 Hoffmann La Roche ARIL-SULTAMO DERIVATIVES AS RORc MODULATORS
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
WO2014028669A1 (en) 2012-08-15 2014-02-20 Biogen Idec Ma Inc. Novel compounds for modulation of ror-gamma activity
WO2014026330A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014026328A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026329A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
RU2015114772A (en) 2012-09-21 2016-11-10 Санофи AMENIDE DERIVATIVES OF BENZOIMIDAZOLE-CARBOXYLIC ACID AS APJ RECEPTOR MODULATORS
CN105073729A (en) * 2012-10-16 2015-11-18 詹森药业有限公司 Phenyl linked quinolinyl modulators of ror-gamma-t
WO2014062938A1 (en) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Rory modulators
LT2928885T (en) 2012-12-06 2017-05-25 Glaxo Group Limited Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
EP2991994B1 (en) 2013-05-01 2018-08-15 Vitae Pharmaceuticals, Inc. Thiazolopyrrolidine inhibitors of ror-gamma
TWI652014B (en) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 Heterocyclic substituted bicycloazole insecticide
KR20160068959A (en) * 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. Phenyl linked quinolinyl modulators of ror-gamma-t
WO2015083130A1 (en) 2013-12-06 2015-06-11 Aurigene Discovery Technologies Limited Fused pyridine and pyrimidine derivatives as ror gamma modulators
KR20160101162A (en) 2013-12-24 2016-08-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Cortistatin analogues and syntheses and uses thereof
JP2015124178A (en) 2013-12-26 2015-07-06 東レ株式会社 Cyclic amine derivative and medicinal use thereof
WO2015101928A1 (en) * 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Fused thiophene and thiazole derivatives as ror gamma modulators
CR20160402A (en) 2014-02-03 2017-02-07 Basf Se Compound of cyclopentene and cyclopentadiene to control invertebrate pests
PL3102576T3 (en) 2014-02-03 2019-12-31 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ror-gamma
WO2015139619A1 (en) * 2014-03-18 2015-09-24 北京韩美药品有限公司 Compound serving as rorγ modulator
WO2015144480A1 (en) 2014-03-26 2015-10-01 Basf Se Substituted [1,2,4]triazole and imidazole compounds as fungicides
JO3512B1 (en) 2014-03-26 2020-07-05 Astex Therapeutics Ltd Quinoxaline derivatives useful as fgfr kinase modulators
EP3122750B1 (en) 2014-03-26 2019-09-04 F.Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
MX2016010675A (en) 2014-03-26 2016-11-10 Hoffmann La Roche Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors.
NZ724602A (en) * 2014-03-27 2022-12-23 Piramal Entpr Ltd Ror-gamma modulators and uses thereof
CA2940264A1 (en) * 2014-04-16 2015-10-22 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl ether compounds as ror gamma modulators
UA118989C2 (en) 2014-10-14 2019-04-10 Вітае Фармасьютікалс, Інк. Dihydropyrrolopyridine inhibitors of ror-gamma
CN107206004A (en) 2014-10-22 2017-09-26 德克萨斯大学系统董事会 Target micromolecular inhibitor of discoidin domain receptor 1 and application thereof
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
CN112679467A (en) 2015-03-11 2021-04-20 Fmc公司 Heterocyclic substituted bicyclic azoles as pesticidal agents
WO2017024018A1 (en) 2015-08-05 2017-02-09 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
CN108463458B (en) 2015-11-20 2022-02-01 生命医药有限责任公司 Modulators of ROR-gamma
TWI757266B (en) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 Modulators of ror-gamma
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No new references cited by the Examiner. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11535614B2 (en) 2014-02-03 2022-12-27 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma

Also Published As

Publication number Publication date
JP2021193131A (en) 2021-12-23
MX2018009257A (en) 2018-11-09
EP3408268A1 (en) 2018-12-05
RU2021133444A (en) 2021-11-29
AU2017212577B2 (en) 2021-05-13
JP6948333B2 (en) 2021-10-13
CN109071509B (en) 2021-11-30
WO2017132432A8 (en) 2017-08-31
US20190352286A1 (en) 2019-11-21
EP3408268B8 (en) 2023-12-06
CN109071509A (en) 2018-12-21
RU2018127360A3 (en) 2020-04-06
TW201734001A (en) 2017-10-01
MA55328A (en) 2022-01-19
SA518392101B1 (en) 2022-03-16
TW202220968A (en) 2022-06-01
EP3939974A1 (en) 2022-01-19
MA45646A (en) 2021-03-24
AU2017212577A1 (en) 2018-08-02
CN114230523A (en) 2022-03-25
JP2019503385A (en) 2019-02-07
EP3408268B1 (en) 2021-08-04
BR112018015273A2 (en) 2018-12-18
TWI757266B (en) 2022-03-11
RU2760366C2 (en) 2021-11-24
RU2018127360A (en) 2020-03-02
CA3011838A1 (en) 2017-08-03
KR20180100697A (en) 2018-09-11
WO2017132432A1 (en) 2017-08-03
UY37098A (en) 2017-08-31
US10829481B2 (en) 2020-11-10

Similar Documents

Publication Publication Date Title
US20210094940A1 (en) Modulators of ror-gamma
US10829448B2 (en) Substituted benzoimidazoles as modulators of ROR-γ
US11008340B2 (en) Modulators of ROR-gamma
US20200339566A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
US10399976B2 (en) Dihydropyrrolopyridine inhibitors of ROR-gamma
US20200079767A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
US20230339886A1 (en) Rev-erb agonists for the treatment of th17-mediated inflammatory disorders

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

AS Assignment

Owner name: VITAE PHARMACEUTICALS, INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CLAREMON, DAVID A.;DILLARD, LAWRENCE WAYNE;FAN, YI;AND OTHERS;SIGNING DATES FROM 20180920 TO 20181109;REEL/FRAME:054982/0124

Owner name: VITAE PHARMACEUTICALS, LLC, NEW JERSEY

Free format text: CHANGE OF NAME;ASSIGNOR:VITAE PHARMACEUTICALS, INC.;REEL/FRAME:055056/0588

Effective date: 20181231

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE